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RESUMÉ 
Streptococcus suis est un pathogène du porc et un agent de zoonose 'causant, entre 
autres, une septicémie et une méningite tant chez le porc que chez l'humain. Le sérotype 2 est 
considéré comme étant le plus virulent des trente cinq sérotypes de s. suis. La pathogenèse de 
l'infection à s. suis demeure mal connue et, pour la plupart, les connaissances sont limitées au 
sérotype 2. De plus, peu des facteurs de virulence proposés se sont avérés être essentiels pour 
la virulence de ce pathogène. Pour causer la méningite s. suis doit atteindre le système nerveux 
central (CNS), ce qui implique traverser les barrières hémato-méningée et/ou hémato-
encéphalique (BBB). Les éellules endothéliales de microvaisseux cérébraux (BMEC) sont des 
composants majeurs de la BBB. En utilisant un modèle d'infection in vitro comportant des BMEC 
porcines immortalisées, il a été démontré que S. suis est capable de s'attacher et d'envahir ces 
cellules. Nous proposons que les gènes qui sont exprimés différentiellement par S. suis lors de 
ses interactions avec les BIVIEC porcines pourraient potentiellement être des facteurs de 
virulence importants de ce pathogène. Afin de déterminer l'expression génique de la bactérie 
lors de l'interaction S. suis-BMEC porcines et évaluer cette hypothèse, nous avons utilisé la 
méthode de capture sélective de séquences transcrites (SCOTS). L'étude a permis l'identification 
de vingt-huit gènes différentiellement exprimés par S. suis lors des processus 
d'adhésion/invasion de ces cellules formant la BBB. Certains de ces gènes ont présenté un clair 
potentiel comme facteurs de virulence. Cinq d'entre eux sont putativement impliqués dans la 
modification de composants de la paroi cellulaire tels que les acides lipotéichoiques (LTA) et le 
peptidoglycane. De plus, l'utilisation de SCOTS a permis l'identification, pour la première fois 
chez s. suis, d'un locus dont les gènes codent pour un pilus. En effet, un gène isolé par SCOTS a 
été reconnu comme codant pour une peptidase signal étant le premier gène dudit locus. 
D'autres gènes identifiés par SCOTS codent putative ment pour différentes protéines de la paroi 
cellulaire, pour des transporteurs, pour des régulateurs transcriptionels, pour des gènes de 
ménage ainsi que pour des protéines à fonction inconnue. 
Nous avons effectué des études additionnelles afin de comprendre la contribution de la 
production de pili à la virulence de s. suis. Des mutants pour chacun des gènes du locus piliare 
ont été construits. De plus, nous avons produits des anticorps dirigés contre les sous-unités 
piliaires. Les résultats préliminaires ont montré qu'une souche hautement virulente produit un 
pilus, lequel est toutefois dépourvu d'adhésine. L'abolition de l'expression de ce pilus sans 
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adhésine n'a pas altéré les interactions de S. suis avec les BIVIEC porcines. De plus, un mutant 
non-pi lié a été aussi virulent que la souche sauvage (WT) dans un modèle murin de l'infection. 
Ces résultats suggèrent que la production de pili n'est pas essentielle pour la virulence de S. suis. 
D'autres gènes identifiés par SCOTS ont aussi été caractérisés. Les gènes ciblés ont été 
dltA, lequel est impliqué dans D-alanylation des LTA, une modification résultant dans une 
stabilisation de la paroi cellulaire par neutralisation des charges négatives chez certains 
pathogènes à Gram positifs; et pgdA, dont le rôle est la N-deacétylation du peptidoglycane, une 
modification qui, chez d'autres pathogènes, a comme conséquence une résistance accrue face à 
l'action hydrolytique du lysozyme. Pour évaluer davantage la contribution du gène dltA à la 
pathogénèse de l'infection à S. suis, un mutant fldltA a été construit chez une souche hautement 
virulente de sérotype 2. L'analyse par résonance magnétique nucléaire a prouvé que les LTA du 
mutant étaient dépourvus de D-alanine, confirmant le phénotype escompté. L'absence de D-
alanylation des LTA a eu comme conséquence une susceptibilité augmentée face à l'action des 
peptides antimicrobiens cationiques. En outre, et contrairement à la souche WT, le mutant 
fldltA a été efficacement tué par des neutrophiles porcines et a montré des interactions 
diminuées avec des BMEC porcines. Finalement, de par sa capacité diminuée à échapper aux 
mécanismes immunitaires innés de l'hôte et à traverser des barrières, le mutant fldltA a été 
atténuée dans les modèles murin et porcin d'infection. 
Pour analyser la contribution du gène de pgdA à la virulence de S. suis nous avons 
déterminé, pour la première fois, la structure fine de son peptidoglycane en utilisant la 
chromatographie en phase liquide de haute performance et la spectrométrie de masse. Le 
peptidoglycane de S. suis s'est avéré être formé par vingt muropeptides, y compris trois qui sont 
N-deacétylés. La comparaison avec un mutant flpgdA a montré que le produit du gène pgdA est 
nécessaire pour cette modification spécifique, laquelle est produite en très faible quantité. Le 
bas niveau de N-deacétylation du peptidoglycane s'est corrélé avec une absence de résistance 
face au lysozyme in vitro par la souche WT. Cependant, l'expression du gène pgdA a été 
fortement régulée à la hausse lors de l'interaction de S. suis avec des neutrophiles porcins aussi 
qu'in vivo chez des souris inoculées expérimentalement, suggérant que 5 suis pourrait 
augmenter le niveau de N-deacétylation de son peptidoglycane dans ces conditions. De par sa 
capacité réduite à persister dans le sang, le mutant flpgdA a été sévèrement atténuée dans les 
modèles murins et porcins d'infection. 
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En conclusion, ce projet de recherche fournit des éléments originaux au sujet de la 
pathogenèse de l'infection à 5 suis. Nous avons montré que la D-alanylation des LTA et la N-
deacétylation du peptidoglycane sont des mécanismes importants employés par ce microbe 
pathogène pour contrer les défenses de l'hôte. Les résultats présentés ici, aussi que la future 
caractérisation d'autres facteurs de virulence candidats identifiés par SCOTS pourrait s'avérer 
d'importance pour réduire le fardeau des maladies causées par S. suis. 
Mots clés: Streptococcus suis, facteurs de virulence, pili, D-alanylation des LTA, N-deacétylation 
du peptidoglycane, capture sélective de séquences transcrites 
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SUMMARY 
Streptococcus suis is a pathogen of swine and a zoonotic agent responsible for, among 
other diseases, meningitis and septicemia in both swine and humans. The pathogenesis of the S. 
suis infection remains poorly known. Indeed, knowledge is limited to the serotype 2, which has 
been shown to be the most virulent of the thirty-five serotypes described so far. Only a few 
virulence factors have been proposed and less shown to be essential for the virulence of this 
pathogen. To cause meningitis, S. suis must cross the blood brain barrier (BBB) and gain access 
to the central nervous system (CNS). Brain microvascular endothelial cells (BIVIEC) are one of the 
main BBB-forming cellular types. Using an in vitro model of infection S. suis has proven able to 
attach to and to invade immortalized porcine BMEC. We hypothesized that genes preferentially 
expressed by S. suis during its interactions with these cells may constitute potential important 
virulence factors of this swine pathogen and zoonotic agent. Therefore, we used the selective 
capture of transcribed sequences (SCOTS) approach to dissect bacterial gene expression upon 
the interactions of S. suis with porcine BMEC. The study led to the identification of twenty-eight 
genes that the pathogen preferentially expressed during attachment/invasion of these BBB-
forming cells. Five of the identified genes were shown to have putative roles in modification of 
cell wall structures such as the lipoteichoic acid (LTA) and the peptidoglycan. Some of these 
genes presented a clear potential as virulence factors. In addition, the use of SCOTS led to the 
identification, for the first time, of a pilus cluster in S. suis. Indeed, one gene encoding a putative 
signal peptidase was isolated which was found to the first gene of that pilus cluster. Other 
identified genes putatively encoded different cell wall proteins, transporters, transcriptional 
regulators, housekeeping genes and proteins of unknown function. 
We performed additional studies in order to understand the contribution of pili 
production to the virulence of S. suis. Characterization of the pilus cluster identified by SCOTS 
included the construction of mutant strains for each member of the cluster as weil as the 
generation of antibodies against the putative pilin subunits. Preliminary results revealed that a 
highly virulent S. suis serotype 2 strain indeed produces a pilus, which is, nevertheless, devoid of 
the putative adhesin subunit. Interestingly, abolition of the expression of this adhesin-Iess pilus 
did not result in impaired interaction with porcine BMEC. Furthermore, a non-piliated mutant of 
a highly virulent serotype 2 strain was as virulent as the wild type (WT) strain when evaluated in 
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a murine model of infection. These results might suggest that pili may be dispensable for the 
virulence of S. suis. 
Other SCOTS identified genes,dltA and pgdA, were further characterized. The dltA gene 
is involved in LTA o-alanylation, a modification resulting in cell stabilization by neutralization of 
negative charges in some Gram positive pathogens. The pgdA gene plays a role in the N-
deacetylation of peptidoglycan, a modification shown in other pathogens to result in enhanced 
resistance to the action of lysozyme. To further evaluate the contribution of the dltA gene to the 
pathogenesis of S. suis infection, a l:J.dltA mutant strain was generated in a highly virulent 
serotype 2 strain. Nuclear magnetic resonance showed that the LTAs of the mutant were devoid 
of o-alanine, confirming the expected phenotype. Absence of LTA o-alanylation resulted in an 
increased susceptibility to the action of cationic antimicrobial peptides. In addition, and in 
contrast to the WT strain, the l:J.dltA mutant was efficiently killed by porcine neutrophils and 
showed impaired interactions with porcine BMEC. Finally, reflecting decreased ability to escape 
immune clearance mechanisms and reduced capacity to traverse across host barriers, the l:J.dltA 
mutant was attenuated in both the murine and porcine models of infection. 
To analyze the contribution of the pgdA gene to the virulence of S. suis, we determined 
for the first time the fine structure of S. suis peptidoglycan using high performance liquid 
chromatography and mass spectrometry. The S. suis peptidoglycan was found to contain twenty 
muropeptides, including three that are N-deacetylated. Comparison with a l:J.pgdA mutant 
showed that the pgdA gene product was required for this specific modification, which occurred 
in very low amounts. Interestingly, the low level of peptidoglycan N-deacetylation correlated 
with absence of significant lysozyme resistance when WT S. suis was grown in vitro. However, 
expression of the pgdA gene was highly upregulated upon interaction with porcine neutrophils , 
as weil as in vivo in experimentally inoculated mice, suggesting that S. suis may enhance 
peptidoglycan N-deacetylation under these conditions. Reflecting a decreased ability to persist 
in blood, the l:J.pgdA mutant was severely attenuated in both the murine and porcine models of 
infection. 
ln conclusion, this research has provided novel insights about the pathogenesis of S. 
suis. We showed that both LTA D-alanylation and peptidoglycan N-deacetylation are important 
mechanisms used by this pathogen to successfully counter the host defenses. Results presented 
viii 
here, as weil as future characterization of other virulence factor candidates identified by SCOTS 
may be of importance to reduce the burden of S. suis disease. 
Keywords: Streptococcus suis, virulence factors, pili, LTA o-alanylation, peptidoglycan N-
deacetylation, selective capture of transcribed sequences 
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I.. INTRODUCTION 
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Streptococcus suis is an important swine pathogen responsible for a wide range of 
diseases in swine, the most striking of which are septicemia and meningitis. In addition to 
causing disease in pigs, S. suis is an emerging zoonotic agent. Indeed, this pathogen is 
increasingly becoming a public health concern in several Asian countries, such as Vietnam, 
Thailand, Hong Kong and China. For instance, during a single outbreak in 2005 in that latter 
country, more than two hundreds cases of human S. suis disease were reported, thirty-nine of 
which resulted in death. Of the thirty-five s. suis serotypes that have _ been described, the 
serotype 2 is considered to be the most virulent. It is also the most prevalent serotype isolated 
from diseased pigs in the majority of countries where the swine production is important. In 
pigs, S. suis is mainly transmitted via the respiratory route and remains localized in the tonsils. 
ln fact, some animais may remain healthy carriers for life (they will never develop disease), 
while, on the other hand, some animais may eventually develop bacteremia, sometimes 
septicemia (fulminant systemic disease), and/or meningitis. 
Multiple lines of evidence suggest that both the pathogen, through the production of 
virulence factors, and the host, through an exacerbated immune response to the infection, are 
responsible for the pathology of s. suis diseases in both swine and humans. The understanding 
of the contribution of the host immunity to the pathogenesis of s. suis infection has 
significantly advanced in recent years. However, des pite increasing research, knowledge on S. 
suis virulence factors remains limited. S. suis is an encapsulated bacterium and it has been 
demonstrated that the capsular polysaccharide (CPS) confer antiphagocytic properties. In fact, 
presence of the CPS is necessary for persistence of the organism in blood, a very important 
condition that must be met for the development of septicemia and meningitis. However, the 
CPS is not sufficient for survival in this tissue as shown by the fact that weil encapsulated 
avirulent strains are rapidly cleared from circulation. Indeed, most avirulent S. suis strains are 
encapsulated. Recently, a serum opacity-like factor (OFS) has been shown to play a critical role 
in the pathogenesis of the s. suis infection. However, the OFS seems to be absent from many 
virulent isolates. As weil, many, but not ail, S. suis virulent strains secrete a hemolysin (known 
as suilysin, a thiol-activated toxin) which may contribute to the virulence of the organism. 
However, isogenic mutants lacking suilysin have been shown to be as virulent as the parent 
strain after experimental infection of pigs. Besides, as stated above, some virulent strains do 
not produce suilysin. Other proposed putative virulence factors include the extracellular 
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protein factor (EF) and the muramidase-released protein (MRP). These factors have been 
shown to be associated to virulence, but several studies using isogenic mutants have shown 
that they are not essential for the full virulence of the organism. In addition, as is the case for 
suilysin, these protein factors are absent from many virulent strains. Other determinants, su ch 
as a fibronectin/fibrinogen-binding protein (Ffbp), have been found to beonly partially 
involved in virulence. Finally, the actual role of some other virulence candidates (several 
putative adhesins and proteases) in the pathogenesis of S. suis infection remains to be verified. 
Interestingly, with the exception of the CPS, extracellular structures of the pathogen, such as 
cell wall components, have not been found to play a direct role in virulence, although they 
have been shown to very much contribute to the exacerbation of the host inflammatory 
response. 
As stated above, S. suis causes meningitis. A prerequisite for the onset of this disease 
is pathogen invasion of the central nervous system (CNS). The actual mechanisms by which S. 
suis gains access to the CNS remain so far unknown. An early hypothesis, known as the "Trojan 
horse", suggested uptake of bacteria by monocytes, intracellular survival and invasion of the 
CNS. However, results of several different studies suggest that this mechanism is unlikely to be 
important for CNS invasion. Indeed, as a result of these studies, a "modified Trojan horse" 
hypothesis has been put forward, in which the pathogen, rather than being phagocytosed, 
establishes an extracellular association with monocytes/macrophages and takes advantage of 
the infiltration of these cells to break into the CNS. It has also been suggested that the 
pathogen might reach the CNS by disrupting or by crossing without disruption the blood brain 
barrier (BBB) and/or the blood-cerebrospinal fluid (CSF) barrier. Indeed, in vivo (murine model 
of infection) studies suggest that the pathogen may gain access to the CNS through the brain 
microvascular endothelium and, also, through the choroid plexus epithelium. Further support 
for these mechanisms has been provided by recent reports showing that S. suis is able to affect 
the viability of porcine choroid plexus epithelial cells (CPEC) composing the blood-CSF barrier 
through necrotic and apoptotic mechanisms. In addition, invasion of BBB-forming cells such as 
brain microvascularendothelial cells (BMEC) has been demonstrated using an in vitro model of 
cultured porcine BMEC. 
Although further studies are needed to definitively ascertain how the pathogen enters 
the CNS, the development of the latter model of S. suis-porcine BMEC interactions offers a 
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unique opportunity to elucidate the weapons this pathogen makes use of during a critical step 
for the development of 5. suis meningitis such as BBB crossing. Indeed, it can be hypothesized 
that genes expressed by 5. suis during its interactions with porcine BMEC may potentially 
constitute important virulence factors of this swine pathogen and zoonotic agent. 
The main objective of this research project is to increase the current understanding of 
the pathogenesis of 5. suis by the identification and characterization of novel virulence factors 
of this organism. It is divided in two specifie objectives: 
1. The first specifie objective is the determination of genes differentially expressed by 5. 
suis during its interactions with porcine BMEC and the identification of putative 
virulence factor candidates. The first specifie objective takes advantage of the 
technological advance of the selective capture oftranscribed sequences (SCOTS), 
which is a state-of-the-art, PCR-based RNA analysis method that directly identifies 
bacterial genes rather than promoter regions and is not confounded by polar effects 
when genes are arranged in polycistronic operons. 
2. The second specifie objective is the characterization of the actual contribution to the 
virulence traits of 5. suis of selected SCOTS-identified putative virulence factors. Since 
the vitro model used for gene identification in specific objective 1 is inherently limited 
and, on the other hand, the SCOTS-identified genes may eventually also contribute to 
the virulence traits of 5. suis at other stages of the infection, selected identified genes 
will be inactivated in a virulent strain and the resulting mutants tested in different 
experimental in vitro and in vivo models of infection. 
II. REVIEW OF THE LITERATURE 
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1. Streptococcus suis 
5. suis is a swine pathogen responsible for important losses to the porcine industry 
worldwide. This organism can produce a wide range of diseases, including meningitis, arthritis, 
pneumonia, septicemia, endocarditis and polyserositis (Higgins and Gottschalk, 2006). 5. suis is 
also a zoonotic agent causing meningitis, septicemia, toxic shock-like syndrome and endocarditis 
in humans (Gottschalk et al., 2007). 5. suis (Figure 1) is a Gram-positive small non-motile ovoid 
coccus, possessing cell wall antigenic determinants related to Lancefield group D, although it is 
genetically unrelated to other members of this group (Higgins and Gottschalk, 2006). 5. suis is 
less than 2 ~m in diameter, it occurs singly, in pairs and, rarely, in short chains. Ali strains are a-
he moly tic on sheep blood agar and many produce ~-hemolysis on horse blood agar. 5. suis is 
chemo-organotroph with fermentative and facultative anaerobic metabolisms (Higgins and 
Gottschalk, 2006). Different biochemical tests have been used for the identification of 5. suis 
and biochemical variations have been noted among different strains (Higgins and Gottschalk, 
1990; Tarradas et al., 1994). However, a minimal number of biochemical tests carried out in 
combination with serotyping can allow for the definitive identification of most 5. suis isolates 
recovered from pigs. The use of at least four tests has been proposed for a presumptive 
identification of S. suis: absence of growth in 6.5 % NaCI agar, a negative Voges-Proskauer test, 
production of acid in trehalose and salicin broth and production of amylase but not acetoin 
(Devriese et al., 1991; Higgins and Gottschalk, 1990). The NaCi (6.5%) test clearly differentiates 
between S. suis and 5treptococcus bovis from the genus Enterococcus. The Voges-Proskauer test 
is critical and the most reliable for differentiating S. suis from S. bovis (Higgins and Gottschalk, 
1990). 
Figure 1. Transmission electron micrography of S. suis 
serotype 2 reference strain S735. 
The ovoid coccus morphology and the thick capsule 
surrounding the pathogen are clearly visible. 
Magnification: 20,000 X. Source : Fittipaldi et al, 
unpublished results. 
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1.1. Diagnosis 
Presumptive diagnosis of 5. suis infections is based on clinical signs and macroscopic 
lesions. Diagnosis is confirmed by the isolation of the infectious agent and the recognition of 
microscopic lesions in tissues. Direct microscopy from affected organs or blood may confirm the 
streptococcal etiology of the disease. Isolation of 5. suis from lungs has to be nevertheless 
interpreted with caution since the organism is almost constantly present in the upper 
respiratory tract (Higgins and Gottschalk, 2006). For species identification, a minimum of 
biochemical tests are necessary, as described above. When the organism is isolated from 
diseased animais and serotyping is available, an a-hemolytic 5treptococcus that produces 
amylase but not acetoin can be considered as 5. suis (Devriese et aL, 1991). Serotype-specifie 
isolation from contaminated tissues, such as tonsils, may also be carried out using a reported 
immunocapture method (Gottschalk et aL, 1999b). Methods such as fluorescent in situ 
hybridization may be used for specifie detection of 5. suis in tissues (Boye et aL, 2000). 
Identification, as weil as partial characterization with respect to serotype and the presence of 
virulence markers,can rapidly be performed by PCR (Marois et aL, 2004; Okwumabua et aL, 
2003; Rasmussen and Andresen, 1998; Smith et aL, 1997; Wisselink et aL, 2002a). 
1.1.1. Serotyping 
5. suis can be classified into thirty-five serotypes (1 to 34 and 1/2) according to the CPS 
antigens (Higgins and Gottschalk, 2006). However, further molecular characterization has shown 
that serotypes 32 and 34 actually belong to another species: 5treptococCUs orisratti (see below) 
(Hill et aL, 2005). Some of the reference strains of these serotypes originated from diseased pigs 
while others were isolated from the nasal cavities of clinieally healthy pigs (Higgins and 
Gottschalk, 2006). Reference strains of serotypes 20, 31 and 33 were isolated from other animal 
species while the reference strain of serotype 14 was from a case of human meningitis 
(Gottschalk et aL, 1991b; Higgins and Gottschalk, 1990; Higgins et aL, 1995). Some serotypes 
cross-react, indicating that some capsular antigenic determinants are shared. This is the case of 
serotype 1/2 cross-reaction with serotype 1 and serotype 2 antisera (Perch et aL, 1983). Two-
way cross-reaétions between serotypes 6 and 16 and one-way cross-reaction between serotypes 
2 and 22 have also been described (Gottschalk et aL, 1991b). Whether the different 5. suis 
serotypes can be considered normal flora of the nasal cavity or they represent actual pathogens 
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remains controversial (Higgins and Gottschalk, 2006). The serotype 2 is the most prevalent 
serotype isolated from diseased pigs in most countries and, in addition, it is the most virulent 
(Higgins and Gottschalk, 2006). Although serotype 2 isolates predominate in most countries, the 
distribution may differ depending on the geographical location. For example, the prevalence of 
serotype 2 strains recovered from diseased animais in Canada and the United States remains 
relatively low (below 25%) (Messier et aL, 2008; Article V, Appendix). In some European and 
Asian countries, however, serotype 2 is isolated more frequently (Berthelot-Herault et aL, 2000; 
Lun et aL, 2007; Takamatsu et aL, 2008c; Wisselink et aL, 2000; Ye et aL, 2006). Under specifie 
circumstances, other serotypes have been found to be highly prevalent, i.e., serotype 14 in the 
United Kingdom (Heath et aL, 1996) and serotypes 1/2 and 5 in Canada (Lapointe et aL, 2002). 
Serotype 7 predominated for several years in Scandinavian countries but, later, serotype 2 was 
reported to be the most prevalent (Higgins and Gottschalk, 1990, 2006). Nevertheless, isolates 
associated with disease belong, for the most part, to serotypes 1 to 8 and 1/2. The number of 
untypable strains isolated from diseased animais (mainly recovered from cases of sporadic 
disease) is, in general, relatively low (Higgins and Gottschalk, 2006; Messier et aL, 2008). 
Serotyping is an important step of the routine diagnostic procedures. Different techniques have 
been described, but nowadays most laboratories use the coagglutination technique (Gottschalk 
et aL, 1993; Higgins and Gottschalk, 1990). 
1.1.2. Molecular typing 
Genetic differences between and within serotypes of S. suis have been detected with 
multilocus sequence typing (MLST, discussed in a separate section), multilocus enzyme 
electrophoresis (MLEE) (Hampson et aL, 1993; Mwaniki et aL, 1994), restriction endonuclease 
analysis (Beaudoin et aL, 1992a; Mogollon et aL, 1991), ribotyping (Okwumabua et aL, 1995; 
Rasmussen et aL, 1999; Rasmussen and Andresen, 1998; Smith et aL, 1997; Staats et aL, 1998), 
sequencing of the cpn60 gene encoding a 60-kDA chaperonin (Brousseau et aL, 2001), pulse 
field gel electrophoresis (PFGE) (Ailgaier et aL, 2001; Berthelot-Herault et aL, 2002; Luey et aL, 
2007), and randomly amplified polymorphie DNA (RAPD) (Chatellier et aL, 1999; Martinez et aL, 
2002). Recently, an approach based on PCR amplification of a fragment of rDNA sequences, 
including a part of the 16S and 23S genes and the 16S-23S rDNA intergenic spacer region (ISR), 
followed by restriction fragment length polymorphism (RFLP) analysis (ISR-RFLP) was also 
described (Marois et aL, 2006). Although many of these studies involved small numbers of 
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isolates, focused on isolates representing a single serotype or geographical location, and used a 
variety of traditional approaches such that it is difficult to compare results among studies, a 
general conclusion that can be drawn from these studies is that genetic diversity among 
members of the S. suis species is important (Higgins and Gottschalk, 2006). This fact should be 
taken into account in diagnosis, surveillance, and control of the disease (Higgins and Gottschalk, 
2006). In addition, it has been suggested that isolates from clinically healthy animais may be 
very heterogeneous, in contrast to most isolates from cases of diseased animais or humans 
(Ailgaier et aL, 2001; Beaudoin et aL, 1992a; King et aL, 2001; Staats et aL, 1998). Moreover, 
there is considerable evidence that virulent isolates are genetically distinct from avirulent 
isolates, suggesting a clonai association with virulence in S. suis. For instance, it has been 
observed that most serotype 2 isolates from septicemia represented a single ribotype, whereas 
less-virulent isolates were genetically heterogeneous (Staats et aL, 1998). Similarly, virulent 
isolates of serotypes 1 and 2 had distinct ribotype profiles, and particular ribotype profiles were 
clearly associated with clinical-pathology observations (Rasmussen et aL, 1999; Smith et aL, 
1997). Similar results were observed using RAPD for serotypes 2 and 1/2 (Chatellier et aL, 1999; 
Martinez et aL, 2002). A recent study of ninety-nine strains by macrorestriction of DNA revealed 
four major clusters, one of which was strongly associated with invasive disease, and indicated 
that isolates from pigs with meningitis and septicemia showed a significantly higher degree of 
genetic homogeneity than isolates from pigs with pneumonia or isolates from healthy pigs 
(Ailgaier et aL, 2001). 
An unforeseen outcome of the use of molecular typing tools was the recent 
reclassification of two S. suis serotypes into another species. Indeed, further analysis of the 
sequences of 165 rDNA and cpn60 genes of the previously described thirty-five serotypes of S. 
suis led to the observation that serotypes 32 and 34 were significantly distinct from the others 
(Hill et aL, 2005). Indeed, sequence data and biochemical profiles indicated that S. suis 
serotypes 32 and 34, isolated from pigs, were clustered with S. orisratti, a Voges-Proskauer 
negative, alpha-hemolytic, esculin-hydrolytic, species isolated from the teeth of rats which 
reacts with Lancefield group A antisera. Therefore, it has been proposed that these two 
serotypes should not longer be considered as belonging to the S. suis species (Hill et aL, 2005). 
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1.1.2.1. Multilocus sequence typing (MLST) 
MLST is an adaptation of the concepts of MLEE, but identifies alleles directly from the 
nucleotide sequences of internai fragments of housekeeping genes rather than bycomparing 
the electrophoretic mobilities of the enzymes they encode (Maiden et aL, 1998). Sequence data 
can be thus readily compared readily between laboratories. Indeed, MLST is fully portable and 
data stored in a single expanding central IVILST data base (http://ssuis.mlst.netf) can be 
interrogated electronically via the Internet, which resolves the major problemall other 
molecular typing methods used for S. suis present, Le., comparison of the results obtained by 
different laboratories (King et al., 2002; Maiden et aL, 1998; Turner and Feil, 2007). An MLST 
scheme for S. suis, using the araA (5-enolpyruvylshikimate 3-phosphate synthase), cpn60, dpr 
(peroxide resistance), gki (glucose kinase), mutS (DNA mismatch repair protein), recA 
(homologous recombination factor) and thrA (aspartokinase) genes has been developed (King et 
al., 2002). Fragments of these seven housekeeping genes from each of 294 S. suis isolates 
obtained from various S. suis diseases and fram asymptomatic carriage representing twenty-
eight serotypes and nine distinct countries of origin were sequenced. Between thirty-two and 
fort y-six alleles per locus were identified, providing the ability to distinguish >1.6 x 1011 
sequence types (ST). However, only ninety-two ST were identified (King et al., 2002). Among 
these ST, eighteen contained multiple isolates. Assignment of the ST to lineages resulted in 
thirty-seven being identified as unique and unrelated ST, while the remaining fifty-five were 
assigned to ten ST complexes (King et aL, 2002). In spite of the observed genetic diversity, three 
major clonai groups dominated the S. suis population: ST complexes l, 87 and 27 (King et aL, 
2002). Most striking was the ST 1 complex, containing 165 isolates, within which 141 isolates 
were found to represent ST 1 itself. While the ST 1 complex was strongly associated with isolates 
from septicemia, meningitis, and arthritis, the ST 87 and ST 27 complexes were found to contain 
significantly higher numbers of lung isolates (King et al., 2002). Hence, it was proposed that ST 1 
isolates may represent a highly successful clone which arose relatively recentlyand which has 
rapidly spread worldwide (King et al., 2002). Indeed, repeated recovery of such indistinguishable 
isolates from invasive disease in different countries clearly implies that ST 1 defines strains with 
an increased capacity to cause disease. This might reflect a variety of factors such ~s increased 
fitness, the possession of certain virulence factors or allelic variants thereof, and the selection of 
clones possessing particular antibiotic resistance profiles by therapeutic or prophylactic use 
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(King et al., 2002). These facts seemed to be confirmed by the recent analysis of whole genome 
data of strains belonging to ST 1 and ST 27 complexes (Chen et al., 2007; Ye et al., 2008). 
Interestingly, most of the S. suis human isolates recovered from outbreaks in China in 1998 and 
2005 (Yu et al., 2006) (see below) belonged to the ST complex 1 and while some of them were 
ST 1, the majority was clustered in the ST 7 (Ye et al., 2006) (Figure 2). These ST 7 isolates were 
more toxie to peripheral blood mononuclear cells than ST 1 strains (Ye et al., 2008; Ye et al., 
2006; Zheng et al., 2008) and represented a single-locus variant of ST 1 (Ye et aL, 2006). These 
findings strongly suggest that ST 7 is another emerging, highly virulent S. suis clone . 
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Figure 2. MLST snapshot of S. suis. 
The entire S. suis multilocus sequence type database is displayed as a single eBURST 
diagram. The six major sequence type (ST) complexes are each denoted by a number. 
Primary founders (dark green) are positioned centrally in the cluster, and subgroup founders 
are shown in light green, except ST 7, which is shown in orange to emphasize its importance. 
The area of each circle in the diagram corresponds to the abundance of the isolates of the ST 
in the input data. Adapted from (Ye et al., 2006). 
IVILST has also been used to assess twenty S. suis Thai isolates recovered from humans 
during 1998-2002 (Takamatsu et al., 2008c). Serotyping showed that nineteen isolates belonged 
to serotype 2, while the remaining strain was serotype 14. MLST analysis resolved the twenty 
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isolates into eight ST. Four isolates (including the serotype 14 strain) belonged to the ST 1 
complex. The remaining isolates (80 %) were assigned to the ST 27 complex. This was an 
interesting finding, since ail the ST 27 complex isolates were isolated from the blood or 
cerebrospinal fluid (CSF) of the patients, suggesting a high degree of invasiveness and 
questioning the proposed lower virulence potential of ST 27 strains (Takamatsu et aL, 2008c). Of 
note, before that study only four human clinical isolates had so far been reported to belong to 
the ST 27 complex (Takamatsu et aL, 2008c). Three were isolates from Canada that belonged to 
ST 25 (contained in the ST 27 complex) (King et aL, 2002) while the remaining one was from 
Japan and belonged to ST 28 (Chang et aL, 2006). Apart from these human Canadian isolates, 
the MLST profile of North American strains has not yet been evaluated~ 
1.2. Infection and transmission 
1.2.1. In pigs 
5. suis causes meningitis, meningo-encephalitis, septicemia, arthritis and endocarditis in 
swine. Pericarditis, polyserositis, rhinitis, abortion and bronchopneumonia are also possible 
outcomes of the 5. suis infection (Higgins and Gottschalk, 2006). The most consistent clinical 
signs reported for swine are neurological signs, including opisthotonus, lateral recumbency, 
paddling, convulsions, and ataxia. Sudden death without premonitory signs has also been 
reported (Reams et aL, 1994). In some cases, compatible meningo-encephalitic lesions are 
found during the histopathological analysis but isolation of 5. suis from the brain and meninges 
fails. In these cases, isolation of the pathogen from internai organs may confirm the etiology 
(Higgins and Gottschalk, 2006). In cases of septicemia, 5. suis is isolated from different organs 
such as the spleen, liver, heart, lung, and brain. Inflammatory lesions are found in these organs 
on histopathological examination, but without a typical pattern of lesions (Galina et aL, 1992). 
Suppurative or fibrinopurulent inflammation of the brain, heart, lungs and serosae are the most 
common histopathological observations (Higgins and Gottschalk, 2006). Infected pigs generally 
have clinical signs and lesions referable to either the respiratory system or to the CNS, but not 
both (Reams et aL, 1994). 5. suis is commonly isolated from the respiratory tract of pigs with 
respiratory disease. However, it is unclear whether the organism is related to pneumonia. 
Indeed, S. suis is often isolated in combination with other respiratory pathogens, such as 
Pasteurella multocida, Actinobacillus pleuropneumoniae, Haemophilus parasuis, Bordetella 
bronchiseptica and others (Galina et aL, 1992; Reams et aL, 1996), suggesting that, in these 
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cases, S. suis may act as an opportunistic pulmonary pathogen. This hypothesis is supported by 
the difficulty to reproduce respiratory clinical signs in experimentally infected animais. In fact 
pre-infection with B. bronchiseptica is needed for the induction of s. suis pneumonia during 
experimental trials (Vecht et aL, 1992). In contrast, in pigs with meningitis or 
meningoencephalitis, S. suis is considered a primary pathogen since it is the only bacterial 
species isolated from the brain of these pigs (Reams et aL, 1996). s. suis can affect pigs of ail 
ages. However, the disease is most common following weaning and mixing, and the majority of 
cases occur between 3 and 12 weeks of age. The incidence of the disease varies from herd to 
herd and also within a herd over a period of time. No seasonal incidence has been noted in pigs 
(Clements et aL, 1982; Clifton-Hadley, 1983). Different management practices and/or the 
presence of other pathogens have been suggested as predisposing factors (Dee et aL, 1993). In 
fact, S. suis infection is associated with stressful conditions such as weaning, mixing and/or 
moving animais, and with overcrowding and poor ventilation (Dee et aL, 1993). Concomitant 
viral infection such as Aujeszky's disease virus, porcine reproductive and respiratory syndrome 
(PRRS) virus and porcine circovirus (PCV) may predispose pigs to infection with S. suis (Feng et 
aL, 2001; Pallares et aL, 2002; Schmitt et aL, 2001). The main S. suis reservoirs are the tonsils 
and nasal cavities of clinically healthy carrier pigs. S. suis is also commonly recovered from the 
lungs, the vagina, and the prepuce of pigs (Clifton-Hadley, 1984; Tarradas et aL, 1994). 
( 
Therefore, healthy pigs carrying pathogenic S. suis strains can be considered the source of 
infection for naive herds. The organism is both vertically and horizontally transmitted. Piglets 
born from sows with uterine and/or vaginal infections are either infected or become infected at 
birth (Cloutier et aL, 2003). They also diversely and heterogeneously acquire the bacterium after 
birth due to close contact with the sow, her feces, and the surrounding environ ment (Higgins 
and Gottschalk, 2006). Infection of newborn piglets may also take place through the respiratory 
route from sow to piglets and among piglets (Berthelot-Herault et al., 2001b). It has been 
proposed that once a pig is infected with S. suis type 2, it may remain a carrier for life 
(Robertson and Blackmore, 1989b). Pigs may harbor different S. suis strains (even of different 
serotypes) in their nasal cavities and tonsils with no relationship with a specific pathological 
condition (Torremorell and Pijoan, 1998). Multiple S. suis serotypes from diseased animais 
within the same herd have also been isolated (Higgins and Gottschalk, 2006; Reams et aL, 1996). 
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1.2.2. In other animal species 
After the isolation of the serotypes 20 and 31 reference strains from diseased ca Ives, 
and capsular type 33 reference strain from a diseased lamb (Gottschalk et aL, 1989; Higgins et 
aL, 1995), S. suis isolates of different serotypes have been recovered from ruminants, horses, 
cats, dogs, birds and hamsters (Devriese et aL, 1992; Devriese et aL, 1993; Devriese and 
Haesebrouck, 1992; Devriese et aL, 1994; Devriese et aL, 1990; Higgins and Gottschalk, 2006; 
Hojo et aL, 2008; Hommez et aL, 1988; Salasia et aL, 1994). This suggests that S. suis may be 
pathogenic for more than one animal species. As described for pigs, tonsils seem to be the 
carriage site for s. suis in these animal species (Cruz Colque et aL, 1993; Devriese et aL, 1993; 
Segers et aL, 1998). In addition, s. suis has also been found in anal swabs of dogs (Devriese et 
aL, 1992). A possible role of these animal species as healthy carriers and as secondary reservoirs 
of s. suis should be further investigated. Finally, wild boars are a possible reservoir for s. suis 
and a major source of s. suis infection for hunters and poachers (Gottschalk et aL, 2007; Halaby 
et aL, 2000; Rosenkranz et aL, 2003). Indeed, the prevalence of s. suis serotype 2 among wild 
boars (11%) is similar to that among domestic pigs (14%) in Germany (Baums et aL, 2007). 
1.2.3. In humans 
S. suis infection has traditionally been considered a rare event in humans. However, it is 
increasingly becoming a public health concern in several Asian countries (Gottschalk et aL, 2007; 
Segura, 2008). Indeed, in addition to the deadly outbreaks in China in 1998 and 2005 (which are 
described below) (Yu et aL, 2006), S. suis has recently been described as the primary cause of 
adult meningitis in Vietnam as weil as the third most common cause of community-acquired 
bacterial meningitis in Hong Kong (Hui et aL, 2005; Ip et aL, 2007; Mai et aL, 2008) . Since the 
first description in Denmark in 1968 (perch et aL, 1968), human S. suis cases have been reported 
in several European (The Netherlands, Italy, Spain, United Kingdom, Belgium, Croatia, Austria, 
Sweden, Germany, Ireland, Hungary, France, Greece, Italy, Hungary, Portugal) and Asian 
countries (Japan, China, Hong Kong, Taiwan, Thailand, Singapore) as weil as in Canada, the 
United States (US), Australia, New Zealand, and Argentina (Gottschalk et aL, 2007; Taipa et aL, 
2008). An additional case originating in The Philippines has been reported as being a US case 
(Lee et aL, 2008). Most cases of s. suis infection have been attributed to serotype 2 strains 
(Gottschalk et aL, 2007). However, cases due to serotype 4 (Arends and Zanen, 1988), serotype 
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14 (Gottschalk et aL, 1989), and serotype 16 (Nghia et aL, 2008) have also been reported. Two 
human cases have been attributed to serotype 1, although the isolates from these cases were 
not confirmed with a serologie reaction using specifie antisera (Kopic et aL, 2002). 
ln humans, S. suis may produce purulent or non-purulent meningitis, endocarditis, 
cellulitis, peritonitis, rhabdomyolysis, arthritis, spondylodiscitis, pneumonia, uveitis and 
endophthalmitis (Arend et aL, 1995; Huang et aL, 2005; Walsh et aL, 1992). An association 
between S. suis infection and colon carcinoma has also been suggested (Voutsadakis, 2006). 
Deafness and/or vestibular dysfunction following S. suis meningitis is a remarkable consequence 
of the infection (Lutticken et al., 1986). For unknown reasons, the recorded incidence of 
deafness following infection caused by S. suis is higher than that reported for other meningitis-
causing bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus 
influenzae, and can reach 50% and 65% in Europe and Asia, respectively (Walsh et aL, 1992). 
Deafness, however, has never been reported in non-meningitis cases of S. suis human infection 
(Gottschalk et aL, 2007). The overall case fatality rate from S. suis infection reaches near 13% in 
Europe and 20% in Asia (Huang et aL, 2005). Interestingly, only three human cases of meningitis 
have been reported in North American (two in Canada and one in the US). These patients 
recovered from the infection with only minor sequelae, suggesting that North American strains 
of S. suis possess a lower virulence potential and/or that human infections caused by this 
organism are highly underdiagnosed in North America (Gottschalk et aL, 2007). 
The route of entry of the organism in humans might be small cuts in the skin, although 
in some cases wounds were not detected (Gottschalk et aL, 2007). Additionally, oral 
contamination has been proposed (Bahloul et aL, 2008). The bacterium may colonize the 
nasopharynx and the gastrointestinal tract, as suggested by diarrhea as a prodromal symptom 
(Fongcom et aL, 2001). The incubation period ranges from a few hours to two days (Fongcom et 
aL, 2001). Almost ail cases of human infection can be ascribed to close contact with pigs or to a 
high degree of exposure to unprocessed pork meat, which in certain markets, has been found to 
be contaminated with S. suis (Cheung et aL, 2008; Ip et aL, 2007). With few exceptions, most 
cases (in general adult males) are pig farmers, abattoirworkers, persons transporting pork, meat 
inspectors, butchers and veterinary practitioners (Huang et al:, 2005; Tang et aL, 2006; Walsh et 
aL, 1992). Surprisingly, in a recent report from Thailand, only three out of fort y-one cases had a 
history of occupational and behavioral exposure to pigs (Wangkaew et aL, 2006). In general, 
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high exposure to S. suis may lead to a colonization of the upper respiratory tract without 
producing any health consequences (Gottschalk et aL, 2007). Only in some cases, clinical disease 
may follow. Splenectomy, alcoholism and diabetes mellitus have been suggested as important 
predisposing factors for the development of serious S. suis disease (Gallagher, 2001; Huang et 
aL, 2005; Watkins et aL, 2001). Most studies showed that strains isolated from humans are 
phenotypically and genotypically similar to those recovered from swine within the same 
geographical region (Berthelot-Herault et aL, 2002; Chatellier et aL, 1999; Marois et aL, 2006; 
Pedroli et aL, 2003; Rehm et aL, 2007; Yu et aL, 2006). In addition, the virulence properties of 
strains isolated from pigs or humans appear to be similar (Gottschalk et aL, 2007). 
1.2.3.1. The 2005 human outbreak in China 
An important outbreak (215 cases with a total of thirty-nine deaths) of acute disease in 
humans caused by S. suis serotype 2 was reported in the Chinese province of Sichuan in 2005 
(Yu et aL, 2006)., ln 1998, another human outbreak had taken place in Jiangsu, China, with an 
outcome of fourteen deaths (Zhu et aL, 2000). These outbreaks were characterized by a high 
incidence of systemic disease with elevated rates of mortality and a proportionally low number 
of cases of meningitis. In the Sichuan outbreak, human cases followed a local swine outbreak 
that killed more than 600 pigs (Yu et aL, 2006). They were associated with backyard practices 
involving direct exposure to S. suis during the slaughtering process of pigs that had presented 
clinical signs of illness or had died from unknown causes (Yu et aL, 2006). It is also possible that 
infection resulted from consumption of affected pigs. In ail cases, there was no evidence of 
human to human infection. Chinese cases were linked at first to streptococcal toxic shock 
syndrome (STSS) based on the presence of the following criteria: sudden onset of high fever, 
diarrhea, hypotension, blood spots and petechia, clear erythematous blanching rash and 
dysfunction of multiple organs, such as acute respiratory distress syndrome, liver and heart 
failure, disseminated intravascular coagulation and acute renal failure (Tang et aL, 2006; Yu et 
aL, 2006). However, the presence of superantigens could not be demonstrated in the strains 
isolated during the Sichuan outbreak (Tang et aL,2006; Ye et aL, 2006; Yu et aL, 2006). The 2005 
isolates were ail S. suis serotype 2 (Tang et aL, 2006; Ye et aL, 2006; Yu et aL, 2006). Using RFLP, 
PFGE and ribotyping, strains involved in both the human and swine outbreaks were shown to 
belong to the same clone responsible for the 1998 outbreak in the Jiangsu province (Tang et aL, 
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2006; Ye et aL, 2006; Yu et aL, 2006). Using MLST, ail but two strains from the 2005 outbreak 
were classified as ST 7 (ST 1 complex) (Ye et aL, 2006). 
Although the Sichuan episode was the first very large human outbreak with many 
patients presenting severe acute symptoms, there is one previous report of an STSS caused by S. 
suis (Suankratay et aL, 2004).There are many other reports in the literature indicating severe 
cases of s. suis sepsis with shock, multiple organ failure, disseminated intravascular coagulation 
and associated purpura fulminans and death within hours (Arends et aL, 1984; Bungener and 
Bialek, 1989; Fongcom et aL, 2001; Francois et aL, 1998; Kopic et aL, 2002; Pedroli et aL, 2003; 
Strangmann et aL, 2002; van Jaarsveld et aL, 1990). Interestingly, ten out of fort y-one cases 
recently described in Thailand had sepsis syndrome in the absence of primary organ infection 
with a clinieal presentation similar to that described in the Chinese outbreak (Wangkaew et aL, 
2006). A serious case of septie shock caused by a non-serotype 2 strain (serotype 14) has also 
been described (Watkins et aL, 2001). However, studies performed with peripheral blood 
mononuclear cells and miee showed that a representative Chinese ST 7 strain was significantly 
more toxie and more mitogenie than the well-characterized ST 1 European virulent strain 31533 
(Ye et aL, 2006; Zheng et aL, 2008). The genomes of representative strains involved in the 
outbreak have recently been sequenced (see below) (Chen et aL, 2007; Yu et aL, 2006). 
1.3. Virulence factors of S. suis 
Most studies on S. suis virulence factors have been performed using serotype 2 strains. 
However, one of the problems in identifying virulence factors of s. suis is the lack of a clear 
definition of virulence for this pathogen, mainly as a result of the different parameters used to 
define whether a strain is virulent or avirulent (Higgins and Gottschalk, 2006). Indeed, the 
simple presence of some proposed virulence factors does not necessarily define the strain as 
virulent or not. Some strains possessing a specific virulence factor are avirulent, while other 
strains devoid of the same factor are still virulent. Indeed, the concept of virulence may differ 
between different groups, since experimental infection models for S. suis can be misleading. For 
example, different studies have designated field strains as virulent or avirulent based on: 1) the 
clinical condition of the animal from which the strain was isolated (clinically healthy or diseased 
animais); 2) on the presence of virulence-related proteins; or 3) different experimental infection 
models, using a) different strains of mice; or b) colostrum-deprived piglets (pre-infected or 
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otherwise with other microorganisms); or c) piglets of different ages from either convention al or 
specific-pathogen-free herds (Beaudoin et aL, 1992b; Berthelot-Herault et aL, 2001a; Galina et 
aL, 1994; Vecht et aL, 1997). In fact, results of experimental infections of pigs with 5. suis may 
depend, among other considerations, on the immunological status of the animais, the route of 
infection, the size of the inoculum and the presence of the organism as normal inhabitant of the 
upper respiratory tract of animais prior to the experimental infection (Higgins and Gottschalk, 
2006). In addition, important discrepancies exist in the literature regarding even the virulence of 
the same strain of 5. suis (Gottschalk et aL, 1999a; Staats et aL, 1999). Despite these 
considerations, several factors may be considered important or putatively involved in the 
pathogenesis of 5. suis infection. Table 1 summarizes the virulence factors of 5. suis proposed so 
far: 
Table 1. Characterized and proposed s. suis virulence factors 
Presence Virulence of Putative function in virulent Virulence factor (Verified/Putative) strains mutants in Reference 
only swine 
'. CPS biosynthesis: (Chabot-Roy et aL, 
CpsE/F Glycosyltransferases No Attenuated 2006; Charland et 
aL, 1998; Smith et (Verified) 
aL, 1999). 
CPS biosynthesis: 
Cps2C Chain length No. Attenuated a (Smith et aL, 1999; determination and Wilson et aL, 2007) 
export. (Putative) 
CPS biosynthesis: N-
NeuB Acetylneuraminic No Attenuated a (Smith et aL, 2000; 
acid synthetase. Wilson et aL, 2007) 
(Putative) 
(Allen et aL, 2001; 
Toxin (Hemolysin) Gottschalk et aL, Suilysin Variable b Unaffected 1995; Jacobs et aL, (Verified) 1994; Lun et aL, 
2003) 
Muramidase-released Unknown Variable b Unaffected (Smith et aL, 1992; protein (MRP) Smith et aL, 1996) 
Extracellular protein Unknown Variable b Unaffected (Smith et aL, 1993; factor (EF)· Smith et aL, 1996) 
Fibronectin- Adhesin: Fibronectin Partly (de Greeff et al., fibrinogen binding No 
protein (Fbps) binding (Verified) attenuated 2002b) 
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Adhesin: Fibronectin (Esgleas et aL, 
a-enolase and plaminogen No Not available 
binding (Verified) 2008) 
Glycera Idehyde-3- Adhesin: Plaminogen, porcine (Brassard et aL, phosphate 
tracheal rings. No Not available 2004; Jobin et aL, dehydrogenase 
(GAPDH) Plasmin acquisition .J 2004) (Verified) 
Adhesin P Hemagglutinin No Not available (Tikkanen et aL, (Verified) 1996) 
(Gottschalk et al., 
1990; Jacques et 
Pili Adhesin (Putative) No Not available aL, 1990; Vanier et 
aL, 2008a; Wang et 
aL, 2008) 
Resitance to iron- (Haataja et aL, 
Dpr mediated toxicity Unknown Not available 2002; Niven and 
(Verified) Ekins, 2001) 
Resitance to zinc-
Zur mediated toxicity Unknown Not tested (Feng et aL, 2008) 
(Verified) 
Superoxide dismutase Resitance to toxicity No Not available (Langford et aL, (Putative) 1991) 
Arginine deiminase Resitance to acidity (Gruening et al., No Not tested 2006; Winterhoff 
system (ADS) (Verified) 
et al., 2002) 
(Osaki et al., 2002; 
Sortase A Protein sorting No Controversia Vanier et al., 
1 results 2008b; Wang et al., 
2008) 
Serum opacity-like (Baums et al., 
factor (OFS) Serum opacification No Attenuated 2006; Takamatsu 
et al., 2008) 
Surface antigen one Unknown No Not available (Li et al., 2006) (Sao) 
Endo-beta-N- Degradation of host 
acetylglucosaminidas surface Unknown Attenuated a (Wilson et al., 
e D (Endo D) oligosaccharides 2007) (Putative) 
SsnA Nuclease Degradation of host No Not tested (Fontaine et aL, DNA (Verified) 2004) 
Degradation of 
Hyaluronate Iyase hyaluronic acid No Nottested (Allen et aL, 2004) 
(Verified) 
Modulation of host 
Phospholipase C arachidonic acid No Not available (Jobin et aL, 200S) 
production (Verified) 
Collagenase Collagen degradation Unknown Partly (Wilson et al., 
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(Putative) attenuated a 2007) 
Restriction (Wilson et al., Iin0523 e ndon uclease Unknown Attenuated a 
(Putative) 2007) 
SalK/SalR Two-component Yes C Attenuated (Li et aL, 2008) 
signal transduction 
Orphan Partly (de Greeff et al., RevS transcriptional No 
attenuated 2002a) 
regulator 
treR gene Transcriptional Unknown Attenuated a (Wilson et al., 
regulator (Putative) 2007) 
Gene homologous to Transcriptional Unknown Attenuated a (Wilson et al., S. mutans SMU_61 regulator (Putative) 2007) 
nadR gene Transcriptional Unknown Partly (Wilson et al., 
regulator (Putative) attenuated a 2007) 
Metabolism: (Okwumabua and Putative 38 KDa protein phosphoglycerate No Not available Chinnapapakkagari 
mutase 
,2005) 
Glutamate Metabolism: (Okwumabua et Glutamate No Not availab/e dehydrogenase (GDH) dehydrogenase al.,2001) 
Metabolism: Sucrase (Wilson et al., 
serR gene operon repressor Unknown Attenuated a 
(Putative) 2007) 
Metabolism: Sucrase (Wilson et al., gtfAgene phosphorylase Unknown Attenuated a 
(Putative) 2007) 
Metabolism: (Wilson et al., purAgene Adenylosuccinate Unknown Attenuated a 
synthetase (Putative) 2007) 
Metabolism: 
purD gene Phosphoribosylamin Unknown Attenuated a (Wilson et al., 
e-glycine ligase 2007) 
(Putative) 
Metabolism: (Wilson et al., 
serS gene Sucrose-6-phosphate Unknown Attenuated a 
hydrolase (Putative) 2007) 
Metabolism: Partly (Wilson et aL, 
edd gene Cytidine deiminase Unknown 
(Putative) attenuated a 2007) 
guaA gene Metabolism: GMP Unknown Unaffected a (Wilson et aL, 
synthase (Putative) 2007) 
Metabolism: Inosine 
guaS gene monophosphate Unknown Unaffected a (Wilson et aL, dehydrogenase 2007) 
(Putative) 
LuxS and Pfs Quorum sensing Unknown Not available (Han and Lu, 2008) 
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(Putative) 
Lipoprotein signal Lipoprotein export No Unaffected De Greeff et al., peptidase (Verified) 2003) 
Ipp gene Lipoprotein Unknown Partly (Wilson et al., (Putative) attenuated a 2007) 
Gene homologous to Lipoprotein Unknown Unaffected a (Wilson et al., GBSSAG0907 (Putative) 2007) 
Permease ABC-type multidrug Unknown Partly (Vanier et al., 
transporter attenuated a 2008a) 
Amino acid ABC (Wilson et al., Permease transporter Unknown Attenuated a 
(Putative) 2007) 
Mannose-specifie (Wilson et al., 
manN gene transport PTS 110 Unknown Attenuated a 2007) (Putative) 
44 kDa membrane Unknown No Nottested (Gottschalk et al., protein 1992) 
Gene homologous to Partly (Wilson et al., S. pneumoniae Unknown Unknown 
attenuated a 2007) 
spr1018 
glnH gene Unknown Unknown Partly (Wilson et al., 
attenuated a 2007) 
a Transposon mutant 
b Results vary depending on the geographical origin of the strains studied 
c Present only in Chinese isolates. 
1.3.1. "Classical" virulence factors 
Since 1993 and for several years, the capsular polysaccharide (CPS), the hemolysin 
known as suilysin and two virulence-related proteins known muramidase-released protein 
(MRP) and extracellular protein factor (EF) were considered the most important virulence factor 
candidates of S. suis (Gottschalk and Segura, 2000). Although the role played by some of these 
, 
factors in S. suis virulence is far from being clear, for historical reasons, in this thesis they are 
presented first and grouped under the title "classical virulence factors". 
1.3.1.1. The capsular polysaccharide (epS) 
S. suis possesses an integral, cel! associated capsule (Jacques et aL, 1990). The CPS of S. 
suis serotype 2 is composed of five different sugars: galactose (Gal), glucose (GIe), N-acetyl 
glucosamine (GleNAc), rhamnose (Rha) and N-acetyl neuraminic (sialic) acid (NeuNAc) (Elliott 
and Tai, 1978; Katsumi et al., 1996). A single cps locus comprising twenty-two genes has been 
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described whose genes putatively encode the capsular biosynthetic machinery (Smith et aL, 
1999a; Smith et aL, 2000). An actual role in capsule biosynthesis has been so far proved for the 
regulator gene cpsB, whose inactivation impairs but does not abolish the production of a 
capsule by S. suis, and for the glycosyltranferases genes cpsEF, whose simultaneous inactivation 
results in an· unencapsulated phenotype (Smith et aL, 1999a). For these latter two genes, 
however, individual mutants have not yet been contructed. Very recently, the absolute sugar 
composition of the serotype 2 capsule was reported to be Gal: 3, Glc: 1; GleNAc: 1; Rha: 1; and 
NeuNAc: 1 (Van Calsteren et aL, 2008). The fine structure of the capsule was also determined 
for the serotype 2 reference strain S735 (Figure 3). Methylation analysis indicated the presence 
of terminal Gal, 6-linked Gal, 3, 4-linked Gal, 4-linked GleNAc, and 3, 4-linked Rha. Sialic acid was 
found to be terminal. When the CPS was quantitatively desialylated by mild acid hydrolysis, the 
terminal Gal signal increased while the 6-linked decreased, indicating a branch ending with 
NeuNAc -(2-6)-Gal in the native S. suis CPS (Van Calsteren et aL, 2008). Further studies using 
mass spectrometry and nuclear magnetic resonance revealed a heptasaccharide repeating unit 
(Figure 3) (Van Calsteren et aL, 2008). Comparison with other streptococci showed that the s. 
suis CPS shares certain common structural elements with the CPS produced by Streptococcus 
agalactiae (Group B Streptococcus, GBS), namely the sequence NeuNAc-Gal-GlcNAc-Gal. 
However, no rhamnose is found in the latter species and sialic acid is 2-3-linked instead of 2-6 
linked (Chaffin et aL, 2005). 
a-D-NeupNAc-(2---76)-~-D-Galp-(1---74)-~-D-GlcpNAc 
1 
J, 
a-D-Galp 
1 
J, 
3 3 
---t4)-6-D-Glcp-(1---t4)-6-o-Galp-(1---t4)-6-L-Rhap-(1---t 
Figure 3. s. suis capsule structure as determined for serotype 2 reference strain 5735. 
See the text for details. Adapted from Van Calsteren et al, 2008. 
The capsule plays an important function in S. suis virulence. Early studies suggested that 
pathogenic strains were able to resist phagocytosis in porcine or human blood in the absence of 
anti-S. suis specifie antibodies (Higgins and Gottschalk, 2006). These observations were 
confirmed with the production of isogenic unencapsulated mutants from virulent S. suis type 2 
strains. The absence of CPS correlated with increased hydrophobicity and phagocytosis rates by 
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both murine and porcine macrophages (Charland et aL, 1998; Smith et aL, 1999a). A similar 
phenotype was observed for porcine neutrophils (Chabot-Roy et aL, 2006). In addition, 
unencapsulated mutants proved to be avirulent in murine and pig models of infection (Charland 
et aL, 1998; Smith et aL, 1999a). Isolates of 5. suis serotype 2 recovered from diseased animais 
have been shown to possess a thicker capsule than those isolated from clinically healthy animais 
(Gottschalk et aL, 1991a). An increase of capsular material thickness following in vivo growth has 
been noted for virulent but not for avirulent strains (Quessy et aL, 1994). On the other hand, 
other reports did not demonstrate any correlation between the thickness of capsular mate rial 
and virulence (Higgins and Gottschalk, 2006). As discussed above, serotype 2 is considered the 
most virulent 5. suis serotype. However, cells of serotype 2 reference strain are not covered bya 
thicker layer of CPS, compared to other serotypes (Higgins and Gottschalk, 2006). It has been 
suggested that the invasive ability of strains of this serotype may depend on the composition of 
the capsular material which contains sialic acid (Jacques et aL, 1990). This latter component has 
already been related to virulence for other bacterial agents of meningitis (Wessels et aL, 1989). 
However, it has been shown that virulent and avirulent strains possess a capsule of similar size 
with similar concentrations of sialic acid (Charland et aL, 1996). In fact, resistance to clearance 
from the bloodstream does not rely solely on the presence of the CPS, since a weil encapsulated 
avirulent strain is eliminated from the blood within forty-eight hours, whereas a virulent strain 
can persist in circulation in relatively high titers for more than five days (Higgins and Gottschalk, 
2006). Actually, and despite the fact that the CPS seems to be a major virulence factor, most 
avirulent strains are encapsulated (Higgins and Gottschalk, 2006). 
Capsular antigens are the basis for 5. suis serotyping. Different strains within a single 
serotype may vary in virulence and tropism, both within and among countries (Higgins and 
Gottschalk, 2006). There are also differences in pathogenicity among serotypes. Several 
serotypes are found mainly in healthy pigs, notably serotype 21 and to a lesser extent, serotypes 
17, 18, and 19 (Gottschalk et aL, 1991b). The correlation between capsular antigens and 
virulence was the basis for the suggestion that these antigens may play a role in the 
pathogenesis of the disease (Robertson et aL, 1991). However, this suggested correlation is not 
widely accepted since some strains belonging to less common serotypes have been associated 
with severe cases of infection (Higgins and Gottschalk, 2006). 
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1.3.1.2. Suilysin 
Hemolysin activity is associated with virulence and pathogenieity of several bacterial 
species. A 54-kDa hemolysin, also known as suilysin, was identified in S. suis serotype 2 (Jacobs 
et aL, 1994); subsequently a 65-kDa hemolysin from the same serotype was described 
(Gottschalk et aL, 1995). These two proteins were shown to be the same toxin and the 
molecular mass variation was in fact related to purification methods (Gottschalk et aL, 1995). 
Suilysin belongs to the family of toxins known as thiol-activated toxins or cholesterol-binding 
cytolytic toxins, which include streptolysin 0, listeriolysin, perfringolysin, and pneumolysin 
(Palmer, 2001). Suilysin shares several characteristies with these toxins, such as 1055 of activity 
upon oxidation, reactivation upon reduction, inhibition by small amounts of cholesterol, 
formation of transmembrane pores and a multi-hit mechanism of action (Gottschalk et aL, 
1995). Cholesterol in the membrane of eukaryotie cells is thought to be the toxin-binding site 
(Alouf et aL, 1991; Palmer, 2001). The gene encoding suilysin (sly) has been sequenced, 
revealing a relative high similarity with that encoding pneumolysin (Segers et aL, 1998). 
While several of these cytolysins have been shown to be determinants of bacterial 
pathogenicity, their biologieal raies may vary, as do the lifestyles of the bacteria producing them 
(Palmer, 2001). Despite the fact that a culture supernatant from a hemolysin-positive S. suis 
injected intraperitoneally failed to cause death in mice (Feder et aL, 1994), a role of suilysin in 
virulence has been suggested since it has been shown to be cytotoxic to endothelial, epithelial 
and phagocytie cells (Chabot-Roy et aL, 2006; Charland et aL, 2000; Lalonde et aL, 2000; Norton 
et aL, 1999; Segura and Gottschalk, 2002). In addition, purified suilysin has been shown to 
induce the release of several pro-inflammatory cytokines by human and porcine BMEC 
(Vadeboncoeur et aL, 2003; Vanier et aL, 2004; Vanier et aL, 2008b), by porcine peripheral 
blood cells (Segura et aL, 2006) and by pig alveolar macrophages (Lun et aL, 2003). Suilysin also 
induced the upregulation of adhesion molecules on human monocytes (AI-Numani et aL, 2003). 
Thus, this hemolysin may play an important role in bacterial dissemination and host 
inflammation, whieh is a hallmark of S. suis infections. Indeed, an allelic-replacement mutant of 
the sly gene was shown to be non-toxie for murine macrophages cells (Allen et aL, 2001). 
However, this mutant was still virulent in an intravenous pig model of infection, although total 
lesion scores were higher in pigs infected with the wild type (WT) strain than those infected with 
the mutant, suggesting that suilysin may have a raie in increasing the severity of clinical signs, 
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and allowing bacterial colonization of infected organs to reach higher levels (Allen et al., 2001). 
On the other hand, an independent group also reported the production of a sly knockout 
mutant (Lun et al., 2003). In vitro bactericidal tests showed that both the WT and suilysin 
mutant were resistant to bactericidal factors present in whole pig blood. Furthermore, in a 
model of experimental pig infection, at either a high or a low dose of inoculation, the mutant 
strain induced disease similarly to the WT strain. Ail diseased pigs showed fever, clinical signs 
and developed septicemia. S. suis was isolated from tissue samples such as brain, 
submandibular Iymph node, lung, spleen, liver, heart or joint (Lun et al., 2003). Thus, the results 
of this study confirm that suilysin is not a critical virulence factor· for S. suis serotype 2 infections. 
ln addition, while most Asian and European serotype 2 strains are suilysin-positive, the 
production of this protein has been observed in a limited number of Canadian and US serotype 2 
strains (Berthelot-Herault et al., 2000; Gottschalk et al., 1998; Gottschalk et al., 2007; 
Okwumabua et al., 1999; Segers et al., 1998; Vecht et al., 1992; Article V, Appendix). 
1.3.1.3. Muramidase-released protein (MRP) and extracellular prote in (EF) factor 
Two proteins, known as muramidase-released protein (MRP) and extracellular factor 
(EF) protein, originally associated with virulent strains, have been reported in serotype 2 strains 
(Vecht et al., 1991). MRP is a 136-kDa protein, present in the cell wall fraction and also released 
into the culture supernatant during bacterial growth, while EF is a 110-kDa protein only 
detected in culture supernatants (Vecht et al., 1991). Serotype 2 strains with the phenotype 
MRP+EF+ induced severe clinical signs of disease in pigs, but strains with the phenotype MRP-EF 
did not (Vecht et al., 1989; Vecht et al., 1992). Molecular weight variants of these two proteins 
were later described. Higher and lower molecular weight variants of MRP, respectively called 
IVIRP* (> 136-kDa) and MRps « 136-kDa), and higher molecular weight EF proteins, called EF* (> 
150-kDa) can be found in phenotypes such as MRP*EF, MRpsEF, MRpsEF+, IVIRP-EF*, and 
MRP+EF* (Gottschalk et al., 1998; Smith et al., 1993; Wisselink et al., 2000). Strains of the last 
phenotype were isolated at high frequency from human patients, but caused almost no clinical 
signs of disease in experimentally infected pigs (Smith et al., 1993). 
Although the epf gene encoding the EF protein has been cloned and characterized, 
sequence comparisons against data bases did not provide information with respect to the 
possible functions of the EF protein (Smith et al., 1993; Smith et al., 1992). MRP, encoded by the 
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mrp gene, is an LPXTG protein and is therefore expected to be anchored to the cell wall 
peptidoglycan by sortase A (Marraffini et aL, 2006). The N-terminal amino acid sequence of MRP 
shows some similarity with a fibronectin binding protein of Staphylococcus aureus (Smith et aL, 
1992). However, binding of MRP to human fibronectin could not be confirmed (Smith et aL, 
1992). 50 far, the function(s) of both EF and MRP proteins in the pathogenesis of the S. suis 
infection remain unclear. Isogenic mutants lacking one or both proteins appeared to be as 
virulent as the WT strain after experimental infection of newborn germfree piglets (Smith et aL, 
1996). It was suggested that the production of these proteins may only be coincidentally 
associated with virulence rather than being actual virulence factors. However, the association of 
MRP and EF with virulence is observed with strains from certain countries. For example, most 
North American serotype 2 strains isolated from acute cases of septicemia and/or meningitis (of 
either pig or human origin) are MRP and/or EF negative (Chatellier et aL, 1999; Gottschalk et aL, 
1998) Article V, Appendix). Interestingly, as demonstrated by (RAPD) analysis, the few IVIRP+EF+ 
North American strains were clustered in the same group as European strains which shared the 
same phenotype (Chatellier et aL, 1999). Thus, the absence of one or more of these proteins 
cannot necessarily be associated with a lack of virulence. Again, since the term virulence is 
poorly defined for S. suis, it is also possible that, under standardized conditions, MRP+ EF+ strains 
might be potentially more virulent than MRP- EF strains. 
1.3.2. Adhesins 
Successful establishment of a bacterial infection depends on efficient adhesion of the organism 
to the epithelium or other cells of the hosto It has been postulated that S. suis may use multiple 
adhesins to attach to host cells and that the types of adhesins expressed by a particular strain 
will determine its tissue specificity (Gottschalk and Segura, 2000). Expression of some adhesins 
may trigger internalization of the pathogen by host cells, which may enable S. suis to evade 
antibiotics and to facilitate the penetration of deeper tissues. They may also be important for 
the interactions of the pathogen with coinponents of the extracellular matrix (ECM) such as 
fibronectin, collagen, elastin, laminin and glycosaminoglycans (GAG), like heparin, and heparan 
sulfate (Marastoni et aL, 2008). Many of these proteins can serve as potential cell receptors for 
bacteria and participate in the infectious process (Nitsche-Schmitz et aL, 2007). Adhesins of 
proteinaceous nature have been proposed to mediate binding of S. suis to porcine BMEC as weil 
as to ECM proteins (Esgleas et aL, 2005; Vanier et aL, 2007). 50 far, however, only a few bon a 
27 
fide S. suis adhesins have been identified. These adhesins are presented in this section. Readers 
will notice that two enzymes clearly involved in basic metabolism but showing adhesive 
capacities are described in this section and not in the section dealing with basic metabolism. 
These two proteins are a-enolase and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
1.3.2.1. Fibronectin-fibrinogen binding protein (Ffbp) 
The complete gene encoding a 64-kDa fibronectin-fibrinogen binding protein (fbps gene) 
from S. suis serotype 2, previously identified by a promoter-trap system as being active in vivo 
(Smith et aL, 2001a), was cloned in Escherichia coli and sequenced (de Greeff et aL, 2002b). The 
occurrence of the gene in various serotypes was analyzed by hybridization studies. It was shown 
that the fbps gene was present in ail known serotypes of S. suis (except in serotypes 32 and 34, 
which are now considered to belong to the S. orisratti species, see above). The protein is 
expressed by strains of serotype 2. However, the expression of the 64 kDa protein by ail the 
serotypes of S. suis has not been studied. Therefore, it is possible that not ail serotype strains 
express the fibronectin-fibrinogen binding protein (de Greeff et aL, 2002b). The recombinant 
Ffbp overexpressed in E. coli was able to bind human fibronectin and fibrinogen (de Greeff et aL, 
2002b). However, an isogenic fbps mutant did not present diminished binding to human 
fibronectin in vitro (Esgleas et aL, 2005), suggesting either that this protein does not play a 
major role in fibronectin binding by S. suis or that redundancy for binding to this ECM protein 
exists. The levels of virulence of the WT and the fbps mutant strains were compared in a 
competitive infection model in young piglets (de Greeff et aL, 2002b). Organ cultures showed 
that fibronectin-fibrinogen binding protein was not required for colonization of the tonsils but 
that it played a role in the colonization of the specific organs involved in an S. suis infection (de 
Greeff et aL, 2002b). Therefore, the fbps mutant was considered partly attenuated. The 
induction of antibodies in piglets was verified upon infection, suggesting that this protein might 
be an interesting candidate for a subunit vaccine (de Greeff et aL, 2002b). 
1.3.2.2. Alpha-enolase 
A 60-kDa immunoglobulin G (lgG)-binding protein (previously reported as a 52-kDa 
protein) has been purified and characterized from S. suis serotype 2 strains (Benkirane et aL, 
1997; Serhir et aL, 1995). It was further observed that the S. suis IgG-binding protein was a 
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member of the heat-shock protein family Hsp60 (Benkirane et aL, 1997). This protein represents 
a common antigen found in ail the 5. suis serotypes including both virulent and avirulent strains 
of 5. suis serotype 2. The IgG-binding protein was found to be associated with the cell surface 
and was also released in a soluble form during bacterial growth. It reacted with a large variety of 
mammalian IgG, with chicken immunoglobulin Y and also with other plasma proteins (Serhir et 
aL, 1995). Recently, it has been reported that this IgG binding protein was indeed a 5. suis a-
enolase (Esgleas et aL, 2008). Gram positive a-enolases are cytoplasmic enzymes critical for 
sugar metabolism. However, they have been shown to be also surface located. At the surface, 
among other'contributions to virulence, a-enolases are able to drive binding of pathogens to 
plasminogen (pancholi, 2001; Pancholi and Fischetti, 1998). However, in an unprecedented 
finding for bacterial a-enolases, recombinant 5. suis a-enolase expressed in E. coli was also able 
to bind fibronectin (Esgleas et aL, 2008; Serhir et aL, 1995). Moreover, surface plasmon 
resonance demonstrated that 5. suis a-enolase binds fibronectin with high (Iow nanomolar) 
affinity (Esgleas et aL, 2008). Since abolition of anchoring to the ,5. suis cell wall of LPXTG 
proteins does not result in full impairment of fibronectin binding by this pathogen (Vanier et aL, 
2008c), it might be hypothesized that a-enolase-mediated binding to fibronectin may be an 
important factor for 5. suis virulence. In addition to fibronectin, and similar to previous reports 
in other Gram positive organisms, 5. suis a-enolase was shown to bind plasminogen in a Iysine-
dependent manner (Esgleas et aL, 2008). Using antisera directed against recombinant a-enolase 
and electron microscopy it was confirmed that the native protein is ubiquitously expressed by ail 
5. suis serotypes and located at the surface of the cell (Esgleas et aL, 2008) (Figure 4). Incubation 
of the pathogen with antibodies against a-enolase resulted in inhibition of the adhesion and 
invasion of porcine BMEC by 5. suis (Esgleas et aL, 2008), suggesting that this protein may 
contribute to the pathogenesis of 5. suis meningitis. Interestingly, 5. suis a-enolase has been 
shown to be expressed in vivo in pigs and highly immunogenic, as demonstrated by the use of 
an immunoproteomic approach (Geng et aL, 2008). 
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Figure 4. S. suis a-enolase is surface located. 
Immunogold electron microscopy detection of the 
surface location of S. suis a-enolase (indicated by the 
arrows) as revealed with rabbit anti-S. suis a-enolase 
IgG, followed by colloidal-gold-Iabelled anti-donkey 
IgG. Magnification: 45,OOOX. Adapted from Esgleas et 
al. 2008. 
1.3.2.3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
Using flow cytometry, binding of S. suis to albumin was observed for virulent as weil as 
for avirulent isolates. Western blot analysis revealed that a 39-kDa S. suis p'rotein was 
responsible, at least in part, for the binding activity (Quessy et aL, 1997). Sequencing of the 
protein showed a high N-terminal homology with Streptococcus pyogenes (Group A 
Streptococcus, GAS) glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The gene encoding 
the GAPDH of S. suis was then cloned and sequenced (Brassard et aL, 2004). The predicted 
translated 336 ami no acid protein exhibited 95% sequence identity with the GAPDH from GAS 
and from other streptococci (Brassard et aL, 2004). Recombinant S. suis GAPDH overexpressed 
in E. coli was found to possess functional GAPDH enzymatic activity after the purification. An 
adherence assay of S. suis to porcine tracheal rings showed a significant reduction in the 
adhesion of the pathogen to the rings when they were preincubated with recombinant GAPDH, 
suggesting the involvement of the protein in the first steps of the bacterial adhesion to host 
cells. In addition, at least in part, GAPDH was responsible for the binding of S. suis to 
plasminogen (Jobin et aL, 2004). The gapdh gene has been demonstrated in isolates of 
serotypes l, 9 and 7, in addition to serotype 2 (Wang and Lu, 2007). Recombinant GAPDH was 
used for adherence assays in another study (Wang and Lu, 2007). Data obtained demonstrated a 
significant reduction in adhesion of S. suis serotype 2 Chinese strains ta HEp-2 cells pre-
incubated with purified GAPDH compared to non pre-incubated controls (Wang and Lu, 2007). 
The contribution of GAPDH to the virulence of S. suis remains to be further characterized. 
Interestingly, it has been reported that S. suis highly upregulates the expression of this gene in 
30 
vivo in different porcine organs (Tan et al., 2008). In addition, GAPDH has been shown to be 
highly immunogenic in pigs (Zhang et al., 2008a). 
1.3.2.4. Hemagglutinins 
S. suis proteins that possess sugar-specific adherence activities for Gal, N-
acetylgalactosamine (GaINAc) and sialic acid have been identified by inhibition of 
hemagglutination based on differences in their binding specificity (Kurl et al., 1989). 
Subsequently, sialylated a-2-3 poly-N-acetyl-Iactosamine glycans were identified as the 
receptors of sialic acid-binding S. suis strains (Liukkonen et al., 1992) Moreover, it has been 
reported that galactose binding strains of S. suis recognize the disaccharide sequence galactosyl-
a-1-4-Gal present in trihexosylceramide (Haataja et al., 1993). This ceramide is expressed on the 
surface of erythrocytes as weil as in many pig and human tissues, and might represent the 
receptor for Gal binding strains in pig pharyngeal epithelium (Haataja et al., 1993). The bacterial 
adhesin responsible for binding to galactosyl-a-1-4-Gal has been identified (Tikkanen et al., 
1995). The purified adhesin of 18 kDa was subtyped in Po and P N variants. The Po variant was 
inhibited by Gal only, whereas P N was inhibited by both Gal and GaINAc. The two variants have 
the same N-terminal amino acid sequence (Tikkanen et al., 1995). An inverse relationship 
between the hemagglutination activity and expression of CPS has been described, suggesting 
that the capsule may influence adhesin accessibility (Tikkanen et al., 1996). Interestingly, the P 
adhesin was present in ail S. suis strains examined so far, was highly immunogenic and induced 
bactericidal activity in mice (Tikkanen et al., 1996). 
1.3.2.5. Pili 
Pilus-like structures were first detected in the Gram-positive species Corynebacterium 
renale (Yanagawa et al., 1968). Subsequently, pili were identified on the surface of other Gram-
positive bacteria and, most recently, in ail three of the principal streptococcal pathogens that 
cause invasive disease in humans: GAS, GBS and S. pneumoniae (Telford et al., 2006; Ton-That 
and Schneewind, 2004). Interestingly, ultrastructural studies of surface components of S. suis 
had revealed the presence of peritrichous, thin, and flexible fimbriae (Jacques et al., 1990). 
Morphologically similar fimbriae were observed on hemagglutinating as weil as on 
nonhemagglutinating strains of S. suis (Gottschalk et al., 1990). A general feature of the Gram-
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positive pili identified to date is that they comprise at least 2 protein subunits, each of which 
contains an LPXTG amino-acid motif (or a variant of this motif) (prott and Baker, 2009), which is 
the target of dedicated sortase enzymes of the class C (Dramsi et aL, 2005) that polymerize the 
pili. The polymerized pili are then attached to the cell wall peptidoglycan by the housekeeping 
sortase (Figure 5). In ail Gram-positive species examined so far, the genes encoding the pilus 
subunits are clustered together in the same genetic locus that also contains one or more class C 
sortases (Proft and Baker, 2009; Scott and Zahner, 2006; Telford et aL, 2006; Ton-That and 
Schneewind, 2004). 
Figure 5. Simplified model for 
pilus assembly in Gram-positive 
bacteria 
Following transport by the Sec 
system, the pilin subunits remain 
associated with the membrane by 
the hydrophobic tail of its LPXTG 
sorting signal. The dedicated 
sortase (Pip) polymerizes the 
growing pilus. Then, the 
housekeeping sortase (SrtA) 
covalently attaches the pilus to 
the peptidoglycan. Adapted from 
Scott and Zahner, 2006. 
Pioneering studies on 5. suis identified the housekeeping sortase SrtA as weil as four 
class C sortases, namely SrtB, SrtC, SrtD and SrtE, (Osaki et aL, 2002). More recently, the 
presence of clusters encoding putative pili in 5. suis has been described (Vanier et aL, 2008a; 
Wang et aL, 2008). However, actual formation of pili and a possible raie of these structures in 5. 
suis virulence remain to be verified. 
1.3.3. Metal uptake and resistance to toxicity 
1.3.3.1. Iron 
Iran is essential for the host and the pathogen, as both require this metal as a cofactor 
or as a prosthetic group for essential enzymes that are involved in many basic cellular functions 
32 
and metabolic pathways (Schaible and Kaufmann, 2004). Ferric iron (Fe3+) is almost insoluble 
under aerobic, aqueous and neutral pH conditions. Specialized iron-uptake systems have been 
identified in most bacterial species studied so far, and they allow microorganisms to compete 
for this vital element within mixed microbial communities in the environment. However, so far 
no su ch systems have been reported for S. suis. Moreover, it has been shown that S. suis 
requires manganese, but not iron, for growth (Niven et aL, 1999). Indeed, a complex medium 
supported normal growth of the reference strain of S. suis serotype 2 irrespective of the 
presence or absence of a high concentration (lIlM) of the iron chelating agent ethylenediamine 
di-o-hydroxyphenylacetic acid. Good growth was aJso obtained using a complex medium that 
had been treated with Chelex-l00 to reduce the iron content, but only if this medium was 
supplemented with manganese (Niven et al., 1999). Growth under iron-restriction (depletion of 
iron in the culture medium with nitrilotriacetic acid) was also studied using a highly virulent S. 
suis strain whicl1 was grown under aerobic and/or COrenriched conditions (Winterhoff et aL, 
2004). Decreased growth rates and down regulation of several proteins were observed, which 
could not be restored by addition of host iron sources such as ferritin, hemin, hemoglobin, 
lactoferrin or transferrin (Winterhoff et al., 2004). Accordingly, S. suis was not able to produce 
detectable amounts of siderophores. On the other hand, growth under iron-restricted 
conditions was fully restored by addition of Mn2+ (under both aerobic and CO2-enriched 
conditions) or Mg2+ (only at CO2-enriched conditions) (Winterhoff et aL, 2004). 
Although iron seems to be dispensable for S. suis growth, 18 unique iron-restriction-
induced (iri) genes were identified using a promoter trap approach (Smith et aL, 2001a). One of 
these genes was identified as the cpsA gene of S. suis which had been previously isolated as a 
part of the cps locus of S. suis serotype 2 and was proposed to play a role in the regulation of 
CPS biosynthesis (Smith et aL, 1999a). A second gene, iri-7, showed similarity to rpgG of 
Streptococcus mutons, which has been shown to be required for the biosynthesis of Rha-GJc 
polysaccharide (Yamashita et al., 1999), suggesting a role of the Ïfi-7 gene in capsule 
biosynthesis (Smith et al., 1999a). Furthermore, it was proposed that because the size of the 
capsule of S. suis is thicker after growth in vivo, where free iron is scarce, upregulated 
expression of cps2A and rpgG under iron starvation might be expected (Smith et al., 2001a). 
However, a clear link between iron starvation and capsule production remains to be verified. 
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Other genes upregulated upon iron starvation showed similarity to ABC transporters, response 
regulators, housekeeping genes and proteins of unknown function (Smith et al., 2001a). 
On the other hand, the readily soluble Fe2+ tends to react with oxygen to create reactive 
oxygen intermediates capable of damaging cellular macromolecules and affecting physiological 
processes. This is particularly important for streptococci, which are catalase negative, and 
therefore unable to break down the hydrogen peroxide they produce during aerobic growth. 
Indeed, streptococci are known to produce H20 1 up to mM-levels into their growth medium 
(Gibson et al., 2000). In addition to the endogenous production, streptococci face H20 2 from 
external sources such as activated leukocytes (Nathan and Shiloh, 2000). Toxicity of H20 2 is 
relatively weak, although it easily diffuses across biological membranes and oxidizes thiols. 
However, if reduced transition metal ions, especially iron, are present, H20 2 is nonenzymatically 
deaved into highly toxic hydroxyl free radicals by Fenton chemistry(H 20 2 + Fe2+ ~ .OH + OH" + 
Fe3+) (Schaible and Kaufmann, 2004). S. suis has been shown to be able to resist damage by 
reactive oxygen species (Niven et aL, 1999). The Dps family members constitute a distinct group 
of multimeric and ferritin-like iron binding proteins (up to 500 iron atoms/12-mer) that are 
widespread in eubacteria and archaea and implicated in oxidative stress resistance and 
virulence (Zhao et aL, 2002). Interestingly, almost in parallel, two teams identified S. suis Dpr, a 
protein member of the Dps family which was shown to be involved in Fe2+ sequestration 
(Haataja et aL, 2002; Niven and Ekins, 2001). Dpr was found to bind iron in the cytosol, an 
activity which proved crucial for Dpr to serve as a H20 2 resistance factor (Pulliainen et aL, 2003). 
ln further studies using dpr deletion mutants and ectopically expression of various recombinant 
Dpr mutant proteins, it was shown that Dpr plays a central role in S. suis iron homeostasis 
control (Haataja et al., 2002; Pulliainen et aL, 2005). By analyzing the effect of single amino acid 
substitutions on the iron incorporation of Dpr it was shown that Fe2+ atoms enter the negatively 
charged 12-mer cavlty of Dpr through four hydrophilic pores. Then, Fe1+ atoms are oxidized by 
molecular oxygen inside the 12-mer cavity at 12 identical ferroxidase centers and are 
subsequently stored as a Fe3+-mineral (Haataja et al., 2002; Pulliainen et al., 2005). 
1.3.3.2. Zinc 
Similar to other transition metals su ch as iron, manganese, and nickel, zinc is recognized 
as an essential trace element for ail living organisms, induding a variety of bacterial pathogens. 
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The Zn2+ ion plays critical roles in various cellular processes and physiologieal functions by either 
serving as a catalytic cofactor for numerous enzymes or maintaining the structure scaffold of 
metal-proteins (Panina et aL, 2003). However, an excess of Zn2+ is toxie to normal physiologieal 
processes because it can trigger the formation of hydroxyl radieals, resulting in severe damage 
to DNA, proteins, and lipids. Consequently, the intracellular level of Zn2+ must be precisely 
regulated to reach a dynamie balance. Bacteria have evolved complex machineries (such as 
effluxjinflux systems) to maintain zinc homeostasis (Panina et aL, 2003). The Zur C~inc !!ptake 
regulator) family members (of whieh the Zur protein is a representative) are involved in the 
precise control of Zn2+ homeostasis. A zur homologue designated as gene 310 was isolated from 
S. suis serotype 2 strain 05ZYH33, a highly invasive Chinese isolate (Feng et aL, 2008). 
Biochemical analysis revealed that the product of gene 310 formed a dimerie protein which 
carried zinc ions. An isogenie gene replacement mutant of gene 310 was obtained by 
homologous recombination. Physiological tests demonstrated that the 310 mutant is specifieally 
sensitive to Zn2+, while functional complementation of the 310 mutant restored its resistance, 
suggesting that 310 is a functional member of the Zur family (Feng et aL, 2008). Two-
dimensional electrophoresis indicated that nine proteins in the 310 mutant are overexpressed in 
comparison with those in the WT strain. DNA microarray analyses suggested that 121 genes in 
the 310 mutant are affected, of which seventy-two are upregulated and forty-nine are 
downregulated. The transcriptome of the parent strain grown under a high Zn2+ concentration 
also showed 117 differentially expressed genes, with seventy-one upregulated and fort y-six 
downregulated (Feng et aL, 2008). More than 70 % of the genes differentially expressed in the 
310 mutant were the same as those in the parent strain that were differentially expressed in 
response to high Zn2+ concentration, consistent with the notion that gene 310 is involved in zinc 
homeostasis (Feng et aL, 2008). Most genes affected by zur deletion encode putative 
proteinases, of whieh twenty-three were upregulated and twelve downregulated (Feng et aL, 
2008). They included some Zn2+-dependent members (e.g., NADPH, quinone reductase and 
lipase) involved in the basic metabolism of carbohydrates, nucleic acids, and fatty acids. There 
were more than 20 other genes which were influenced by 310 deletion (Feng et aL, 2008), 
including, interestingly, cpsC, a gene whieh is putatively involved in the production of CPS (Smith 
et aL, 1999a). 
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1.3.3.3. Superoxide dismutase 
Superoxide ions (02-) are a major antibacterial free radical in macrophage 
phagolysosomes. Thus, the capacity to secrete superoxide dismutases (SodA), which convert 
superoxide ions to molecular oxygen and H20 2, may be important in virulence. Indeed, these 
enzymes constitute one of the major defense mechanisms of cells against oxidative stress 
(poyart et al., 2001; Poyart et al., 1998). The presence of a gene (sodA), encoding SodA as weil as 
SOD activity was reported in 5. suis serotype 2 strains (Langford et al., 1991). However, no 
correlation was observed between specifie SOD activity and virulence. Therefore, it seems 
unlikely that the production of SodA by 5. suis can be related to resistance of phagocytic killing 
by virulent isolates (Langford et al., 1991). As stated above, it has been reported that 5. suis 
requires manganese, but not iron, for in vitro growth, and that manganese availability during 
growth affects the activity of the SodA enzyme (Niven et al., 1999). Further studies are'needed 
concerning the specific role of this enzyme in 5. suis virulence. 
1.3.3.4. Arginine deiminase system (ADS) 
The arginine deiminase system (ADS) catalyzes the conversion of arginine to ornithine, 
ammonia, and carbon dioxide. ADS are widely distributed among prokaryotic organisms and, in 
oral streptococci and GAS, they seem to provide protection against acidic stress by the 
production of ammonia (Casiano-Colon and Marquis, 1988; Degnan et al., 2000). Furthermore, it 
has been shown that the ADS of GAS is involved in adhesion to and invasion ofepithelial cells 
(Degnan et al., 2000). In 5. suis two cell wall-associated proteins with homologies to an ornithine 
carbamoyl-transferase (OCT) and the streptococcal acid glycoprotein (SAG) from GAS were 
identified (Winterhoff et al., 2002). Cloning and sequencing of the respective genes, adi5 (80.2% 
homology to the sagP gene), and oet5 (81.2% homology to an OCT of GAS) and their adjacent 
upstream and downstream regions revealed that they were clustered together with two 
addition al open reading frames (ORF). The first ORF (orf2) showed 59.8% homology to a gene 
encoding a hypothetical cytosolic protein. The second ORF (ek5) showed 70.1% homology to a 
carbamate kinase of GAS (Winterhoff et al., 2002). The genes adi5, oet5, and ek5 have been 
recently renamed areA, areB, and areC, respectively (Gruening et al., 2006) (Figure 6). 
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Figure 6. Genetic organization of s. suis ADS. 
The S. suis ADS comprises the arcABC, whereas genes flpS, areD, arcT, arch and argR (the 
last three genes are not shown in the figure) are located outside the operon. Adapted from 
Gruening et al, 2006. 
Additional putative ADS-associated genes were identified that, however, did not belong 
to the arcABC operon. These were the flpS gene upstream of the arcABC operon with homology 
to the flp transcription regulator of Streptococcus gordonii and the are D, arc T, arcH, and argR 
genes downstream of the arcABC operon with high homologies to a putative arginine-ornithine 
antiporter, a putative dipeptidase of S. gordonii, a putative ~-N-acetylhexosaminidase of S. 
pneumoniae, and a putative arginine repressor of S. gordonii, respectively (Gruening et aL, 
2006). It was demonstrated that the S. suis ADS is inducible by arginine and reduced O2 tension 
and that it is supject to carbon catabolite repression (Gruening et aL, 2006), Furthermore, the 
comparison of an arcA knockout mutant, in which expression of the three operon-encoded 
proteins was abolished, to the WT strain showed that the S. suis arcABC operon contributes to 
survival under acidic conditions (Gruening et aL, 2006). 
1.3.4. Cell wall-anchored proteins 
Many surface proteins which are covalently linked to the peptidoglycan of gram-positive 
bacteria have a consensus (-terminal motif LPXTG. In ail Gram positive bacteria examined so far, 
this sequence is cleaved, and the processed protein is attached to an amine group of a cross-
bridge in the peptidoglycan by enzymes known as housekeeping sortases (Marraffini et aL, 
2006). Several LPXTG proteins of S. suis have been involved in virulence of the organism. MRP 
(Smith et aL, 1992) and the putative Fbps (de Greeff et aL, 2002b) have been described above. 
For functional reasons, the LPXTG SsnA nuclease (Fontaine et aL, 2004) will be discussed in a 
different section. Other LPXTG proteins are presented in this section, along with the 
housekeeping sortase SrtA 
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1.3.4.1. Sortase A 
Using the reference strain of 5 suis serotype 2, genes encoding proteins that were 
homologous to sortases of other bacteria were identified (Osaki et al., 2002). One of these 
genes, designated srtA, was linked to gyrA, similarly to the housekeeping sortases genes of 
other streptococci (Igarashi, 2004; Lalioui et al., 2005; Osaki et al., 2002; Paterson and Mitchell, 
2004, 2006). The deduced amine acid sequence of SrtA showed 65% identity with that of s. 
gordonii. Isogenic mutants deficient for srtA were generated by allelic exchange (Osaki et al., 
2002). The protein fraction released from partially purified cell walls by digestion with N-
acetylmuramidase was profiled by two-dimensional gel electrophoresis. More than fifteen of 
the protein spots were missing in the profile of the srtA mutant compared with that of the 
parent strain, and this phenotype was completely complemented by srtA cloned from S. suis. 
Four genes encoding proteins corresponding to such spots were identified and sequenced. The 
deduced translational products of the four genes possessed the LPXTG motif in their C-terminal 
regions (Osaki et al., 2002). The ability of the srtA mutant to interact with host cells and ECM 
proteins, as weil as its virulence in a mouse infection model was further investigated. It was 
found that the mutant was impaired in its interactions with porcine BMEC compared to the WT 
strain (Va nier et al., 2008c). In addition, it showed lower level of adherence to plasma 
fibronectin, cellular fibronectin and collagen type 1 (Vanier et al., 2008c). However, disruption of 
srtA had little effect on the virulence of s. suis in a mouse intraperitoneal model of infection 
(Vanier et al., 2008c). Although these results suggest that surface proteins anchored by SrtA are 
required for a normal level of bacterial binding but not essential for s. suis virulence, different 
results were obtained in a parallel study carried out using an isogenie srtA mutant of the highly 
virulent Chinese strain 05ZYH33 (Wang et al., 2008). That study confirmed the role of SrtA in 
anchoring of cell wall proteins by using immunofluorescence analysis whieh revealed the 
absence in the cell wall of the LPXTG protein MRP. Different to the previous study, however, 
experimental infections of piglets showed that deletion of srtA attenuated the full virulence of 
the 05ZYH33 strain and impaired its colonizing potential in specifie organs. Furthermore, the 
srtA mutant displayed significant reduction in adherence to human cells (Hep-2 and human 
umbilical vein endothelial cells) (Wang et al., 2008). Again, interpretation of tl;!e results is 
hampered by absence of a consistent definition of virulence and the use of different animal 
models by these two studies. However, it should be taken into account that the virulence of the 
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serotype 2 reference strain is controversial (Higgins and Gottschalk, 2006) and that, although 
the mouse reproduces several aspects of the S. suis infection (Dominguez-Punaro et aL, 2007), 
the pig is the natural host of S. suis (Higgins and Gottschalk, 2006). 
1.3.4.2. Serum opacity-like factor (OFS) 
S. suis OFS presents structural homology to members of the microbial surface 
components recognizing adhesive matrix molecules (MSCRAMM) family and aC-terminai LPXTG 
sorting signal (Baums et aL, 2006). The N-terminal region of OFS was found to be homologous to 
the respective regions of fibronectin-binding protein A of Streptococcus dysgalactiae and the 
serum opacity factor of GAS. Similar to these two proteins, the N-terminal domain of OFS was 
able to opacify horse serum (Baums et aL, 2006). Heterologous expression of S. suis OFS in 
Lactococcus lactis demonstrated that a high level of expression of OFS is sufficient to provide 
surface-associated serum opacification activity. However, the C-terminal repetitive sequence 
elements of OFS differed significantly from the respective repeat regions of S. dysgalactiae 
fibronectin-binding protein and GAS serum opacity factor as weil as from the consensus 
sequence of the fibronectin-binding repeats of MSCRAMMs. Consistently, fibronectin binding by 
recombinant S. suis OFS was not detectable (Baums et aL, 2006). To investigate the functions of 
OFS in the pathogenesis of invasive S. suis diseases, piglets were experimentally infected with an 
isogenic mutant strain in which the ols gene had been inactivated by in-frame deletion. The 
mutant was severely attenuated in virulence but not in colonization (Baums et aL, 2006). The 
prevalence and variations of the ols gene among 108 S. suis isolates from diseased and healthy 
pigs, and human patients was further investigated. Regardless of their' origins, only 
approx.imately 30 % of the isolates possessed a functional OFS (Takamatsu et al., 2008b). These 
results show that despite the observed attenuation of the ols mutant, OFS contributes tothe 
virulence of a limited number of S. suis isolates. Indeed, PCR screening and sequencing analysis 
showed that there are four allelic variants of ols (designated types 1 to 4) (Takamatsu et aL, 
2008b). Type-l and type-2 ols genes encoded functional OFS, and sodium dodecyl sulfate (SDS) 
extracts of the isolates with type 1 and type 2 ols opacified horse serum. In contrast, type-3 ols 
contained a point mutation while type-4 ols genes were disrupted by an insertion of an insertion 
sequence element or had undergone other genetic rearrangements. Consistently, the SDS 
extracts and culture supernatants of the isolates with type 3 and type 4 ols did not show serum 
opacification activity (Takamatsu et aL, 2008b). 
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1.3.4.3. Surface antigen one (Sao) 
Surface antigen one (Sao) is a S. suis surface protein reacting with convalescent-phase sera from 
pigs clinieally infected by S. suis serotype 2 (Li et aL, 2006). Analysis of the predicted translated 
primary sequence showed that Sao presents a signal sequence for the Sec export machinery and 
an LPXTG anchor motif recognized by the housekeeping sortase SrtA. Interestingly, Sao did not 
share significant homology with other known Gram-positive proteins (Li et aL, 2006). Electron 
mieroscopy studies using a Sao-specific antiserum confirmed the surface location of the Sao 
protein on S. suis and the SrtA-mediated anchoring of Sao to peptidoglycan (Li et aL, 2006; 
Wang et aL, 2008). Three allelic variants of the saD gene, namely sao-5, sao-M, and sao-L, based 
on the different lengths of the genes (approximately 1.5, 1.7, and 2.0 kb, respectively) have 
been described. These differences were determined to be caused by heterogeneity in the 
number of occurrences of a (-terminal repeat. Two of these saD variants (M and L) were found 
among serotype 2 strains only (Feng et aL, 2007). Interestingly, Sao-specifie antibodies reacted 
with cell Iysates of twenty-eight out of thirty-three S. suis serotypes and twenty-five out of 
twenty-six serotype 2 isolates in immunoblots, suggesting the potential use of Sao for 
vaccination. Indeed, as described below in the vaccination section, immunization with Sao has 
been shown to provide protection ta' miee and pigs against lethal challenge with 5. suis serotype 
2 strains (Li et aL, 2007). So far, the contribution of Sao to the virulence of S. suis remains 
unknown. 
1.3.4.4. Endo-beta-N-acetylglucosaminidase D (Endo D) 
ln S. pneumoniae the LPXTG-containing, cell wall-anchored protein endo-beta-N-
acetylglucosaminidase D (Endo D) cleaves the di-N-acetylchitobiose structure in asparagine-
linked oligosaccharides. The enzyme, encoded by the endoD gene, generally acts on complex 
type oligosaccharides after removal of external sugars by neuraminidase, beta-galactosidase, 
and beta-N-acetylglucosaminidase (Muramatsu et aL, 2001). These enzymes are cell surface-
associated and contribute to pathogenesis of the bacteria by removing complex type 
oligosaccharides through their concerted actions. As an example, IgG becomes ineffieient in 
complement-mediated cell Iysis after removal of the oligosaccharides by exoglycosidases and 
Endo D (Koide et aL, 1977). Recently, an LPXTG-containing EndoD homologue of S. suis was 
identified by signature-tagged mutagenesis (STM) (Wilson et aL, 2007). Interestingly, the endoD 
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transposon mutant was found to be highly attenuated in both the murine and porcine models of 
infection. Future studies aimed at the characterization of this protein should shed light on the 
mechanisms by which EndoD contributes to the virulence of S. suis. 
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1.3.5. Cell wall-associated and secreted enzymes with degradative capacities 
1.3.5.1. Proteases 
Four major S. suis proteolytic activities (Arg-aminopeptidase, dipeptidyl peptidase (DPP) 
IV, chymotrypsin-like and caseinase) have been reported and partially characterized (Jobin and 
Grenier, 2003). These activities were produced not only by some S. suis type 2 strains, but also 
by the reference strains of serotypes l, 1/2 and 3. The Arg-aminopeptidase of S. suis (55 kDa) 
was found to be both extracellular and cell-associated. It was suggested that the presence of 
this proteolytic activity would be useful for the production of ATP and other essential metabolic 
precursors (Jobin and Grenier, 2003). The DPP IV activity was found in the culture supernatant . 
and on the cell surface of S. suis (Jobin and Grenier, 2003). This activity is also present in 
mammals on activated T cells (CD26) and in a soluble form in plasma where it regulates 
bioactiv~ peptides such as cytokines (Mentlein, 1999). However, further studies are needed to 
evaluate the potential contribution of DPP IV (70 KDa) to the virulence of S. suis. The cell-
associated caseinase activity was detected in ail tested strains of S. suis serotype 2. The protease 
responsible for this caseinase activity (putatively belonging to the class of metalloproteases) 
showed a molecular mass of 36 kDa and may have a nutritional function (Jobin and Grenier, 
2003). In addition, it has been suggested that it may participate in the maturation of bacterial 
protein precursors. However, further studies are needed to evaluate this hypothesis. The cell-
associated chymotrypsin-like activity, belonging to the class of serine proteases, was detected in 
European, but not in North American, strains of serotype 2 tested (Jobin and Grenier, 2003). It 
has been suggested that these proteases may help S. suis meet nutrîtional requirements, to 
neutralize the host defense system and to contribute to tissue invasion and destruction. Further 
analysis should be carried out to determine their physiological and pathological functions. On 
the other hand, preliminary results indicate that S. suis serotype 2 strains do not produce IgG or 
immunoglobulin A proteases, or other enzymes with fibrinogen and fibronectin degradation. In 
contrast, a putative collagenase was recently identified by a STM study (Wilson et al., 2007). 
Although its activity has not been not verified, a transposon mutant of this putative collagenase 
was impaired in its virulence in both the murine and porcine models of infection (Wilson et al., 
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2007). Further studies should be done to determine the prevalence of this putative collagenase 
among serotype 2 strains, as weil as its actual role in collagen degradation. 
1.3.5.2. SsnA Nuclease 
A nuclease (SsnA) was identified in the virulent S. suis serotype 2 isolate SX332 and 
subsequently in each of the reference strains of serotypes 1 through 9 (Fontaine et aL, 2004). 
Screening of 258 porcine clinical isolates from surface (nasal mucosa or palatine tonsil) or 
internai (joints, brain or other internai organs) locations revealed a significant relationship 
between expressio~ of nuclease and isolation from an internai site. The gene ssnA (3,126 bp), 
was identified and analysis of the predicted translated SsnA sequence revealed a 35-amino-acid 
Sec signal sequenée, a 22-amino acid DNA-binding domain, and a typical gram-positive LPXTG 
cell wall sorting motif (Fontaine et aL, 2004). The protein was cloned and characterized. A 
requirement of Ca2+ and Mg2+ for SsnA activity was determined, and the substrate specificity 
was found to be for single- and double-stranded linear DNA (Fontaine et aL, 2004). RT-PCR 
experiments revealed that ssnA is expressed throughout ail stages of s. suis growth. Western 
blots with porcine anti-S. suis immune sera against a recombinant, truncated SsnA derivative 
(rSsnADelta) confirmed that SsnA is expressed in vivo. Furthermore, anti-rSsnA antibodies were 
sufficient to neutralize SsnA activity in vitro. Analyses of subcellular fractions of SX332 and 
insertional ssnA mutants on DNA-containing polyacrylamide gels and by Western blotting 
suggest that SsnA is cell wall located, consistently with a proposed SrtA-mediated anchoringto 
the cell wall (Fontaine et aL, 2004). The actual contribution of this DNase to the virulence of s. 
suis remains to be verified. 
1.3.5.3. Hyaluronate lyase 
Hyaluronic acid is a linear GAG consisting of a polymer of the ~-1-4 linked GleNAc and 
glucuronic acid disaccharide. It is present in many mammalian tissues, including synovial fluid, 
cartilage, skin and brain, and forms a major part of the ECM. Hyaluronate Iyase, which catalyzes 
the degradation of hyaluronic acid has been described in several pathogenic streptococcal 
species (Hynes and Walton, 2000). The gene hyl encoding a putative hyaluronate Iyase from S. 
suis was inactivated in a serotype 7 strain (Allen et aL, 2004). Using that mutant it was shown 
that hyaluronate Iyase activity is required for s. suis to use the hyaluronic acid polymer as a 
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carbon source. Interestingly, hyaluronate Iyase activity was not found in many S. suis strains 
isolated from diseased animais (Allen et al., 2004). Further work showed that although the gene 
hyl was present in 309 bona fide S. suis isolates representing diverse serotypes, geographic 
sources, and clinical backgrounds, the corresponding enzyme activity was detected in fewer 
than 30% of the isolates (King et al., 2004). In most cases, lack of enzymatic activity correlated 
with the presence of mutations (either sequence duplications or point mutations) within the hyl 
gene that resulted in a truncated polypeptide (King et al., 2004). The absence of hyaluronate 
Iyase activity in a large majority of isolates from classic S. suis invasive disease (King et al., 2004), 
suggests that this protein is probably not a crucial virulence factor. 
1.3.5.4. Phospholipase C 
Phospholipase C hydrolyzes phosphatidylcholine into choline phosphate and 
diacylglycerol, a messenger that activates protein kinase C, an important metabolite of 
arachidonic acid production. Since arachidonic acid is the main precursor of prostaglandins, 
small lipids that enhance BBB vascular permeability and nitric oxide production (Wakelam, 
1998), this activity may be of importance for S. suis to achieve tissue destruction and cell 
migration. A protein with phospholipase C activity has recently been identified in S. suis and 
shown to be active during the interactions of the bacterium with human BMEC (Jobin et al., 
2004). However, the data suggested that phospholipase C required the previous action of 
suilysin. Indeed, even though a mutant lacking suilysin activity still possessed phospholipase C 
activity against 14C-labelled phosphatidylcholine, it failed to induce the release of arachidonic 
acid from human BMEC. The phospholipase activity was found both on the surface of S. suis and 
in the culture supernatant (Jobin et al., 2004). Additional studies are required to better 
characterize the phospholipase C produced by S. suis. 
1.3.6. Signal transduction 
1.3.6.1. Response regulator RevS 
The first described response regulator of S. suis serotype 2 was designated RevS (de 
Greeff et al., 2002a). Since no histidine kinase was found in the vicinity of the gene encoding this 
protein (revS), RevS was considered to be an orphan response regulator. The revS gene had 
previously been shown to be induced in vivo by the use of a promoter trap system (Smith et al., 
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2001a). An isogenic knock-out revS mutant was generated and shown to be attenuated in 
colonization of specifie organs in a competitive assay in piglets, indicating that revS plays a role 
in the pathogenesis of S. suis infections (de Greeff et aL, 2002a). When the protein expression 
profiles of various fractions of the virulent parent strain 10 and the revS mutant strain were 
analyzed, the expression of virulence markers of S. suis such as IVIRP, EF and suilysin was not 
different between the parent and the mutant strains. However, one protein in the protoplast 
fraction, with unknown function was shown to be repressed by revS in the exponential growth 
phase of the mutant (de Greeff et aL, 2002a). 
1.3.6.2. The two-component signal transduction system SalKjSalR 
The 89K island is a newly predicted pathogenieity island (PAl) whieh is specifie to 
Chinese epidemie strains isolated from the two S. suis huma_n outbreaks in China (Chen et aL, 
2007). Further bioinformatics analysis revealed a unique two-component signal transduction 
system located in the 89K PAl, whieh is orthologous to the SalKjSalRregulatory system of 
Streptococcus solivorius (Li et aL, 2008). Suggesting that SaIK/SaIR is required for the full 
virulence of Chinese isolates of highly pathogenic S. suis serotype 2, inactivation by allelic 
exchange of so/KIR eliminated the lethality of the strains in an experimental porcine model of 
infection (Li et aL, 2008). Functional complementation of so/KR into the isogenic mutant 
restored its full pathogenicity. Further characterization of the mutant by means of colonization 
experiments showed that the so/KIR mutant failed to colonize susceptible tissuesjorgans of 
piglets. Moreover, bactericidal assays demonstrated that resistance of the mutant to neutrophil-
mediated killing was greatly decreased. Consistent with its putative role as global regulator of 
virulence', expression microarray analysis exhibited a transcription profile alteration of twenty-
six genes that were downregulated in the so/KIR mutant (Li et aL, 2008). 
1.3.7. Proteins involved in basic metabolism 
Some proposed S. suis virulence factors are enzyme involved in basic metabolism. Two of these 
enzymes (a-enolase and GAPDH) which clearly belong to this group have been presented above 
in the adhesin section. By the use of high-throughput technologies, other proteins involved in 
metabolism have been recently shown to contrinute to the S. suis virulence. In this section we 
present two other metabolic proteins considered to be virulence factor candidates. 
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1.3.7.1. Putative phosphoglycerate mutase(38 KDa protein) 
A S. suis genomic DNA library was constructed and screened with a polyclonal antibody 
raised against the whole-cell proteins of S. suis serotype 2 (Okwumabua and Chinnapapakkagari, 
2005). A clone that reacted with the antibody was characterized. Analysis revealed that the gene 
encoding the reactive protein was localized within a 2.0-kbp EcoRI DNA fragment. The 
nucleotide sequence contained an ORF that encoded a polypeptide of 445 ami no acid residues 
with a calculated molecular mass of 46.4 kDa. However, the recombinant protein exhibited an 
electrophoretic mobility of approximately 38 kDa. At the time it was first reported, the amino 
acid level of the deduced primary sequence showed homology with sequences of unknown 
function from S. pneumonioe (89%) and S. mutons (86%) (Okwumabua and Chinnapapakkagari, 
2005). The protein was later annotated as a putative phosphoglycerase mutase (GenBank 
Accession AF389083). Southern hybridization analysis revealed the presence of the gene in ail 
the S. suis serotypes but 20, 26, 32, and 33. Consistently, Western-blot showed that these 
positive serotypes expressed the protein. Subcellular fractioning revealed that the protein was 
present in the surface and cell wall extracts. (Okwumabua and Chinnapapakkagari, 2005). The 
recombinant protein was reactive with serum from pigs experimentally infected with virulent 
strains of S. suis serotype 2, suggesting that the protein is immunogenic and may serve as an 
antigen of diagnostic importance for the detection of S. suis infections. In addition, pigs 
immunized with the recombinant 38-kDa protein mounted antibody responses to the protein 
and were completely protected against challenge with a homologous strain of serotype 2. The 
functional role of this protein with respect to pathogenesis remains to be determined, as does 
the potential protective immunity it may confer against a heterologous challenge. 
1.3.7.2. Glutamate dehydrogenase (GDH) 
Screening of the same S. suis genomic DNA library described above identified an 
additional 45-kDa protein. Restriction analysis showed that the gene encoding the 45-kDa 
protein was present on a 1.6-kb Dral region on the cloned chromosomal fragment. The 
nucleotide sequence contained an ORF that encoded a polypeptide of 448 amino acid residues 
with a calculated molecular mass of 48.8 kDa, in close agreement with the size observed on 
Western blots. Database searches revealed that the derived ami no acid sequence was 
homologous to the sequence of GDH proteins isolated from vario'us sources. Because of these 
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similarities, the protein was designated the GDH of S. suis (Okwumabua et aL, 2001). Activity 
staining showed that the S. suis GDH activity is NAD(P)H dependent but, unlike the NAD(P)H-
dependent GDH from various other sources, that of S. suis utilizes L-glutamate rather than 
alpha-ketoglutarate as the substrate (Okwumabua et aL, 2001). Hybridization studies showed 
that the gene is conserved among serotype 2 strains. The native protein was found to be surface 
exposed by using immunogold labeling and electron microscopy. Antiserum raised against the 
purified recombinant protein was reactive with a protein of the same molecular size as the 
native protein in S. suis strains, suggesting expression of the gene in ail of the isolates and 
antigenic conservation of the protein (Okwumabua et aL, 2001). As for the 38 KDa protein 
described above, recombinant GDH was reactive with serum from pigs experimentally infected 
with a virulent strain of S. suis serotype 2, suggesting that the protein might also serve as an 
antigen of diagnostic importance (Okwumabua et aL, 2001). 
1.3.8. Proteins putatively involved in quorum sensing 
Quorum sensing is a process by which bacteria communicate with diffusible chemical 
signaling molecules called autoinducers (AI). The autoinducer-2 signal (AI-2) mediates 
interspecies communication among Gram-positive and Gram-negative bacteria (Kolenbrander et 
aL, 2002). AI-2 is derived from S-adenosylmethionine (SAM), which acts as a methyl donor to 
yield S-adenosylhomocysteine (SAH). The adenine base of SAH is removed by the Pfs enzyme to 
produce S-ribosylhomocysteine (SRH). SRH is the substrate of LuxS and is cleaved by the enzyme 
to generate homocysteine and 4, 5-dihydroxy-2, 3-pentanedione (DPD). The unstable DPD 
spontaneously converts into AI-2 (Schauder et aL, 2001). Recently, it was shown that cell-free 
culture supernatants of S. suis induced luminescence of Vibrio harveyi BB170, indicating that AI-
2-like molecules were produced by S. suis (Han and Lu, 2008). AI-2 activity peaked in the late 
exponential phase, and NaCI or Glc increased the production of AI-2. The maximum induction 
took place during the late exponential growth phase and sharply dropped in the stationary 
phase, suggesting that the activity of the molecule is density dependent in S. suis (Han and Lu, 
2008). Homologues of luxS and pfs, encoding these two enzymes, were identified in the S. suis 
genome (Han and Lu, 2008). S. suis luxS was able to complement the luxS-negative phenotype of 
E. coli DH5-a. Q-RT-PCR showed that the level of transcription of pfs, but not that of luxS was 
highly correlated with the level of AI-2 production. Although the direct link between production 
of AI-2 and biofilm formation has recently been questioned (Hardie and Heurlier, 2008), further 
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studies on the production of this signaling molecule may help understand the recently reported 
ability of certain strains of S. suis to produce biofilms (Grenier et al., 2007) . 
1.3.9. Lipoproteins 
ln Gram positive organisms several roles have been attributed to lipoproteins such as 
participation in antibiotic resistance, ABC transporter systems, adhesion and protein export 
(Sutcliffe and Harrington, 2002). The abun~ance of putative lipoproteins in typical bacterial 
genomes suggests that this class of proteins is of considerable physiological significance. Indeed, 
in streptococci other than S. suis, several lipoproteins have been shown to be involved in 
virulence (Brown et al., 2001). Lipoprotein signal peptidase (Lsp, encoded by the Isp gene) is 
involved in the removal of the signal peptide from diacylglyceride-modified prolipQproteins 
(Sankaran and Wu, 1994). While Lsp of Baeil/us subtilis is not necessary for growth and viability, 
mutants disrupted in Isp have been shown to be attenuated in STM studies of Staphylococcus 
aureus (Mei et aL, 1997). In S. suis the Isp gene was found to be part of a putative operon 
containing three overlapping genes (De Greeff et aL, 2003). Besides Isp, this putative operon 
contained a gene encoding a protein that is predicted to belong to the LysR family of 
transcriptional regulators and a gene encoding a putative pseudouridine synthase. Interestingly, 
the LysR family transcriptional regulator had been previously identified as being in vivo 
regulated by the use of a promoter trap system (Smith et aL, 2001a). To study the role of Lsp in 
the pathogenesis of S. suis, an isogenic knockout mutant of Isp was constructed in the S. suis 
serotype 2 strain 10 (De Greeff et al., 2003). Comparison of the lipoprotein profiles for strain 10 
and the Isp mutant indicated that multiple radiolabelled bands accumulated in a higher 
molecular mass form, consistent with a failure to rem ove signal peptides from prolipoproteins. 
This observation was confirmed by Western blot analysis, which demonstrated the accumulation 
in the mutant strain of the prolipoprotein form of the S. suis pneumococcal surface adhesin A 
(PsaA) homologue (De Greeff et al., 2003). PsaA is a surface-exposed common 37-KDa multi-
functional lipoprotein detected in ail known serotypes of S. pneumoniae, which belongs to the 
ABC-type transport protein complex that transports Mn2+ (Rajam et al., 2008). The virulence of 
the S. suis Isp mutant was tested in an experimental infection model in piglets in a competitive 
co-colonization assay in piglets. The data showed that the Isp mutant strain was capable of 
colonizing both the tonsil and the organs specific for an S. suis infection as efficiently as the WT 
strain. This means that both strains are equally virulent, and that the knockout mutant of Isp is 
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not attenuated in vivo. Thus, this phenotype contrasts to that of other Gram positive pathogens 
defective in enzymes necessary for lipoprotein biosynthesis (Mei et aL, 1997). This could suggest 
that lipoproteins do not play a role in the pathogenicity of S. suis but may also indicate that 
lipoproteins can be processed via an alternative route, independently of Lsp. Interestingly, data 
indicated that the S. suis PsaA homologue was not processed by an alternative signal peptidase 
(De Greeff et aL, 2003). Further research is necessary to determine whether lipoproteins can be 
alternatively processed in S. suis. Interestingly, a recent STM study identified two genes 
encoding lipoproteins as being essential for virulence of S. suis in swine (Wilson et aL, 2007). The 
first lipoprotein was homologous to Lpp of S. mutons and the second to GBS SAG0907. However, 
upon reevaluation of their virulence in pigs, mutants for these putative lipoprotein factors were 
found to be only partially attenuated (Ipp mutant) or unaffected in virulence (SAG0907 mutant) 
(Wilson et aL, 2007). 
1.3.10. Proteins with unknown function 
1.3.10.1. 44 kDa membrane protein 
A 44-kDa cell wall protein of unknown function has been proposed as a virulence factor 
as weil as an important immunogen of S. suis serotype 2 after two avirulent mutants (M2 and 
M42) were produced from a highly virulent_ S. suis strain (Gottschalk et aL, 1992). SDS-
polyacrylamide gel electrophoresis (PAGE) of lysozyme treated cells demonstrated that the 44-
kDa native protein, present in the parent strain, was absent in both mutants. Immunoblotting 
using rabbit whole cell homologous antisera revealed that the protein was strongly 
immunogenic. However, the actual contribution of this protein has not been further verified. 
Indeed, absence of virulence of these mutants may result from other genetic events that may 
have taken place during the procedure for isolation. In fact, mutant M2 was obtained after seriai 
subcultures of the parent strain in the presence of rabbit anti-capsular type 2 serum and no 
longer possessed the type-specific capsular antigen (Gottschalk et aL, 1992). On the other hand, 
mutant M42, obtained after passages of the parent strain at 42°(, remained encapsulated 
(Gottschalk et aL, 1992) but it is not known whether factors other than the 44 kDa protein were 
also lost in this mutant in comparison to the WT strain. Despite the presence of antibodies 
against the capsule, antiserum prepared against M42 only partially protected mice against a 
challenge with the parent strain (Gottschalk et aL, 1992). 
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1.3.10.2. Gain of virulence by complementation 
A genomic library of the S. suis highly pathogenic strain (strain 10) was constructed and 
introduced into the less pathogenic strains S735 and 24 (Smith et aL, 2001b). After infection of 
the library into· young piglets pathogenic clones were selected. One specifie transformant 
containing a 3-kb fragment of strain 10 appeared to be dominantly enriched in diseased pigs. 
Infection of piglets with the less pathogenic strains complemented with this fragment increased 
the virulence of these strains considerably (Smith et aL, 2001b). In contrast, complementation 
with the corresponding fragment of a weakly pathogenic strain had only minor effects on 
virulence. Nucleotide sequence analysis of the selected fragment of the highly pathogenic strain 
revealed the presence of two potential ORFs, an accessory gene regulator B and a putative 
folylpolyglutamate synthetase, both of which were found to be mutated in the corresponding 
fragment of the less pathogenic strain (Smith et aL, 2001b). These data strongly suggest that 
thesegenes are important for the virulence of S. suis. However, the actual contribution of each 
of these genes must be assessed by inactivation of the corresponding genes. 
1.3.11. Global approaches for the identification of virulence factors 
1.3.11.1. Whole genome sequencing 
Availability of genome sequence data for S. suis is relatively novel and ail the sequenced 
isolates belong to serotype 2. The whole genome sequences of three virulent strains isolated 
from human cases of toxic shock-like syndrome, Chinese MLST ST 7 strains 98HAH12 and 
05ZYH33 and Chinese MLST ST 1 strain GZl have recently been published (Chen et aL, 2007; Ye 
et aL, 2008). A partial sequence for a Chinese avirulent strain has also been released (Chen et 
aL, 2007). Sequencing of the European MLST ST 1 strain Pl/7 (meningitis, pig) (King et aL, 2002) 
is finished, but data has not yet been published. Sequencing of the Chinese MLST ST 7 strain 
SC84 (human) (Ye et aL, 2006) and the Vietnamese MLST ST 1 strain BM407 (human) (Mai et aL, 
2008) are unfinished. These latter 3 genomes are available at the Sanger Institute 
(http://www.sanger.ac.uk/Projects/S suis/). Finally, the Canadian IVILST ST 25 strain 89-1591 
(meningitis, pig) (King et aL, 2002) sequencing project is at the stage of gap closing at the DOE 
Joint Genome Institute (http://genome.jgi-psf.org/draftmicrobes/strsu/strsu.home.html). The 
genomes of the two Chinese virulent strains 98HAH12 and 05ZYH33 are 2,095,720 bp and 
2,096,331 bp in length and have 2,191 and 2,194 predicted coding sequences (CDS), respectively 
Î 
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(Chen et aL, 2007). These genomes have been compared to that of the European strain Pl/7. A 
high degree of conservation was noted in the genome organizations and gene contents. Ali 3 
genomes presented strong strand-biased gene distribution with a preference of genes to reside 
on the leading strand. Comparison showed a core genome of almost 1,900 common genes, 
while the number of strain-specific genes varied from fort y-four to 101. Single nucleotide 
polymorphism (SNP) analysis of the homologous genes from the genomes of 05ZYH33 and 
98HAH12 showed 744 synonymous substitutions (Ks) and 1,971 nonsynonymous substitutions 
(Ka). Similarly, 433 Ks and 1,194 Ka in both 98HAH12 and Pl/7 were found. Both Ka/Ks ratios do 
not seem to be significantly different from each other, suggesting a similar intensity of selective 
pressure among the three serotype 2 strains (Chen et aL, 2007). Nevertheless, the exact 
contribution of point mutations to the physiological activities and pathogenicity must be 
experimentally assessed. Several general pathogenicity-related pathways were identified at the 
genomic level besides those documented as virulence-associated factors, such as the above 
mentioned CPS, suilysin, EF, MRP and GDH. In detail, there werè fifteen groups of putative two 
component signal transduction systems in strains 98HAH12 and 05ZYH33 while there were only 
thirteen in European strain Pl/7. More than ten type two secretion systems were found in the 
genomes of strains 98HAH12, 05ZYH33 and Pl/7. Interestingly, strains 98HAH12 and 05ZYH33 
separately harbor four and three components from type four secretion systems, respectively, 
while strain Pl/7 lacks them (Chen et aL, 2007). Via the genome-wide display of G+C contents, 
six regions with abnormal G+C contents, varying in length from 15 kb to 40 kb were identified. 
Interestingly, co-linearity comparisons of 98HAH12 and 05ZYH33 genomes with that of Pl/7 
demonstrated an additional DNA fragment of 89 kb in the Chinese strains, which were named 
89K PAis. Further bioinformatics analysis showed that 89K shares an average G+C content of 
36.8%, much lower than the average genomic G+C content of 41.1%. The 89K PAis were 99% 
identical between 98HAH 12 and 05ZYH33 and they encode sixty-seven and seventy-one 
potential ORFs, respectively. 
A recent study has reported the sequencing of the Chinese human isolate GZl (Ye et aL, 
2008). This strain was isolated during the human outbreak of 2005 in Guizou province, China . 
. Interestingly, this strain belonged to the MLST ST l, similar to European virulent strains (King et 
. al., 2002) and not ST 7, as was the case for the majority of human S. suis isolates associated with 
the outbreak (Ye et aL, 2006). The genome of strain ST 1 GZl was reported to be a single circular 
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chromosome of 2,038,034 bp with a G+C content of 41.44%. The strain did not harbor any 
plasmids. The chromosome had 1,987 predicted CDS (Ye et aL, 2008). Genome wide 
comparisons were carried out against the Chinese ST 7 strain 05ZYH33 described above and the 
ST 25 strain 89-1591. The genome sequence of STl GZl and the draft sequence of strain ST 25 
89-1591 shared a common backbone sequence that was colinear. The homology was found to 
be punctuated by deletions and insertions of hundreds of genes, which were designated as "Iost 
islands" (LI) or "acquired islands" (AI). Putative virulence genes present in both strains ST 25 89-
1591 and ST 1 GZ 1 included those encoding GAPDH, sortases, GDH, ADS, hyaluronidase, Ffbp 
and OFS (Ye et aL, 2008). Lis were found to be present in ST 25 strain 85-1591 but not in either 
ST 1 strain GZl or ST 7 strain 05ZYH33, whereas Ais were present in ST 1 strain GZl and ST 7 
strain 05ZYH33 but not in ST 25 strain 85/1591. The Ais and Lis were also compared with ST 25 
strain 89-1591 individual contiguous sequences that could not be linked to others. The results 
showed that ST 1 strain GZl has sixt y-four Lis and that ST 7 05ZYH33 has fifty-four Lis (Ye et aL, 
2008). On the other hand, comparative analyses revealed that strain ST 1 GZl gained 132 Ais, 
including five PAis containing genes encoding virulence factors such as suilysin, EF, SodA, 
extracellular serine protease, and prolipoprotein signal peptidase. Other Ais included one 
putatively conferring antibiotic resistance, five encoding determinants of cell structure, eleven 
for DNA/RNA processing, nine for regulation, six for DNA recombination, six for signal 
transduction, forty-three for metabolism, twenty-two for transport, one for immunogenic 
protein, and twenty-one of unknown function (Ye et aL, 2008). The total size of the combined 
Ais was 478,262 bp. A comparison between ST 7 strains 05ZYH33 and SC84 was also carried out 
(Ye et aL, 2008). A total of five Ais with sixt y-four CDS comprising 66,829 bp were found to be 
unique to strain ST 7 SC84; these Ais were classified as ST 7-specific genomic islands and 
included 1) determinants for tetracycline resistance and a two-component signal-transduction 
system, 2) a second two-component signal-transduction system, 3) a recombinase, 4) an ABC-
type metal-ion transporter, and 5) a second ABC transporter (Ye et aL, 2008). 
1.3.11.2. Suppression subtractive Hybridization (SSH) 
ln order to identify gene sequences unique to virulent strains, suppression subtractive 
hybridization (SSH) was conducted using the sequenced serotype 2 Chinese strain ST 7 HA9801 
and the avirulent serotype 2 European isolate Tl5 (Jiang et aL, 2008). The study identified thirty 
genomic regions that were absent in Tl5. Of these, fourteen were widely found among isolates 
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of Chinese origin. The DNA sequences of the thirty regions in HA9801 were determined and 
found to encode twenty-eight proteins that were homologous to proteins involved in various 
aspects of cellular surface structure, molecular synthesis, energy metabolism, regulation, 
transport systems and others of unknown function (Jiang et aL, 2008). Unfortunately, the study 
did not test whether these regions were present in virulent strains of other geographical origins. 
However, most of these regi_ons identified by SSH mapped to the 89K PAl, which is found in 
Chinese strains only (Chen et al., 2007). 
1.3.11.3. 
approach. 
ln vivo induced genes identified by the use of a promoter trap-based 
A promoter selection system has been used for the identification of iron- and in vivo-
regulated genes potentially involved in the pathogenesis of S. suis (Smith et al., 2001a). 
Chromosomal DNA fragments of S. suis were cloned into a plasmid in front of a promoterless 
erythromycin resistance gene. Subsequently, the library was used for the selection of bacteria in 
which erythromycin resistance was induced under iron-restricted conditions. lron-regulated 
genes identified by the study have been described above in a separate section. In addition, 
erythromycin-resistant bacteria were selected after infection of piglets with the library and 
treatment of the piglets with erythromycin (Smith et al., 2001a). From the materials and 
methods it seems clear that the system used differed from the classic in vivo expression 
technology (IVET) (Merrell and Camilli, 2000; Rediers et al., 2005) in that a plasmid-based 
instead of an integrative promoter trap system was used. Therefore, this promoter trap study 
may have been unable to detect in vitro silent genes due to gene dose effects and, indeed, none 
of the selected genes were exclusively induced in vivo (Smith et al., 2001a). However, a number 
of interesting genes were selected (Ivs genes). Clones Ivs21,26,30 were shown to be identical to 
the epf gene which encodes the EF protein (Smith et aL, 1993). Clone Ivs31 showed similarity to 
a Ffbp of S. gordonii and GAS (Smith et aL, 2001a). Clones Ivs23, 24 were similar to cpsY of GBS 
involved in the regulation of capsule expression (Koskiniemi et aL, 1998). In S. suis, this gene is 
not present in the cps locus (Smith et al., 1999a; Smith et al., 2000) and therefore its implication 
in CPS production was highly speculative (Smith et aL, 2001a). Interestingly, a gene homologous 
to the competence gene comE of B. subtilis was identified (Smith et al., 2001a). This was an 
interesting finding, since natural competence for S. suis has not yet been described. Three other 
genes showed similarity to response regulators or were putatively involved in regulatory 
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functions: these were clones Ivs16 (similar to Staphylococcus epidermidis altR), Ivs20 (similar to 
L. lactis aldR) and ivs25 (similarity to the sapR gene of S. mutans encoding a response regulator 
of bacterial two-component signal-transduction systems) (Smith et al., 2001a). The latter gene 
was renamed revS in a subsequent study and shown to be an orphan response regulator (de 
Greeff et aL, 2002a). In addition to the above, three Ivs clones showed similarity to genes 
encoding ABC transporters, four clones to housekeeping genes involved in metabolism, two 
clones showed similarity to transposon sequences and, finally, five Ivs clones were similar to 
sequences encoding proteins of unknown function (Smith et aL, 2001a). 
1.3.11.4. Signature tagged mutagenesis (STM) of S. suis 
A STM system for S. suis serotype 2 reference strain was developed (Wilson et aL, 2007) 
and used to identify genes essential for growth of the bacterium in vivo. Approximately 2,600 
mutants were screened through both mouse and caesarian-derived, colostrum-deprived pig 
models. A total of twenty-two mutants were found to be attenuated in both the murine and 
porcine models of infection (Wilson et aL, 2007). Among the genes identified there were purA 
(Adenylosuccinate synthetase), purD (Phosphoribosylamine-glycine ligase), gtfA (Sucrose 
phosphorylase), scrB/R (Sucrose-6-phosphate hydrolase/Sucrose operon repressor, and guaB/ A 
(GMP synthase/lnosine monophosphate dehydrogenase), which are known to be involved in the 
virulence of a variety of Gram positive and Gram negative organisms (Baumier et aL, 1994; 
Garsin et aL, 2001; McFarland and Stocker, 1987; Yamashita et aL, 1993). Two genes related to 
capsule synthesis, cpsC, involved in CPS export (Smith et aL, 1999a) and neuB, a putative sialic 
acid synthase (Smith et aL, 2000) were also attenuated in both models (Wilson et aL, 2007). 
Several of the identified genes have homologues that are putative transcriptional regulators in 
other Gram positive bacteria (Wilson et al., 2007). The remaining genes included a variety of 
hypothetical and conserved proteins with similarity to putative lipoproteins, proteases, 
nucleases and transporters. Since the STM mutants were obtained by transposition and 
complementation studies were not carried out, the presence of polar effects cannot be 
excluded. Interestingly, STM data demonstrated that a manN insertion mutant was attenuated 
in both mice and pigs (Wilson et aL, 2007). The product of manN is the IID component of the 
mannose-specific phosphotransferase (PTS) system. In bacteria, the phosphoenolpyruvate 
(PEP):carbohydrate PTS accomplishes both the translocation and phosphorylation of its 
substrates (Postma et aL, 1993). PTS consists of two general energy-coupling proteins, enzyme 1 
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and HPr, as weil as the carbohydrate-specific enzyme Il proteins. In the mannose-specifie PTS 
system, enzyme Il of S. salivarius consists of IIABMan, IICMan, and IIOMan (Lortie et aL, 2000; 
Vadeboncoeur et aL, 2000). Neither IICMan nor IIOMan is phosphorylated, but ail 3 proteins of the 
mannose-PTS are required for phosphorylation of mannose in these species (Postma et aL, 
1993). A separate study has shown that in S. suis, a single insertion of the transposon pGh9:ISSl 
in manN was responsible for a hyper-hemolytic phenotype due to upregulation of suilysin 
expression by unknown mechanisms (Lun and Willson, 2005). Whether the observed 
attenuation of the STM manN mutant (Wilson et aL, 2007) was the result of suilysin 
overexpression or a lack of a phosphotransferase metabolic function remains unclear and 
deserves further investigation. However, it has been reported that the growth of the manN 
mutant in media with mannose as the sole carbohydrate was similar to that of the WT strain, 
suggesting that IIOMan of S. suis is not essential for mannose transport, phosphorylation and 
metabolism (Lun and Wilison, 2005). In addition, the mutant grew equally weil as its WT parent 
in media with glucose, suggesting that S. suis may have other pathway(s) for glucose 
translocation and phosphorylation, or that the mannose-specifie PTS is used by S. suis for 
glucose transport but the IIOMan does not play an essential role in this process (Lun and Willson, 
2005). 
1.3.11.5. Screening of a transposon Tn917 mutant library 
A transposon Tn917 mutant library of S. suis serotype 2 strain Pl/7 has been 
constructed (Slater et aL, 2003). This library was screened for mutants showing impaired 
invasion of porcine BMEC. The screening led to the identification of nineteen poorly invasive 
mutants. Of them, five were selected and their virulence abilities assessed in a mouse model of 
infection. Two out of these five mutants were attenuated as measured by decreased 
colonization of organs and reduced mortality and morbidity. These two mutants were F80, in 
which the transposon insertion interrupts an ABC-type multidrug transporter and B8A, in which 
Tn917 interrupts an LPXTG protein member of a putative pili cluster (Vanier et al., 2008a). When 
tested in swine, these two attenuated mutants led to decreased bacterial loads in blood, less 
severe and delayed clinical signs, and lower plasma IL-6 levels than did infection with the WT 
strain. These results suggest that these two genes may contribute to the virulence of S. suis 
(Vanier et aL, 2008a). However, as for the STM study, since complementation studies were not 
carried out the possibility of polar effects in downstream genes cannot be excluded. 
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1.4. Pathogenesis of the S. suis infection 
For the most part, studies on the pathogenesis of S. suis infections have been carried 
out with serotype 2 strains (Higgins and Gottschalk, 2006). Despite increasing research in recent 
years, the current understanding of the subject is limited. As stated above, both vertical and 
horizontal transmission of S. suis have been demonstrated in pigs (Higgins and Gottschalk, 
2006). Colonized animais may harbor the bacteria in their palatine and pharyngeal tonsils 
(Madsen et aL, 2002a). These animais are clinieally healthy and may not develop disease (carrier 
animais). On the other hand, some carriers will eventually develop bacteremia, septieemia 
and/or meningitis. For these events to happen, S. suis must first be able to disseminate from 
tonsils and/or other mucosal surfaces and reach the circulation (both blood and Iymph). 
1.4.1. Reaching the circulation 
It is not known how S. suis, which is found in low quantities in tonsils, manages to 
traverse the first line of host defense to initiate disease. It has been postulated that the 
pathogen breaches the mucosal epithelia in the upper respiratory tract (Gottschalk and Segura, 
2000) (Figure 7), but very few studies are available regarding the interactions between S. suis 
and epithelial cells. It has been reported that virulent S. suis strains can invade, to a certain 
extent, an epithelial cell line of human origin (Norton et aL, 1999). However, invasion of 
epithelial cells by S. suis is controversial since failure to invade epithelial cells has been reported 
in another study (Lalonde et aL, 2000). Moreover, other reports showed invasion of epithelial 
cells by (probably non virulent) unencapsulated strains, but not by weil encapsulated strains 
(Benga et aL, 2004; Valentin-Weigand, 2004). Suilysin positive strains may use cell disruption to 
reach the bloodstream and, in fact, it has been reported that suilysin is toxie for epithelial cells 
(Gottschalk and Segura, 2000). However, strains not producing this hemolytic toxin are also able 
to reach the circulation and disseminate (Higgins and Gottschalk, 2006). 
1.4.2. Survival in blood, dissemination and sepsis 
Once in circulation, S. suis is able to survive and multiplicate (Higgins and Gottschalk, 
2006) (Figure 7). Survival of S. suis in blood has important immunological consequences that are 
discussed below and largely depends on the production of CPS. In fa ct, it has been widely 
documented that, in the absence of specific antibodies, the CPS protects S. suis from neutrophil 
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and monocytefmacrophage-mediated killing (Higgins and Gottschalk, 2006). Indeed, several 
different in vitro and in vivo experiments using isogenic unencapsulated strains have 
conclusively showed that absence of CPS correlates with highly augmented phagocytosis andfor 
killing of the mutant strain by phagocytic cells and rapid clearance from circulation (Chabot-Roy 
et al.; 2006; Charland et al., 1998; Segura et al., 2004; Smith et al., 1999a). Suilysin positive 
strains seem to additionally benefit from the toxie effects of this hemolysin for survival in blood. 
Indeed, suilysin has been reported to be toxic not only for epithelial and endothelial cells but 
also for monocytes and neutrophils. Moreover, suilysin appears to affect complement-
dependent killing by decreasing the opsonization of 5. suis and the bactericidal capacity of 
neutrophils (Chabot-Roy et al., 2006; Charland et al., 2000; Gottschalk and Segura, 2000; 
Lalonde et al., 2000; Segura and Gottschalk, 2002; Segura et al., 2006). Upon entry of the 
pathogen into the bloodstream, bacterial cell wall components interact with the host immune 
system via pattern-recognition receptors (PRR), mainly CD14 and TolI-like receptor"c(TLR)-2 
(Dominguez-Punaro et al., 2007; Graveline et al., 2007; Segura et al., 2002; Segura et al., 2006), 
and induce the production of pro-inflammatory mediators. Indeed, it has been shown that 5. 
suis is able to induce the production of pro-inflammatory cytokines by in vitro cultured murine 
and human phagocytic cells (Segura and Gottschalk, 2002; Segura et al., 1999). Porcine whole 
blood stimulated by live 5. suis also released highlevels of tumor necrosis factor alpha (TNF)-a, 
interleukin (IL)-l~ and IL-6 and intermediate levels of IL-8 and monocyte chemotactic protein 
(MCP)-l. The bacterial cell wall was the major cytokine-inducing component (Segura et al., 
2006). Stimulation of human monocytes by whole encapsulated 5. suis or purified cell wall 
components triggered the release of these cytokines and chemokines, whieh were signifieantly 
reduced by antibody-mediated neutralization of TLR-2 but not TLR-4. In addition, stimulatio'n 
influenced the expression by monocytes of TLR-2 and CD14 mRNA (Graveline et al., 2007). 
Following exposure to 5. suis, macrophages isolated from a TLR-2 knock-out murine strain 
showed a highly reduced, but not completely abrogated, IL-6 and MCP-1 production, suggesting 
the involvement of other TLRs in cytokine production. The CPS was also shown to modulate 5. 
suis interactions with TLRs, since unencapsulated bacteria induced cytokine and chemokine 
production via TLR 2 dependent as weil as independent pathways. However, the CPS 
contributed to MCP-1 production in a MyD88-independent manner (Graveline et al., 2007). 
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Although activation of the immune system during microbial infection is generally 
protective, septic shock may result as a consequence of excessive or poorly regulated immune 
response to the offending organism (Tsiotou et al., 2005). Such an unbalanced reaction may 
harm the host through a maladaptive release of endogenously generated inflammatory 
compounds, leading to septic shock or, in the case of highly mitogenie Chinese strains of ST 
7(Zheng et al., 2008), to toxie shock-like syndrome (Gottschalk et al., 2007; Higgins and 
Gottschalk, 2006; Ye et al., 2008). Since most of the in vitro induced cytokines mediate 
responses associated with septic shock, a murine model of infection was developed and used to 
study the inflammatory response following S. suis infection (Dominguez-Punaro et al., 2007). 
Results showed that S. suis induces in mice a Th-1-type immune response characterized by the 
release of TNF-a and remarkably high levels of IL-6 production. Interestingly, high levels of these 
two immune mediators inversely correlate with survival time in patients with sepsis (Norrby-
Teglund et al., 1995). High levels of IL-12 were also observed, whieh may influence NK and others 
cell and to produce interferon (IFN)-À, suggesting a positive feedback regulation in the 
proinflammatory cytokine cascade (Dominguez-Punaro et al., 2007). IFN-y contributes to 
immune control of invading pathogens but also, when its production is excessive or 
uncontrolled, may cause pathology leading to death (Goldmann et al., 2005). Levels of IL-1~ 
were not as high as those observed for otherTh-1 cytokines (Dominguez-Punaro et al., 2007). As 
for the chemokines, high levels of keratinocyte-derived chemokine (KC), MCP-1 (CCL2)and 
RANTES (CCL5) were detected during the first 36 h post infection in the septie phase of the 
infection, and their presence in plasma lasted longer than most of the proinflammatory 
cytokines tested (Dominguez-Punaro et al., 2007). Finally, the relatively delayed upregulation of 
the anti-inflammatory cytokine IL-10 might indicate a negative feedback mechanism to control 
the extent of the inflammatory response. Failure to regulate this response was observed in miee 
treated with neutralizing antibodies against IL-lO, which resulted in an increased rate of septic 
shock (Dominguez-Punaro et al., 2008). These observations in miee may be extended to the pig. 
Indeed, pigs experimentally infected with virulent S. suis showed high levels of IL-6 and IL-8 
(Vanier et al., 2008b). Finally, it has been recently reported in human patients that serum levels 
of TNF-a, IL-1~, IL-6, IL-8, IL-12p70, and IFN-y were significantly higher in six patients with severe 
shock than in nine patients with meningitis only during the acute phase of S. suis infection in 
humans (Ye et al., 2008). 
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Figure 7. Current knowledge and 
proposed hypotheses for the 
different steps involved in the 
pathogenesis of s. suis infection. 
Hem+: suilysin-positive strains; Hem-: 
suilysin-negative strains; Mo: 
monocytes; M4>: macrophages; CAMs: 
cell adhesion molecules; BBB: blood-
brain barrier; CI\lS: central nervous 
system. Steps a and b show S. suis 
interactions with the epithelial cell 
layers of the upper respiratory tract 
and access to circulation. Hem+ strains 
may use cell disruption (toxicity) and 
invasion to reach the bloodstream, 
while the mechanisms used by 
adhered Hem- strains are still 
uncertain (Step a). S. suis might also 
be directly uptaken by Mo/M4> and 
enter to the bloodstream within 
circulating cells (Step b). Steps c and d describe bacterial dissemination in blood. This cou Id 
be as Mo-associated (bacteria (Step c) or as free bacteria (Step dl, resulting in bacteremia or 
septicemia. Steps e-h describe the possible mechanisms used by S. suis to cross the BBB. 
Free bacteria might enter the CNS directly by transcytosis, or by affecting BBB permeability, 
via cell toxicity (Hem+ strains; Step e) or via local cytokine production (Step f). Local cytokine 
production might also increase CAMs expression and leukocyte migration, allowing for 
further bacterial trafficking (Step hl. On the other hand, Mo-associated bacteria would enter 
the CNS via the "Trojan horse" (bacteria inside cells) or "modified" Trojan horse (bacteria 
adhered to cells) mechanisms favored by activated phagocyte cytokine release (Step g). In 
addition, S. suis may gain access to the CNS via disruption of the choroid plexus epithelium 
forming the blood-CSF barrier (not depicted). Adapted from Gottschalk and Segura, 2000. 
1.4.3. S. suis meningitis 
If death from sepsis or toxic shock-like does not occur, but the level of bacteremia 
remains high, then S. suis may cause meningitis (Gottschalk and Segura, 2000; Higgins and 
Gottschalk, 2006). As other blood-borne pathogens, S. suis must cross the BBB and/or the blood-
CSF barrier in order to cause CNS infection (Figure 7). The BBB is an anatomically and 
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functionally unique barrier that separates the brain from the intravascular compartment and 
maintains the homeostasis of the CNS environment (Rubin and Staddon, 1999). The tight 
junctions of BMEC, whieh constitute mierovessels, form the anatomieal base of the BBB. These 
microvessels are covered by pericytes and outgrowths of astrocytes, whieh are referred to as 
astrocytie end-feet (Rubin and Staddon, 1999). The endothelial cells of brain mierovessels differ 
from those in other tissues in two important aspects. Firstly, BMEC are joined by tight junctions 
with high electrical resistance between cells. Secondly, a relatively low number of pinocytotic 
vesieles, a slow rate of fluid-phase endocytosis and high densities of mitochondria are present in 
BMEC (Huang and Jong, 2001). The differences in both of these aspects account for the ability of 
the BBB to exclude certain molecules, protecting brain tissue against fluctuations in 
concentrations of respective components occurring in blood plasma and against destructive 
blood components. An early hypothesis, known as the "Trojan horse" suggested uptake of 
bacteria by monocytes (in the absence of specific antibodies), intracellular survival and 
subsequent invasion of the CNS by these intracellular s. suis (Williams and Blakemore, 1990). 
The hypothesis received support from studies carried out with flow cytometry that indieated 
uptake of s. suis by swine and human phagocytes (Busque et aL, 1998). However, the number of 
monocytes containing bacteria in the preparations from s. suis bacteremic pigs was found to be 
very low « 2%) (Williams and Blakemore, 1990). Indeed, a relatively high level of adhesion 
without phagocytosis of s. suis to phagocytic cells has been reported (Segura et aL, 1999). 
Therefore, a "modified Trojan horse" hypothesis was put forward, in which the pathogen wou Id 
travel and gain access to the CNS in association with monocytes (Gottschalk and Segura, 2000). 
If the modified Trojan horse theory (or the original Trojan horse) proved true, S. suis might use 
monocytes to reach the CNS. As the CNS is considered to be an immunoprivileged organ, normal 
circulation of monocytes to the CNS is controversiaL However, it is accepted that the immune-
privileged status of the brain is not absolute, and the permeability to some immune cells cou Id 
be modified as an adaptation to the specifie local microenvironment (Gottschalk and Segura, 
2000). 
S. suis may also travel extracellularly as free bacteria and like most meningeal pathogens 
such as E. coli K1, Listeria monocytogenes, s. pneumoniae and GBS, directly interact with cells of 
the BBB (Tuomanen, 1996). Interestingly, ail these pathogens are able to invade BMEC (Huang 
and Jong, 2001). Adhesion to, but not invasion of human BIVIEC has been demonstrated for s. 
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suis (Charland et aL, 2000). On the other hand the pathogen proved able not only to attach to 
but also to invade porcine BMEC (Vanier et aL, 2004). Indeed, both North American and 
European S. suis serotype 2 strains adhered to and invaded these cells, as demonstrated by 
antibiotic protection assays and by electron microscopy. The CPS of S. suis partially interfered 
with the adhesion and invasion abilities of the bacterium, perhaps by hindering the display of 
putative adhesins (Vanier et aL, 2004). S. suis survived up to 7 h within porcine BMEC (Vanier et 
al., 2004), which is an interesting finding since a crucial factor for the development of meningitis 
is the ability of pathogens to cross the BBB as live bacteria (Kim, 2006). It has been also 
proposed that suilysin positive straÎns may a)so disrupt the BBB through cytotoxie effects, since 
at high bacterial doses suilysin-positive strains were toxie for porcine BMEC. However, suilysin 
was not necessary for invasion, as a suilysin-negative mutant successfully invaded these cells 
(Vanier et aL, 2004). Despite the fact that further characterization of the invasion process 
suggested that proteinaceous adhesins/invasins, cell wall components, lipoteichoic acid, and 
serum components (including fibronectin) are involved in the interactions between 5. suis and 
porcine BMECs (Vanier et aL, 2007), the molecular events underlying the interactions between 
the pathogen and these cells remain unknown. 
Another CNS entry portal for S. suis may be the choroid plexus epithelium. Choroid 
plexus epithelial cells (CPEC), which also possess tight junctions, are the structural basis of ~he 
blood-CSF barrier (Strazielle and Ghersi-Egea, 2000). The choroid plexus maintains homeostasis 
in the CNS and also participates in neurohumoral brain modulation and neuroimmune 
interaction. It has been shown that CPEC are capable of restricting growth of 5. suis upon 
activation with proinflammatory cytokines by creating an unfavorable microenvironment for the 
bacteria (Adam et aL, 2004). However, and despite that finding, it has been shown that 5. suis 
affects porcine CPEC barrier function and integrity by, for the most part, the induction of CPEC 
necrosis, although apoptosis might also play a role in the process of CPEC cell death 
(Tenenbaum et aL, 2005; Tenenbaum et aL, 2006). 
Meningitis-associated brain in jury and neuronal death is not mediated simply by the 
presence of viable bacteria but occurs as a consequence of the host reaction to bacterial 
components (Scheld et aL, 2002). Indeed, fibrin, edema and cellular infiltrates in the meninges 
are typically observed during 5. suis meningitis (Madsen et aL, 2002b). S. suis can induce the 
release of arachidonic acid by BMEC, a mechanism that may facilitate the ability of bacteria to 
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penetrate the CI\JS and to modulate local inflammation (Jobin et aL, 2005). In addition, bacterial 
CPS induces human macrophages to secrete prostaglandin E2 and matrix metalloproteinase 9, 
whieh also may be involved in disruption of the BBB (Jobin et aL, 2006). Finally, other studies 
have shown that S. suis is able to induce the release of pro-inflammatory cytokines and 
chemokines by human and porcine BIVIEC and to up-regulate the expression of adhesion 
molecules on human monocytes with consequent increased adherence of s. suis-activated 
monocytes to endothelial cells (AI-Numani et aL, 2003; Vadeboncoeur et aL, 2003; Vanier et al, 
2008b). In vivo experiments showed that infected mice that survive the septicemic phase can 
develop serious signs of inflammation at the CNS, with suppurative and necrotizing lesions at 
the meninges and brain parenchyma, especially in the cortex, hippocampus, thalamus, 
hypothalamus, and corpus callosum (Dominguez-Punaro et aL, 2007). Bacterial antigens were 
detected in association with microglia residing only in the affected zones. In situ hybridization 
combined with immunocytochemistry showed transcriptional activation of TLR 2 and TLR 3 as 
weil as of CD14, nuclear factor {NF)-KB, IL-1~, MCP-1 and TI\IF-a at these brain structures. 
Mieroglial cells were probably the main cellular sources of cytokine induction in the brain. 
Interestingly, early transcriptional activation of TLR 2, CD14 and inflammatory cytokines in the 
choroid plexus and brain endothelial cells seem to confirm that these structures are possible 
bacterial portais of entry into the CNS, as previously suggested (Dominguez-Punaro et aL, 2007; 
Gottschalk and Segura, 2000; Tenenbaum et aL, 2005; Tenenbaum et aL, 2006; Vanier et aL, 
2004). 
1.5. Prevention, treatment and control of the infection 
1.5.1. Management practices 
S. suis infection is associated with the intensification of the swine industry. Thus, control 
of environ mental and stress factors, such as mixing and moving, using ail in-ail out systems of 
housing with adequate cleaning and drying of rooms between batches, decreasing the 
population density, and improving the ventilation constitute the first line of defense against the 
disease (Higgins and Gottschalk, 2006). These management measures coupled with strategie 
medication of clinically ill animais have been recommended for control and prevention of 
mortality caused by streptococci (Amass et aL, 1996; Clifton-Hadley, 1983; Dee et aL, 1993). 
Production technologies such as medicated early weaning and segregated early weaning have 
been used to improve the health status of pigs and to eliminate some infectious organisms. 
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However, early weaning has been shown to be ineffective for the elimination of the carrier state 
of S. suis (Dee et aL, 1993; Robertson and Blackmore, 1989b; Torremorell and Pijoan, 1998). S. 
suis persists in tonsils in the presence of circulating antibodies and in pigs receiving feed 
medication with penicillin. This may explain how the organism can persist indefinitely in a herd 
and why most attempts of control or eradication by blanket medication have failed (Clifton-
Hadley, 1984). It has been suggested that S. suis might only be eradicated by the use of extreme 
management procedures or by delivering ail pigs by cesarean section (Dee et aL, 1993). 
1.5.2. Disinfectants and antibiotics 
S. suis survives in feces for 104 days at O°C, for up to 10 days at 9°C, and for up to 8 days 
at 22-25°C. It can also survive in dust for up to 54 days at O°C and for up to 25 days at 9°C. 
However, isolation from dust stored at room temperature for 24 h failed (Clifton-Hadley, 1984). 
S. suis can also survive in water for 10 min at 60°C, making the scalding process in abattoirs a 
possible source of contamination. On the other hand, the organism is rapidly inactivated by 
disinfectants and commonly used cleansers at concentrations lower than those recommended 
by the manufacturers (Clifton-Hadley, 1984). Streptococci are, in general, sensitive to ~­
lactamins and this group of antibiotics has been used prophylactically in herds where S. suis 
serotype 2 was a problem, especially at periods of high risk, i.e., weaning (Higgins and 
Gottschalk, 2006). Treatment of individual cases has to be undertaken early in the course of the 
disease to be successful (Clifton-Hadley, 1983). Since the inflammatory reaction against 
infection may be detrimental in some cases, adjunctive therapy with anti-inflammatory agents is 
recommended for treatment of S. suis meningitis in pigs (Higgins and Gottschalk, 2006). 
Recently, it has been shown that dexamethasone prevents alteration of tight junction-
associated proteins and barrier function in porcine CPEC after infection with S. suis in vitro 
(Tenenbaum et aL, 2008), a fact that may help to explain the excellent results obtained when 
post-weaning meningitis is treated with both penicillin and dexamethasone in the very early 
stages of the disease (Higgins and Gottschalk, 2006). On the other hand, several cases were 
difficult to treat with penicillin and several moderately susceptible and some resistant strains of 
S. suis have been isolated (Gottschalk et aL, 1991c; Woo and Li, 1987; Zhang et aL, 2008b). It has 
been suggested that modifications in the penicillin-binding proteins of certain field strains, 
rather than ~-Iactamase production, are involved in the mechanism of resistance to penicillin 
(Higgins and Gottschalk, 2006). Thus, penicillin sensitivity can no longer be assumed for ail S. 
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suis strains, and the routine treatment of S. suis infections with this antibiotic may need to be 
reevaluated if resistant strains become more prevalent (Higgins and Gottschalk, 2006). In 
addition to penicillin, an increase in resistance to erythromycin, clindamycin, tetracycline and. 
fluoroquinolones has been reported (Escudero et aL, 2007; Higgins and Gottschalk, 2006). S. suis 
strains recovered from humans are typically sensitive to penicillin, with a few exceptions 
(Gottschalk et aL, 2007). Therefore, intravenous penicillin G has been used to successfully treat 
most cases. Since at least two cases of relapse have occurred after two and four weeks of 
treatment, antibiotics should be administered for a relatively long period of time (at least 6 
weeks) (Gottschalk et aL, 2007). As previously mentioned, hearing loss and vestibular 
disturbances are frequently observed sequels unrelated to antibiotic use. Resistance to 
norfloxacin has also been reported in strains recovered from humans (Gottschalk et aL, 2007). 
1.5.3. Vaccination 
Passive immunization as weil as maternai antibodies can protect against S. suis 
infection. Indeed, early studies have shown that transfer of serum from convalescent pigs 
provided pigs with complete protection against subsequent S. suis serotype 2 infections (Elliott 
et aL, 1966). Protection could also be passively transferred to susceptible pigs by the inoculation 
of sera from pigs repeatedly immunized with live virulent S. suis serotype 2 strains, suggesting 
that humoral immunity plays an important role in S. suis infections (Holt et aL, 1988). Maternai 
antibodies against S. suis serotype 2 can be transferred from vaccinated sows to their piglets. 
However, sows may respond poorly to vaccination with whole cell vaccines. Furthermore, good 
protection of piglets can be obtained only when titers of maternai antibodies reach a high level 
(Blouin et aL, 1994). 
Currently, no effective vaccine is available which can protect against S. suis infections in 
pigs (Higgins and Gottschalk, 2006). Available commercial vaccines are based on formalin-killed 
whole cell preparations that may prevent clinical disease (although the results are controversial) 
but do not eliminate local tissue invasion or carriership (Holt et aL, 1988; 1990). Vaccination 
with live virulent and avirulent S. suis serotype 2 strains appears to confer good protection in 
pigs, but sometimes only after repeated immunizations (Holt et aL, 1988; Busque et aL, 1997; 
Article IV, Appendix). The efficacy of these vaccines, however, has only been evaluated after a 
homologous challenge with serotype 2 strains and it is not known whether whole cell vaccines 
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can elicit cross-protective immunity against S. suis (Higgins and Gottschalk, 2006). The potential 
of temperature-sensitive mutants of S. suis serotypes 1/2, 1, 2 and 3 as vaccines has been 
evaluated in mice (Kebede et al., 1990). Ali mutant strains provided protection against a 
challenge with a strain of homologous serotypes except for the S. suis serotype 1/2 mutant 
whieh provided protection to challenge with serotypes 1 and 2 strains (Kebede et al., 1990). A 
streptomycin-dependant mutant of S. suis serotype 1/2 was also tested as a vaccine. 
Homologous and heterologous trials in mice resulted in complete protection against challenge 
with S. suis serotypes 1 and 1/2 but only partial protection was observed against a challenge 
with S. suis serotype 2 strains (Foster et al., 1994). In many encapsulated bacteria, antibodies 
directed against the CPS are protective against infection (Ovodov, 2006). However, attempts to 
elicit an immune response in pigs by vaccination with purified S. suis CPS have not been 
successful (Elliott et al., 1980). Only when the CPS was used in combination with Freund's 
incomplete adjuvant, opsonizing antibodies were observed against S. suis serotype 2 (Elliott et 
al., 1980). Antibody responses against the CPS are probably not essential for full protection, 
since it has been reported that re-challenged pigs were completely protected against an 
experimental S. suis infection even when CPS-specific antibody levels were very low (dei Campo 
Sepulveda et al., 1996). Moreover, heat-killed S. suis has been shown to elicit CPS-specifie 
opsonizing antibodies, yet failed to provide protection against a homologous challenge with S. 
suis (Holt et al., 1990). However, comparison of the protective capacities of a live 
unencapsulated strain and an encapsulated bacterin indieate that the CPS (and also other 
bacterial components) are probably essential for full protection against homologous challenge 
(Wisselink et al., 2002b). 
Interest has recently shifted to the experimental assessment of subunit vaccines 
(Higgins and Gottschalk, 2006). A subunit vaccine based on purified suilysin efficiently protected 
pigs against challenge with virulent S. suis serotype 2 strains (Segers et al., 1998). However, the 
absence of suilysin in a substantial number of isolates recovered from diseased pigs (Higgins and 
Gottschalk, 2006) limits the value of this vaccine. Attractive candidate antigens for use in a 
subunit vaccine are also the MRP and EF proteins since both antigens are recognized by 
convalescent sera of pigs infected with virulent serotype 2 strains (Vecht et al., 1991). These 
proteins were used for protective purposes using various different formulations. At challenge, 
the pigs vaccinated with MRP+EF emulsified with water in oil emulsion had high anti-IVIRP and 
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anti-EF antibody titers and were protected as effectively as pigs vaccinated with water-in-oil-
formulated vaccines with bacterin (Wisselink et aL, 2001). As for suilysin, however, MRP and EF 
proteins are absent from a large number of field strains (Higgins and Gottschalk, 2006). 
Recently, the Sao protein, which is highly conserved among the 5. suis species, was shown to be 
recognized by convalescent swine sera (Li et aL, 2006). Indeed, convalescent animais had high 
titers of antibodies against this protein, suggesting that Sao is a potent immunogen that is 
expressed during 5. suis infection (Feng et aL, 2007; Li et aL, 2006). When recombinant Sao was 
mixed with the oil-in-water Emulsigen in a vaccination trial, it triggered a predominant 
production of IgG1 in piglets. However, these antibodies lacked opsonophagocytic function and 
did not confer protection (Li et aL, 2006). This suggested that the quality of the Th1/Th2 
immune response bias was inappropriate to mediate protection against 5. suis. It is known that 
host protection against infection caused by 5. suis, a highly encapsulated microorganism, is 
mediated primarily by opsonophagocytosis, which is mainly associated with a Th-1-type immune 
response characterized by IgG2a production (Gottschalk et aL, 2007). The vaccine formulation 
and components, such as adjuvants, can dramatically influence the vaccine-induced antibody 
response, including bias to type 1 or type 2 responses, which may have a significant effect on the 
protective efficacyof a vaccine (O'Hagan et aL, 2001). Consistently, using the Th-1-directing 
adjuvant QuilA to promote a Th-1-type immune response, the efficacy of recombinant Sao was 
demonstrated by protection of mice and pigs against S. suis infection (Li et aL, 2007). Recently, 
three genes of the virulent 5. suis North American strain 89/1591, encoding putative divalent-
cation-binding lipoproteins, were isolated. Recombinant proteins were produced and purified, 
and their immunogenic and protective abilities were analyzed (Aranda et aL, 2008). Ali three 
lipoproteins (SsuiDRAFT 0103, SsuiDRAFT 0174, and SsuiDRAFT 1237) were found to be 
immunogenic, but only one of them (SsuiDRAFT 0103) induced a significant protective response 
(87.5%) against a challenge with the homologous strain. These data suggest that bacterial 
envelope lipoproteins putatively involved in the uptake of diva lent cations other .than iron may 
be useful for protective purposes. In recent years, a multitude of putative protective candidates 
for vaccination against 5. suis infection have been reported by several research teams which 
have used reverse vaccinology and/or different immunoproteomics approaches (Liu et aL, 2008; 
Okwumabua and Chinnapapakkagari, 2005; Wilson et aL, 2007; Wu et aL, 2008; Zhang et aL, 
2008a; Zhang and Lu, 2007a, b). The actual protective capacities of these candidates remain to 
be verified experimentally. 
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S. suis vaccines for humans do not exist sa far (Gottschalk et aL, 2007). Interestingly, 
there is one report of a patient with recurrent septic shock, 15 years after the first episode, due 
ta S. suis serotype 2 (Francois et aL, 1998). The second and fatal episode was considered as a re-
infection rather than a recurrence of the previous infection. Absence of immunity after the first 
infection was suggested, which highlighted the importance of constant prevention in exposed 
workers (Francois et aL, 1998). Law prevalence of antibodies against S. suis is also reported in 
healthy individuals professionally exposed ta this microorganism (Elbers et aL, 1999; Robertson 
and Blackmore, 1989a; Smith et aL, 2008). 
2. The selective capture of transcribed sequences (SCOTS) 
Although substantial developments have recently occurred in the determination of 
numerous complete bacterial genome sequences, analysis of bacterial genome function by 
direct examination of bacterial RNA is inherently difficult due ta the nature of prokaryotic 
mRNA. Formidable obstacles include short message half-lives, limited polyadenylation, and 
scarcity of material, particularly for pathogens growing in the natural environments of hast cells 
and tissues. These barriers continue ta slow progress in terms of global RNA-based analysis of in 
vivo gene expression in bacterial pathogens. SCOTS is a method for the identification of cDNAs 
for RNAs produced by bacterial pathogens only during growth in association with the hast or 
under specific culture conditions (Graham and Clark-Curtiss, 1999). SCOTS directly identifies 
bacterial genes specifically expressed in different environments, without specialized genetic 
techniques, DI'JA microarrays, libraries, or species-specific cloning vectors, and is applicable ta 
any microorganism from which genomic DNA can be obtained (Daigle et aL, 2002; Graham and 
Clark-Curtiss, 1999). Unlike other recently described methods for analysis of in vivo gene 
expression (i.e. IVET, STM), SCOTS identifies potentially important genes, rather than promoter 
regions, and is not confounded by polar effects when genes are arranged in prokaryotic 
polycistronic operons. SCOTS also has the distinct advantage of being able ta determine 
differential expression from very small numbers of bacterial cells (Daigle et aL, 2002). 
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Figure 8. Schematic representation of the SCOTS technique as used in 
this research project. 
The left panel describes the procedures for obtaining the 
transcriptomes. The center panel describes the enrichment in bacterial 
sequences representing mRNA sequences. The right panel describes 
the enriehment in condition-specifie sequences (interaction with 
porcine BMEC in the example) which are then cloned and sequenced 
. (not shown). Adapted from Graham and Clark-Curtiss, 1999. 
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SCOTS uses a hybridization scheme in whieh total RNA from a given condition (Le., total 
RNA isolated from microbe-host interactions either in vivo or in vitro) is converted en masse to 
uniquely tagged cDNAs by using an oligonucleotide primer containing a random nonamer at 
their 3' end and a defined terminal sequence (tag) in the S'end (Daigle et al., 2002; Graham and 
Clark-Curtiss, 1999). In parallel, total RNA from a second condition (i.e., the mierobe growing in 
normallaboratory medium) is reverse transcribed using the same procedure but with a different 
tag in the primer. Then, for each condition, the bacterial cDNAs are selectively recovered from 
the mixture by hybridization against biotinylized genomie DNA that has been previously blocked 
with an excess of bacterial rD NA sequences. The recovered cDNAs are then PCR amplified using 
primers annealing to the specific tags and the procedure is repeated 3 times. Then, enrichment 
in sequences specifie for one condition can be carried out by a variation of the procedure above, 
in whieh the genomic DNA is blocked with rDNA and cDNAs from the second condition. As a 
result, bacterial genes that are differentially expressed in the tested condition (in our example, 
interaction with the host) are identified (Daigle et al., 2002; Graham and Clark-Curtiss, 1999). 
These genes are cloned and sequenced, and differentially expressed gene sequences are 
compared to data bases. Figure 8 shows the SCOTS procedure as used in this research project. 
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SCOTS has been used with success with many Gram positive and Gram negative 
pathogens after its initial description for elucidation of M. tuberculosis gene expression upon 
phagocytosis by human macrophages (Graham and Clark-Curtiss, 1999). Indeed, in addition to 
this species, SCOTS has been used to identify genes expressed in vivo or in vitro under specifie 
conditions by animal and human pathogens such as Salmonella sp (Daigle et aL, 2001; Faucher 
et aL, 2005; Faucher et aL, 2006), L. monocytogenes (Liu et aL, 2002), Helicobacter pylori 
(Graham et aL, 2002), Mycobacterium avium (Hou et al., 2002; Zhu et aL, 2008), avian 
pathogenie E. coli (Dozois et al., 2003), Actinobacillus pleuropneumoniae (Baltes et aL, 2007; 
Baltes and Gerlach, 2004), Haemophilus ducreyi (Bauer et aL, 2008), and Haemophilus parasuis 
(Jin et aL, 2008). In addition to the use of SCOTS as the main approach for elucidation of gene 
expression, the cDNAs obtained by SCOTS can be used in conjunction with microarrays to 
determine global gene expression by a pathogen during infection as recently demonstrated with 
S. enterica serovar Typhi (Faucher et aL, 2006). 
3. The Gram positive cell envelope 
The two major classes of bacteria, Gram positive and Gram negative, are differentiated 
primarily because of differences in their surfaces. Gram positive bacteria have much thicker 
peptidoglycan cell wall layers and no outer membrane external to this structure. Thus, Gram-
positive bacteria also lack a morphologically distinct periplasmie space, which is usually defined 
as the region between the cytoplasmic membrane and the outer membrane. For Gram positive 
bacteria, a single cytoplasmie membrane surrounded by a thick layer of peptidoglycan provides 
both a physical barrier for protection from the environ ment and a scaffold for the attachment of 
secondary cell wall glycopolymers (CWG) such as the wall teichoie acids (WTA) (Neuhaus and 
Baddiley, 2003; Weidenmaier and Peschel, 2008) as weil as certain surface proteins (Dramsi et 
aL, 2008; Marraffini et aL, 2006; Navarre and Schneewind, 1999). In addition, most Gram-
positive bacteria possess other surface structures. These are highly variable and include 
capsules, S-Iayer proteins, and mycolic acids that can form an outer-membrane-like structure or 
combinations of these elements. One constant motif of Gram-positive cell envelopes, however, 
is the presence of additional glycopolymers, which form part of the fabric of the cell wall and are 
attached either to the peptidoglycan or to membrane lipids. For the needs of this thesis, certain 
characteristics of peptidoglycan and selected CWG will be described. 
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3.1. Peptidoglycan 
Peptidoglycan (murein) is an essential and specific component of the bacterial cell wall 
found on the outside of the cytoplasmic membrane of almost ail bacteria. Its main function is to 
preserve cell integrity by withstanding the turgor. Any inhibition of peptidoglycan biosynthesis 
(mutation, antibiotic) or its specific degradation (e.g. by lysozyme) during cell growth will result 
in cell Iysis. Peptidoglycan is intimately involved in the processes of cell growth and cell division. 
It also contributes to the maintenance of a defined cell shape. The S. suis peptidoglycan 
structure and traits have, to the best of our knowledge, never been described. Therefore the 
next six subsections describe features observed in, and conclusions drawn from, other species. 
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Figure 9. Peptidoglycan structure. 
Peptidoglycan is a polymer of ~(1-4)-linked 
GlcNAc and MurNAc, with ail lactyl groups of 
MurNAc substituted with stem peptides, typically 
containing four alternating L- and D-amino acids. 
The stem peptides from adjacent strands are 
often crosslinked, either directly or through short 
peptides. The structure of the polysaccharide 
backbone ofpeptidoglycan is conserved in ail 
bacteria. By contrast, the composition of the 
peptide varies: Most Gram positive cocci have L-
lysine as the third amine acid (Lys-type 
peptidoglycan; see figure). Lys-type peptides are 
usually crosslinked through an interpeptide 
bridge that varies in length and amino-acid 
composition in different bacteria. The stem 
peptides from adjacent strands are often 
crosslinked, either directly or through short peptides. Adapted from Vollmer et al, 2008a. 
3.1.1. General structure and characteristic features 
The main structural features of peptidoglycan are linear glycan strands cross-linked by 
short peptides (Vollmer et al., 2008a) (Figure 9). The glycan strands are made up of alternating 
GlcNAc and N-acetylmuramic acid (MurNac) residues linked by ~-1~4 bonds. The o-Iactoyl 
group of each MurNac residue is substituted bya peptide stem whose compositionis most often 
L-Ala-y-o-Glu-meso-A2pm (or L-Lys}-o-Ala-o-Ala (A2pm, 2,6-diaminopimelic acid) in nascent 
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peptidoglycan, the last D-Ala residue being lost in the mature macromolecule (Vollmer et al., 
2008a). Cross-lin king of the glycan strands generally occurs between the carboxyl group of D-Ala 
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at position 4 and the amine group of the diamino acid at position 3, either directly or through a 
short peptide bridge (Vollmer et al., 2008a). Therefore, the chemical traits of peptidoglycan 
involve the presence of an unusual sugar (MurNAc), of y-bonded D-Glu, of L-D (and even D-O) 
bonds and of nonprotein amine acids (e.g. A2pm). These structural features are retrieved in ail 
bacterial species known to date. However, a certain degree of variation exists either in the 
peptide stem, in the glycan strands or in the position or composition of the interpeptide bridge. 
Interspecies variation is the general case (Schleifer and Kandler, 1972). However, in the same 
species, there can be variations in the fine structure according to the growth conditions (growth 
phase, medium composition, intraJextraceliular growth, presence of antibiotics) (Vollmer et al., 
2008a). 
3.1.2. The glycan strands in peptidoglycan 
The glycan strands are formed by oligomerization of monomeric disaccharide peptide 
units (Iipid Il) by transglycosylation reactions. Secondary modifications in the glycan strands such 
as N-deacetylation, O-acetylation and N-glycolylation are frequently found (N-deacetylation is 
, 
discussed below) (Vollmer et al., 2008a). In 5. aureus, the glycan strands may contain either a 
MurNAc or a GlcNAc residue at the reducing end; the latter residue indicates that cleavage of 
the strand by an I\I-acetylglucosaminidase had occurred. In ail Gram-negative and some Gram-
positive species (e.g. B. subtilis), the glycan strands do not have a reducing (MurNAc or a 
GlcNAc) end but terminate with a l, 6-anhydro MurNAc residue, which has an intramolecular 
ring from Cl to C6. It is not known whether the l,6-anhydro MurNAc residues present in the 
sacculi have been formed during termination of glycan strand synthesis, or whether they are the 
result of degradation by Iytic transglycosylases, or both (Vollmer, 2008). In species with high 
activity of glycan strand-cleaving enzymes (glucosaminidases and muramidases), the 
peptidoglycan may contain glycan strands with ail possible combinations of GleNAc and MurNAc 
residues at the ends (Schleifer and Kandler, 1972). There are only limited data on the average 
chain length and the chain length distribution of the glycan strands in different species. 
Remarkably, the average chain length of the glycan strands does not correlate with the 
thickness of the peptidoglycan layer, as there are Gram positive species with a thick cell wall 
with either short (5. aureus) or long (B. subtilis) glycan strands (Vollmer, 2008). 
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3.1.3. Variation in the peptide stem 
The variations of the peptide stem can be divided into two categories: 1) those due to 
the specificity of the Mur ligases, the enzymes responsible for its biosynthesis, and 2) those 
occurring at a later step of the biosynthesis (Vollmer, 2008). The first amino acid of the peptide 
stem is added by the MurC ligase. In most bacterial species, this amino acid is L-Ala; in rare 
cases, Gly or L-Ser is added instead. The amino acid at the second position is added by the MurO 
ligase. In ail species this enzyme adds o-Glu, the modifications encountered occurring at a later 
step (Vollmer, 2008). The greatest variation is found at position 3. The addition of the third 
amino acid is catalyzed by the MurE ligase. This amino acid is generally a diamino aCid, either 
meso-A2pm (Gram negative bacteria, Mycobacteria, Bacilli) or L-Lys (most Gram-positive 
bacteria). As for the second position, further _modifications of the third amino acid occur 
posterior to MurE action (Vollmer, 2008). In most cases, the MurE enzyme is highly specific for 
the relevant amino acid; this has been demonstrated for the meso-A2pm-adding and L-Lys-
adding enzymes from E. coli and S. aureus, respectively. (Vollmer et aL, 2008a). However, the 
MurE enzyme sometimes seems to be devoid of strict specificity, and this affects the final 
composition of peptidoglycan. In certain species of the genus Bifidobacterium, two diamino 
acids, L-Lys and L-Orn, are retrieved at the third position of the peptide stem (Schleifer and 
Kandler, 1972). Amino acids at positions 4 and 5 are added as a dipeptide, in most cases o-Ala-o-
Ala. The synthesis of the dipeptide is carried out by the Ddl enzyme and its incorporation into 
the peptide stem by the MurF ligase. It has been established that the latter enzyme has a high 
degree of specificity for the C-terminal amino acid (Bugg et aL, 1991; Duncan et aL, 1990). This is 
complementary to the specificity of the former enzyme, which resides mainly on the N-terminal 
amino acid, and this constitutes a 'double-sieving' mechanism ensuring the synthesis of a 
pentapeptide stem ending mainly in o-Ala-o-Ala (Neuhaus and Struve, 1965). o-Ala is 
predominantly found at position 4 in ail species. o-Lactate (o-Lac) or o-Ser is found at position 5 
in strains endowed with natural or acquired resistance to vancomycin, the affinity of the o-Ala-
o-Lac and o-Ala-o-Ser moieties for the antibiotic being much lower than that of the conventional 
o-Ala-o-Ala moiety (Healy et aL, 2000). A certain proportion of Gly, presumably escaping from 
the double-sieving mechanism, is often found at position 4 or 5 in lieu of o-Ala(Volimer et aL, 
2008b). 
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3.1.4. Other variations in peptidoglycan composition 
Amidation, hydroxylation, acetylation, attachment of amine acids or other groups and 
attachment of proteins occur after the action of the Mur ligases. These modifications concern 
essentially positions 2 and 3. Most enzymes responsible for these modifications are still 
unknown (Vollmer, 2008; Vollmer et aL, 2008b). Amidation of the a-carboxyl of glutamic acid 
(yielding D-isoglutamine) and the E-carboxyl group of meso-A2pm is very frequent. It has been 
shawn in Mycobacterium smegmatis that lipid Il is the substrate for amidation reactions; in fa ct, 
lipid Il in this species appears as a mixture of non-, mono- and di-amidated molecules 
(Mahapatra et aL, 2005). The hydrocarbon chain of D-Glu, meso-A2pm or L-Lys is hydroxylated in 
some species. In the case of D-Glu, it was demonstrated that hydroxylation occurs after' the 
cytoplasmic steps (Vollmer, 2008). In Corynebacterium insidiosum, where unsubstituted L-2,4-
diaminobutyric acid is the substrate for MurE, the y-amino group of the diamino acid is 
acetylated in the UDP-MurNAc-pentapeptide precursor and in peptidoglycan (Vollmer, 2008). In 
certain organisms, an amino acid or another amine-containing moiety, such as glycine 
(Micrococcus luteus, Arthrobacter tumescens), glycine amide (Arthrobacter athrocyaneus), D-
alanine amide (Arthrobacter sp. NCIB9423), cadaverine (Selenomonas ruminantium) or N-
acetylputrescine (Cyanophora paradoxal, is added to the a-carboxyl group at position 2 
(Schleifer and Kandler, 1972; Vollmer, 2008). The peptide stem constitutes the point of covalent 
anchoring of some cell envelope proteins to peptidoglycan (Dramsi et aL, 2008) 
3.1.5. Variation in cross-linking 
Most variations of the peptide moiety of peptidoglycan occur in its mode of cross-
linkage and in the composition of the interpeptide bridge (Schleifer and Kandler, 1972; Vollmer, 
2008). There are two main groups of cross-linkage. In the first group (3-4 cross-linkage), the 
cross-linkage extends from the amine group of the side-chain of the residue at position 3 of one 
peptide subunit (acyl acceptor) to the carboxyl group of D-Ala at position 4 of another (acyl 
donor). As, mentioned above, this is the most common kind of cross-linkage. It can be either 
direct (most Gram-negative bacteria) or through an interpeptide bridge (most Gram-positive 
bacteria) (Vollmer, 2008; Vollmer et aL, 2008b). The cross-linking reactions are catalyzed by the 
transpeptidase domain of penicillin-binding proteins, enzymes that have been studied 
extensively, in particular in human pathogenic bacteria (Sauvage et al., 2008). In the second 
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group (2-4 cross-linkage), found only among coryneform bacteria, the cross-linkage extends 
between the a-carboxyl group of o-Glu at position 2 of one peptide subunit (acyl acceptor) and 
the carboxyl group of o-Ala at position 4 of another (acyl donor). In this case, for the first 
subunit to be an acceptor, an interpeptide bridge containing a diamine acid must be present. 
The size of the interpeptide bridge ranges from one to seven amine acid residues. 
Various amine acids are encountered: Gly, L-Ala, L- or o-Ser, o-Asx, L- or o-Glu, or others. The 
interpeptide bridges of 2-4 cross-links contain necessarily (but not exclusively) a diamine acid (L-
or o-Lys, o-Orn, 0-2, 4-diaminobutyrate). For many years, the important diversity of composition 
of the interpeptide bridges has contrasted with the poor knowledge of the branching enzymes 
responsible for their biosynthesis. In fact, it is only recently that some branching enzymes have 
been purified and characterized (Vollmer, 2008; Vollmer et aL, 2008b). They can be divided into 
two groups according to the nature of the amine acid incorporated: 1) Glycine and L-amino acids 
are activated as aminoacyl-tRNAs and transferred to the precursors by a family of nonribosomal 
peptide bond-forming enzymes called Fem transferases (Mainardi et aL, 2008). 2) o-Amino acids 
are activated as acyl phosphates by proteins belonging to the ATP-grasp family, which is 
composed of highly diverse enzymes that catalyze the ATP-dependent ligation of a carboxyl 
group to an amine or imino nitrogen, a hydroxyl oxygen or a thiol sulfur (Galperin and Koonin, 
1997). The precursor substrate of the branching enzymes varies among species: lipid Il for s. 
aureus enzymes, UDP-MurNAc-pentapeptide for Weissella viridescens FemX or both for 
Enterococcus faecalis enzymes (Vollmer, 2008). As for the main peptide chain, the interpeptide 
bridge can be further modified after its assembly. In Enterococcus faecium, where the Asl fm 
enzyme ligates the ~-carboxyl group of o-Asp to the UDP-MurNAc-pentapeptide, part of the a-
carboxyl groups are subsequently amidated, thereby leading to a peptidoglycan composed of ~­
o-aspartyl and o-isoasparaginyl residues in similar amounts (Bellais et aL, 2006). 
Besides the diversity in the nature of cross-linkage, there is a considerable variation in 
the degree of cross-linkage, which varies from 20% in E. coli to over 93% in S. aureus. Translated 
in terms of muropeptide content, these figures mean that in E. coli, most peptidoglycan units 
appear as monomers (50%) or dimers (40%), higher oligomers being a minority (Glauner et aL, 
1988); conversely, in S. aureus, the percentage of monomers is low «10%), most peptidoglycan 
units being present as oligomers (Snowden and Perkins, 1990). 
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3.1.6. Peptidoglycan N-deacetylation. 
The muramidase lysozyme hydrolyzes the glycan strands of peptidoglycan between Cl 
of MurNAc and (4 of GlcNAc. In 1971, the presence of a high proportion of nonacetylated 
glucosamine (GlcN) residues in the peptidoglycan of Baeil/us cereus was identified (Araki et aL, 
1971). A later study also identified nonacetylated muramic acid (MurN) residues in the 
peptidoglycan of Baeil/us anthraeis (Zipperle et aL, 1984). The presence of these nonacetylated 
amino sugars accounted for the observed lysozyme resistance, as isolated cell walls could not be 
digested by lysozyme unless they were chemically N-acetylated by acetic anhydride. Other 
Baeil/us species, including B. anthraeis, Baeil/us thuringensi~ and B. subtilis strain 168, contain 
deacetylated GlcN and MurN residues in their peptidoglycan (Vollmer, 2008). Nonacetylated 
GlcN was detected in the peptidoglycan of several other bacteria, such as S. pneumoniae (Ohno 
et aL, 1982; Vollmer and Tomasz, 2000), L. monoeytogenes (Boneca et aL, 2007) and L. laetis 
(Meyrand et aL, 2007) whereas nonacetylated Murl\! was detected in small quantities in S. 
pneumoniae (Vollmer and Tomasz, 2000) and Mieroeoeeus Iysodeiktikus (Hoshino et aL, 1972). 
Deacetylated amino sugars appear to be widespread in peptidoglycan. 
Deacetylated amino sugars are formed from the MurNAc and GlcNAc residues by 
peptidoglycan deacetylases. The supernatant of B. cereus cells contains an enzymatic activity 
capable of deacetylating GlcNAc residues in peptidoglycan. It was noted that the peptidoglycan 
deacetylase present in the crude fraction has a different biochemical pro pert y to that of the 
known GlcNAc-6-phosphate deacetylase (Araki et aL, 1971). The deacetylation reaction is most 
likely to occur on polymerized peptidoglycan because deacetylated precursors have not been 
detected in species with deacetylated peptidoglycan, and known deacetylases have a predicted 
extracytoplasmic localization (Vollmer and Tomasz, 2000). Furthermore, inactivation of 
deacetylase genes is tolerated in different species with none or at most minor effects on cell 
growth (Boneca et aL, 2007; Meyrand et aL, 2007; Vollmer and Tomasz, 2000). Therefore, the 
absence of deacetylated amino sugars in the peptidoglycan does not appear to affect the 
peptidoglycan biosynthetic enzymes, the transglycosylases and transpeptidases in these 
mutants (Vollmer, 2008; Vollmer et aL, 2008a). 
The first gene encoding a peptidoglycan GlcNAc deacetylase, pgdA, was identified in S. 
pneumoniae (Vollmer and Tomasz, 2000). A pgdA mutant strain lacked deacetylated amino 
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sugars in its peptidoglycan. The amino acid sequences of the pneumococcal peptidoglycan 
deacetylase PgdA, rhizobial NodB chitooligosaccharide (nodulation factor) deacetylases and 
fungal chitin deacetylases are similar, which is not surprising because their substrates share a 
common structural feature. Ali three substrates (peptidoglycan, nodulation factor and chitin) 
have a backbone of ~-1, 4-linked GleNAc residues (In fact, MurNAc in peptidoglycan is the 3-
lactyl ether of GleNAc). These enzymes belong to carbohydrate esterase family 4 (CE4, 
PFAIVI01522), which includes peptidoglycan GleNAc deacetylases (EC 3.1.1.-), rhizobial NodB 
chitooligosaccharide deacetylases (EC 3.5.1.-), chitin deacetylases (EC 3.5.1.41), acetyl xylan 
/ 
esterases (EC 3.1.1. 72), and xylanases A, C, D and E (EC 3.2.1.8) (Vollmer, 2008). Members of this 
family hydrolyze either N-linked acetyl groups from GleNAc residues (peptidoglycan 
deacetylases, rhizobial NodB chitooligosaccharide deacetylases, chitin deacetylases) or O-linked 
acetyl groups from O-acetylxylose residues (acetyl xylan esterases and xylanases A, C, D and E) 
of their substrates. 
The carbohydrate estera se family CE4 contains over 800 members (Bornscheuer, 2002), 
many of which encode hypothetical polysaccharide deacetylases in bacterial genomes and have 
been reported to be metal ion-dependent. The amino acid sequence alone of CE4 family 
enzymes is not sufficient to determine the substrate (peptidoglycan, chitin, chitooligosaccharide 
or xylan) of a hypothetical deacetylase .. Therefore, both structural analysis of the peptidoglycan 
of a mutant strain lacking a hypothetical gene as weil as biochemical characterization of the 
gene product are required to establish its functional activity. PgdA from s. pneumoniae is about 
twice the size of typical CE4 family proteins. PgdA has a predicted N-terminal membrane anchor 
followed by a large region of unknown function, and aC-terminai deacetylase domain (Vollmer 
and Tomasz, 2000). The crystal structure of a soluble form of PgdA was solved, showing a three-
domain architecture, with the N-terminal domain from amino acids 46 to 160, a sm aller domain 
from amino acids 161 to 268 and the deacetylase domain from amino acids 269 to 463 (Blair et 
al., 2005). Although there are significant topological differences between PgdA and PdaA from B. 
subtilis, the overall fold of the deacetylase domain and the catalytic core are similar in both 
structures. Structural analysis did not reveal possible in vivo functions for the N-terminal and 
middle domains of PgdA, both of which are absent in PdaA. PgdA contained a Zn2+ ion, 
complexed with two histidines and an aspartic acid, and this metal binding triad is conserved in 
members of the CE4 family. As expected from the crystal structure, the activity of PgdA is metal-
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dependent and the addition of EDTA inactivates the enzyme (Blair et aL, 2005). The enzyme 
activity was highest in the presence of C02+, but PgdA was also active in the presence of Zn2+, 
Ni2+ or Fe2+, whereas it showed little or no activity with Cu2+, Cd2+, Mg2+ or Ca2+. PgdA 
deacetylated the middle GlcNAc residue of an artificial GlcNAc3 substrate (Blair et aL, 2005). Two 
other peptidoglycan Glcl\lAc deacetylases have been characterized biochemically, BC1960 and 
BC3618 from B. cereus (Psylinakis et aL, 2005). Both were inactive against GlcNAc but were 
active against the oligosaccharides GlcNAc2-8 and showed highest activity against GlcNAc4' In 
these substrates, ail GlcNAc residues were deacetylated except the one at the reducing 
terminus. Both enzymes deacetylated GleNAc residues in a peptidoglycan fragment (GleNAc 
NeuNAc -L-Ala-D-Glu) and in peptidoglycan from Helicobacter pylori and B. cereus (Psylinakis et 
aL,2005). 
3.2. Cell-wall glycopolymers (CWG) 
Within the fabric of the cell wall, Gram-positive bacteria contain additional CWGs. CWG 
structures are highly diverse and their functions are only partially understood (Weidenmaier and 
Peschel, 2008). CWGs differ with regards to their sugar bUilding blocks and non-glycosyl 
residues. According to net charge, CWGs can be classified into zwitterionic, anionic and 
uncharged polymers. Polyanionic CWGs include, for example, pyruvylated polysaccharides from 
S-Iayer-protein-displaying bacilli and their relatives, teichuronic acids and succinylated 
lipoglycans. Uncharged, often branched CWGs are found, for example, in the cell walls of 
Mycobacterium tuberculosis and other actinobacteria (Weidenmaier and Peschel, 2008). 
Zwitterionic CWGs comprise WTA and lipoteichoic acids (LTA). For the needs of this thesis, 
certain characteristics of WTA and LTA will be reviewed. Since the current knowledge on S. suis 
WTA and LTA is insignificant, the following subsections will comprise, for the most part, data 
and conclusions from other organisms. 
3.2.1. Wall Teichoic and Lipoteichoic Acids (WTA and LTA) 
The presence of phosphate groups in the repeating units is the hallmark of teichoic acids 
(Figure 10). Due to the presence of these negatively charged phosphate groups as weil 
modifications with free amino groups that are contained in residues such as D-alanine, teichoic 
acids have zwitterionic properties. WTA are most often formed by glycerol or ribitol groups that 
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are connected by phosphodiester bonds (for example, in S. oureus), although tetroses, hexoses 
or complex sugar combinations have also been described (for example, in S. pneumonioe). The 
polymers are peptidoglycan-attached via the linkage unit (Gro-P) 2 or 3ManNAc-(131-4)-GlcNAc-P 
(Gro-P, glycerol phosphate) to C6 of the MurNAc residues (Araki and Ito, 1989; Coley et al., 
1978). To the best of our knowledge, WTA from S. suis have not been studied, perhaps because 
of technical difficulties. Indeed, attempts to obtain WTA from S. suis using common phenol 
extraction have failed (Elliott et al., 1977). 
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Figure 10. Structures of wall 
teichoic and lipoteichoic acids. 
Trioses, peptoses and hexoses 
are shown as triangles, 
pentagons and hexagon~ 
respectively. Sugars, sugar-
derived aleohols and sugar-
derived acids are shown in 
yellow, orange and purple, 
respectively. Fatty acids are 
shown as zigzag lines. Non-
glycosyl residues: A, D-alanine; C, 
choline; P, phosphate; Glycosyl 
residues: AAT-Gal, 2-acetamido-
4-amino-2,4,6-trideoxy-D-galactose; Ara, arabinose; Gal, galactose; GalNAc, N-
acetylgalactosamine; GIe, glucose; GIeA, glucuronic acid; Gro, glycerol; Ins, inositol; Man, 
mannose; ManNAc, N-acetylmannosamine; Rha, rhamnose; Rto, ribitol. Adapted from 
Weidenmaier and Pesche!. 2008. 
The membrane-anchored LTA are less diverse than WTA. LTA polymers are usually 
formed by Gro-P or ribitol phosphate repeating units and are connected to glycolipids. However, 
more complicated structures have been described; for example, in pneumococci, the LTA 
repeating units of which are identical to pneumococcal WTA (Neuhaus and Baddiley, 2003). The 
l,3-glycerol-phosphate (-Gro-P-) and 1,5 D-ribitol -phosphate monomers are joined via anionic 
phosphodiester linkages to form linear chains (Baddiley, 1972). In many LTAs composed of poly 
(Gro-P) the polymer (which can vary from 5 to 50 units, depending on the species and/or growth 
conditions) is attached to the C6 of the nonreducing glucosyl of the glycolipid anchor (Neuhaus 
and Baddiley, 2003). In staphylococci, Boeil/us sp, and most streptococci (one important 
77 
exception is 5. pneumoniae) the glycolipid is Glc(~1-6)Glc(~1-3)(gentiobiosyl)diacyl-Gro 
(Neuhaus and Baddiley, 2003). It has been reported that the 5. suis LTA has a structure differing 
from that described above, possibly in the attachment of its glucosyl substituents (Elliott et aL, 
1977). Precipitation reactions between 5. suis LTA and Group D antisera were specifically 
inhibited by glucose, but extracts from 5. faeca/is and 5. faecium were not. This fact may indicate 
a monosaccharide glucosyl substituent in teichoic acid from 5. suis instead of the disaccharide 
previously postulated as the glucosyl substituent in the teichoic acid of 5. faecalis. With the 
exception of these findings, very little is known regarding LTA from 5. suis. 
Most teichoic acids are decorated with additional sugars and amino acids. WTA and LTA 
from low G+C Gram positive bacteria are usually modified with D-alanine (Neuhaus and 
Baddiley, 2003), whereas acetyl, glutamyl and Iysyl modifications have been described in WTA 
from high G+C Gram positive bacteria (Neuhaus and Baddiley, 2003; Weidenmaier and Peschel, 
2008). WTAs and LTAs make up a polyanionic network or matrix that provides functions relating 
to the elasticity, po rosit y, tensile strength, and electrostatic steering of the envelope. The D-
alanyl esters of these polymers, resulting from a single D-alanine incorporation system encoded 
by the dIt (for "Q.-alanyl-LTA") operon (see below) (Neuhaus et aL, 1996), constitute important 
substituents for modulating the properties of the envelope in many species. For this reason, 
knowledge of these ester residues is essential for understanding the functions of teichoic acids 
in bacterial physiology as weil as in host-mediated responses. A wide structural diversityof 
WTAs exists among Gram positive bacteria. Some of this diversity is confined to the presence 
and nature of the glycosyl substituents, D-alanyl esters, and repeating units (monomers) 
(Baddiley, 1972; Neuhaus and Baddiley, 2003). 
3.2.2. D-Alanylation of L TA 
Without exception, the alanyl esters of teichoic acids are of the D-configuration 
(Armstrong et aL, 1959). The D-alanyl ester content in WTAs and LTAs is highly variable. The 
molar ratios of D-alanine to P (degree of D-alanylation) in LTA from a variety of species vary from 
not detectable to 0.88. WTAs generally have a lower ratio of D-alanine to P than do LTAs. For 
example, the ratio of D-alanylation (WTAjLTA) in 5. aureus is 0.75 (Neuhaus and Baddiley, 2003). 
The D-alanyl ester contents of LTAs and WTAs of 5. aureus and B. subtilis are a fu nction of the pH 
of the growth medium (MacArthur and Archibald, 1984). Interestingly, 5. mutans deficient in D-
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alanine esters loses its acid tolerance response (Boyd et al., 2000). In addition to medium pH, 
the degree of D-alanylation is a function of the temperature as sublethal heating of s. aureus 
resulted in a loss of 65% of the D-alanyl ester content of teichoic acids (Neuhaus and Baddiley, 
2003). The degree of D-alanylation is also affected by growth on media containing increasing 
concentrations of Nael (Neuhaus and Baddiley, 2003). 
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Figure 11. Model for the 
incorporation of o-alanyl ester 
residues into LTAs. 
DItO provides binding sites for Dite 
(Dcp) and DltA (Del) on the 
cytoplasmic leaflet. DltB provides a 
putative channel for the secretion of 
D-alanyl-Dcp to the periplasm where 
D-alanylation occurs. Adapted from 
Neuhaus and Baddiley, 2003. 
Although biosynthetic pathways for WTA and LTA differ, the D-alanyl-ester substituents 
of WTA are derived from those of D-alanyl-LTA (Neuhausand Baddiley, 2003), consistently with 
a single dltoperon encoding the machinery for D-alanine incorporation(Perego et al., 1995). One 
of the remarkable features of the D-alanyl esters of teichoic acids is their dynamic turnover. For 
example, a t1/ 2 of 37 min was observed for D-alanyl-LTAs in S. aureus growing at pH 7. It was 
postulated that the turnover is an enzyme-catalyzed process. In toluene-treated cells of this 
organism, the D-alanyl esters are lost from LTA and replaced by the ATP-dependent 
incorporation of new ones. "Reesterification" of vacant sites in LTA and WTA maintains the D-
alanyl ester content of both teichoic acids. The rate of D-alanyl LTA synthesis is correlated with 
the rates of ester loss that occurs through transfer to WTA and through "base-catalyzed" 
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hydrolysis. Thus, from both in vitro and in vivo pulse-chase experiments, it was concluded that 
the D-alanyl esters of LTA are the precursors of those in WTA (Neuhaus and Baddiley, 2003). 
Isolation of the gene encoding the activating enzyme (dltA) from L. rhamnC?sus ATCC 
7469 provided the key for identifying the role of this enzyme in D-alanine incorporation (Heaton 
and Neuhaus, 1992). The enzyme (DltA, Del) is a member of a large protein family that both 
activates and transfers amine or fatty acids via a 4'-phosphopantetheine prosthetic group of a 
carrier protein or coenzyme A (Neuhaus and Baddiley, 2003). A heat-stable protein encoded by 
c1ltC contains this prosthetic group and functions as the D-alanyl carrier protein (DltC, Dcp) 
(Heaton and Neuhaus, 1994). Thus, DltA not only activates D-alanine but also ligates the 
activated ester to the 4'-phosphopantetheine prosthetic group of the carrier protein. Therefore, 
the activating enzyme is now designated D-alanine:DltC ligase (AMP forming) (Neuhaus and 
Baddiley, 2003). In addition to dltA and dltC, the operon contains two additional genes, dltB and 
ditO. The hydropathy profile of DltB shows a pattern of 12 putative membrane-spanning 
domains (Neuhaus et aL, 1996). While it is not established, it has been suggested that one of the 
functions of DltB is the secretion of unfolded D-alanyl-DltC (Neuhaus and Baddiley, 2003). The 
reversibilityof the thermal denaturation of DltC is consistent with this suggestion (Volkman et 
aL, 2001). Comparison of DltB with a variety of O-acyltransferases identified two conserved 
motifs that may also link this transport protein to a superfamily of membrane-bound 0-
acyltransferases (Hofmann, 2000). Whether DltB functions in the actual secretion of D-alanyl-
DltC, whether it functions as an acyltransferase, or whether it is bifunctional is not known. The 
membrane protein, DltD, functions in the selection' of the correct carrier protein, DltC, for 
ligation with D-alanine and in the hydrolysis of mischarged D-alanyl-acyl carrier proteins 
(Debabov et aL, 2000). It has been proposed that DltD facilitates the binding of DltC and DltA for 
ligation of DltC with D-alanine and that DltD functions in the final esterification step (Neuhaus 
and Baddiley, 2003). The transfer of the D-alanyl residue from D-alanyl-Dcp to LTA requires only 
that the acceptor LTA be membrane associated (Heaton and Neuhaus, 1994). None of the acyl 
carrier proteins involved in fatty acid metabolism replace the requirement for Dcp, even though 
Dcl ligates D-alanine to acyl carrier proteins in the absence of DltD (Heaton and Neuhaus, 1994). 
Figure 12 summarizes the current proposed mechanism of D-alanyl ester incorporation to LT A. 
80 
3.2.3. Roles of WTA and L TA in attachment, colonization and virulence 
S. aureus mutants that lack WTA are profoundly inhibited in their ability to bind to nasal 
epithelial cells, and were unable to colonize the nares of cotton rats in an experimental nasal 
colonization model (Weidenmaier, 2004, 2008). WTA seems to play a similar role in S. aureus 
adhesion to endothelial cells (Weidenmaier, 2005b). The impact of WTA deficiency is markedly 
increased under flow conditions in which the bacterial cells move over the host cell surface with 
sufficient velocity. In vitro and in vivo evidence indicate that WTA contributes to a similar extent 
to S. aureus adhesion to epithelial and endothelial cells as staphylococcal proteinaceous 
adhesins that bind, for example, to fibronectin or fibrinogen, and a lack of WTA does not seem 
to influence adhesin activities (Weidenmaier, 2005b). 
LTA has also been implicated in adhesion to host cells. It has been shown that S. suis 
LTAs are important for adhesion of this bacterium to porcine BMEC. Indeed, inhibition of the 
adhesion of S. suis to this cellular type can be obtained by pre-incubation of PBMEC with 
purified LTA (Vanier et al., 2007). In other species, inactivation of the dIt operon resulted in a 
significantly reduced ability of S. aureus to bind to epithelial and endothelial cells and cause 
infections (Weidenmaier, 2005a). In addition, formation of D-alanyl-LTAs has been shown to be 
required to resist the action of antimicrobial peptides in L. monocytogenes, S. aureus, S. 
pneumoniae, GAS and GBS (Abachin et al., 2002; Kovacs et al., 2006; Kristian et al., 2005; Poyart 
et al., 2003; Weidenmaier et al., 2005). In addition, virulence of S. aureus mutants deficient in 
LTA D-alanylation was severely impaired in rabbit models of infection (Weidenmaier et al., 
2005). Similar observations have been made upon deletion of the dIt operon in L. 
monocytogenes (Abachin et al., 2002) and GAS (Kristian et al., 2005). 
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Abstract 
Using the selective capture of transcribed sequences (SCOTS), we identified 28 genes 
preferentially expressed by the major swine pathogen and zoonotic agent Streptococcus suis 
upon interaction with porcine brain microvascular endothelial cells. Several of these genes may 
be considered new s. suis virulence factor candidates. Results from this study demonstrate the 
suitability of SCOTS for the elucidation of gene expression in streptococcal species and may 
contribute to a better understanding of the pathogenesis of s. suis infections. 
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Main Text 
5treptococcus suis is a Gram-positive bacterium responsible for, among other diseases, 
meningitis and septicemia in swine (14). 5. suis is also a zoonotic agent: Many cases of humans 
5. suis infections have been reported in different Asian and European countries as weil as in New 
Zealand, Australia, Argentina and Canada (25). Very recently, the first case of human meningitis 
caused by 5. suis was recorded in the United States (43). Indeed, 5. suis is increasingly becoming 
a public health concern. For instance, during a recent outbreak in China more than 200 cases of 
human 5. suis infection were reported, 39 of which resulted in death (33,45). Despite increasing 
research in recent years, knowledge on the pathogenesis of 5. suis infection remains limited (11, 
14). Only the capsular polysaccharide (CPS) and a recently described serum opacity-like factor 
have been shown to play a critieal role in the pathogenesis of the infection (3, 14). Proposed 
putative virulence factors such as the suilysin, the extracellular protein factor (EF) and the 
muramidase-released protein (l'v1RP), although associated to virulence, have been found to be 
nonessential factors (6, 14). Other determinants, such as a fibronectin/fibrinogen-binding 
protein were found to be partially involved in virulence (6, 14) while the actual role of some 
other virulence candidates (e.g., the cell wall and several putative adhesins and proteases) in the 
pathogenesis of 5. suis infection remains to be verified (11, 14). 
5. suis needs to attain the central nervous system (CNS) in order to cause meningitis in 
swine. It has been suggested that this pathogen might reach the CI\lS by crossing the porcine 
blood brain barrier (BBB) by transcytosis through porcine brain mierovascularendothelial cells 
(PBMEC) and/or porcine choroid plexus epithelial cells (PCPEC), as weil as by disruption of the 
barrier caused by toxie effects on BBB forming cells (11, 36). Support for these mechanisms has 
been provided by recent studies showing that 5. suis is able to affect the viability of PCPEC 
through necrotic and apoptotic mechanisms {37} and to adhere to and to invade in vitro-
cultured PBMEC (38). However, little is known on the molecular means by which 5. suis 
accomplish these processes. 
The selective capture of transcribed sequences (SCOTS) is a PCR-based RNA analysis 
method that offers several advantages in comparison to other genomic approaches such as the 
in vivo expression technology (IVET) or the signature tagged mutagenesis {STM} (29). In fact, 
SCOTS directly identifies bacterial genes rather than promoter regions andis not confounded by 
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polar effects when genes are arranged in polycistronic operons (29). The SCOTS approach has 
been used with success in many Gram-negative bacteria as weil as in Mycobacterium 
tuberculosis and Listeria monocytogenes (S, 10, 13, 22). In this work, we used the SCOTS 
approach in order to identify genes preferentially expressed by S. suis during its interactions 
with cells of the BBB, a process that might be essential for the pathogenesis of the meningitis 
caused by this pathogen. 
Experimental model and bacterial transcriptome recovery. 
S. suis serotype 2 highly virulent strain 31533 (38) and the PBMEC line PBMEC/Cl-2 (34) 
were used in this study. PBMEC were grown in Primaria 6-well tissue culture plates (Becton 
Dickinson, Franklin Lakes, NJ) using IF culture medium (a mixture of 1:1 Iscove's modified 
Dulbecco's and Ham's F-12 media, Invitrogen, Burlington, ON, Canada) as previously described 
(38). S. suis was grown in Todd-Hewitt broth (Becton Dickinson, Sparks, MD) for 16 h at 37"C, 
harvested by centrifugation, washed twice in phosphate-buffered saline, pH 7.3 and 
resuspended in fresh IF culture medium at 106 CFU/ml. Confluent monolayers of PBMEC (at 3 x 
106 cells per weil) were inoculated with 3 ml of this bacterial suspension (MOI=l). Plates were 
centrifuged at 800 x 9 for 10 min and incubated for 4 h at 37"C with 5% CO 2 • After incubation, 
actual S. suis adhesion to and invasion of PBMEC were verified in selected wells and found to be 
in agreement with reported values (38) (data not shown). For identification of genes transcribed 
during interaction, total RNA from S. suis infected PBMEC cells was prepared from 24 
independent P6-wells using RNAwiz (Ambion, Austin, TX) according to the manufacturer's 
instructions. Total RNA from S. suis grown under the same conditions but without cells (mock-
infection) was prepared from 5 P6-wells. Samples were treated with TurboDNAse (Ambion), and 
absence of contaminating DNA was verified by PCR using primers AROA-F and BA9 (Table 1), 
which target the aroA gene. RNA was quantified by measurement of absorbance at 260 nm and 
its integrity was verified by visualization on 1% denaturing agarose gels. 
Selective capture of transcribed sequences 
Five Ilg of total RNA prepared from both infection and mock-infection samples were 
reverse transcribed by random priming using SuperScript Il (Invitrogen). Primers CELL-RNA or 
MOCK-RNA, with· a defined terminal sequence at the S'-end and a random nanomer at the 3'-
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end were used (Table 1). Thereafter, cDNA sequences corresponding to bacterial mRI\JAs were 
selectively captured from the mixture of total PBMEC-S. suis RNAs or total s. suis RNAs by 
performing 3 rounds of SCOTS as previously described (5). Briefly, samples were normalized by 
self hybridization, then hybridized overnight at 68D C to biotinylated genomic s. suis 31533 DNA 
that had previously been blocked using PCR-generated DI\JA representing 16S and 23S s. suis 
rRNA sequences (primers RDNA-F and RDNA-R, Table 1). Bacterial cDNAs were then separated 
using streptavidin-coupled magnetic beads. After elution, cDNAs were PCR re-amplified using 
primers CELL-PCR or MOCK PCR (Table1), that correspond to the defined sequences added 
during reverse transcription and specifie to each condition. Sequences preferentially transcribed 
by s. suis upon interaction with PBMEC were obtained after three rounds of enrichment carried 
out as previously described (5). Briefly, cDNAs obtained during PBIVIEC interaction were 
subjected to the procedure outlined above, but this time the biotinylated genomic s. suis DNA 
used for capture had previously been pre-hybridized with DNA sequences corresponding to 16S 
and 23S s. suis rRNA and cDNAs from the mock infection. Resulting interaction-specifie cDNAs 
were cloned into vector pCR4 (TOPO TA Cloning kit, Invitrogen) and sequenced. DNA sequences 
were determined at the DNA Sequencing Facility of the University of Maine (Orono, ME), on a 
373A DNA Sequencing System (Applied Biosystems, Foster City, CA). 
Identification of preferentially expressed genes 
The BLAST software package was used to determine sequence homologies in the 
GenBank data bases (http://www.ncbi.nlm.nih.gov/BLAST/). Sequence comparison was also 
performed against sequence data produced by the s. suis Sequencing Group at the Sanger 
Institute (http://www.sanger.ac.uk/cgi-bin/blast/submitblast/s suis) for European strain P 1/7 
and at the Joint Genome Institute Microbial Genomics (http://genome.jgi-psf.org/cgi-
bin/runAlignment?db=strsu&advanced=l) for North American strain 89-1591. We report in this 
study the identification, using SCOTS, of 28 genes as being preferentially expressed by s. suis 
upon interaction with PBMEC. These genes can be divided into 8 functional groups: 
metabolismjhousekeeping, cell envelope, secreted proteases, cell divisionjreplication, 
regulatory, protein sorting and transportfbinding related genes, as weil as genes with unknown 
function. To the best of our knowledge, none of the identified genes has ever before been 
associated to the s. suis pathogenesis of infection. Similar to other studies on host-pathogen 
interaction (2, 5, 31), most of the genes identified by SCOTS in this study are putatively involved 
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in metabolic/housekeeping functions and do not encode "genuine" virulence factors. However, 
identification of these genes may be of importance, since new information about the 
metabolism of S. suis is rendered that may eventually prove useful for vaccine development. On 
the other hand, some genes identified using SCOTS in this study are known to be important for 
the virulence of other Gram-positive bacteria (including at least three different streptococcal 
species). The relevance of these genes will be discussed below. For ail other genes identified in 
this study, putative functions as weil as references to publications describing in vivo expression 
and/or involvement in virulence in other organisms are listed in Table 2. 
Validation of SCOTS results by quantitative PCR 
The SCOTS approach, as used in this study, should result in the identification of genes 
that are upregulated by S. suis upon interaction with PBMEC (5). Therefore, to validate our 
SCOTS results, we measured by quantitative PCR (q-PCR) the level of expression of random 
selected genes on a new series of infection replicates. Infection of PBMEC, mock-infections and 
RNA extraction from both samples was performed as described above. cDNAs were synthesized 
in triplicate by using SuperScript Il with random hexamers (Roche, Laval, Qc, Canada). Q-PCR was 
performed by using the QuantiTect SybrGreen PCR Kit (Qiagen, Mississauga, ON, Canada) 
according to the manufacturer's instructions. For each sample, a no-reverse transcription 
reaction was run as a control. Primers are described in Table 1. For each q-PCR run, the 
calculated threshold cycle (Ct) was normalized to the Ct of the internai control rpoO gene 
amplified from the corresponding sample, and the fold change was calculated using the 2-
[l?elta][Delta] Ct method, as described (23). Results of q-PCR analysis for these selected genes 
showed that they were indeed upregulated by S. suis upon interaction with PBMEC (Figure 1), 
with fold changes ranging from 2.18 to 10. The gene aroA, known to be expressed in equal 
amounts in both conditions (our unpublished results), was also used. 
Genes involved in cell envelope modification 
As stated above, some genes identified by SCOTS might be considered, based on their 
functions in other organisms, as potential virulence factor candidates for S. suis. For instance, 
the gene ssu0597 (dltB) belongs to an operon comprising four genes, dltA, dltB, dltC, and dItO, 
which is prese;nt in ail genomesof low-G+c bacteria determined so far (28). In ail species where 
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this operon has been studied, ail four genes are required to catalyze the incorporation of D-
alanine residues into the lipoteichoic acids (LTAs). D-alanylation of LTAs allows Gram-positive 
bacteria to modulate their surface charge, to regulate ligand binding and to control the 
electromechanical properties of the cell wall (28). In addition, formation of D-alanyl-LTAs is 
required to resist the action of antimicrobial peptides in L. monocytogenes, Staphylococcus 
. aureus, Streptococcus pneumoniae, Streptococcus pyogenes (GAS) and Streptococcus agalactiae 
(GBS) (1, 20, 21, 30,42). Besides, virulence of mutants deficient in D-alanylation of LTAs of GBS, 
L. monocytogenes or s. aureus was severely impaired in the murine or rabbit models of infection 
(1,30,42). The D-alanylation of s. suis LTAs has not yet been documented. However, it is known 
that wild-type S. suis LTAs are important for adhesion of this bacterium to PBMEC. Indeed, 
inhibition of the adhesion of s. suis to this cellular type can be obtained by pre-incubation of 
PBIVIEC with purified LTA (39). From our SCOTS results, it might be hypothesized that S. suis 
might be able to modulate the degree of D-alanylation of its LTAs by upregulation of its dIt 
operon upon interaction with PBMEC. Further studies focusing on this operon of s. suis are 
underway to evaluate this hypothesis. However, it is interesting to note that in some Gram-
positive pathogens it has been shown that D-alanyl-LTAs contribute to adhesion to and invasion 
of various cell lines and that these steps may depend on a high ratio of D-alanine to 
glyceroljribitol phosphate in their LTAs (1, 21, 30, 42). 
The main c1inical feature of s. suis is meningitis, and this bacterium is often isolated 
from the CSF of animais or patients with meningitis (14). On the other hand, it has been 
reported that patients suffering from meningitis present increased titers of lysozyme in their CSF 
(19). As shown in this study, S. suis differentially expressed a gene (ssu1448) highly homologous 
to S. pneumoniae pgdA, which encodes a peptidoglycan N-acetylglucosamine deacetylase. 
Peptidoglycan is an essential component of the bacterial cell wall and an important target for 
the innate immune system. Peptidoglycan modification by deacetylation seems to be important 
for Gram-positive pathogens. Indeed, pneumococci in which pgdA was inactivated became 
hypersensitive to the action of lysozyme (41) and showed reduced virulence in a murine model 
of infection (40). In addition, it has very recently been reported that a pgdA mutant strain of L. 
monocytogenes was impaired in its ability to induce disease in the murine model of infection 
and that the pgdA gene was required by this species to resist the host innate immune response 
mediated by lysozyme (4). In this regard, it may be of interest to further evaluate the hypothesis 
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that S. suis, through the action of the pgdA gene product, has the ability to modify its 
peptidoglycan by deacetylation and, therefore, resist a host innate response mediated by this 
enzyme. On the other hand, it is intriguing that, in our in vitro model, where the immune 
response of the host would not be as relevant as in the in vivo situation, the pgdA gene was 
found to be highly upregulated. However, it has been proposed that, in vivo, S. suis might gain 
access to the CNS by transcytosis across PBMEC (38). It might therefore be plausible that du ring 
the interactions with PBMEC, in addition to genes required for adhesion/invasion of these cells, 
S. suis also upregulates genes required for the steps immediately following the BBB crossing. 
Further studies are required to evaluate this hypothesis. 
Identification of a putative pilus island in S. suis 
Pili in several Gram-positive bacteria have recently been described and it has been 
proposed that they may play an important role in virulence (35). For instance, in GBS, pili 
participate in adhesion to human epithelial cells (7) and their role in adhesion to extracellular 
matrix (ECM) proteins has been suggested (27). In this work we identified a gene (ssu0424) 
putatively encoding a signal peptidase homologous to the LepB-type signal peptidases of Gram-
negative bacteria. An homologous LepB-type signal peptidase is the first gene in the GBS pilus 
island 2b (PI-2b), one of the 3 identified pili islands in this species (35). The GBS PI-2Q contains 5 
other downstream genes, encoding two LPXTG proteins (suggested to be an ancillary protein 
and the main pilus subunit), a class C sortase, a third LPXTG protein (ancillary protein) and a 
second class C sortase (35) (Figure 2). The presence of thin pilus-like structures on the surface of 
S. suis has been revealed by electron microscopy (15). Interestingly, analysis of data from the 
two S. suis sequencing projects strongly suggests that S. suis possesses a truncated version of 
this pilus island. As a matter of fact, in S. suis sequenced strains P 1/7 and 89-1591, two genes 
encoding LPXTG proteins (highly homologous to the ancillary and main pilus subunits of GBS, 
respectively) and a gene encoding an undescribed putative class C sortase-like protein are found 
downstream the LepB signal peptidase that was identified by SCOTS (Figure 2). Although the S. 
suis putative pilus island lacks the last 2 genes in comparison to that of GBS, the similarity of the 
genetic organization, the strong homology showed by the LPXTG proteins to the main and 
ancillary pilus proteins of this latter species and the current proposed mechanism for pili 
formation in Gram-positive bacteria (7, 27), suggest that a pilus might be formed by the gene 
products of this island. In addition, we speculate that this pilus might participate in S. suis 
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adhesion to or invasion of PBIVIEC. In fact, pili have been very recently shown to be important 
for GBS adhesion to and invasion of human BMEC (26). Although functional analysis of this S. 
suis putative pilus island is needed to fully evaluate this hypothesis, it is interesting to note that 
the LepB signal peptidase was found to be highly upregulated by q-PCR (4-fold change) upon 
interaction of S. suis with PBMEC (Figure 1). Additionally, we identified in this study the gene 
ssu0453, previously named srtE and encoding one of the 4 class C sortases already described in 
s. suis (8, 29). In GBS and GAS models of pili assembly, class C sortases have been proposed to 
catalyze the covalent polymerization of the pilin subunits encoded by genes within the pilus 
island bearing the class C sortases (7, 27). However, previous work on S. suis (29), as weil as 
analysis of sequenced strains P 1/7 and 89-1591, indicate that the s. suis srtE gene is not flanked 
by genes encoding LPXTG proteins and, as such, it does not seem to be part of a pilus island. 
Therefore, a putative participation of s. suis ssu0453/srtE in pili formation following the 
proposed model is unlikely. However, it might be interesting to evaluate whether this sortase 
might be required for, or contribute to, the assembly of pilin subunits encoded by the island 
described in this work or by other, yet unidentified islands. 
Interaction of S. suis with ECM proteins 
It has been shown that S. suis is able to interact with ECM proteins (9). As weil, S. suis 
has the ability to degrade ECM proteins through the upregulation of metalloproteinase 9 
production by human macrophages (16), that may result in tissue destruction and BBB 
disruption. However, the direct ability to degrade ECM proteins has not yet been demonstrated 
for S. suis. Interestingly, one of the genes identified by SCOTS (ssu0457) is a putative 
collage nase, which, in sequenced strains P 1/7 and 89-1591, is located upstream of a gene 
putatively encoding a second collage nase, in an operon-like organization. It has been suggested 
that the impairment of BBB barrier function during infection with different S. suis strains may 
depend on proteases produced by this pathogen (17). It is thus tempting to speculate, even if 
we lack evidence regarding its exact function, that upregulating the expression of the 
collagenase identified in this work upon interaction with PMEC might, in vivo, be useful to 
increase the permeability of the BBB and therefore contribute to the migration of s. suis to the 
CNS. 
Suitability of the SCOTS approach to elucidate gene expression in S. suis 
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The SCOTS approach has been used with success in several bacterial species (S, 10, 13, 
22). To the best of our knowledge, this is the first report of its use in a streptococcal species. 
Results presented here clearly demonstrate that SCOTS is also suitable for the elucidation of 
gene expression in streptococci and particularly in organisms like S. suis, for which very few 
molecular tools exist. Indeed, with the exception of the present study, only one genomic 
approach has been used· to study this pathogen (32). In that work, an adapted in vivo expression 
technology (lVET) approach identified several S. suis iron-induced and/or in vivo (porcine 
infection model)-expressed genes (32). However, ail the genes identified in that study were also 
expressed in vitro under standard laboratory growth conditions. These results can be explained 
by the absence of promoter sequences exclusively expressed under the conditions tested (32). 
However, since a plasmid-based instead of an integrative promoter trap system was used, 
results might as weil be explained by the inability of that system to detect in vitro silent genes 
due to gene dose effects (32). On the other hand, using SCOTS we clearly showed condition-
specific differences in S. suis gene expression. In fact, currently, SCOTS may be considered the 
only approach available for the direct study of global differential gene expression in S. suis. 
Despite the fact that IVET and SCOTS have identified the same genes in some cases (31), there 
were no overlapping genes between the IVET and SCOTS S. suis studies. This was not surprising, 
however, since only a small number of genes were identified in either study, and, more 
importantly, the experimental conditions used were essentially different. Therefore, in this 
study, the use of the SCOTS approach resulted in original insights on the molecular mechanisms 
that this pathogen might use to cross the BBB. Indeed, the identification of the 28 genes 
preferentially expressed upon interaction of S. suis with PBMEC, several of which show a great 
potential as virulence factor candidates, may result in a better understanding of how this 
pathogen causes meningitis. In addition, extending the SCOTS analysis to identifytranscriptional 
differences at different in vivo localizations (Le., brain, heart, tonsils) as weil as at different 
stages of infection may lead to the comprehension of the mechanisms of disease progression 
and provide clues to its prevention. 
Addendum in proof 
While this work was under revis ion an article was published (44), describing the use of 
the STM approach to study genes important for the virulence of S. suis in a pig model of 
infection. The gene ssu0457 reported in the present article was also found in that study. 
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Article 1 Tables 
J'able Il. Article l, Table 1. Oligonucleotide primers used in this study. 
Primer name Sequence (5'-3'1 
AROA-F AACGTGACCTACCTCCGTIG 
AROA-R 
CELL-RNA 
MOCK-RNA 
RDNA-F 
RDNA-R 
MOCK-PCR 
CELL-PCR 
RPOD-F 
RPOD-R 
SSU0424-F 
SSU0424-R 
SSU0870-F 
SSU0870-R 
SSU0067-F 
SSU0067-R 
SSU1448-FQ 
SSU1448-RQ 
SSU0457-F 
SSU0457-R 
SSU0597-F 
SSU0597-R 
CGGTCATCGTAGAATICGAGT 
GACACTCTCGAGACATCACCGGT ACCN NN N N NN NI\! 
CTIAGCCACTACGTGCGGATCCAGACNNNNNNNNN 
GGCTCAGGACGAACGCTG 
GCTAAGCGACTACCGTATCT 
CTIAGCCACTACGTGCGGATCCAGAC 
GACACTCTCGAGACATCACCGGTACC 
TCTTICAAATACATGCGGACTG 
ATICCATTIACGCTIGATGCTG 
AATCAAAGATIGGACGAGCC 
CAATCCATCCCAATICAGACAG 
GGTATCATGAATACGGACGAAG 
GAATGGATGGGCAATGAGAG 
ATCAATCATCAAGGGATGCG 
GATAGCCACCTCTITTICCAC 
TICTCTCTGTACTIGCTCCC 
GGTCGCTCTAACCTTIGATG 
ACCCAGATAGCCACTATICC 
CTGATCATAAGTGAAGTCGCC 
TGCGTCTGGTIAAGACTTIG 
GTICTIGCCCAGC 1 1 1 1 1 1 1 C 
99 
100 
Table III. Article l, Table 2. Genes differentially expressed by s. suis upon interaction with 
porcine brain microvascular endothelial cells identified using selective capture of transcribed 
sequences. 
Clone Gene 1 Putative function [Organism] Genbank 10 
Metabolism 1 Housekeeping 
03C3 ssu0707 Putative exonuclease RexB [5. suis ZP _00874950 
89/1591]. 
2H6 ssu0767 1-phosphofructokinase [5. suis 89/1591]. ZP _00875124 
2G7 ssu1411 Aminotransferase, class 1 and Il [5. suis ZP _00875661 
89/1591] 
03G2 ssu1527 Aminodeoxychorismate Iyase-like protein ZP _00876086 
[5. suis 89/159H 
1B7 ssu1445 Uridine kinase 
CNRZ1066]. 
[5. thermophilus AAV _62804 
01B7 ssu0844 Haloacid dehalogenase-like hydrolase [5. ZP _00874652 
suis 89/1591]. 
1G10 ssu1044 Ribonucleoside-diphosphate reductase ZP _00875241 
[5. suis 89/1591]. 
01H10 
1C7 
2F10 
1All 
ssul159 Ribosome recycling factor [5. suis ZP _00875081 
89/1591]. 
ssu0870 Nucleotidyl transferase [5. suis 89/159~.] ZP _00874394 
ssu0871 Glucose-1-phosphate adenylyltransferase ZP _00874395 
[5. suis 89/1591]. 
ssu0764 tRNA (guanine-N1-)-methyltransferase [5. ZP _00875121 
suis 89/1591]. 
Cel! envelope 
2A11 ssu0597 Membrane bound O-acyl transferase, ZP _00875261 
OltB [. suis 89/1591]. 
2A8 
1H9 
1E9 
01Gll 
Regulatory 
ssu1184 O-alanine-O-alanine ligase [5. suis ZP 00875052 
89/1591]. 
ssu1448 Peptidoglycan polysaccharide ZP _00876135 
deacetylase PgdA [5. suis 89/1591] 
ssu1487 VanZ like protein [5. suis 89/1591]. ZP _00875572 
ssul114 Glycosyl transferase, group 1 [5. suis ZP _00875224 
89/1591]. 
0204 ssu0869 Putative transcriptional regulator, LysR AAK74821 
family [5. pneumoniae TIGR4]. 
Protein sorting 
1C11 ssu0424 Signal peptidase S24, S26A and S26B [5. ZP _00875273 
suis 89/1591]. 
1B8 ssu0453 Sortase-like protein SrtE [5. suis] BAB83972 
Secreted proteases 
01E9 ssu0457 Collagenase-Peptidase U32 [5. suis]. BAB83975 
Cel! division 1 Replication 
1G5 ssu0002 ONA polymerase III, ~-chain [5. suis ZP _00875475 
89/1591]. 
Reference 
(24) 
(12) 
(12) 
(18) 
(40,41) 
(12) 
(29) 
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2F4 ssu0432 Cell division protein FtsQjDivlB [5. suis ZP_OO876117 (12) 
89/1591] 
TransQort L Binding 
D1H3 ssu1787 Multidrug ABC transporter, ATP-binding AAU18528 
protein [B. cere us E33L]. 
D3Gl ssul023 Putative permease [5. suis 89/1591] ZP_OO874974 
Unknown function 
D1Gl ssuOO67 Protein of unknown function DUF925 ZP_OO876271 
[5treptococcus suis 89/1591]. 
2F6 ssu1424 Hypothetical protein [5. suis 89/1591] ZP_OO875489 
D1H2 ssu0858 Protein of unknown function UPF0153 [5. ZP_OO875788 
suis 89/1591.]. 
D1A3 ssu1792 Conserved hypothetical protein [5. suis ZP_OO876058 
Genes named after 5. suis strain P 1/7 sequencing project nomenclature. 
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Figure 12. Article l, Figure 1. Fold change in expression of selected S. suis genes identified by 
SCOTS as measured by q-PCR upon interaction of the bacterium with PBMEC. 
See the text for details. 
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Figure 13. Article l, Figure 2. Putative pilus island in S. suis (upper panel) and its counterpart, 
pilus island 2b (PI-2b), found in S. agalactiae strain COHl (Iower panel). 
ln S. suis, the first gene of the locus is a LepB-type signal peptidase (identified by SCOTS and q-
PCR to be upregulated upon interaction with PBMEC), which is followed downstream by a 
putative ancillary protein and a main pilus subunit. A previously undescribed class C sortase is 
the last gene of the island. The S. agalactiae PI-2b, which is organized in a similar way, 
comprises an additional ancillary pilus subunit and a second class C sortase (Genbank entry 
NZ AAJR01000022). 
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Abstract 
We generated by allelic replacement a l1d/tA mutant in a virulent Streptococcus suis 
serotype 2 field strain and evaluated the contribution of lipoteichoic acid (LTA) D-alanylation to 
the virulence traits of this swine pathogen and zoonotic agent. Absence of LTA D-alanylation 
resulted in increased susceptibility to the action of cationic antimicrobial peptides. In addition, 
and in contrast to the wild type strain, the l1d/tA mutant was efficiently killed by porcine 
neutrophils and showed diminished adherence to and invasion of porcine brain microvascular 
endothelial cells. Finally, the l1d/tA mutant was attenuated in both the CDl mouse and porcine 
models of infection, probably reflecting decreased ability to escape immune clearance 
mechanisms and impaired capacity to traverse across host barriers. The results of this study 
suggest that LTA D-alanylation is an important factor in S. suis virulence. 
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Introduction 
Streptococcus suis is a major swine pathogen and a zoonotic agent responsible for, 
among other diseases, meningitis and septicemia (15). In swine, S. suis causes severe losses to 
the industry (15) while human S. suis infection is emerging as an important public health issue 
(13). Very recently, more than 200 cases of human S. suis infection were reported during an 
outbreak in China, 38 of which resulted in death (39). S. suis is consi~ered the primary cause of 
adult meningitis in Vietnam (20) and human S. suis infection resulting in death or in severe post-
infection sequelae has already been reported in different Asian and European countries as weil 
as in New Zealand, Australia, Argentina, Canada and the United States (13). Among S. suis 
serotypes, serotype 2 is responsible for most cases of disease in both swine and humans, and 
almost ail studies on virulence factors and pathogenesis of the infection have been carried out 
with this serotype (13, 15). Despite the increasing number of studies, our understanding of the 
pathogenesis of S. suis infection remains limited. The polysaccharide capsule is known to play a 
critical role in the pathogenesis of S. suis infection (15). It has been shown that unencapsulation 
of S. suis correlated with increased phagocytosis by porcine macrophages and killing by porcine 
neutrophils (4, 6, 29) and that it severely impaired virulence in a porcine model of infection (29). 
Recently, an isogenic mutant for a serum opacity-like factor was found to be highly attenuated 
in pigs (2). Other proposed putative virulence factors su ch as the suilysin, the extracellular 
protein factor, the muramidase-released protein and a fibronectin/fibrinogen-binding protein 
were found to be associated with and/or partially involved in, but not essential for, virulence (7, 
15). 
S. suis can affect the viability of porcine blood brain barrier (BBB)-forming cells such as 
porcine choroid plexus epithelial cells (CPEe) through necrotic and apoptotic mechanisms (34). It 
also can adhere to and invade in vitro-cultured porcine brain microvascular endothelial cells 
(porcine BMEe), another type of BBB-forming cells (35). The ability of S. suis to interact with 
these cells is thought to be important for attaining the central nervous system (CNS) and causing 
meningitis in swine (13). In a recent study (11), the selective capture of transcribed sequences 
(SCOTS) approach was used to elucidate genes that this pathogen preferentially upregulates 
upon its interactions with porcine BMEC. Among other genes, the study identified a gene 
member of a putative S. suis dIt operon (11). In ail bacteria where this operon has been studied, 
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it has been found to be responsible for the incorporation of D-alanine residues into lipoteichoic 
acids (LTA), surface-associated amphiphilic molecules found in most Gram positive bacteria (23). 
The cell wall of S. suis has been proposed as an important virulence factor. Several 
studies have shown that the cell wall or its purified components such as the LTA contribute to 
exacerbate the host inflammatory response to infection (13, 15). However, the structure and 
composition of S. suis LTA are poorly known. I~ has been proposed that LTA from S. suis may 
have a backbone structure similar to that of Group A streptococcal teichoic acid, but with 
differences in the attachment of glucosyl substituents (9). Besides its involvement in 
inflammation, LTA may also play a direct role in S. suis virulence. Indeed, a recent study has 
shown that inhibition of the adherence of S. suis to porcine BMEC can be obtained by pre-
incubation of the cells with purified LTA (36). In addition, it has been proposed that S. suis may 
D-alanylate its LTA and that a high ratio of D-alanine to glycerol phosphate in this molecule may 
be important for the interaction of this pathogen with host cells (11). It is known from previous 
reports that D-alanylated LTA is important for the virulence of Gram-positive pathogens based 
on findings that it enables these organisms to modulate their surface charge, to regulate ligand 
binding and to control the electromechanical properties of the cell wall (23). In addition, 
formation of D-alanyl-LTA is required to resist the action of cationic antimicrobial peptides 
(CAMPs) (1, 17, 18, 26). The D-alanylation of S. suis LTA and its contribution to the pathogenesis 
of infection have yet to be documented. In this study, we demonstrate that S. suis D-alanylates 
its LTA and that this modification is important for the virulence traits of this pathogen. 
Materials and methods 
Bacterial strains, plasmids, media, culture conditions and chemicals. 
Bacterial strains and plasmids used in this study are listed in Table 1. Unless otherwise 
indicated, S. suis strains were grown in Todd-Hewitt {Becton Dickinson, Sparks, MD} broth (THB) 
or agar (THA) at 3rC under 5% CO2• Escherichia coli strains were cultured in Luria-Bertani (LB) 
broth or agar medium (Becton Dickinson) at 3rc. When needed, antibiotics (Sigma, Oakville, 
Ontario, Canada) were added to the culture media at the following concentrations: for S. suis, 
chloramphenicol (Cm) at 5 Ilg/ml and spectinomycin (Sp) at 100 Ilg/ml; for E. coli, kanamycin 
108 
(Km) and Sp at 50 ~g/ml; Cm at 10 ~g/ml. Unless otherwise indicated, ail chemicals were 
purchased from Sigma. 
DNA manipulations. 
Restriction enzymes, DNA-modifying enzymes and Taq and Pwo DNA polymerases were 
purchased from GE Healthcare (Piscataway, l'lU, USA) or Takara Bio (Otsu, Shiga, Japan) and used 
according to the manufacturers' recommendations. S. suis genomic DNA was prepared by the 
guanidium thiocyanate method (24). Mini-preparations of recombinant plasmids from E. coli 
and transformation of E. coli were performed by standard procedures (27). Southern 
hybridizations were performed by the procedures described previously (28), except that 
hybridization was carried out at 68°(, For preparation of probes, DNA fragments were labelled 
with digoxigenin (DIG) using the DIG-PCR labeling mixture (Roche Diagnostics, Laval, Qc, Canada) 
according to the manufacturer's instructions. Oligonucleotide primers were from Invitrogen 
(Burlington, Ontario, Canada). 
Allelic replacement. 
(j) Construction of the knockout vector. DNA fragments corresponding to regions 
upstream and downstream the dltA gene (Fig. lA) were amplified from genomic DNA of S. suis 
strain 31533 by PCR using the primer sets 2872F plus 3765R (Ieft arm) and 5250F plus 5809R 
(right arm). A Sp resistance cassette (gene aad9) was amplified from plasmid pSmali with 
primers specF3 and specR. Ail three primers sets introduce unique restriction sites (Table 2). PCR 
amplicons were digested using the appropriate restriction enzymes, and sequentially ligated in 
the order left arm-Sp cassette-right arm using T4 DNA ligase. The resulting fragment was 
amplified by PCR using primers 2872F and 5809R, c10ned into vector pCR4 (TOPO TA PCR c10ning 
kit; Invitrogen), excised with Hindlll and BamHI and recloned into the Hindlll and BamHI sites of 
the temperature sensitive S. suis-E. coli shuttle vector pSET5s, which carries the gene cat 
conferring Cm resistance (32), giving rise to knockout vector p5~dltA (Fig. lB). (ii) Generation of 
S. suis ~dltA. Procedures for selection of mutants by allelic exchange via double crossover have 
been described previously (32). Briefly, S. suis strain 31533 was transformed with p5~dltA by 
electroporation as previously described (31). The cells were grown at 28°C in the presence of Cm 
and Sp selection. Bacteria at mid-Iogarithmic growth phase were diluted with THB containing Sp 
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and grown at 28°C to early logarithmic phase. The cultures were then shifted to 37"C and 
incubated for 4 h. Subsequently, the cells were spread onto THA agar containing Sp and 
incubated at 28°C. Temperature-resistant, Sp-resistant colonies were screened for loss of 
vector-mediated Cm resistance to detect putative mutants whieh had exchanged their wild-type 
allele for a genetie segment containing the aad9 gene as a consequence of homologous 
recombination via a double crossover. Allelie replacement in candidate clones was verified by 
PCR and Southern hybridization, which confirmed the expected genotype (data not shown). 
Transmission electron microscopy. 
Transmission electron mieroscopy was performed as previously described (12). Briefly, 
overnight (ON) cultures of S. suis wild type (WT) or mutant f:J.dltA strains were mixed with rabbit 
anti-S. suis serotype 2 polyclonal serum and incubated at room temperature for 1 h. Cells were 
then fixed in cacodylate buffer (OJ.M cacodylate, 5% glutaraldehyde, 0.15% ruthenium red, pH 
7.2) for 2 h. After fixation, cells were immobilized in 4% agar, washed in cacodylate buffer and 
post-fixed ON at 4°C in 2% osmium tetraoxyde. Samples were dehydrated in graded series of 
ethanol and embedded in Spurr low-viscosity resin. Thin sections were post-stained with uranyl 
acetate and lead citrate and examined with a transmission electron mieroscope (Model 420, 
Philips Electronies, The Netherlands). 
Determination of LTA D-alanine content. 
S. suis WT and f:J.dltA mutant strains were cultured in tryptic soy broth (Becton 
Dickinson) containing beef extract (5 g/I) and glucose (8 g/I) at 37"C for 18 h with shaking. After 
incubation, bacteria were harvested by centrifugation at 4225 x g for 20 min. Integrity of 
bacteria and potential contamination by Gram-negative species were checked by Gram staining 
and microscopy. LTA were prepared by butanol extraction (whieh preserves the integrity of the 
D-alanine substitutions) and hydrophobie interaction chromatography as previously described 
(22). Nuclear magnetic resonance (NMR) spectra from LTA were recorded on a Bruker Avance 
DRX 600 spectrometer (Bruker BioSpin, Ettlingen, Germany) equipped with an inverse TXI-H/C/N 
triple resonance probe at 300 K using 3 mm Bruker Match sample tubes. Spectra were measured 
in D20 using sodium 3-trimethylsilyl- 3,3,2,2-tetradeutero-propanoate as an internai standard 
for lH NMR (OH 0.00 ppm). 
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Antimicrobial peptides sensitivity. 
Assays were carried out in sterile 96-well mierotiter plates. Logarithmic-phase s. suis 
cells were adjusted to approximately 104 CFU/ml in 100 j..ll THB containingone of the following 
antimierobial compounds in seriai dilutions: Colistin (0 to 200 j..lg/mll, polymyxin B (0 to 300 
j..lg/ml) and magainin Il (0 to 45 j..lg/ml). Plates were incubated for 24 h at 3rc. The IVIIC was 
defined as the lowest antimierobial concentration yielding no detectable bacterial growth by 
OD6oo nm measurement. 
Killing by porcine neutrophils. 
Experiments were carried out as described previously (4). Briefly, blood samples were 
collected by venous puncture from high health status pigs which tested negative by ELISA (19) 
for s. suis serotype 2. Cell populations were separated by Fieoll-Hypaque (GE Healthcare) density 
gradient centrifugation and neutrophils isolated by sedimentation in 6% dextran. Contaminating 
erythrocytes were removed by Iysis with 0.83% ammonium chloride. Neutrophils were 
resuspended at a final concentration of 5xl06 cells/ml in RPMI 1640 medium (Invitrogen) 
supplemented with 10% heat-inactivated porcine serum. Bacteria (WT or tJ.dltA mutant strains 
at approx. lxl04 CFU/ml) were opsonized with complete normal porcine serum for 30 min at 
3rc and then mixed in mierotubes with neutrophils at 5xl06 cells/ml. The mixture was 
incubated for 90 min at 3rC under 5% CO2 • Under these conditions bacteria are not toxie to 
neutrophils (4). After incubation cells were Iysed with sterile water and viable bacterial counts 
on THA were performed. 
Experimental infections. 
Ali experiments involving animais were conducted in accordance with the guidelines and 
policies of the Canadian Council on Animal Care. (i) Pigs: A total of 20, 4-week-old, second-
generation of caesarean-derived pigs were used in this study. Strict biosecurity measures were 
implemented to avoid undesirable contamination of the pigs; these included an air filtration 
system and airlocks for each unit. Pigs were divided in 3 groups. Six out of 7 animais in groups 1 
and 2 were inoculated by intravenous injection of 108 CFU of the s. suis WT 31533 or mutant 
tJ.dltA strains, respectively. The remaining animal in both the WT and tJ.dltA mutant groups was 
not inoculated although it was housed with inoculated animais and served as sentinel. Group 3 
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(N=6) were sham-inoculated animais. Clinical signs and presence of 5. suis in blood were 
monitored during the trial. Surviving animais in ail 3 groups were sacrificed 7 days pi and 
examined for pathological lesions. Bacteriological isolation from different organs (Iiver, spleen, 
lungs, heart and articulations) was performed as described below for mice. (ii) COl mice: A 
recently described murine model for 5. suis infection was used (8). A total of 60 female COl mice 
aged 6. weeks (Charles River laboratories, Wilmington, MA) were used for virulence assessment. 
At day 0, animais were divided in 4 groups of 15 mice. Group 1 was inoculated by 
intraperitoneal injection of 1 ml of 5. suis strain 31533 suspension at 5 x 107 CFU/ml, while group 
2 received the sa me dose of mutant strain tJ.dltA. Groups 3 and 4 received 1 ml of a 5 x 106 
CFU/ml suspension of the WT and the mutant strains, respectively, using the same route of 
inoculation. Mice were monitored 3 times/day for 10 days for clinical signs and assigned clinical 
scores as previously described (8). Blood samples (5 Ill) were collected daily (from the tail vein) 
and at euthanasia (by cardiac puncture) and used to evaluate bacterial load by plating onto 
sheep blood agar plates. Isolated tiny a-hemolytic colonies were counted and assigned to 5. suis 
by serotyping as previously described (16). Surviving animais in both groups were sacrificed at 
day 10 and macroscopic examination was performed. Bacterial colonization of the liver, spleen 
and brain of infected animais was also evaluated. Briefly, small pieces of these organs weighing 
0.5 g were trimmed, placed in 500 III of PBS and homogenized. Thereafter, 50 III of the 
suspensions were plated as described above. In addition, an enrichment of the samples was 
carried out by inoculation of 300 III of homogenized organ samples or 100 III of blood into THB, 
followed by ON incubation at 37"C and subsequent dilution and plating onto sheep blood agar 
plates as described above. 
Adherence to and invasion of porcine BMEC. 
The porcine BMEC cell line PBMEC/Cl-2 (33) was grown in Primaria 24-well tissue 
culture plates (Becton Dickinson, Franklin Lakes, NJ) using IF culture medium (a mixture of 1:1 
Iscove's modified Dulbecco's and Ham's F-12 media, Invitrogen) supplemented as previously 
described (35). 5. suis was grown in THB for 16 h at 37"C, harvested by centrifugation, washed 
twice in phosphate-buffered saline (PBS), pH 7.3, and resuspended in fresh IF culture medium. 
The invasion assays were performed as described previously (35). Briefly, confluent monolayers 
of porcine BMEC at 105 cells/well were infected with 1-ml aliquots of bacterial suspensions at 
105 CFU/ml (multiplicity of infection (MOI) of 1). The plates were centrifuged at 800 x 9 for 10 
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min and incubated for 2 h at 3rC with 5% CO2 • The monolayers were then washed twice with 
PBS. A 1 ml volume of cell culture medium containing 100 I1g/ml of gentamicin and 5 I1g/ml of 
penicillin G was added to each weil, and incubation continued for 1 h. After incubation, 
monolayers were washed 3 times with PBS, trypsinized and disrupted by repeated pipetting. 
Seriai dilutions of the cell Iysates were plated onto THA and incubated ON at 3rc. To confirm 
that 100% of the extracellular bacteria were killed after the antibiotic treatment, a 100-111 
sample of the last PBS wash was plated onto THA (results not shown). Adherence assays were 
performed essentially as described for invasion, but neither antibiotic treatment nor extended 
incubation was performed. After 2 h incubation, cells were vigorouslywashed 5 times with PBS, 
trypsinized, disrupted, and seriai dilutions of the cell Iysates were plated as described above. 
Results and Discussion 
The dit operon is responsible for LTA D-alanylation in s. suis. 
The genetic organization of the s. suis dIt operon is depicted in Fig. lA. Sequence 
comparison at The National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/BLAST/), as weil as previous reports (17, 18,25), showed that the 
s. suis dIt operon is organized in a fashion similar to that of ail dIt operons reported in 
pathogenic streptococci so far, with the exception of s. agalactiae, which also includes 2 
regulatory genes upstream of the dltA gene (25). Accordingly, the deduced proteins showed a 
high degree of similarity to streptococcal Dit proteins (data not shown). To assess the 
contribution of the dIt operon to LTA D-alanylation, we constructed by allelic replacement a 
fldltA mutant strain and analyzed the content of D-alanine in purified LTA of the WT and fldltA 
mutant strains by NMR. Fig. 2 shows the NMR spectra for LTA of the two strains. Both LTA 
showed the expected peaks for fatty acids (0.85 and 1.3 ppm) and sugars (3.5 to 4.5 ppm). 
However, peaks for D-alanine (1.65, 4.3 and 5.4 ppm) were absent in the fldltA mutant 
spectrum, suggesting that the LTA of the mutant is devoid of this amino acid substitution. In 
vitro growth of the fldltA mutant was comparable to that of the WT strain (Fig. 3A) and no other 
major phenotypic changes were observed .. In contrast to previous reports on s. agalactiae and 
Streptococcus pyogenes fldltA mutants, which were either poorly separated or multiseptated in 
the stationary phase of growth (18, 26), the s. suis fldltA mutant was encapsulated, weil 
separated ànd presented normal septation (Fig. 3B). 
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S. suis L TA D-alanylation contributes to antimicrobial peptide resistance and decreases 
susceptibility to neutrophil killing. 
CAMPs kill bacteria by forming pores in the cytoplasmic membrane (30). Introduction of 
positively charged O-alanine residues into the LTA would reduce the global negative charge of 
the S. suis envelope, thus providing the bacterium with a physical mechanism of resistance 
against the action of CAMPs (23). To assess this hypothesis, we performed an evaluation of the 
sensitivity of the WT and lldltA mutant to selected CAMPs. The S. suis lldltA mutant was more 
sensitive than the WT strain against the bacteria-derived cationic peptide polymyxin 6 and 
colistin and the frog-derived peptide magainin Il (Table 3). These results were in agreement with 
previous reports of inactivation of the dltA gene in streptococcal species (17, 18, 26) and 
indicate that O-alanylation of LTA is an important component of the intrinsic resistance of S. suis 
to CAMPs killing. On the other hand, the WT and dltA mutant strains were equivalent in their 
susceptibility to the antibiotics gentamicin and penicillin Gand to lysozyme (data not shown). 
Functional homologues of the CAMPs tested in this study are secreted by neutrophils both into 
the phagosome as weil as extracellularly. (21). Wh en we compared killing of WT and lldltA 
mutant strains by purified porcine neutrophils, in agreement with a previous study (4), the WT 
strain avoided killing by neutrophils when opsonized with normal complete porcine sera. On the 
other hand, 20% of the lldltA mutant bacteria were killed by neutrophils (Fig. 4). This level of 
killing was similar to that of the unencapsulated mutant strain 60102, despite the fact that the 
lldltA mutant does not have altered capsule expression (Fig. 4). This was surprising, since 
encapsulated WT S. suis has been shown to prevent phagocytosis by porcine neutrophils (unless 
opsonized by specifie antibodies) (4). However, it is known that neutrophils are also able to 
destroy infecting microorganisms in the absence of phagocytosis in the so-called neutrophil 
extracellular traps (NETs) (3). Interestingly, it has recently been shown in Streptococcus 
pneumoniae that absence of LTA D-alanylation results in enhanced extracellular killing in NETs 
by neutrophils but not in an increased phagocytosis of this organism by these 
polymorphonuclear cells (37). Although our killing assay is not able to discriminate between 
intra and extracellular killing, taking ail these findings together, it might be proposed that the 
encapsulated S. suis lldltA mutant is ki"ed by porcine neutrophils extracellularly, perhaps after 
being trapped in NETs. In addition, we speculate that the enhanced killing of the S. suis lldltA 
mutant might be the consequence of the absence of LTA O-alanylation, which results in an 
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increased susceptibility to CAIVIPs released by neutraphils. Further experiments are needed to 
evaluate this hypothesis. 
Virulence of the IlditA mutant is attenuated in pigs. 
Several IlditA mutants in different Gram positive pathogens have been reported and 
almost ail of these mutants were highly susceptible to CAMPs and killing by neutraphils and/or 
macrophages (1, 5, 10, 14, 17, 18, 26, 37, 38). However, only a limited number of studies have 
analyzed in vivo the contribution of LTA D-alanylation to the virulence of these pathogens. In 
these cases, virulence of the tested IlditA mutants greatly varied between bacterial species 
preventing the drawing of conclusions regarding the contribution of LTA D-alanylation to 
virulence traits of pathogens fram previous studies (1, 26, 37, 38). Finally, for various valid 
reasons, previous studies on the virulence of IlditA mutants in Gram positive species have used 
surrogated models of infection instead of the natural hosts (1, 26, 37, 38). S. suis shares certain 
characteristics with pathogens for which IlditA mutants have been described. However, its 
pathogenesis of infection is essentially different (15). In this study, we have for the first time 
evaluated the virulence of a Gram positive IlditA mutant in the context of its natural host by 
intravenous inoculation of pigs. Animais in the sham-inoculated group did not present any 
clinical signs during the entire duration of the trial. In contrast, severe clinical signs were , 
recorded in 5 out of the 6 animais inoculated with the WT strain during the first 4 days of the 
trial. These 5 pigs died or were sacrificed for ethical reasons at day 2 pi (3 animais) and at day 4 
pi (2 pigs). The remaining inoculated animal and the sentinel pig in this group survived until the 
end of the trial (Fig. 5). Animais infected with the IlditA mutant presented, on average, less 
severe clinical signs during the 4 first days pi. However, 2 animais died and an additional was 
euthanized by ethical reasons in this group (Fig. 5). l'Jevertheless, the remaining inoculated 
animais noticeably recovered starting at day 4 pi, and, along with the sentinel pig in the IlditA 
group, survived until the end of the trial. Hyperthermia (:> 40SC) was observed in ail pigs 
infected with either WT or IlditA strain at 24 h pi. Temperatures returned to normal values after 
day 4 in both groups. However, in the WT group, the sentinel pig developed hyperthermia from 
day 6 pi. S. suis serotype 2 could be isolated from the blood of ail inoculated pigs in both groups 
and the sentinel animal in the WT group. Pigs in the latter group had higher bacterial counts (as 
high as 1 x 1010 CFU/ml in some cases) than those infected with the IlditA mutant (average of 1 x 
108 CFU/ml) during the first 4 days pi. Similar to the blood, bacterial titers in organs were 
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slightly lower in pigs inoculated with the f:.dltA mutant compared with animais inoculated with 
the WT strain. However, examination at necropsy did not find major differences between the 
WT and f:.dltA mutant groups regarding damage to tissues or organs. At euthanasia, macroscopic 
lesions typical of S. suis infection were found in most animais infected with the WT or f:.dltA 
strains, especially at the pleura, pericardium and peritoneum. Fibrin deposits were observed in 
the liver and spleen of most animais in both groups. Pneumonia and fibrinal pleurisy were also 
observed in some animais. Additionally, the meninges showed inflammation consistent with 
meningitis. Lameness was observed in ail pigs infected with the WT or f:.dltA strain. At necropsy, 
articulations showed inflammation, with fibrin deposits and excess of synovial liquid. Results 
from the experimental infection showed that the f:.dltA mutant is attenuated in the pig and 
suggest that LTA D-alanylation provides an advantage to the WT strain. However, this conclusion 
is mitigated by the facts that disseminàtion of the bacterium was not prevented and mortality 
was observed among animais inoculated with the f:.dltA mutant. Since clearance of the mutant 
from circulation might primarily rely on neutrophil activity, the high dose used to inoculate the 
animais may explain, at least in part, the mortality observed. Indeed, it has been proposed that 
suilysin may affect complement activity and suilysin-producing S. suis strains, su ch as the WT 
and mutant strains used in this study, have been shown to be toxic to neutrophils at high titers 
(4). In addition, since CAMPs activity primarily occurs at mucosal surfaces, the extremely 
aggressive intravenous route of administration may have also influenced the clinical onset 
observed in pigs. 
Absence of LTA Dwalanylation impairs S. suis virulence in mite. 
To better evaluate the attenuation of the S. suis f:.dltA mutant observed in the pig we 
performed additional in vivo trials using the COl mouse model of infection that uses the 
intraperitoneal route of inoculation (8). We performed two different trials at high and 
intermediate doses of infection. At the high dose (5 x 107 CFU per animal) most mice in both the 
WT and f:.dltA mutant groups presented severe clinical signs associated with septicemia, such as 
depression, swollen eyes, weakness and prostration during the first 72 h pi. At this dose we did 
not find a clear reduction in the ability of the f:.dltA mutant to successfully initiate infection and 
induce septicemia in mice. In fact, several mice died from septicemia in both groups during the 
first 3 days of the trial (Fig. 6A). S. suis was isolated at high titers (> 1 x 107 CFU/ml) from blood 
samples and organs such as the liver and spleen of septicemic animais (> 1 x 107 CFU/O.S g of 
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tissue in some animais). From day 5 pi, some mice in both WT and b.dltA groups developed 
clinical signs associated with S. suis meningitis in the mouse (8), such as hyperexcitation, 
episthotonus, opisthotonus, bending of the head and walking in circles. It has been proposed 
that maintaining a high level of bacteremia is essential for CNS disease to appear at later stages 
of the infection (13). Interestingly, the number of meningitis-presenting mice was lower in the 
b.dltA group (N=l) than in the WT group (1\1=6), and this observation was consistent with the 
reduction in the bacterial load in blood among animais inoculated with the b.dltA mutant 
compared to those having received the WT strain (data not shown). Therefore, we performed a 
second trial in the mouse using an intermediate dose of infection (5 x 106 CFU per animal) in 
order to avoid development of septicemia. Mice in both groups presented moderate clinical 
signs during the first 72 h pi, but no animais died from septicemia in either group. However, 
from day 7 pi, several mice in the WT group developed clinical signs associated with meningitis. 
S. suis was isolated from the brain of these animais at high titers (>1 x 106 CFU/0.5 g of tissue). 
ln strong contrast, no clinical signs of meningitis were observed in the b.dltA group nor was S. 
suis isolated from the brain of any animal infected with the b.dltA mutant. Significant differences 
in the mortality rate were noted between mice inoculated with the WT and those with the b.dltA 
mutant strain (Kaplan-Meyer, P < 0.05) at the intermediate dose of infection (Fig. 6B). 
S. suis LTA D-alanylation promotes adherence to and invasion of porcine BMEC. 
Experimental infection of mice at the intermediate dose of infection clearly 
demonstrated that the b.dltA mutant is less fit to induce CNS disease. A recent study of S. suis 
meningitis in the mouse showed that cells lining the choroid plexus and the brain endothelium 
are potential entry sites for this pathogen into the CNS (8). In addition, previous studies 
demonstrated the ability of S. suis to adhere to and invade immortalized porcine BIVIEC (35, 36). 
Recently, it has been shown that expression of the dIt operon'is upregulated upon interaction of 
S. suis with porcine BMEC (11). Therefore, to assess the contribution of the LTA D-alanyl 
modification to adherence to and invasion of porcine BMEC, we compared the interactions of 
WT and b.dltA mutant strains with cultured monolayers of these cells. After 2 h-incubation of S. 
suis with porcine BMEC at a MOI of l, followed by vigorous washing, we found a marked 
decrease in the total number of cell-associated b.dltA mutant bacteria compared with the WT 
parent strain (Fig. 7). Using antibiotic protection to quantify bacteria which had invaded the 
intracellular compartment, a similar reduction in internalization of the b.dltA mutant was 
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observed (Fig. 7). Therefore, LTA D-alanylation itself plays a role in facilitating 5. suis adherence 
to and invasion of porcine BMEC and we speculate that this occurs, mainly, through cell 
envelope charge stabilization that allows efficient display of proteinaceous adhesins and/or 
invasins (23). Porcine BMEC are one of the main cellular types forming the porcine BBB, a 
structure that successful meningitis-causing pathogens must cross in order to develop 
meningitis. Interestingly, a previous report proposed that the diminished resistance to killing by 
leucocytes was responsible for the impairment in its ability to induce meningitis in the mouse of 
a 5. agalactiae l:J.dltA mutant (26). Taking together our results with porcine BMEC and the 
observed outcome of the experimental infections in both the murine and porcine models of 
infection, we speculate that in addition to failure of the l:J.dltA mutant to maintain a high level of 
bacteremia, impaired interaction with BIVIEC are also responsible for the reduced ability of the 
l:J.dltA mutant to induce meningitis. 
ln summary, 5. suis LTA D-alanylation mediated by the dIt operon contributes 
phenotypically to resistance to CAMPs, likely through an increased net positive surface charge. It 
also enhances the resistance of 5. suis to neutrophil killing as weil as its capacity for adherence 
to and invasion of porcine BMEC. In addition, LTA D-alanylation contributes to 5. suis virulence in 
both the murine and the porcine models of infection, probably through interference with innate 
immune clearance mechanisms and by facilitating penetration of host barriers. The results of 
this study strongly suggest that LTA D-alanylation is an important virulence factor of this swine 
pathogen and zoonotic agent. 
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Article II Tables 
Table IV. Article Il, Table 1. Bacterial strains and plasmids used in this study 
Bacterial 
strains 
E. coli Top 
la 
s. suis 
31533 
Relevant characteristics 
General strain for cloning. F- mcrA fl(mrr-hsdRMS-mcrBC) 
q,801acZflM15 fllacX74 recAl araD139 fl(ara-Ieu) 7697 ga/U 
ga/K rpsL (StrR) endAl nupG 
Serotype 2 field strain. Highly virulent 
s. 
fldltA 
S. 
suis t:.dltA mutant strain derived fram strain 31533 
suis Unencapsulated mutant strain derived from strain 31533 
BD102 
Plasmids 
pCR4 
pSmali 
pSET5s 
p5flpgdA 
E. coli vector for cloning of PCR fragments 
E. coli-S. suis shuttle vector. SpR. Source of aad9 
Temperature sensitive suicide vector for S. suis mutagenesis. 
Cm R (cat) 
pSET5s carrying the construction for allelic exchange 
Source 
Invitrogen 
(35) 
This work 
(12) 
Invitrogen 
Willson, 
(unpublished 
results) 
(32) 
This work 
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P 
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Table V. Article Il, Table 2. Oligonucleotide primers used in this study. Restriction sites are in 
bold 
Primer name Sequence (S' - 3') Restriction site 
2872F GCAGTTACCTCTAAGCTTGCGACAACGG Hindlll 
376SR CTGCTAATCATTTGGATCCTCTCCTC BamHI 
S2S0F CTTCCTTTGACTGCAGATGGGAAGATT Pstl 
S809R CGTCTATAAGGATCCATAGGG BamHI 
specF3 GCCAATGAGATCTATAAATAAAC BglIl 
AAAGTGTTTCCTGCAGnnnTCAA Pstl 
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Table VI. Article II, Table 3. Sensitivity of the s. suis WT and Il.dltA mutant strains to the action 
of selected antimicrobial peptides. 
Peptide (origin) 
Colistin (Baci/lus colistinus) 
Polymyxin B (Baci/lus polymyxa) 
Magainin II ( c1aw frog skin) 
Net charge 
+5 
+5 
+4 
MICs (~g/ml) 
31533 (WT) 
50 
75 
45 
~dltA 
25 
18.75 
5.6 
Article Il Figures 
A p 
•• altA dltB 
i, i 1 
,4$ 
B 'Iefi'arm' . d'el' 'd' righlarin' , reglon ete. ".' . l, -- j ~' ,-r-j 
HindITI BIirriHI Pst! B,mHI 
'-;==-1' 
HindIII 1 Pst! ,BamHI 
~ iow temperat.ure 
~qUir~~J , '. . . 
éJltD.~protei'1\ 
126 
j, 
Figure 14. Article Il, Figure 1. Genetic organization of the s. suis dit operon and strategy for the 
construction of the Il.dltA mutant. 
A) Genetic organization of the S. suis dIt operon as determined by sequencing of the region in 
strain 31533 and comparison with data from sequenced strain Pl/7 available at the Sanger 
Institute (http://www.sanger.ac.uk/Projects/S_suis/).TheS.suis dIt operon comprises 4 genes, 
dltABCD, and extends for 4340 bp. A putative strong promoter (indicated by P) was predicted 
upstream of the dltA gene. The operon comprises 4 genes, dltA (1563 bp), dltB (1242 bp), dltC 
(240 bp) and dItO (1266 bp). A putative strong promoter was predicted 228 bp upstream of the 
start codon for dltA using the software package Softberry BProm 
(http://www.softberry.com/berry.phtml?topic=bprom&group=programs&subgroup=gfindb). B) 
Strategy followed in this study to construct the knock-out vector used to generate the tJ.dltA 
mutant. See Materials and Methods for details. 
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MItA 
Figure 15. Article Il, Figure 2. Nuclear magnetic resonance spectra of WT (upper panel) and 
IlditA mutant (bottom panel) LTA analysis. 
The arrows show the peaks for D-alanine residues in the WT strain spectrum. These peaks are 
missing in the IlditA mutant spectra. No other differences between LTA of the two strains were 
found. 
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Figure 16. Article Il, Figure 3. Growth curves and morphology of the WT and I1dltA mutant 
strains. 
A) Growth curves of 5. suis WT and Ad/tA mutant strains. The Ad/tA mutant grew similarly as the 
WT parent strain under normallaboratory conditions. B) Morphology of the Ad/tA mutant (Ieft) 
and the WT (right) strains. Transmission electron microscopy showed that both strains were weil 
separated, presented normal septation and were surrounded bya thick polysaccharide capsule. 
Bar = 0.5 Ilm. 
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Figure 17. Article Il, Figure 4. Percentage of bacteria killed after 90 min incubation with 
porcine neutrophils. 
The different strains were opsonized with complete porcine sera before incubation. The level of 
killing of the fldltA mutant was similar to that observed for the unencapsulated mutant BD102 
and significantly higher than that of the WT strain. Data are from at least 3 independent 
experiments. Error bars show standard deviation. Asterisks indicate significant differences, t-
test, P<O.OS. 
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Figure 18. Article Il, Figure 5. Survival of pigs inoculated with the WT (dotted line) or the IlditA 
mutant (solid line) strains and pigs that were sham-inoculated (dashed line). 
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Ail the sham-inoculated animais survived the trial. The survival rate of pigs in the fldltA mutant 
group was 50%, while in the WT group most animais died from septicemia in the first days of the 
trial (survival rate of 17%). The sentinel animais were not considered in this analysis. See text for 
details. 
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Figure 19. Article Il, Figllre 6. Survival of mice inoculated with the WT (dotted line) or the 
ad/tA mutant (solid line) strains. 
A) 1\10 significant differences in survival were observed between groups at the high dose of 
inoculation. However, fewer animais in the mutant group died from meningitis. (B) At the 
intermediate dose of inoculation ail mice in the fldltA mutant group survived, while 35% of the 
WT group died from meningitis. Significant differences in survival, Kaplan-Meyer, P<0.05. 
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Figure 20. Article Il, Figure 7. Interactions of the Il.dltA mutant and the WT strains with porcine 
BMEC. 
The Il.dltA mutant showed reduced levels of adherence to and invasion of porcine BMEC. Data 
for the WT strain has been normalized to 100%. Data are from at least 4 inde pendent 
experiments. Error bars show standard deviation. Asterisks indicate significant differences, t-
test, P<O.OS. 
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Summary 
Streptococcus suis is a major swine pathogen and emerging zoonotic agent. In this study 
we have determined the muropeptide composition of s. suis peptidoglycan (PG) and found, 
among other modifications, N-deacetylated compounds. Comparison with an isogenic mutant 
showed that the product of the pgdA gene is responsible for this specific modification which 
occurred in very low amounts. Low level of PG N-deacetylation correlated with absence of 
significant lysozyme resistance when wild type S. suis was grown in vitro. On the other hand, 
expression of the pgdA gene was increased upon interaction of the bacterium with neutrophils 
in vitro as weil as in vivo in experimentally inoculated mice, suggesting that S. suis may enhance 
PG N-deacetylation under these conditions. Evaluation of the /::"pgdA mutant in both the COl 
murine and the porcine models of infection revealed a significant contribution of the pgdA gene 
to the virulence traits of s. suis. Reflecting a severe impairment in its ability to persist in blood 
and decreased ability to escape immune clearance mechanisms mediated by neutrophils, the 
/::"pgdA mutant was severely attenuated in both models. The results of this study suggest that 
modification of PG by N-deacetylation is an important factor in S. suis virulence. 
135 
Introduction 
Streptococcus suis is a major swine pathogen responsible for severe economic lasses ta 
the porcine industry (Higgins & Gottschalk, 2005). It is also the causative agent of serious 
infections in humans, especially in people in close contact with swine or park by-products 
(Gottschalk et al., 2007). In bath swine and humans the main clinical manifestations of S. suis 
are meningitis and septicaemia. While S. suis outbreaks in swine are common and sometimes 
devastating, most reports in humans describe sporadic cases resulting in either death or severe 
post-infection sequelae (Gottschalk et al., 2007). In recent times, however, S. suis has strongly 
emerged as an important public health issue in some Asian countries. For instance, it has very 
recently been shawn that it is the primary cause of adult meningitis in Vietnam (Mai et al., 
2008). Moreover, during an episode in China, more than 200 human S. suis cases, 39 of which 
resulting in death, were reported in a single outbreak (Yu et al., 2006). Most cases of disease in 
bath swine and humans are caused by S. suis serotype 2 and, therefore, almost ail studies on 
virulence factors and pathogenesis of the infection have been carried out with this serotype 
(Higgins & Gottschalk, 2005). However, the current understanding of the S. suis pathogenesis of 
infection remains limited. It has been shawn that the polysaccharide capsule is essential for the 
virulence of the bacterium (Chabot-Rayet al., 2006, Charland et al., 1998, Smith et al., 1999). 
Recently, an isogenic mutant for a serum opacity-like factor was found ta be attenuated in pigs 
(Baums et al., 2006). Several other factors, such as a heamolysin (suilysin), the sa-ca lied 
extracellular protein factor and muramidase-released protein, as weil as a 
fibronectinjfibrinogen-binding protein, have been shawn ta be linked ta, but not essential for, 
\ 
the virulence of S. suis (de Greeff et al., 2002, Higgins & Gottschalk, 2005). 
Cell wall components of S. suis have also been proposed ta be important virulence 
factors and several studies have shawn that they contribute ta exacerbate the hast 
inflammatory response ta infection (Gottschalk et aL, 2007, Higgins & Gottschalk, 2005). The 
main cell wall component of Gram-positive bacteria is peptidoglycan (PG), which ensures the 
stability and rigidity of the cell wall. PG consists of glycan strands made of alternating 6-1,4-
linked N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) which are cross-linked by 
short peptide chains (Vollmer et al., 2008a). This rather invariant structure is exploited by the 
hast for bath recognition of bacteria, through the nucleotide-binding oligomerisation domain 
(Nod)l and Nod2 proteins, which recognise muropeptides released during cell wall turnover, as 
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weil as for destruction of the microorganisms through the hydrolytic activity of lysozyme 
(Boneca, 2005, Chaput & Boneca, 2007). However, some Gram positive bacteria have developed 
efficient mechanisms to circumvent these host defences. For instance, Staphylococcus aureus, 
Enterococcus faecalis and Streptococcus pneumoniae modify their PG by O-acetylation of the C-6 
atom of NAM through the action of the OatA protein (Crisostomo et al., 2006, Hebert et al., 
2007, Herbert et al., 2007). Some pathogens, such as Streptococcus pneumoniae and Listeria 
monocytogenes, deacetylate the NAG (mostly) and NAM (to a lesser extent) residues into 
glucosamine or muramic acid through the action of the pgdA gene product (Boneca et al., 2007, 
Vollmer & Tomasz, 2000). These modifications have been shown to result in escaping Nod1 and 
Nod2 surveillance and/or increased resistance to lysozyme. 
The structure of S. suis PG has not yet been reported. However, a recent study identified 
a S. suis homolog of the S. pneumoniae pgdA gene which was highly upregulated during the 
interactions of S. suis with porcine brain microvascular endothelial cells, suggesting that this 
bacterium might be able ta modify its PG by N-deacetylation (Fittipaldi et al., 2007a). In this 
study, we determined the S. suis PG composition and compared it to that of a t:.pgdA isogenic 
mutant. We demonstrate that S. suis N-deacetylates its PG through the action of the pgdA gene 
product and show that the deletion of this gene has a significant impact on the virulence traits 
of this pathogen. 
Results 
Fine structure of S. suis PG. 
The fine structure of S. suis PG has never been reported. To determine it, we used the 
classical method, i.e. isolation and purification of the SOS-insoluble cell wall, removal of teichoic 
acids by hydrofluoric acid, release of muropeptides by the muramidase cellosyl, separation of 
muropeptides by high-performance liquid chromatography (HPLC), and matrix assisted laser 
desorption-ionization-tirre of flight (MALOI-TOF) mass spectrometry (MS) of the collected 
muropeptide fractions. Based on previous reports on the amino acids present in the PG of 
streptococci (Schleifer & Kandler, 1972) the chromatographic behaviour of the muropeptides 
and their molecular masses, the structures of 13 muropeptides isolated from S. suis PG cou Id be 
proposed with high confidence. The PG of S. suis had mainly O-isoglutamine in position 2 and L-
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lysine in position 3 of the peptide. The cross-links did not contain an interpeptide bridge 
frequently found in streptococci. Thus, the muropeptide profile of S. suis appeared relatively 
simple (Fig. lA), with three major compounds accounting for >75% of the total material, the 
monomer Tri (the disaccharide tripeptide, compound 1) (Fig. lB), the dimer TetraTri (bis-
disaccharide tetratripeptide, compound 7), and the trimer TetraTetraTri (tris-disaccharide 
tetratetratripeptide, compound 15). Minor compounds identified had either non-amidated D-
glutamate at position 2 (compounds 2 and 8) or a free tetrapeptide or penta peptide instead of 
the prevailing tripeptide at the acceptor site of the peptide (compounds 5, 6, 13, 14). Other 
minor muropeptides had lost a GleNAc residue (compounds 3, 10, 17), indicating the previous 
activitiy of a PG glucosaminidase, or a GlcNAcMurNAc moiety (compound 12) due to the activity 
of a PG amidase. These major and minor muropeptides accounted together for >93% of the 
total UV-absorbing material (Supplemental Table 1). 
Strikingly, the classical method for PG analysis failed to detect any deacetylated 
muropeptides in the PG of S. suis wild-type (WT) field strain 31533, des pite the presence of an 
intact pgdA N-deacetylase gene in its genome (see below). Thus, if present at ail, deacetylated 
muropeptides were expected in very small quantities. Therefore, we analysed the muropeptide 
mixture on a linear ion trap-Fourier transform (LTQ-FT) mass spectrometer which has superior 
sensitivity and mass accuracy. LTQ-FT-MS detected ail 13 major and minor muropeptides from 
the previous HPLC-MALDI-TOF analysis (Table 1). In addition, 7 new muropeptides were 
identified including the trimer TetraTetraTetra (compound 19), the tetramer TetraTetraTetraTri 
(compound 20) and two additional muropeptides with losses of two GlcNAc residues 
(compounds 11 and 18). Interestingly, LTQ-FT-IVlS identified the deacetylated versions of ail 
three major muropeptides (compounds 4, 9, 16, Fig. :LB and Table 1). Deacetylated 
muropeptides were identified in very low quantities, probably lower than 1% of the total 
muropeptides, preventing determination of the site of deacetylation (NAG or NAM). However, 
the observed mass intensities of these deacetylated muropeptides were weil above the signal 
noise (Table 1). 
The pgdA gene product is responsible for N-deacetylation of S. suis PG. 
N-deacetylation of PG has been shown to occur through the action of the pgdA gene 
product in some Gram-positive species (Boneca et al., 2007, Meyrand et al., 2007, Vollmer & 
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Tomasz, 2000). A S. suis pgdA homolog has recently been identified (Fittipaldi et al., 2007a). 
Genomic searches at the 4 currently available S. suis sequenced genomes available at the NeBI 
(http://www.ncbLnlm.nih.gov/genomes/lproks.cgi). the Wellcome Trust Sanger Institute 
(http://www.sanger.ac.uk/Projects/S suis/ ), and the DOE Joint Genome Institute 
(http://genome.jgi-psf.org/draftmicrobes/strsu/strsu.home.html) databases, as weil as 
Southern hybridizations using specific probes revealed that pgdA is the only putative PG N-
deacetylase encoded by S. suis (data not shown). The S. suis pgdA gene comprises 1398 bp and 
seems to be transcribed from a putative promoter located 30 bp upstream of the beginning of 
the coding sequence (identified using the Bprom software at 
http://www.softberry.com/berry.phtml?topic=bprom&group=programs&subgroup=gfindb) (Fig. 
2A). A region of dyad symmetry that might function as a Rho-independent transcription 
terminator was detected 11 bp downstream the stop codon using the Findterm program 
(http://www.softberry.ru/berry.phtml?group=programs&subgroup=gfindb&topic=findterm). 
The predicted translated sequence of the S. suis pgdA gene showed strong homology to 
previously reported PgdA proteins, including the presence of ail the conserved catalytic residues 
and metal ligand amine acids previously reported for S. pneumoniae PgdA (Blair et al., 2005) 
(Fig. 2B). In order to investigate the involvement of S. suis pgdA in PG N-deacetylation we 
inactivated the gene via a double crossover event, generating a mutant strain in which the pgdA 
gene was replaced bya spectinomycin (Sp) resistance cassette (aad9 gene). Inactivation of pgdA 
had no major consequences on growth either in normal laboratory medium (Fig. 3A) or in the 
presence of 10 % porcine or foetal bovine sera (data not shown). In addition, the I1pgdA mutant 
strain presented a normal morphology and was as encapsulated as the WT strain (Fig 3B). 
However, when we prepared PG from the I1pgdA mutant and analysed it as described above for 
the parent strain, no N-deacetylated muropeptides were found (Table 1), showing that N-
deacetylation of S. suis PG is achieved through the action of the pgdA gene product. 
s. suis is susceptible to lysozyme in vitro and inactivation of the pgdA gene does not result in 
an increased susceptibility. 
ln some Gram positive species N-deacetylation of NAG and/or NAM residues has been 
shown to confer resistance to lysozyme (Boneca et al., 2007, Meyrand et al., 2007, Vollmer & 
Tomasz, 2000). Since S. suis modifies its PG by N-deacetylation, we sought to evaluate whether 
this modification results in resistance against this hydrolytic enzyme. We therefore performed a 
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comparison of the sensitivity to lysozyme of both the S. suis WT and tJ.pgdA mutant strains. 
Growth of WT S. suis was found to be inhibited by lysozyme in a dose-dependent manner. This 
behaviour was observed both when lysozyme was added at the beginning of the stationary 
phase of growth (Fig. 4) or at the mid-log phase (data not shown). Growth of S. suis was 
inhibited at concentrations (5 j..lg/ml) which were much lower than those not affecting growth of 
several other Gram-positive species such as S. pneumoniae (80 j..lg/ml) and L. monocytogenes (10 
j..lg/ml), probably reflecting the low percentage of N-deacetylated muropeptides in its PG. 
Although recorded values of 00600 nm were slightly lower than those of the WT strain, the tJ.pgdA 
mutant behaved essentially as the WT strain at ail the concentrations tested. Since the 00600 nm 
assay does not prove Iysozyme-mediated killing, we performed plating and colony counts for 
every condition and time tested. Results showed a strong correlation between the reported 
decrease in 00600 nm and loss of viability of S. suis (data not shown). 
The virulence of the IlpgdA mutant is severely impaired in the murine model of infection. 
Components of the S. suis cell wall have been proposed to play an important role in the 
pathogenesis of infection of this pathogen (Higgins & Gottschalk, 2005). In arder to evaluate if 
PG N-deacetylation contributes to the virulence of S. suis we performed an experimental 
infection of COl mice using a recently described model of infection (Oominguez-Punaro et al., 
2007). Results of the trial showed that most animais in the WT group presented severe clinical 
, , 
signs associated with septicaemia and septic shock, such as de pression, swollen eyes, weakness 
and prostration during the first 72 h post-inoculation (pi). Several mice died from septicaemia in 
this group. From day 5 pi, some animais in the WT group developed clinical signs associated with 
S. suis meningitis in the mouse (Oominguez-Punaro et al., 2007), such as hyperexcitation, 
episthotonus, opisthotonus, bending of the head and walking in circles. In strong contrast, mice 
in the tJ.pgdA group did not present any major clinical sign associated with S. suis infection 
during the trial, with the exception of slight de pression following inoculation which subsided 48 
h pi (24 h pi in some cases). No mouse died in this group and significant differences in the 
mortality rate were noted between the WT and tJ.pgdA groups (LogRank test, P < 0.05) (Fig. SA). 
S. suis was isolated at high titres for several days (> 1 x 107 CFU/ml in some cases) from blood 
samples (Fig. SB) and, at euthanasia, from organs such as the liver and spleen of septicaemic 
animais in the WT group (data not shown). In addition, isolation from the brain and 
cerebrospinal fluid of animais showing clinical signs of meningitis demonstrated the presence of 
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s. suis at high titres in both samples (data not shown). In strong contrast, titres in blood·· 
following inoculation were lower on average in the flpgdA mutant group and decreased rapidly. 
After day 3 pi S. suis could was not isolated from this tissue, even if an enrichment of the sample 
was performed, suggesting that the bacterium had been cleared from circulation (Fig. SB). In 
addition, at euthanasia, the flpgdA mutant could not be isolated from the liver, spleen or brain 
of any animal in the mutant group (data not shown). No macroscopic lesions associated with S. 
suis were observed in this group at post-mortem examination. 
Induction of key cytokines involved in septic shock is abolished in mice inoculated with the 
Il.pgdA mutant. 
Differences in PG composition between the WT and flpgdA mutant strains might result 
in a dissimilar ability to induce production of several cytokines, as demonstrated for L. 
monocytogenes (Boneca et al., 2007). On the other hand, it has been suggested that an 
exacerbated inflammatory response leading to septic shock is responsible for death at early 
stages of the infection of most mice infected with S. suis (Dominguez-Punaro et al., 2007). Since 
we did not observe clinical signs associated with septic shock in mice inoculated with the flpgdA 
mutant, we studied kinetically the ability of this strain to induce cytokine production in the 
mouse. Analysis of the response showed that production of both interferon-y (IFN-y) and 
interleukin (IL)-6 was severely impaired in animais which received the flpgdA mutant in 
comparison to those inoculated with the WT strain. In fact, mice that received the WT strain 
presented an important peak of both IFN-y and IL-6 at 6 h pi followed by a graduai return to 
basallevels at 48 h pi. In contrast, animais in the mutant group did not show production of these 
cytokines above basal levels (Fig. 6A and 6B). Animais in the WT group also showed augmented 
production of IL-1~ up to 48 h pi, whereas the flpgdA mutant induced very low amounts of this 
cytokine (Fig. 6C). On the other hand, production of tumour necrosis factor-a (TNF-a) was 
essentially similar in mice inoculated either with the WT or flpgdA mutant strains (data not 
shown). We also studied the chemokine response. Induction of both KC RANTES chemokines 
was abolished in the flpgdA mutant group while in the the WT group animais reached peak 
production between 6 and 12 h pi to return to baseline at 48 pi (Fig. 60 and 6E). Levels of 
monocyte chemotactic protein-1 (MCP-1) were similar in both groups during the 12 first hours 
pi, but, thereafter, this chemokine abruptly dropped in the mutant group while it persisted in 
the WT group up to 36 h pi (Fig. 6F). Overall, with the exception of TNF-a, the flpgdA mutant 
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failed to stimulate the production of pro-inflammatory cytokines and chemokines at ail the time 
points tested. On the other hand, the observed production of these inflammatory mediators in 
the WT group was in perfect agreement with a previous report (Dominguez-Punaro et al., 2007). 
The Il.pgdA mutant is killed by porcine neutrophils. 
It has been shown that in the absence of a specific humoral response, weil encapsulated 
S. suis can avoid killing by phagocytes and persist in blood (Chabot-Roy et al., 2006, Charland et 
al., 1998, Smith et al., 1999). However, our in vivo results suggested that the impaired virulence 
of the Il.pgdA mutant may result from its reduced ability to survive in this tissue. Based on 
previous results in L. monocytogenes that showed diminished ability of a Il.pgdA mutant to resist 
killing by phagocytic cells (Boneca et aL, 2007), and taking into account that S. suis rapidly 
disappeared from blood, we postulated that clearance of the organism was primarily driven by 
neutrophils. Indeed, neutrophils are significantly increased in pigs infected with S. suis virulent 
strains and are usually predominant in lesions caused by this pathogen (Salles et al., 2002, 
Sanford, 1987). When we compared in vitro killing of the WT and Il.pgdA mutant strains by 
porcine neutrophils, under our conditions, in the absence of opsonising antibodies but in the 
presence of normal complete porcine sera, the WT strain resisted the bactericidal effect of 
porcine neutrophils. On the other hand, suggesting a potential contribution of PG N-
deacetylation to this resistance, the Il.pgdA mutant strain was efficiently eliminated at rates 
similar to those observed for an unencapsulated mutant. At the end of the assay, more than 
20% of the Il.pgdA mutant bacteria were killed by neutrophils compared to less than 5% of the 
WT strain (Fig. 7). 
The Il.pgdA mutant is attenuated in the porcine model of infection. 
To confirm the observed impaired virulence of the Il.pgdA mutant, we conducted a trial 
in the pig, which is the natural host of S. suis. To this end, we used a well-standardised infection 
model that utilises the aggressive intravenous route of inoculation but provides repeatability 
(Berthelot-Herault et al., 2001). Animais in the sham-inoculated group did not present any 
clinical signs during the entire extent of the trial. On the other hand, severe clinical signs such as 
depression, prostration, lameness and shaking were observed in ail 10 animais inoculated with 
the WT strain. Four pigs died or were sacrificed for ethical reasons within 24 h pi and 4 others at 
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day 2 pi (Fig. 8). One of these pigs developed clinical signs of meningitis, including convulsions, 
episthotonus, opisthotonus and bending of the head. At euthanasia, macroscopic lesions typical 
of S. suis infection were found in most animais infected with the WT strain. Fibrin deposits were 
observed at the pleura and the pericardium of most animais in this group. In addition, ail pigs 
inoculated with the WT group presented at least one swollen articulation with fibrin deposits 
and excess of synovial liquid. Additionally, some animais in the WT showed damage at the 
meninges consistent with meningitis. In comparison, animais inoculated with the f:lpgdA mutant 
strain showed less severe clinical signs during the trial. No animal presented shaking or 
convulsions in this group and no cases of meningitis were recorded. However, depression, 
prostration and lameness were common during the first 24 h pi. Mortality was also observed in 
this group, as 4 pigs were sacrificed for strict ethical reasons within the first 3 days pi (Fig. 8). 
Differences between groups regarding mortality were nonetheless significant (LogRank test, 
p<O.OS). The remaining animais in the mutant group recovered starting from day 3 pi (day 2 pi in 
some cases) and survived until the end of the trial. Examination at necropsy did not reveal major 
damages to tissues or organs in this group, with the exception of swollen articulations in some 
animais. Hyperthermia was observed in ail pigs infected with either the WT or f:lpgdA strains at 
24 h pi and no mqjor differences were observed between groups. Temperatures returned to 
normal values in surviving animais after day 3 in the f:lpgdA group and the 2 surviving inoculated 
animais in the WT group. S. suis could be isolated from the blood of ail surviving pigs in both 
groups 48 h pi. However, pigs infected with the WT strain showed higher bacterial counts (1 x 
109 CFU/ml in some cases) than those infected with the f:lpgdA mutant (average of 5 x 106 
CFU/ml). Bacterial isolation from different organs revealed a high bacterial colonization of the 
liver, the spleen and (in some cases) the brain of pigs in the WT group. In contrast, isolation 
from the brain was negative in the f:lpgdA group, although the bacterium was found in the liver 
and spleen of most animais in this group. Similar to the blood, bacterialload in organs was lower 
in pigs inoculated with the f:lpgdA mutant compared with animais inoculated with the WT strain. 
The pgdA gene is upregulated upon interaction with porcine neutrophils and within the hosto 
ln vitro results obtained in this study showing a high sensitivity of the WT strain to 
lysozyme seem incompatible with the observed outcomes of the experimental infections of both 
mice and swine as weil as with the reported ability of S. suis to initiate and establish infections in 
other hosts (Gottschalk et al., 2007). However, absence of lysozyme resistance in vitro might be 
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explained bya rather inactive'pgdA gene and a subsequent low extent of PG deacetylation when 
S. suis grows in Todd-Hewitt broth (THB). We therefore hypothesised that S. suis might express 
the pgdA weakly in THB and upregulate its expression upon interaction with the host or host 
cells in order to resist the deleterious effects of lysozyme. To assess this hypothesis, we 
compared the relative expression levels of the S. suis pgdA gene under standard laboratory 
. conditions to that observed upon interaction (as described above) with porcine neutrophils. 
After reverse transcription, the quantitative PCR {Q-PCRl assays showed that while the 
expression of the pgdA gene by S. suis remained essentially unchanged in the mock-infection 
sample (without neutrophils), it was highly upregulated (mean fold change of 6.7) after 90 min 
incubation with neutrophils (Fig. 9). We also performed the same analysis from in vivo samples 
(Iiver and spleen) collected after experimental infection of CD1 mice. Data obtained showed that 
S. suis consistently upregulated the expression of the pgdA gene in ail the mice tested, with fold 
changes ranging from 3 to 13, depending on the animal and organ tested (Fig. 9). 
Discussion 
Even though it has been proposed as an important factor for S. suis virulence (Higgins & 
Gottschalk, 2005), knowledge on the cell wall composition of this pathogen is very limited. A 
partial structure of S. suis (lipo)teichoic acids (LTA) has been reported (Elliott et al., 1977), and 
very recently it has been shown that S. suis modifies LTA by D-alanylation (Fittipaldi et 01.,2008). 
However, PG composition of this bacterium has largely remained elusive. In this study we 
provide for the first time evidence regarding the composition of this essential polymer in S. suis, 
which was found to bel in several aspects, typical of species within the low GC-content Gram-
positive phylum Lactobacillales. Like in other streptococci, in S. suis mostly D-Gln is found at 
position 2 of the stem peptide, and an L-Lys residue is present at position 3, which can 
participate in 4-3 cross-links with neighbouring peptides (Schleifer and Kandler, 1972). However, 
unlike other streptococci, the PG of S. suis lacks an interpeptide bridge but contains direct L-Lys-
D-Ala cross-links. Consistently, database searches revealed the absence in S. suis of homologues 
of genes encoding for known peptide branching enzymes of the Fem transferase or ATP-grasp 
famllies (Bellais et 01.,2006, Fîlipe & Tomasz, 2000) (data not shown). About 67% of the peptides 
are present in dimeric or trimeric cross-links (Supplemental Table 1). S. suis PG has a low 
proportion of pentapeptides and tetrapeptides indicating high activities of DD- and LD-
carboxypeptidases in this species. Some of the minor muropeptides correspond to modifications 
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of canonical structures, suggesting the presence of glucosaminidase, amidase and N-deacetylase 
activities. While the enzymes responsible for the two former activities remain to be identified, 
N-deacetylation could be linked to the 5. suis pgdA gene product. To fully ascribe this link, we 
tried to restore the WT phenotype by complementation of the ô.pgdA mutant strain with several 
different constructions and E. coli-S. suis shuttle vectors but, perhaps because it has deleterious 
effects in E. coli, we failed to obtain recombinant plasmids carrying the 5. suis pgdA gene (data 
not shown). However, repeated generation of ô.pgdA mutants (3 additional independent 
mutants, ô.pgdA 2, 3 and 4, Supplemental Table 3) and consistent verification of a key 
phenotype such as neutrophil killing for each of them (Supplemental Figure 1) suggest that the 
occurrence of genetic events elsewhere in the genome other than inactivation of pgdA during 
the procedures for mutant isolation are unlikely. In addition, the genetic organization of the 
region (Fig. 2A) suggests that polar effects are highly improbable. 
5. suis is an important swine pathogen and a zoonotic agent causing septicaemia and 
meningitis in both pigs and humans (Gottschalk et aL, 2007). In order to establish an infection 5. 
suis must first overcome the innate immune response of the hosto One important mediator of 
this response is lysozyme. However, some bacterial species resist lysozyme activity by means of 
PG N-deacetylation and it has been proposed that the level of this modification may correlate 
with the level of resistance (Hebert et aL, 2007, Vollmer et al., 2008b). Consistently with this 
suggestion, the 5. suis WT strain, which N-deacetylates PG during growth in normal laboratory 
culture medium to a very little extent, was sensitive to lysozyme at concentrations much lower 
than those allowing growth of 5. pneumoniae and L. monocytogenes (Boneca et aL, 2007, 
Vollmer & Tomasz, 2000). Furthermore, we did not observe any major differences between 5. 
suis WT and ô.pgdA mutant strains regarding resistance to the action of this enzyme in vitro. In 
fact, these results may be explained by an already low degree (probably < 1 % of total 
muropeptide) of PG N-deacetylation of the WT strain. By comparison, resistance to lysozyme in 
5. pneumoniae correlated with over 80% of N-deacetylated glucosamine residues (Vollmer & 
Tomasz, 2000). In L. monocytogenes the extent of N-deacetylation was lower, but still very 
important, with up to 50 % of N-deacetylated muropeptides (Boneca et al., 2007). In this regard, 
the demonstration that 5. suis upregulates the expression of the pgdA gene upon interaction 
with neutrophils as weil as during growth in vivo constitutes an interesting and unprecedented 
finding of this work. Since it is apparent that the 5. suis pgdA gene product is responsible for PG 
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N-deacetylation, it is tempting to speculate that this increased expression of the pgdA gene 
correlates with a higher degree of PG N-deacetylation under these conditions that, in turn, 
results in enhanced resistance to lysozyme produced by neutrophiJs. However, in view of the 
fact that it is technically impossible to prepare PG from these samples in amounts and purity 
suitable to perform HPLC and LlQ-FT mass spectrometry, we are unable to provide conclusive 
evidence for this hypothesis. 
Results of the experimental infections carried out in this study using the llpgdA mutant 
suggest that PG N-deacetylation is a major factor in the virulence of S. suis. Overall, the infection 
outcome in the mouse clearly indicates that the llpgdA mutant is severely hampered in its ability 
to inflict damage to the host. The most important consequences of PG N-deacetylation are 
increased survival of S. suis at early stages of the infectious process and an increased ability of 
the pathogen to survive in blood. Interestingly, there was a complete absence of septic shock 
signs in mice inoculated with the llpgdA mutant and the production of inflammatory mediators 
was completely abrogated in mice inoculated with the llpgdA mutant, while, in perfect 
agreement with a previous study (Dominguez-Punaro et al., 2007), an exacerbated T helper-1 
inflammatory respdnse in mice inoculated with the WT strain was observed. Different results 
were obtained in a previous study with L. monocytogenes showing that the absence of PG N-
deacetylation does not result in muropeptides unable to activate the NF-KB pathway, but, 
instead, in enhanced activation of that pathway in a Nod1- and Nod2-dependent manner 
(Boneca et al., 2007). With the results obtained in our study we thus propose that, rather than 
an impaired ability of the unmodified PG to induce exaggerated inflammation, the observed 
basal levels of pro-inflammatory cytokines in mice inoculated with the llpgdA mutant might 
result from the rapid clearance of the mutant by neutrophils (Iow levels of bacteraemia) along 
with an irrelevant activation of macrophages, lymphocytes and NK cells in this process. 
ln spite of the fact that the llpgdA mutant was able to induce clinical signs in some pigs, 
conclusions obtained for the mouse may be extended to the pig. Indeed, mortality observed in 
the llpgdA mutant group may be explained, at least in part, by the fact that we have prioritised 
the use of the highly aggressive intravenous route of administration and a high dose of inocula 
in order to use a validated model of infection (Berthelot-Herault et al., 2001). Nevertheless, in 
contrast to the WT group, pigs that survived septic shock in the llpgdA mutant group noticeably 
recovered and it was apparent that the llpgdA mutant was less fit to survive in blood. This 
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inability to persist in blood might also be important for later stages of the infection. Firstly, 
colonisation of organs was hampered in the mutant group in both the mouse and pig. In 
addition, it has been shown that if S. suis fails to induce acute fatal septicaemia but the level of 
bacteraemia remains high, CNS disease may appear afterwards (Dominguez-Punaro et al., 2007, 
Segura et al., 2006). Interestingly, and in agreement with its observed rapid clearance from 
blood, we did not record any case of meningitis in neither model withthe flpgdA mutant. On the 
other hand, meningitis was responsible for the death of 35 % of mice and 10 % of pigs in the 
respective WT groups. 
Enhanced clearance of the flpgdA mutant strain from blood might be attributed to an 
increased susceptibility of the mutant to killing by neutrophils, as shown in this study. 
Interestingly, neither the WT or flpgdA mutant strains showed differences in resistance to the 
action of cationic antimicrobial peptides such as polymixin B, magainin Il, colistin, human 
neutrophil peptide (HNP)-l and HNP-2 (Supplemental Table 2), functional homologues of which 
are secreted by porcine neutrophils. We speculate that differences observed in killing by 
neutrophils between strains might primarily be explained by the enhanced resistance of the WT 
strain to lysozyme secreted by neutrophils, due to increased PG N-deacetylation after induction 
of the pgdA gene. On the other hand, since our killing assay does not differentiate between intra 
and extracellular killing it is diffieult to estimate if increased killing of the flpgdA mutant 
correlate with increased phagocytosis. However, since the flpgdA mutant is as encapsulated as 
the WT strain and, on the other hand, it has been shown that capsular material interferes with 
the uptake of S. suis by phagocytes (Chabot-Roy et al., 2006, Charland et al., 1998, Segura et al., 
2004, Smith et al., 1999), enhanced phagocytosis of the mutant might be unlikely. Interestingly, 
it has been suggested, although not proved, that an encapsulated S. suis fldltA mutant might be 
killed by porcine neutrophils extracellularly in the so ca,lIed neutrophil extracellular traps (NETs) 
(Fittipaldi et al., 2008). Since neutrophils, in addition to delivering their complex antibiotie 
arsenal into the phagosome, also discharge their Iysozyme-rieh specifie granules extracellularly 
in the NETs (Cho et al., 2005, Mollinedo et al., 2006) it might be postulated that the flpgdA 
mutant may also be killed through the action of this enzyme after being trapped in these 
extracellular structures. Further experiments are needed to confirm this hypothesis. 
ln conclusion, we have determined the muropeptide composition of S. suis and showed 
that this bacterium, through the action of the pgdA gene product, modifies its PG by means of 
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N-deacetylation. We showed that this PG modification, which is probably enhanced in vivo, 
greatly contributes to the virulence of S. suis in both the murine and porcine models of 
infection. The results of this study strongly suggest that PG N-deacetylation is a major virulence 
factor of this swine pathogen and zoonotic agent. 
Experimental procedures 
Bacterial strains, plasmids, and culture conditions. 
Bacterial strains and plasmids used in this study are listed in Supplemental Table 3. S. 
suis strains were grown in THB or in Todd-Hewitt agar (THA) (Becton Dickinson, Sparks, IVID, 
USA) at 37"C under 5% C02. Escherichia coli strains were cultured in Luria-Bertani broth or agar 
medium (Becton Dickinson) at 37"C for 18 h. When necessary, antibiotics (purchased from 
Sigma-Aldrich, Oakville, On, Canada) were added to culture media at the following 
concentrations: for E. coli, kanamycin, 50 Ilg/ml; chloramphenicol (Cm), 10 Ilg/ml and Sp, 50 
Ilg/ml; for S. suis, Cm, 5 Ilg/ml and Sp, 100 Ilg/ml. 
Purification of PG. 
S. suis cell wall was prepared from cultures in the exponential growth phase as 
described for S. pneumoniae (Garcia-Bustos & Tomasz, 1987, Severin et al., 1997) Wall teichoic 
acid and acid-Iabile modifications (such as O-acetylation) were removed by treatment with 
hydrofluoric acid to obtain PG (Severin et al., 1997). 
Preparation and HPLC-analysis of muropeptides. 
PG (ca. 1.25 mg/ml) was stirred with 25 Ilg/ml cellosyl (kindly provided by Hoechst, 
Frankfurt, Germany) in 20 mM sodium phosphate pH 4.8 for 24 h at 37"C. Then, a second 25 
Ilg/ml-aliquot of cellosyl was added and the incubation continued for another 24 h. The sample 
was boiled for 10 min and centrifuged at room temperature for 15 min at 16000 x g. The 
supernatant was recovered and reduced with sodium borohydride as described (Glauner, 1988). 
The reduced muropeptides were separated on a 250x4.6 mm, 3 Ilm Prontosil 120-3-C18 AQ 
reversed-phase column (Bischoff, Leonberg, Germany) as described (Glauner, 1988), with the 
exception of the running buffers. Buffer A was 10 mM sodium phosphate pH 6.0 supplemented 
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with 13 Ill/lof 10% sodium azide; buffer B was 10 mM sodium phosphate pH 6.0 with 30% 
methanol. The eluted muropeptides were detected at 205 nm. 
MALDI-TOF analysis of muropeptides. 
Muropeptides eluted from the C18 column were collected, concentrated in a SpeedVac 
to 10-20 Ill, and acidified with 0.1% trifluor acetic acid (TFA). The sample was then zip-tipped (C-
18 material, Millipore, UK) according to the manufacturer's standard protocol, eluted from the 
zip-tip with 3 III of 50% acetonitrile, 0.1% TFA and mixed with a-cyano-4-hydroxycinnamic acid 
matrix prior to spotting on a target plate. MALDI-TOF analysis was done on a Voyager-DE STR 
mass spectrometer (Applied Biosystems, Warrington, UK) operating in positive ion reflectron 
mode over the mass range (m/z) of 500 to 3000. 
Preparation of muropeptides and LlQ-FT-MS analysis. 
Different conditions for muropeptide preparation were used for samples subjected to 
LTQ-FT-MS analysis. PG (ca. 0.8 mg/ml) was digested with 13 Ilg/ml cellosyl in 20 mM 
ammonium acetate buffer, pH 4.8, for 16 h at 3rc. The sam pie was boiled for 10 min and 
centrifuged at room temperature for 15 min at 16.000xg. The sample (1 Ill) was applied on a 
C18-reversed phase self-packed 100xO.s mm column and eluted with a linear gradient of 
acetonitrile in water, 0.1% formic acid. The eluted fractions were sprayed directly into an LTQ-FT 
mass spectrometer (Thermo, Bremen, Germany) operating in the positive ion mode. The details 
of the method will be published elsewhere (Bui et al., manuscript in preparation). 
DNA manipulations. 
Restriction enzymes, DNA-modifying enzymes and DNA polymerase were purchased 
from GE Healthcare (Piscataway, NJ, USA) or Takara Bio (Otsu, Shiga, Japan) and used 
accordingly to the manufacturer's recommendations. Minipreparations of recombinant plasmids 
from, and transformation of E. coli were performed by standard procedures (Sam brook et al., 
1989). Transformation of S. suis was carried out as previously described (Takamatsu et al., 
2001a). S. suis genomic DNA was isolated by the guanidium thiocyanate method (Pitcher et al., 
1989). Southern hybridizations were performed by the procedures described previously 
(Sekizaki et al., 2001). For preparation of probes, DNA fragments were labelled with digoxigenin 
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(DIG) using the DIG-PCR labeling mixture (Roche Diagnostics, Laval, QC, Canada) according to the 
manufacturer's instructions. Oligonucleotide primers (Invitrogen, Burlington, ON, Canada) are 
listed in Supplemental Table 4. 
Construction of the knockout vector for gene replacement. 
DNA fragments were amplified from genomic DNA of s. suis strain 31533 by PCR using 
the primer sets 4197F-PG plus 4985R-PG (Ieft arm) or 6276F-PG plus 6838R-PG (right arm) 
(Supplemental Table 4). A Sp resistance cassette (aad9 gene) was amplified from pSmali with 
primers specF3 and specR. Ali three primer sets introduce unique restriction sites. PCR 
amplicons were digested using the appropriate restriction enzymes, and sequentially ligated in 
the order left arm-Sp cassette-right arm using T4 DNA ligase. The resulting fragment was 
amplified by PCR using primers 4197F-PG and 6838R-PG, cloned into pCR4 using the TOPO TA 
PCR cloning kit (Invitrogen) following the manufacturer's instructions and propagated in E. coli. 
The insert was then cut out with Hindlll and BamHI and recloned into the Hindlll and BamHI 
sites of the thermosensitive vector pSET-5s, which carries the Cm resistance gene cat 
(Takamatsu et al., 2001b), generating knockout vector p5ôpgdA. 
Generation of s. suis ôpgdA. 
Procedures for selection of mutants by allelic exchange via double crossover were 
described previously (Takamatsu et al., 2001b). Briefly, S. suis strain 31533 was transformed 
with p5ôpgdA, and the cells were grown at 28°C in the presence of Cm and Sp selection. 
Bacteria at the mid-Iogarithmic growth phase were diluted with THB containing Sp and grown at 
28°C to early logarithmic phase. The cultures were then shifted to 37"C and incubated for 4 h. 
Subsequently, the cells were spread on THA containing Sp and incubated at 28°C. Temperature-
resistant Sp-resistant colonies were screened for loss of vector-mediated Cm resistance to 
detect putative mutants which had exchanged their WT allele for a genetic segment containing 
the aad9 gene as a consequence of homologous recombination via a double crossover. Finally, 
the genetic organization of the resulting ôpgdA mutant was verified by PCR and by Southern 
hybridisation (data not shown). Three additional independent ôpgdA mutants (named ôpgdA 2, 
3, and 4 respectively, Supplemental Table 3) were generated using the same strategy. 
Transmission electron microscopy. 
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ON cultures of S. suis WT strain 31533 or mutant strain l1pgdA were mixed with specific 
polyclonal serum anti-S. suis serotype 2 and incubated at room temperature for 1 h, followed by 
fixation in cacodylate buffer (O.lM cacodylate, 5%, v/v, glutaraldehyde 0.15%, w/v, ruthenium 
red, pH 7.2) for 2 h. Cells were then immobilised in 4% (w/v) agar and post-fixed ON at 4°C in 2% 
(v/v) osmium tetraoxyde. Samples were dehydrated in graded series of ethanol and embedded 
in Spurr low-viscosity resin. Thin sections were post-stained with uranyl acetate and lead citrate 
and examined with a transmission electron microscope (Madel 420, Philips Electronics, The 
Netherla nds). 
Lysozyme and cationic antimicrobial peptide sensitivity. 
S. suis WT and l1pgdA mutant were grown in THB ta which was added hen egg lysozyme 
(final concentrations ranging from 2 ta 50 ~g/ml; Sigma-Aldrich). Growth was monitored by 
following the optical density at 600 nm and by plating seriais dilutions onto THA followed by CFU 
enumeration after ON incubation. Assays for sensitivity ta cationic antimicrobial peptides were 
carried out in sterile 96-well microtiter plates. Logarithmic-phase S. suis cells were adjusted ta 
approximately 104 CFU/ml in 100 ~I THB containing one of the following antimicrobial 
compounds (purchased from Sigma-Aldrich) in seriai dilutions: Colistin (0 ta 200 ~g/ml), 
polymyxin B (0 ta 300 ~g/ml), magainin Il (0 ta 45 ~g/ml), HNP-1(0 ta 15 ~g/ml) and HNP-2 (0 ta 
15 ~g/ml). Plates were incubated fo"r 24 h at 37"C. The MIC was defined as the lowest 
antimicrobial concentration yielding no detectable bacterial growth by OD600 nm measurement. 
Killing by porcine neutrophils. 
Blood samples were collected by venous puncture from high health status pigs which 
tested negative by ELISA (Lapointe et al., 2002) for S. suis serotype 2. Cell populations were 
separated by Ficoll-Hypaque (GE Healthcare) density gradient centrifugation and neutrophils 
isolated by sedimentation in 6% dextran, as decribed (Chabot-Rayet al., 2006). Contaminating 
erythrocytes were removed by Iysis with 0.83% ammonium chloride. Neutrophils were 
resuspended in RPMI 1640 medium (Invitrogen) supplemented with 10% of heat-inactivated 
porcine serum at a final concentration of 5x106 cells/ml. Bacteria (WT or l1pgdA mutant strains 
at approx. 1x104 CFU/ml) were opsonised with complete normal porcine serum for 30 min at 
37"C and then mixed in microtubes with neutrophils at 5x106 cells/ml. The mixture was 
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incubated for 90 min at 3rC under 5% CO2• Under these conditions bacteria are not toxie to 
neutrophils (Chabot-Roy et al., 2006). After incubation cells were Iysed with sterile water and 
viable bacterial counts on THA were performed. 
Experimental infection of mice. 
Ali experiments involving animais were conducted in accordance with the guidelines and 
policies of the Canadian Council on Animal Care. For virulence studies a total of 30 female CDl 
mice aged 6 weeks old (Charles River laboratories, Wilmington, MA, USA) were used. At day 0, 
animais were divided in two groups. Group 1 was inoculated by intraperitoneal injection of 1 ml 
of a S. suis strain 31533 suspension at 5 x 107 CFU/ml, while group 2 received the same dose of 
the mutant strain flpgdA using the same route of administration. Miee were monitored 3 times 
a day during 10 days for clinical signs and assigned clinieal scores as previously described 
(Dominguez-Punaro et al., 2007). Surviving animais in both groups were sacrificed at day 10 pi. 
Blood was collected daily from the tail vein and at euthanasia by cardiac puncture and used to 
evaluate bacterial load in this tissue by plating onto sheep blood agar plates and enumeration 
after ON incubation. Bacterial colonisation of the liver, the spleen and the brain of infected 
animais was also evaluated. Briefly, small pieces of these organs weighing 0.5 g were trimmed, 
placed in 500 III of phosphate buffered saline (PBS), pH 7.3, and homogenised. Thereafter, 50 III 
of the suspensions were plated as described above. In addition, an enriehment of the samples 
was carried out by inoculation of 300 III of homogenised organ samples or 100 III of blood into 
THB, followed by ON incubation at 3rc and subsequent dilution and plating onto sheep blood 
agar plates as described above. 
Analysis of the systemic immune response in mice. 
A total of 42 female CDl mice aged 6weeks old (Charles River) were used to study the 
systemic immune response. The WT strain (1 ml of a 5 x 107 (FU/ml suspension) was inoculated 
as described above to 18 mice. The same number of mice received the flpgdA mutant (1 ml of a 
5 x 107 CFU/ml suspension). Finally, 6 mice were sham-inoculated. At defined intervals (3h, 6h, 
12 h, 24 h, 36 h and 48 h) pi infected mice were sacrifieed (3 animais per time for those 
inoculated with the WT or mutant strains, and 1 mouse per time for those sham-inoculated), 
and blood was collected by cardiac puncture. The bacterial dose and time points used were 
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those reported in a previous study (Dominguez-Punaro et al., 2007). For validation of the 
conditions, we previously performed an additional independent study with a limited number of 
animais and time points which showed results consistent with those obtained in the major 
experiments described in the manuscript (data not shown). Plasma wa.s recovered from blood 
samples by centrifugation and the levels of IFN-y, IL-6, IL-l~, TNF-a, MCP-l, KC and RANTES 
were determined using a liquid multiarray system (Luminex Molecular Diagnostics, Toronto, ON, 
Canada). Commercial Multiplex coated beads and biotinylated antibodies, as weil as the 
Beadlyte microtiter 96 weil filter plates were obtained from Millipore, (Billerica, MA, USA). Each 
multiplex assay was performed in duplicate following the manufacturer's specifications. Data 
were collected using the Luminex-l00 system Version 15 2.2 and analysed by MasterPlex 
Quantitation Software (MiraiBio, San Francisco, CA, USA). Standard curves for immune response 
mediators were obtained using the standards supplied by the manufacturer. 
Analysis of the pgdA gene expression. 
Total RNA was prepared from 1 ml of an early stationary phase S. suis culture in THB 
("untreated control", approx 107 CFU/ml) using RNAwiz (Ambion,Austin, TX, USA) accordingto 
the manufacturer's instructions. To analyzeexpression of pgdA upon interaction of S. suis with 
neutrophils, the WT type strain was treated as described above in the killing section and allowed 
to interact with porcine neutrophils for 90 min. Five tubes of the mixture of neutrophils and 
bacteria were then pooled and total RNA was prepared as described above. In addition, 5 tubes 
of a "killing mock-infection" (RPMI plus 10 % porcine serum without neutrophils, as described in 
the killing section) were pooled and total RNA prepared from using RNAwiz. For analysis of in 
vivo expression, 5 female CDl mice aged 6weeks old were inoculated as described above with 1 
ml of a S. suis strain 31533 suspension at 5 x 107 CFU/ml. Animais were sacrificed 24 h pi. Pieces 
of spleen and liver (weighing approx 0.2 g) were collected and disrupted with 0.1 mm glass 
beads using a mini bead beater (Biospec Products, Bartlesville, OK, USA) and total RNA prepared 
with RNAwiz, as described. Ali RNA samples were treated with TurboDNAse (Ambion), and 
absence of contaminating DNA was verified by PCR using primers AROA-F and BA9 
(Supplemental Table 4), which target the aroA gene. RNAs were quantified by measurement of 
absorbance at 260 nm and their integrity verified by visualization on 1% denaturing agarose 
gels. Synthesis of cDNAs was performed in triplicate using SuperScript Il (Invitrogen) with 
random hexamers (Roche, Laval, Qc, Canada). Q-PCR was carried out by using the QuantiTect 
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SybrGreen PCR Kit (Qiagen, Mississauga, ON, Canada) according to the manufacturer's 
instructions. For each sample, a no-reverse transcription reaction was run as a control. For each 
Q-PCR run, to normalize for the amount of sample cDNA added to each reaction, the Ct value of 
the pgdA gene was subtracted by the Ct value of the endogenous control rpoO gene (delta 
Ct = Ct pgdA -Ct rpoO), and the n, for a comparison between the "untreated control" (bacteria 
grown in THB) group and the "treated" groups (upon interaction with neutrophils, "killing mock 
infection", in vivo samples), the delta Ct values of the treated groups were subtracted by the 
delta Ct value of the untreated control (delta delta Ct = delta Ct treated group - delta Ct 
untreated control). The fold changes were calculated by the formula of rdelta delta Ct (Livak & 
Schmittgen, 2001). Primers were SSU1448-FQ and SSU1448-RQ for pgdA and RPDO-F and RPDO-
R for rpoO (Supplemental Table 4). 
Experimental infection of pigs. 
A total of 24 high-health-status p,igs (ages 4 to 5 weeks) which tested negative by ELISA 
(Lapointe et al., 2002) for S. suis serotype 2 were used. Strict biosecurity measures were 
implemented to avoid undesirable contamination of the pigs; these included an air filtration 
system and airlocks for each unit. Pigs were divided in 3 groups. Animais in groups 1 (N=10) and 
2 (N=10) were inoculated by intravenous injection of 1 ml of 1 x 108 CFU/ml of S. suis WT strain 
31533 or mutant l:lpgdA, respectively. Group 3 (N=4) were sham-inoculated animais. Clinical 
signs and presence of S. suis in blood were monitored during the trial. Surviving animais in ail 3 
groups were sacrificed 5 days pi and examined for pathological lesions. Bacteriological isolation 
from different organs (liver, spleen, lungs, heart and articulations) was performed essentially as 
described above for the mice. 
Statistics. 
Unless otherwise specified, ail the data were expressed as means ± standard deviations. 
Unless otherwise specified, data were analysed by two-tailed, unpaired t test and ail assays 
were repeated at least three times. For data analysis of the systemic immune response and 
bacteremia in mice the Mann-Whitney test was used. For in vivo virulence experiments, survival 
was analysed with the LogRank test. For ail tests, a value of P < 0.05 was considered as the 
threshold for significance. 
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Article III Tables 
Table VII. Article III, Table 1. Muropeptides detected by LTQ-FT mass spectrometry. 
Muropeptide WT f:J.pgdA 
theoretical 
neutral signal neutral signal No proposed structure neutral 
mass (Da) intensity mass (Da) intensity 
mass (Da) (A.U.)l (A.U.)l 
1 Tri 823.3811 823.3793 157,566 823.3795 124,676 
2 Tri (Glu) 824.3889 824.3644 n. q. 2 824.3646 n. q. 
3 Tri (-G) 620.3017 620.3012 5,961 620.3012 4,212 
4 Tri (deAc) 781.3705 781.3708 450 n.d.3 n.d. 
5 Tetra 894.4182 894.4171 17,168 894.4173 15,822 
6 Penta 965.4553 965.4541 9,763 965.4549 4,835 
7 TetraTri 1699.7887 1699.7874 108,961 1699.7871 59,454 
8 TetraTri (Glu) 1700.7966 1700.7580 n.q. 1700.7598 n.q. 
9 TetraTri (deAc) 1657.7781 1657.7766 5,488 n.d. n.d. 
10 TetraTri (-G) 1496.7093 1496.7084 5,551 1496.7083 3,095 
11 TetraTri (-2G) 1293.6299 1293.6287 10,318 1293.6291 3,716 
12 TetraTri (-GM) 1221.6088 1221.6080 3,021 1221.6086 903 
13 TetraTetra 1770.8259 1770.8249 2,588 1770.8261 1,288 
14 TetraPenta 1841.8630 1841.8620 3,834 1841.8626 2,013 
15 TetraTetraTri 2576.1964 2576.1952 17,734 2576.1995 7,391 
16 TetraTetraTri (deAc) 2534.1858 2534.1944 139 n.d. n.d. 
17 TetraTetraTri (-G) 2373.1170 2373.1174 1,813 2373.1226 544 
18 TetraTetraTri (-2G) 2170.0376 2170.0369 2,191 2170.0407 780 
19 TetraTetraTetra 2647.2335 2647.2275 84 2647.2398 19 
20 TetraTetraTetraTri 3452.6040 3452.6084 1.972 3452.6113 708 
1 the noise of the signal is ::::10 A.U. 
2 not quantified because the signal partly overlaps with the isotope signal of the amidated 
compound 
3 n.d. not detected 
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Table VIII. Article III, Supplemental Table 1. Quantification and MALDI-TOF-MS analysis of the 
muropeptides separated by HPLC. 
Positive mass (Da) 
Muropeptide Area % From collected peaks2 
reduced, Na+ form 
No proposed structurel WT l1pgdA measured calculated 
1 Tri 18.8 20.9 848.40 848.39 
2 Tri (Glu) 2.2 2.4 849.38 849.40 
3 Tri (-G) n.q.3 n.q. 623.334 623.334 
4 Tri (deAc) n.d. 5 n.d. n.d. 806.38 
5 Tetra 2.6 2.7 919.46 919.42 
6 Penta 1.5 1.7 990.51 990.46 
7 TetraTri 46.0 46.7 1726.86 1726.81 
8 TetraTri (Glu) 2.5 1.9 1727.88 1727.82 
9 TetraTri (deAc) n.d. n.d. n.d. 1684.80 
10 TetraTri (-G) 3.3 4.1 1523.77 1523.73 
11 TetraTri (-2G) n.d. n.d. n.d. 1320.65 
12 TetraTri (-GM) 1.1 0.3 1246.67 1246.61 
13 TetraTetra 1.7 1.3 1797.97 1797.85 
14 TetraPenta 1.9 2.0 1869.02 1868.88 
15 TetraTetraTri 11.7 10.2 2605.34 2605.23 
16 TetraTetraTri (deAc) n.d. n.d. n.d. 2563.22 
17 TetraTeVaTri (-G) n.q.6 n.q.6 2402.27 2402.15 
18 TetraTetraTri (-2G) n.d. n.d. n.d. 2199.07 
19 TetraTetraTetra n.d. n.d. n.d. 2676.27 
20 TetraTetraTetraTri n.d. n.d. n.d. 3483.65 
1 see Fig. lB 
2 peaks were collected From the WT sample 
3 not quantified, co-elutes with Tri 
4 mass of the H+ form 
5 n.d., not detected 
6 
n.q., not quantified, co-elutes with TetraTetraTri 
Table IX. Article III, Supplemental Table 2. Sensitivity of the S. suis WT and llpgdA mutant 
strains to the action of selected antimicrobial peptides. 
MICs (f..lg/ml) 
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Peptide (origin) Net charge WT f:.pgdA 
Colistin (Boeil/us eolistinus) +5 50 50 
Polymyxin B (Boeil/us polymyxa) +5 75 75 
Magainin Il (claw frog skin) +4 45 45 
HNP-1 (human) +3 6 6 
HNP-2 +3 5 5 
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Table X. Article III, Supplemental Table 3. Bacterial strains and plasmids used in this study. 
Bacterial strains 
f. coli Top ten 
S. suis 31533 
S. suis tJ.pgdA 
S. suis tJ.pgdA 2 
S. suis tJ.pgdA 3 
S. suis tJ.pgdA 4 
S. suis BD102 
Plasmids 
pCR4 
pSmali 
pSET5s 
p5tJ.pgdA 
Relevant characteristics 
General strain for cloning. F- mcrA tJ.{mrr-hsdRMS-mcrBC) 
<t>80IacZtJ.M15 tJ.IacX74 recA1 araD139 tJ.{ara-leu) 7697 
ga/U ga/K rpsL (StrR) endA1 nupG 
Serotype 2 field strain. Highly virulent 
Derived from strain 31533. Deletion of the pgdA gene 
Derived from strain 31533. Deletion of the pgdA gene 
Derived fram strain 31533. Deletion of the pgdA gene 
Derived fram strain 31533. Deletion of the pgdA gene 
Derived from strain 31533. Deletion of the promoter of 
the aro operon. Unencapsulated. 
f. coli vector for cloning of PCR fragments 
f. coli-S. suis shuttle vector. SpeeR. Source of aad9 
Thermosensitive suicide vector for S. suis mutagenesis. 
CmR (cat) 
pSET5s carrying the construction for allelic exchange 
Source 
Invitragen 
(Vanier et al., 
2004) 
This work 
This work 
This work 
This work 
(Fittipaldi et al., 
2007) 
Invitragen 
P. Wilison 
(unpublished) 
(Takamatsu et 
al., 2001) 
This work 
Table XI. Article III, Supplemental Table 4. Oligonucleotide primers used in this study. 
Restriction sites are in bold. 
Primer name Sequence (S' - 3') 
4197F-PG GACGGGTGGTCAAGCTTITGAATA 
4985R-PG CCA TI ATGCCGAGCAAGGAGATCTTG 
6276F-PG 
6838R-PG 
SPECF2 
SPECR 
COMPPGDA-F3 
COMPPGDA-R 
AROA-F 
AROA-R 
SSU1448-FQ 
SSU1448-RQ 
RPOD-F 
RPOD-R 
GTAACAGACTIACTCTGCAGTCCTC 
GTGAACGTTIGGATCCTCTACGTAA 
TIATCAGGATAGATCTTCGTTCGTGA 
AAAGTGTTICCTGCAGTITTICAA 
GGATITAAGGGTACCCGTCGCAAGGA 
ACCAGGGATCCTACTAACATGATIC 
AACGTGACCTACCTCCGTTG 
CGGTCATCGTAGAATTCGAGT 
TICTCTCTGTACTTGCTCCC 
GGTCGCTCTAACCTTIGATG 
TCTTICAAATACATGCGGACTG 
ATTCCATTIACGCTIGATGCTG 
Restriction site 
Hindlll 
BglIl 
Pstl 
BamHI 
BglIl 
Pstl 
Kpnl 
BamHI 
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Figure 21. Article III, Figure 1. S. suis muropeptide composition and proposed structures. 
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A. Muropeptide composition of s. suis WT and lJ.pgdA mutant. The numbers correspond to the 
structures shown in B. The profiles of both strains showed similar muropeptide composition. 
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However, see Table 1 and the text for differences between the WT and I1pgdA mutant. B. 
Proposed structures for s. suis muropeptides. G indicates N-acetylglucosamine residue; M 
indicates N-acetylmuramic acid residue. Asterisks indicate deacetylation of G or M. In 
compounds marked with 1 it is not known which of the residues is modified. 
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Figure 22. Article III, Figure 2. Genetic organization of the pgdA region and Clustal alignment of 
the predicted s. suis PgdA. 
A. Genetic organization of the s. suis pgdA gene showing the predicted putative strong promoter 
(indicated by P) and the Rho-independent putative terminator. The region deleted in the I1pgdA 
mutant (replaced by gene aad9) is also indicated. See the text for details B, Sequence alignment 
of s. suis (SsPgdA) and the described N-acetylglucosamine deacetylases from s. pneumoniae 
(SpPgdA) L. lactis (LlPgdA) and L. monocytogenes (LmPgdA), Sequences were aligned using the 
CLUSTALW software (http://www.ebi.ac.uk/Tools/clustalw/). Residues in grey and black boxes 
indicate the conserved catalytic residues and metal ligand amino acids characterised for s. 
pneumoniae PgdA (Blair et al., 2005), respectively. Asterisks below alignment indicate identical 
aminoacids, colons strongly conserved aminoacids and dots weakly conserved aminoacids. 
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Figure 23. Article III, Figure 3. Growth curves and morphology of the WT and IlpgdA mutant. 
A. Growth curves of S. suis WT and Ilpgda mutant strains. The IlpgdA mutant (open triangles) 
grew similarly as the WT parent strain (closed circles) under normal laboratory conditions. B. 
Morphology of the WT (Ieft) and the IlpgdA mutant (right) strains. Transmission electron 
microscopy showed that both strains were weil separated and surrounded by a thick 
polysaccharide capsule. Original magnification : 30 OOOX. 
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Figure 24. Article III, Figure 4. Lysozyme sensitivity of s. suis WT and IlpgdA mutant strains. 
The WT and the tJ.pgdA mutant strains were grown at 37 C; until the beginning of stationary 
phase of growth was reached, at which point, indicated by the arrow, lysozyme was added at 
different concentrations. Growth was monitored by measuring absorbance at 600nm . 
Experiments were performed at least 3 times. Error bars are not shown for simplicity. 
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Figure 25. Article III, Figure 5. Results of the WT and IlpgdA muta/nt infection in mice. 
A. Survival of mice inoculated with the WT (sol id line) or the tJ.pgdA mutant (dotted line) strains. 
Ali the mice in the tJ.pgdA mutant (N=lS) group survived, while 80% of the WT group (N=lS) died 
from septicaemia or meningitis. Significant difference in survival were noted (LogRank test, 
P<O.OS). B. Kinetics of bacterial clearance from blood in the WT and tJ.pgdA mutant. The tJ.pgdA 
mutant was isolated at lower titers than the WT strain following inoculation and was 
undetectable in this tissue from day 3 pi. Squares and triangles represent values from individual 
mice. The horizontal lines indicate the median for each group (WT: solid line; tJ.pgdA mutant: 
dashed line). Significant differences in isolation from blood were noted between groups from 
day 1 to day 4 pi (Mann-Whitney, P<O.OS). 
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Figure 26. Article III, Figure 6. Production of inflammatory mediators by mice inoculated with 
the WT strain (black bars, 3 animais per time), the âpgdA mutant (white bars, 3 animais per 
time) or sham-inoculated mice (dashed bars, 1 animal per time). 
A. IFN-V; B. IL-6; C. IL-1~; D. KC; E. RANTES; F. MCP-l. Significant differences (Mann-Whitney test 
P<O.OS) were observed between the WT and the flpgdA mutant for ail the inflammatory 
mediators at different time points (indicated by asterisks). Error bars indicate the standard 
errors of the median. See the text for further details. 
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Figure 27. Article III, Figure 7, Percentage of bacteria killed after 90 min incubation with 
porcine neutrophils. 
The level of killing of the tJ.pgdA mutant was similar to that observed for an unencapsulated 
mutant BD102 and significantly higher (t-test, P<O.OS) than that of the WT strain. The different 
strains were opsonised with complete porcine sera before incubation. The experiment was 
repeated at least 5 times. Error bars indicate standard deviations calculated from biological 
repetitions. 
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Figure 28. Article III, Figure 8. Results of the WT and tJ.pgdA mutant infection in swine. 
Survival of pigs inoculated with the WT (solid line, N=10) or the tJ.pgdA mutant (dotted line, 
N=lO). Sham inoculated animais are not shown for simplicity. Significant differences in survival 
were noted, LogRank test, P<O.OS. The survival rate of pigs in the tJ.pgdA mutant group was 60%. 
ln the WT group 80 % of the animais did not survive the trial. See the text for further details. 
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Figure 29. Article III, Figure 9. Q-PCR analysis of the level of expression of the S. suis pgdA gene 
upon 90 min interaction of the bacteria with porcine neutrophils, or in vivo in the liver and 
spleen of experimentally infectedmice. 
The listed fold changes are relative to expression of pgdA when the bacteria were grown in THB 
(defined as 1 and shown by the dashed line). Fold changes were calculated using the delta-delta 
Ct method (Uvak & Schmittgen, 2001). Please see the materials and methods section for further 
details, For in vitro samples (neutrophils), bars show the mean ± standard deviation of at least 
three biological repetitions. For in vivo samples, bars represent individual animais (mean ± 
standard deviation of three technical repetitions). 
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Figure 30. Article III, Figure 51. Killing of the different IlpgdA mutants by porcine neutrophils. 
IV. DISCUSSION 
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Current knowledge on S. suis virulence factors. 
As with many other extracellular bacteria, S. suis produces a polysaccharide capsule that 
allows for resistance to complement-mediated Iysis and phagocytosis by leukocytes. At the 
beginning of this research project, the single most critical virulence factor described for s. suis 
was the CPS (Chabot-Roy et aL, 2006; Charland et aL, 1998; Smith et aL, 1999a). Still today, the 
CPS is the best characterized S. suis virulence factor (Gottschalk et aL, 2007). However, most S. 
suis avirulent strains are encapsulated, and many avirulent weil encapsulated strains are rapidly 
cleared from the circulation (Gottschalk and Segura, 2000). In addition to the CPS, a 
fibronectin/fibrinogen-binding protein (de Greeff et aL, 2002b) seems to be partially involved in 
virulence. Other factors are not essential for virulence, are absent from some virulent strains, or 
have not yet been properly studied due to the unavailability of knockout mutants (Gottschalk et 
aL, 2007). Recently, an OFS has been described and shown to be critical for the virulence of s. 
suis (Baums et aL, 2006). However, like the CPS, this factor is present in both virulent and 
avirulent S. suis strains (Takamatsu et aL, 2008b). Some other proposed putative virulence 
factors have been shown to be dispensable for the virulence of s. suis. This is the case for MRP 
and EF proteins (Smith et aL, 1993; Smith et aL, 1992), as weil as for suilysin, (Gottschalk et aL, 
1995; Jacobs et aL, 1994). Indeed, MRP and EF do not seem to confer virulence attributes 
directly, as shown by the use of isogenic mutants (Smith et aL, 1996). On the other hand, 
suilysin has been identified as a toxie factor for various cell types (Charland et aL, 2000; Segura 
and Gottschalk, 2002; Vanier et aL, 2004; Vanier et aL, 2008b). This toxin also'has the ability to 
interfere with complement-mediated opsonophagocytosis (Chabot-Roy et aL, 2006). 
Nevertheless, isogenie mutants lacking suilysin were shown to be as virulent to pigs as the 
respective parent strain (Allen et aL, 2001; Lun et aL, 2003). Though, there is a positive 
association between the presence of these proteins and virulence in Eurasian strains of serotype 
2. Furthermore, avirulent strains expressing MRP, EF and suilysin have not been described so 
far. On the other hand, the absence of one or more of these proteins is not necessarily 
associated with a lack of virulence. Indeed, besides experimental trials with isogenic mutants, 
some European and most Canadian virulent isolates do not produce these factors (Berthelot-
Herault et aL, 2000; Gottschalk et aL, 1998; Quessy et aL, 1995; Segers et aL, 1998). Recent data 
(Article V, Appendix) suggest that the situation in the United States is similar to that in Canada 
regarding the lack of production of these virulence markers for serotype 2 strains. 
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Whether a single isolate of s. suis should be classed as virulent or avirulent is still a 
matter of controversy (Berthelot-Herault et aL, 2005; Gottschalk and Segura, 2000; Gottschalk 
et aL, 2007). Despite increasing research in the last four years that led to the genome 
sequencing of several S. suis strains, as weil as the recent identification of novel putative 
virulence determinants (see the Review of the literature), the paragraph above still represents, 
to a certain extent, the current knowledge on S. suis virulence. Therefore, the need for the 
discovery of novel S. suis virulence factors was beyond doubt justified. The development of the 
in vitro model of s. suis-porcine BMEC interactions (Vanier et aL, 2004) offers an excellent 
chance to interrogate S. suis gene expression during a key step in meningitis development such 
is BBB crossing. Indeed, BMEC are one of the major cellular types forming the BBB, the 
impermeable barrier that only certain bacteria, including E. coli, N. meningitidis, M. tuberculosis, 
GBS, S. pneumonioe, L. monocytogenes and s. suis are able to cross (Kim, 2006). Therefore, 
genes expressed by S. suis during its interactions with porcine BMEC may potentially be 
considered important virulence factors of this swine pathogen and zoonotic agent. 
To that end, in this research project we used an efficient molecular approach (SCOTS), 
which selects for and identifies differences in bacterial gene expression and the vitro model of s. 
suis adhesion/invasion of porcine BMEC. In a considerable step forward for our understanding of 
the pathogenesis of the s. suis infection, in this research project we identified twenty-eight 
genes that were upregulated by S. suis during its interactions with porcine BMEC. Selected genes 
were further studied and the role they play in s. suis virulence was evaluated. 
Validity of the SCOTS approach and general considerations about the identified genes 
The SCOTS approach has been used with success in several bacterial species (Baltes et 
aL, 2007; Baltes and Gerlach, 2004; Bauer et aL, 2008; Daigle et aL, 2001; Dozois et aL, 2003; 
Faucher et aL, 2005; Faucher et aL, 2006; Graham and Clark-Curtiss, 1999; Graham et aL, 2002; 
Hou et aL, 2002; Jin et aL, 2008; Liu et aL, 2002; Zhu et aL, 2008). To the best of our knowledge, 
Article l, presented in the body of this thesis, is the first report of the use of the SCOTS approach 
for analysis of differential gene expression in streptococci. Results presented in Article 1 clearly 
demonstrate that SCOTS is also suitable for the elucidation of gene expression in this important 
bacterial genus. To fully realize the importance of the use of the SCOTS approach, it has to be 
taken into account that at the beginning of this research project, very few molecular tools had 
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been developed for s. suis and most of today's finishedjongoing who le genome sequencing 
projects had not even been started. Therefore, SCOTS, which is a technique that does not 
require specialized mutagenesis systems or a detailed knowledge of genome sequence data, 
provided us with an extraordinary opportunity for seeking novel virulence factors of this 
pathogen. Indeed, before the present research project, only one genomic approach had been 
used for the identification of s. suis virulence factors (Smith et aL, 2001a). In that work, a 
promoter-trap system (an adapted IVET approach) identified several S. suis promoters that were 
expressed upon iron-starvation conditions or in vivo (porcine infection model) (Smith et aL, 
2001a). Interestingly, in that study, ail the promoters identified as being active in vivo by the use 
of the promoter-trap approach were also expressed in vitro under standard laboratory growth 
conditions, a fact that the authors of that study explained by the absence of promoter 
sequences exclusively expressed in vivo (Smith et aL, 2001a). However, since a plasmid-based 
instead of an integrative promoter trap system was used, the results obtained might as weil be 
explained by the inability of that system to detect in vitro silent genes due to gene dose effects. 
ln this research project, by using SCOTS we clearly showed condition-specifie differences 
in S. suis gene expression that were confirmed in selected cases by the use of Q-RT-PCR. A 
comparison between the genes identified by SCOTS and those detected by the use of the 
promoter-trap approach revealed that there were no overlapping genes between the two S. suis 
studies. This was an interesting finding, because IVET and SCOTS have identified the same genes 
in some cases (Rediers et aL, 2005). However, absence of overlapping genes was not surprising, 
since only a small number of genes were identified in either study, and, more importantly, the 
experimental conditions used were essentially different. Therefore, in this research project, the 
use of the SCOTS approach resulted in original data leading to the identification of several 
interesting-virulence factor candidates, further study of which might provide new insights on the 
molecular mechanisms that this pathogen might use to cross the BBB. However, it is important 
to note that based on comparison against thecurrent reports available in the literature, none of 
the identified genes might be, per se, responsible for BBB crossing. As discussed, blood-borne 
bacteria able to invade the CNS may cross the BBB or the blood-CSF barriers following direct 
interaction with the luminal side of the cerebral endothelial tissue or choroid plexus epithelial 
cells. Only a limited number of bacterial pathogens are able to traverse these barriers, a fact 
that suggests that these organisms have developed specifie strategies and possess specific ' 
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attributes. However, no specific gene implicated directly in the crossing of BBB, giving clues for a 
better understanding of this phenomenon, has ever been found by the use of global approaches 
such as IVET or STM (Kim, 2006). The SCOTS study presented in Article 1 was no exception, 
although many of the genes identified may play important roles in virulence. Indeed, the 
currently acknowledged hypothesis is that crossing of the BBB and/or the blood-CSF barrier is 
the result of the concerted and synergistic action of many genes. Abolition of the crossing would 
probably need inactivation of several of them (Autret and Charbit, 2005; Kim, 2006). 
As mentioned above, the identification of the twenty-eight genes preferentially 
expressed upon the interactions of S. suis with porcine BMEC may result in a better 
understanding of how this pathogen causes meningitis. Indeed, several of these genes show a 
great potential as virulence factor candidates. On the other hand, many genes putatively 
involved in metabolism were also identified by SCOTS. These genes are often disregarded or at 
least considered of less interest because they are linked to housekeeping functions and do not 
encode "genuine" colonization or virulence factors. However, they can provide new information 
about the metabolism of the microbe that may, in the case of animal pathogens such as S. suis, 
prove useful for vaccine development. Metabolic genes are isolated frequently in practically ail 
IVET, STM and SCOTS studies (Autret and Charbit, 2005; Daigle et al., 2002; Rediers et al., 2005) 
and their increased expression clearly means that fulfilling nutritional requirements is 
important. It can nevertheless be considered intriguing that, using our in vitro model where 
nutritional elements are unlimited, a relatively high proportion of SCOTS-identified genes are 
putatively involved in metabolism. However, it is known that transcriptional activation of most 
bacterial promoters in their natural environments is not a simple on/off decision, as the 
expression of cognate genes is integrated in layers of Iterative regulatory networks that ensure 
the performance not only of the whole cell, but also of the bacterial population, in a changing 
environment (Cases and de Lorenzo, 2005). One environmental signal (whether it is nutritional 
or physicochemical) can upregulate or downregulate the activity of many promoters, and this 
regulatory network is known as a regulon. From a mechanistic point of view, regulons involve 
regulatory proteins that allow different promoters to respond to the same signal. Moreover, a 
common stimulus can drive entire regulons to act in concert (a stimulon) (Cases and de Lorenzo, 
2005). Although we are far from having identified the specific signal(s) that trigger upregulation 
of SCOTS-identified genes, it can be hypothesized that upon contact with porcine BIVIEC, in 
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addition to genes required for adhesion/invasion of these cells, S. suis also upregulates other 
genes required for optimal ecological performance. 
The hypothesis mentioned above is also supported by the isolation of other, non-
metabolic, genes such as pgdA, whose role in S. suis virulence will be extensively discussed 
below. Indeed, this gene has been shown to be primarily involved in resistance to lysozyme, an 
effector of the innate immune response of the host (Boneca et al., 2007; Vollmer and Tomasz, 
2000). Interestingly, the pgdA gene was found to be upregulated in the presence of porcine 
BMEC, even if no lysozyme was present in our in vitro model of infection. However, assuming a 
yet unknown signal(s) and the concept of regulon- or even stimulon-driven expression of S. suis 
genes upon interaction with porcine BMEC, induction of the pgdA gene may represent a logical 
response to an in vivo situation where the immune response of the host would be much more 
relevant than it is in vitro. Knowledge on the signal(s) that elicit or repress gene expression in S. 
suis remains so far truly vague, not only for the novel SCOTS-identified genes, but also for 
almost ail of the proposed virulence factors of this pathogen. Even the regulation of the CPS, so 
far the most characterized critical virulence factor of S. suis, remains unknown, despite the 
identification of the cps locus (Smith et al., 1999a; Smith et al., 2000) and previous reports 
accounting for increased production of capsular material in vivo (Quessy et al., 1994). Indeed, 
data presented in the Appendix of this thesis (Article 4) seem to indicate that regulation of 
capsule production may perhaps be linked to the aromatic amino acid pathway. Without a 
doubt, the naive notion that "everything is connected to everything" in biological systems 
applies also to S. suis and emphasizez that further efforts are needed to shed light into the 
complexity of virulence regulation in this important pathogen. 
Putative collagenase 
As stated above, some genes identified by SCOTS might be considered potential 
virulence factor candidates for S. suis. Interestingly, at the time of publication of Article l, a 
report was published describing the use of STM for S. suis. In that report, twenty-two 
transposon mutants were shown to be attenuated in either the pig or mouse model of infection 
(Wilson et al., 2007). A variety of genes were thus identified, including genes previously found to 
be essential to the virulence of other organisms (Wilson et al., 2007). These findings have been 
described in the Review of the literature section of this thesis. As for the promoter trap 
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approach discussed above, no overlap was found between the SCOTS and STM studies, with the 
exception of one common gene. Interestingly, the STM study (Wilson et aL, 2007) reported the 
identification of a gene putatively involved in collagen degradation (SSU0457) that had also 
been isolated using the SCOTS approach in this research project. It has been shown that S. suis is 
able to interact with ECM proteins and to bind, among others, fibronectin, fibrinogen and 
collagen (Esgleas et aL, 2005). On the other hand, S. suis has the ability to induce the 
upregulation of matrix metalloproteinase 9 and metalloproteinase 3 production by human 
macrophages and porcine CPEC (Jobin et aL, 2006; Tenenbaum et aL, 2008). One proven action 
of these enzymes is the digestion of the ECM, an action that may result in tissue destruction and 
disruption of the BBB and blood CSFbarrier, which may in turn facilitate (further) trafficking of 
bacteria and leucocytes. However, the direct ability to degrade ECM proteins has not yet been 
demonstrated for S. suis. Therefore, the identification by SCOTS and, in parallel, by STM, of this 
putative collagenase might be of importance for better understanding the mechanisms used by 
S. suis to reach the CNS. Interestingly, in sequenced strains P 1/7 and 89-1591, the putative 
collagenase identified by SCOTS is located upstream of a gene putatively encoding a second 
putative collagenase, in an operon-like organization. It has been suggested that the impairment 
of BBB barrier function during infection with different S. suis strains may depend on proteases 
produced by this pathogen (Jobin and Grenier, 2003). It is thus tempting to speculate, even if we 
lack evidence regarding its exact function, that upregulating the expression of this collagenase in 
vivo might be useful for S. suis to increase the permeability of the BBB and blood-CSF and 
therefore contribute to the migration of S. suis to the CNS. From the STM study, it seems that 
the action of this collagenase is essential for full virulence of the pathogen (Wilson et aL, 2007). 
Further assessment of the action of this protein in vitro should clarify its involvement in collagen 
degradation. 
Pili 
Pili in several Gram positive bacteria have recently been described (Telford et aL, 2006). 
ln contrast to those produced by Gram negative bacteria, Gram positive pili are formed by 
covalent polymerization of pilin subunits in a process that requires a dedicated sortase enzyme 
(Proft and Baker, 2009). Pilin subunits are added to the fiber by the dedicated Class C sortase, 
and then are covalently linked to the cell wall peptidoglycan by the housekeeping sortase 
(Dramsi et aL, 2006; Dramsi et aL, 2005; Telford et aL, 2006). In ail Gram positive pili described 
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so far, the structural pilin subunits, as weil as the class C sortases required for polymerization, 
have been shown to be encoded by genes which are clustered together in discrete loci (Proft 
and Baker, 2009; Telford et al., 2006). In addition to the dedicated sortase, Gram positive pili 
clusters comprise at least two genes encoding the pilin subunits, each of which contains an 
LPXTG (or a variant thereof) amino-acid motif (Proft and Baker, 2009). One of these proteins 
(known as the major pilin subunit) constitutes the backbone of the pilus, while the second 
(minor or ancillary pilin subunit) might be located atthe tip of the structure and might 
constitute the adhesin. The exact location of the minor pilin subunit within the pilus structure is 
yet a matter of discussion (Proft and Baker, 2009). Pili clusters with more than one minor pilin 
subunit have also been described, and in these cases the exact role of each minor subunit is 
controversial (Telford et al., 2006). Sometimes, the pili clusters may contain a signal peptidase 
gene, which, in GAS, has been shown to be required for pili polymerization (Zahner and Scott, 
2008). 
ln S. suis, the presence of thin pilus-like structures on the surface of the bacterium has 
been revealed by electron microscopy (Jacques et al., 1990). In this research project, by the use 
of the SCOTS approach, we identified for the first time a pili cluster in S. suis (Article 1). Indeed, 
SCOTS isolated a gene putatively encoding a signal peptidase homologous to the LepB-type 
signal peptidases of Gram-negative bacteria. An homologous LepB-type signal peptidase is the 
first gene in the GBS pilus island 2b (PI-2b), one of the three identified pili islands in this species 
(Telford et al., 2006). The GBS PI-2b contains five other downstream genes, encoding two LPXTG 
proteins (putative ancillary pilin subunit and the main pilin subunit), a class C sortase, a third 
LPXTG protein (ancillary pilin subunit) and a second class C sortase (Telford et al., 2006) [Figure 
14, (Article l, Figure 2)]. Interestingly, in S. suis sequenced strains P1/7 and 89-1591, two genes 
encoding LPXTG proteins (highly homologous to the ancillary and main pilin subunits of GBS, 
respectively) and a gene encoding an undescribed putative class C sortase-like protein were 
found downstream of the LepB signal peptidase that was identified by SCOTS (Article l, Figure 2). 
Although the S. suis putative pilus island lacks the last 2 genes in comparison to that of GBS, 
based on the similarity of the genetic organization, the strong homology showed by the LPXTG 
proteins to the main and ancillary pilin subunits of this latter species and the current proposed 
mechanism for pili formation in Gram-positive bacteria (Dramsi et al., 2006; Mora et al., 2005), 
we suggested that a pilus might be formed by the gene products of this island. In addition, since 
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pili have been very recently shown to be important for GBS adhesion to and invasion of human 
BMEC (Maisey et aL, 2006), we speculated that this putative pilus might participate in S. suis 
adhesion to or invasion of porcine BMEC (Article I). Following the identification of this pilus 
cluster, a project aimed at further characterizing pili production by S. suis has been established. 
Research is ongoing and some unpublished results showing that the pilus cluster F indeed drives 
the expression of pili, as weil as a short discussion, will be presentedin the appendix section of 
thesis. 
D-a]any]ation of the L T A and the virulence of S. suis 
LTA is an amphiphilic polymer of poly-Gro-P or polyphosphoribitol, anchored to the 
cytoplasmic membrane by a glycolipid (Weidenmaier and Pesche 1, 2008). Each poly-Gro-P or 
phosphoribitol present on this molecule may be modified by glycosylation or, more often, may 
contain D-alanine residues (Neuhaus and Baddiley, 2003). One of the SCOTS-identified genes, 
the gene dltB (ssu0597) belongs to an operon comprising four genes, dltABCD, which is present 
in ail genomes of low-G+C bacteria determined so far. In ail species where this operon has been 
studied, ail four genes are required to catalyze the incorporation of D-alanine residues into the 
LTA (Neuhaus and Baddiley, 2003). It has been shown that the dltA gene encodes the D-alanyl 
carrier protein ligase DltA which activates D-alanine for ligation to the D-alanyl carrier protein 
(Dite). The product of the ditO gene (DItO) functions in the selection of the carrier protein DltC 
for ligation with D-alanine (Debabov et aL, 2000), while DltB, a membrane protein, has been 
proposed to be involved in the secretion of D-alanyl-DltC, which would then transfer the D-
alanine molecule to the LTA (Figure 11). D-Alanylation of the LTA has important consequences: it 
allows Gram positive organisms to modulate their surface charge, to regulate ligand binding and 
to control the electromechanical properties of the cell wall (Archibald et aL, 1973; Neuhaus and 
Baddiley, 2003). In addition, formation of D-alanyl-LTAs has been shown to be required to resist 
the action of cationic antimicrobial peptides (CAMPs) in L monocytogenes, S. aureus, S. 
pneumoniae, GAS and GBS (Abachin et aL, 2002; Kovacs et aL, 2006; Kristian et aL, 2005; Poyart 
et aL, 2003; Weidenmaier, 2005a). Besides, virulence of mutants deficient in D-alanylation of 
LTA of GBS, L. monocytogenes and S. aureus has been shown to be severely impaired in the 
murine or rabbit models of infection (Abachin et al., 2002; Poyart et aL, 2003; Weidenmaier, 
2005a). 
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Before this research project, the D-alanylation of S. suis LTAs had not been documented. 
Indeed, the structure and composition of S. suis LTA are so far poorly known. It has been 
proposed that LTA from S. suis may have a backbone structure similar to that of GAS teichoic 
acid, but with differences in glucosyl substituents: a monosaccharide glucosyl substituent is 
found in the LTA from S. suis instead of the di- or trisaccharide previously postulated as the 
glucosyl substituent in the teichoic acid of GAS (Elliott et aL, 1977). Despite the fact that the 
structure of the LTA has not yet been revealed, it is known that WT S. suis LTA is im·portant for 
adhesion of this bacterium to porcine BMEC. Indeed, inhibition of the adhesion of S. suis to this 
cellular type was obtained by pre-incubation of porcine BMEC with purified LTA (Vanier et aL, 
2007). 
From our SCOTS results and previous reports in other organisms, we hypothesized that 
S. suis might be able to modulate the degree of D-alanylation of its LTAs by upregulation of the 
dIt operon. We anticipated that this modification may have a profound impact not only for the 
interactions of this pathogen with porcine BMEC but also at other stages of the infection. 
Further studies focusing on this operon of S. suis were therefore carried out to evaluate this 
hypothesis. To that end, we inactivated the first gene of the dIt operon in a virulent field strain 
of this pathogen and carried out several in vitro and in vivo experiments. The results of this 
research project (Article Il) demonstrate that S. suis modifies its LTA by D-alanylation and that 
this modification is dependent on the action of the product of the dltA gene and, by extension, 
of the dIt operon. The absence of LTA D-alanylation had no major effect on S. suis growth under 
normal laboratory conditions. On the other hand, previous reports have shown that GBS and 
GAS 8.dltA mutants were either poorly separated or multiseptated in the stationary phase of 
growth (Kristian et aL, 2005; Poyart et aL, 2003). However, no major differences were found 
regarding the morphology of the S. suis 8.dltA mutant strain when analyzed by transmission 
electron microscopy. Indeed, the mutant was encapsulated, weil separated and presented 
normal septation. 
Results obtained in this research project are consistent with previous reports of 
inactivation of the dltA gene in several streptococcal species (Kovacs et aL, 2006; Kristian et aL, 
2005; Poyart et aL, 2003). For instance, addition of D-alanine residues to the LTA greatly 
improved the resistance of S. suis to the action of CAMPs. These compounds, classified into 
several groups based on their structure and origin, kil! bacteria by forming pores in the 
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cytoplasmic membrane (Taheri-Araghi and Ha, 2007). Changes in the bacterial surface via 
introduction of positively charged o-alanine residues into the LTA molecules would reduce the 
global negative charge of the s. suis envelope, thus providing the bacterium with a physical 
mechanism of resistance against the action of CAMPs (Neuhaus and Baddiley, 2003). An early 
response of the immune system to bacterial infection is the migration of neutrophils to the 
infected tissue (Nathan, 2006). I\leutrophils sense inflammatory mediators, such as 1 L-8, and 
translocate from the bloodstream to the site of infection where they initiate mechanisms that 
help clear infecting bacteria (Nathan, 2006). It has been shown, however, that WT S. suis resists 
killing by porcine neutrophils (unless opsonized by specific antibodies). This resistance has been 
primarily attributed to the production of a thick polysaccharide capsule that prevents 
phagocytosis of the bacterium by the polymorphonuclear cells (Chabot-Roy et aL, 2006). 
Consistently, in this research project an unencapsulated mutant strain was effectively 
eliminated by porcine neutrophils, while the capsulated WT strain resisted killing by these cells 
even wh en opsonized with complete porcine serum (Article Il). Interestingly, although the fldltA 
mutant does not have altered capsule expression, it was also killed by porcine neutrophils under 
the same experimental conditions. 
Opsonization of foreign microbes occurs after complement activation through 
deposition of C3b and its cleavage fragment iC3b on the microbial surface. Complement 
receptors on neutrophils engage the bound C3b or iC3b to facilitate phagocytosis (Nizet, 2007). 
The presence of o-alanyl esters has been shown to diminish purified LTA binding to Cl, 
decreasing activation of the classical complement pathway (Loos et aL, 1986). It may be th us 
hypothesized that the enhanced killing of the fldltA mutant by porcine neutrophils might be the 
result of better opsonization resulting in improved phagocytosis. However, in intact bacteria, 
complement activation by LTA seems to be of minor importance because peptidoglycan itself is 
a pote nt activator (Wilkinson et aL, 1981). On the other hand, neutrophils are also able to 
destroy infecting microorganisms in the absence of phagocytosis in the so-called neutrophil 
extracellular traps (NETs) (Brinkmann, 2004). While this extracellular killing is effective against 
some Gram positive pathogens (Brinkmann, 2004; Wartha et aL, 2007), not surprisingly, other 
pathogenic bacteria have developed ways to resist killing by neutrophils in I\IETs (Beiter, 2006;, 
Buchanan, 2006; Wartha, 2007). Interestingly, it has recently been shown in S. pneumoniae that 
absence of LTA o-alanylation results in enhanced extracellular killing in NETs by neutrophils but 
183 
not in an increased phagocytosis of this organism by these polymorphonuclear cells (Wartha, 
2007). Although our killing assay was not able to discriminate between intra and extracellular 
killing, taking ail these findings together, it may be proposed that the capsulated S. suis f:J.dltA 
mutant is killed by porcine neutrophils extracellularly, perhaps after being trapped in NETs. In 
addition, we speculate that this enhanced killing of the s. suis f:J.dltA mutant might be the 
consequence of the absence of LTA D-alanylation, which results in an increased susceptibility to 
CAMPs released by neutrophils. Further experiments are needed to evaluate this hypothesis. 
The contribution of LTA D-alanylation to virulence varies among different streptococci. 
For instance, the virulence of a GBS f:J.dltA mutant was severely impaired in mice (Poyart et aL, 
2003), while the reduction in virulence of a s. pneumoniae f:J.dltA mutant was less significant 
(Wartha, 2007), despite the fact that both species showed increased susceptibility to CAMPs and 
killing by murine or human neutrophils and/or macrophages. These differences may reflect the 
unique lifestyles and pathogenic features of these bacteria. Although S. suis shares certain 
characteristics with the former two species, its pathogenesis of infection is essentially different 
(Higgins and Gottschalk, 2006). It is believed that, once in the blood of infected animais, S. suis 
escapes leukocyte killing and, by unknown mechanisms, migrates to different organs where it 
causes tissue damage which often results in septic shock (Gottschalk et aL, 2007; Higgins and 
Gottschalk, 2006). Results obtained in this research project by evaluating the performance of 
the f:J.dltA mutant in vivo show that LTA D-alanylation contributes to S. suis virulence during the 
onset of the infection and provides an advantage to the WT strain in the pig, as shown by the 
higher survival rate of the animais infected with the mutant compared with the WT strain. 
However, despite this reduction in virulence, bacterial dissemination was not prevented and 
some pigs developed an exacerbated inflammatory response resulting in septic shock. In 
addition, we did not observe a clear reduction in the ability of the f:J.dltA mutant to successfully 
initiate infection and induce septicemia in mice infected with a high dose of inoculum. Since 
clearance of the mutant from circulation seems to rely on neutrophil activity, the high dose used 
to inoculate the animais may explain, at least in part, the results observed. Indeed, it has been 
proposed that suilysin may affect complement activity and suilysin-producing S. suis strains, 
such as the WT and mutant strains used in this study, have been shown to be toxic to 
neutrophils at high titers (Chabot-Roy et aL, 2006). In addition, since CAMPs activity primarily 
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occurs at mucosal surfaces, the extremely aggressive intravenous route of administration may 
have also influenced the clinical onset observed in pigs. 
Some of the in vitro phenotypes resulting from absence of LTA D-alanylation presented 
in Article Il confirm previous reports in other Gram positive bacteria. Actually, l:ldltA mutants in a 
few Gram positive pathogenic species showed similar or comparable increases in susceptibility 
to CAMPs and/or killing by neutrophils and/or macrophages as those reported in the present 
research project for s. suis. However, a review of the literature shows that virulence of l:ldltA 
mutants has been tested for some species only. Interestingly, in these cases strong variations in 
the pathogenic power of these mutants was found between bacterial species, despite the 
apparent similarity of in vitro phenotypes (Abachin et aL, 2002; Poyart et aL, 2003; Wartha, 
2007; Weidenmaier, 2005a). Therefore, drawing conclusions regarding the contribution of LTÀ 
D-alanylation to virulence traits of pathogens from previous studies may not be reliable. In this 
regard, a major contribution to the field of this research project is the in vivo data presented. 
Indeed, we provide truly original data since we have for the first time evaluated the virulence of 
a Gram positive l:ldltA mutant in the context of its natural host by intravenous inoculation of 
pigs. Given that only a small number of studies have characterized the virulence of l:ldltA 
mutants and, for various valid reasons, these studies have used surrogated models of infection 
instead of the natural hosts (Abachin et aL, 2002; Poyart et aL, 2003; Wartha, 2007; 
Weidenmaier, 2005b), data presented in our work is relevant and contributes to a better 
comprehension of the contribution of D-alanylation of LTA to the virulence traits of pathogenic 
Gram positive organisms. 
ln most scenarios, invasion of the CNS occurs in the context of a systemic disease and 
typically follows bacterial dissemination via the bloodstream (Kim, 2006). Extracellular bacteria 
have developed efficient strategies (LTA D-alanylation seems to be an important one) to solve 
the biological problem of how to escape elimination by host defenses such as phagocytes and 
serum proteins. As a result, these pathogens typically achieve a high-density bacteremia that is 
important for CNS invasion (Autret and Charbit, 2005; Kim, 2006). It has been proposed that, if 
s. suis fails to induce acute fatal septicemia but the level of bacteremia remains high, CNS 
disease may appear in later stages of the infection (Gottschalk et aL, 2007). A recent study of s. 
suis meningitis in mice showed that cells lining the choroid plexus and the brain endothelium 
are potential entry sites for this pathogen into the CNS (Dominguez-Punaro et aL, 2007). In 
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addition, a previous study demonstrated the ability of S. suis to adhere to and invade 
immortalized porcine BMEC (Vanier et aL, 2004). An important role in these two processes has 
been suggested for surface proteins of S. suis (Vanier et aL, 2007). On the other hand, it is 
known that one of the major outcomes of cell envelope charge stabilization by LTA D-alanylation 
is the efficient display of proteinaceous adhesins and/or invasins (Neuhaus and Baddiley, 2003). 
Indeed, in a number of Gram positive pathogens it has been shown that absence of LTA D-
alanylation impairs adherence to and invasion of various cell lines (Abachin et aL, 2002; Kristian 
et aL, 2005; Poyart et aL, 2003). Our SCOTS results showed that expression of the dIt operon is 
upregulated upon interaction of S. suis with porcine BMEC (Article 1). In Article Il, we clearly 
demonstrate that the interactions of S. suis with these cells are impaired in the absence of LTA 
D-alanylation, perhaps as the consequence of inefficient display of putative adhesins/invasins in 
a more electronegative envelope surface. We speculate that this impaired interaction with 
porcine BMEC, together with failure of the t,.dltA mutant to maintain a high level of bacteremia, 
are responsible for the reduced ability of the t,.dltA mutant to induce meningitis. Indeed, 
experimental infection of mice at the intermediate dose of infection clearly demonstrated that 
the t,.dltA mutant was less fit to survive in blood and to induce CNS disease. On the other hand, 
it should be pointed out that absence of LTA D-alanylation did not prevent the development of 
meningitis in both swine and mice at the high dose of infection. This was not surprising, since 
levels of bacteremia were high for several days in inoculated animais and, although it was 
impaired in its interactions, the t,.dltA mutant was still able to invade porcine BMEC. 
As stated above, many previous studies have shown impaired interaction of t,.dltA 
mutants with different cell lines (Abachin et aL, 2002; Kristian et aL, 2005; Poyart et aL, 2003). 
However, an important novel finding of the present research project is the demonstration of 
reduced adhesion to and invasion of porcine BMEC by the S. suis t,.dltA mutant. In the 
characterization of a t,.dltA mutant of GBS using the neonatal mouse model, it has been shown 
that this strain was impaired in its ability to induce CNS disease and was hardly found in the 
brain of infected animais (Poyart et aL, 2003). These findings were attributed by the authors to 
the decreased survival of the mutant in blood. In this study, we provide further and novel 
evidence. We provide further and novel evidence that in addition to increased blood clearance, 
impaired interactions with BMEC are important mechanisms that explain why t,.dltA mutants of 
meningitis-causing streptococcal species are less fit to induce this disease. 
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ln summary for this section, S. suis LTA D-alanylation mediated by the dIt operon 
contributes phenotypically to resistance to CAMPs, likely through an increased net positive 
surface charge. It also enhances the resistance of S. suis to neutrophil killing as weil as its 
capacity for adherence to and invasion of porcine BMEC. In addition, LTA D-alanylation" 
contributes to S. suis virulence in both the murine and the porcine models of infection, probably 
through Interference with innate immune clearance mechanisms and by facilitating penetration 
of host barriers. These results strongly suggest that LTA D-alanylation is an important virulence 
factor of S. suis. 
Determination of S. suis peptidoglycan fine structure 
Peptidoglycan is an essential component of the bacterial cell wall and, also, an 
important target for the innate immune system (Boneca, 2005; Chaput and Boneca, 2007). One 
of the most important and widespread compounds of the constitutive defense system is 
lysozyme, a muramidase that cleaves peptidoglycan between the glycosidic ~-1, 4-linked 
residues of NeuNAc and GlcNAc. It is produced by various tissues (mucous membranes, lower 
respiratory tract or intestinal tract) and is present in body fluids, such as serum, saliva, sweat 
and tears (Bera et aL, 2005). The lysozyme titer is increased by infection, and lysozyme is 
induced in numerous types of mammalian cells, including monocytes and macrophages as weil 
as neutrophils (Keshav et aL, 1991). An increase in lysozyme concentration in blood is an 
indicator for monocyte and granulocyte proliferation. Interestingly, it has been reported that 
patients suffering from meningitis present increased titers of lysozyme in their CSF (Klockars et 
aL, 1978). Lysozyme is clearly an important defense compound of the hosto Therefore, 
pathogenic bacteria that colonize the host over a longer period or that are able to cause chronic 
infections have developed mechanisms to evade or resist the lysozyme defense. One of the 
mechanisms used by pathogenic bacteria is I\I-deacetylation of their peptidoglycan (Boneca et 
aL, 2007; Vollmer and Tomasz, 2000). Indeed, several studies have shown that N-deacetylated 
peptidoglycan is a poor substrate for lysozyme, and that the activity of lysozyme can be restored 
by chemical acetylation of the substrate (Amano et aL, 1977; Boneca et aL, 2007; Vollmer and 
Tomasz, 2000; Westmacott and Perkins, 1979). 
Peptidoglycan N-deacetylation is not the only modification with an effect on the activity 
of lysozyme. For example, O-acetylation of MurNAc and the covalent linkage of other cell-wall 
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polymers such as teichoic acid also increase resistance to lysozyme (Bera, 2007; Bera et al., 
2005). However, peptidoglycan modification by N-deacetylation seems to be important for at 
least two major Gram-positive human pathogens. Indeed, pneumococci lacking a functional 
pgdA gene became more sensitive to lysozyme in the stationary phase of growth (Vollmer and 
Tomasz, 2000) .. A second S. pneumoniae pgdA mutant exhibited significantly reduced virulence 
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in the intraperitoneal mouse model wh en compared to the parental strain, indicating that PgdA 
is a putative virulence factor (Vollmer and Tomasz, 2002). In addition, it has been reported that 
a pgdA mutant strain of L. monocytogenes was impaired in its ability to induce disease in the 
murine model ofinfection and that the pgdA gene was required by this species to resist the host 
innate immune response mediated by lysozyme (Boneca et al., 2007). 
As shown in Article " S. suis upregulated pgdA (SSU1448) expression upon interaction 
with porcine BMEC. We therefore put forward the hypothesis that S. suis, through the action of 
the pgdA gene product, has the ability to modify its peptidoglycan by N-deacetylation. We 
reasoned that by modifying its peptidoglycan, S. suis might achieve resistance to the innate host 
immune response mediated by this enzyme. We therefore decided to carry out an assessment 
of the contribution of this putative modification to the virulence traits of S. suis. Functional 
analysis of S. suis pgdA function faced, however, an important drawback caused by the lack of 
knowledge on the composition and fine structure of S. suis peptidoglycan. Indeed, even though 
it has been proposed as an important factor for S. suis virulence (Higgins and Gottschalk, 2006), 
knowledge on the cell wall composition of this pathogen was very limited at the beginning of 
this research project. As discussed above, a partial structure of S. suis LTA had been reported 
(Elliott et al., 1977). However, the peptidoglycan of this bacterium had largely remained elusive. 
Therefore, we first carried out the determination of S. suis peptidoglycan fine structure. In fact, 
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this research project describes for the first time the composition of this essential polymer in this 
important swine pathogen. 
S. suis peptidoglycan was found to be, in several aspects, typical of species within the 
low G+C-content Gram-positive phylum Lactobacillales. Like in most other streptococci, in S. suis 
mostly D-Gln is found at position 2 of the stem peptide, and an L-Lys residue is present at 
position 3, which can participate in 4-3 cross-links with neighboring peptides (Schleifer and 
Kandler, 1972). However, unlike other streptococci, the peptidoglycan of S. suis lacks an 
interpeptide bridge but contains direct L-Lys-D-Ala cross-links. This direct link is common among 
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Gram negative bacteria but rare among Gram positive bacteria (Vollmer et aL, 2008a). In fact, 
interpeptide bridges are found in the peptidoglycan of other human or animal streptococcal 
pathogens such as GAS (L-Lys-L-Ala2-3L GBS [L-Lys-L-Ala2 (L-Ser)], S. bovis [L-Lys-L-Thr-L-Ala (L-
Ser)] or Streptococcus uberis (L-Lys-L-Ala3_4) (Schleifer and Kandler, 1972). Consistent with the 
observed results, database searches revealed the absence in S. suis of homologues of the genes 
encoding for known peptide branching enzymes of the Fem transferase or ATP-grasp families 
(Bellais et aL, 2006; Filipe and Tomasz, 2000) (data not shown). In S. suis about 67% of the 
peptides were found to be present in dimeric or trimeric cross-links [Table VIII, (Article III, 
Supplemental Table 1)]. S. suis peptidoglycan has a low proportion of pentapeptides and 
tetrapeptides indicating high activities of DD- and LD-carboxypeptidases in this species. Finally, 
some of the minor muropeptides correspond to modifications of canonical structures, 
suggesting the presence of glucosaminidase, amidase and N-deacetylase activities (Article III). 
N-deacetylation ofpeptidoglycan and the virulence of S. suis 
As mentioned above, in this research project we determined the muropeptide 
composition of S. suis peptidoglycan and found N-deacetylated compounds. Comparison with an 
isogenic b.pgdA mutant showed that the product of the pgdA gene was responsible for this 
specific modification. As mentioned, some bacterial species resist lysozyme activity by means of 
peptidoglycan N-deacetylation and it has been proposed that the level of this modification may 
correlate with the level of resistance (Herbert, 2007; Vollmer, 2008). Interestingly, in the S. suis 
WT strain, peptidoglycan N-deacetylation occurred in very low amounts during growth in normal 
laboratory culture medium (Article III). Consistently, the WT strain was sensitive to lysozyme at 
concentrations much lower than those allowing growth of S. pneumoniae and L. monocytogenes 
(Boneca et aL, 2007; Vollmer and Tomasz, 2000). Furthermore, no major differences between 
the S. suis WT and b.pgdA mutant strains regarding resistance to the action of lysozyme in vitro 
were observed. In fact, these results may be explained by an already low degree (probably < to 1 
% of total muropeptide) of peptidoglycan N-deacetylation of the WT strain. By comparison, 
resistance to lysozyme in S. pneumoniae correlated with over 80% of N-deacetylated 
glucosamine residues (Vollmer and Tomasz, 2000). In L. monocytogenes the extent of N-
deacetylation was lower, but still very important, with up to 50 % of N-deacetylated 
muropeptides (Boneca et aL, 2007). In this regard, this research project presents novel and 
interesting data. Indeed, only six reports on pgdA are currently available in the literature 
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(Boneca et aL, 2007; Deng et aL, 2008; Hebert et aL, 2007; Meyrand et aL, 2007; Vollmer and 
Tomasz, 2000, 2002). 
50 far, four other reports have shown that PgdA confers a high level of N-deacetylation 
for s. pneumoniae, L. monocytogenes and L. lactis when these species are grown in vitro 
(Boneca et aL, 2007; Meyrand et aL, 2007; Vollmer and Tomasz, 2000, 2002). Interestingly, the 
other two studies (Deng et aL, 2008; Hebert et aL, 2007) have questioned the link between 
expression of PgdA homologues and peptidoglycan N-deacetylation. In fact, s. mutans cells in 
which the pgdA gene had been deleted displayed a different colony texture and a slightly 
increased cell surface hydrophobicity, yet did not become hypersensitive to lysozyme. 
Moreover, recombinant s. mutans PgdA (highly homologous to the former two species PgdA) 
showed no activity towards shorter chitooligosaccharides or a synthetic peptidoglycan 
tetrasaccharide. The authors suggested that S. mutans PgdA may not act on peptidoglycan but, 
instead, on an as yet unidentified polysaccharide within the bacterial cell surface (Deng et aL, 
2008). In the same line, E. faecalis PgdA seems to lack peptidoglycan N-deacetylase activity, in 
spite of its high homology to s. pneumoniae and L. monocytogenes PgdA enzymes. 5imilar to s. 
mutans, no evidence for peptidoglycan N-deacetylase activity was found for the histidine-tagged 
recombinant E. faecalis protein when incubated directly with purified peptidoglycan (Hebert et 
aL, 2007). These data are in agreement with the literature, since no N-deacetylated 
peptidoglycan has been reported for E. faecalisin previous studies (Hebert et aL, 2007). 
The two later articles relied on the use of recombinant proteins to disregard 
involvement of PgdA in peptidoglycan modification (Deng et aL, 2008;Hebert et aL, 2007). 
However, it is not uncommon that the level of activity of a recombinant protein does not reflect 
its activity in the celL Indeed, unpublished work by Bui et al at the Vollmer's laboratory has 
shown that a soluble form of recombinant s. pneumoniae PgdA [the only peptidoglycan 
deacetylase in S. pneumoniae (Vollmer and Tomasz, 2000)] expressed in E. coli had only poor 
activity against isolated peptidoglycan or muropeptides, although the fraction of deacetylated 
muropeptides in WT S. pneumoniae cells is very important and the s. pneumoniae pgdA mutant 
strain did not contain any detectable amount of deacetylated muropeptides (Dr. Waldemar 
Vollmer, personal communication). In addition, these two reports have used the less sensitive 
HPLC-MALDI-TOF-M5 to investigate the presence of N-deacetylated muropeptides~ As shown in 
Article III for s. suis, this approach may result in false negative results. 
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Despite contradictory results in the literature regarding the role of pgdA, the S. suis 
pgdA gene product is clearly involved in peptidoglycan N-deacetylation. In this regard, the 
demonstration that S. suis upregulates the expression of the pgdA gene upon interaction with 
neutrophils as weil as during growth in vivo (Article III) constitutes an interesting and 
unprecedented finding of this work. Since it is apparent that the S. suis pgdA gene product is 
responsible for peptidoglycan I\J-deacetylation, it is tempting to speculate that the increased 
expression of the S. suis pgdA gene in vivo correlates with a higher degree of PG N-deacetylation 
under these conditions that, in turn, results in enhanced resistance to lysozyme produced by 
neutrophils. However, in view of the fact that it is technically impossible to prepare 
peptidoglycan from these samples in amounts and purity suitable to perform HPLC and LTQ-FT 
mass spectrometry, we are unable to provide conclusive eviaence for this hypothesis. A possible 
way to further assess this issue in future studies might be the complementation in trans of both 
the WT and mutant strain with the S. suis pgdA gene placed under the control of a strong 
constitutive promoter. 
Results of the experimental infections carried out in this research project using the 
flpgdA mutant suggest that peptidoglycan N-deacetylation is a major virulence factor of S. suis. 
Overall, the infection outcome in the mouse clearly indicates that the flpgdA mutant is severely 
hampered in its ability to inflict damage to the hosto The most important consequences of 
peptidoglycan N-deacetylation are increased survival of S. suis at early stages of the infectious 
process and an increased ability of the pathogen to survive in blood. Interestingly, there was a 
complete absence of septic shock signs in mice inoculated with the flpgdA mutant and the 
production of inflammatory mediators was completely abrogated in mice inoculated with the 
flpgdA mutant, while, in perfect agreement with a previous study (Dominguez-Punaro et al., 
2007), an exacerbated Th1 inflammatory response in mice inoculated with the WT strain was 
observed. Different results were obtained in a previous study with L. monocytogenes. In fact, 
peptidoglycan purified from the WT L. monocytogenes poorly activated the NF-KB pathway 
leading to the production of various chemokines, growth factors, antimicrobial peptides, 
proinflammatory cytokines, and other products required for clearance of the infection. In 
comparison, fully acetylated peptidoglycan purified from the pgdA mutant increased f\lF-KB 
activation in a Nod1- and Nod2-dependent manner (Boneca et al., 2007). On the other hand, the 
L. monocytogenes study evaluated NF-KB activation using in vitro experiments and did not 
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actually investigate the production of cytokines in experimentally inoculated animais. 
Nevertheless, and although we have not yet tested this hypothesis, we consider it unlikely that 
the S. suis fully acetylated peptidoglycan has an impaired capacity to activate the I\IF-KB 
pathway. Instead, we propose that the observed basal levels of pro-inflammatory cytokines in 
mice inoculated with the l:J.pgdA mutant might result from the rapid clearance of the mutant by 
neutrophils (Iow levels of bacteremia), along with an irrelevant activation of macrophages, 
lymphocytes and NK cells in this process. 
ln spite of the fact that the l:J.pgdA mutant was able to induce clinical signs in some pigs, 
conclusions obtained for the mouse may be extended to the pig. Indeed, mortality observed in 
the l:J.pgdA mutant group may be explained, at least in part, by the fact that we have prioritized 
the use of the highly aggressive intravenous route of administration and a high dose of inoculum 
in order to use a validated model of infection (Berthelot-Herault et aL, 2001a). Nevertheless, in 
contrast to the WT group, pigs that survived septic shock in the l:J.pgdA mutant group noticeably 
recovered, and it was apparent that the l:J.pgdA mutant was less fit to survive in blood. This 
inability to persist in blood might also be important for later stages of the infection. Firstly, 
colonization of organs was hampered in the mutant group in both the mouse and pig. In 
addition, it has been shown that if S. suis fails to induce acute fatal septicemia but the level of 
bacteremia remains high, (I\lS disease may appear afterwards (Dominguez-Punaro et aL, 2007; 
Segura et aL, 2006). Interestingly, and in agreement with its observed rapid clearance from 
blood, we did not record any case of meningitis in either model with the l:J.pgdA mutant. On the 
other hand, meningitis wa's responsible for the death of 35 % of mice and 10 % of pigs in the 
respective WT groups. 
Enhanced clearance of the l:J.pgdA mutant strain from blood might be attributed to an 
increased susceptibility of the mutant to killing by neutrophils, as showed in Article III. We 
speculate that differences observed in killing by neutrophils between strains might primarily be 
explained by the enhanced resistance of the WT strain to lysozyme secreted by neutrophils, due 
to increased peptidoglycan N-deacetylation after induction of the pgdA gene. However, it is 
possible that the effect of peptidoglycan N-deacetylation on the interactions of pathogens with 
the host might be multifactorial and not restricted to the effect of lysozyme activity. In fact, 
peptidoglycan N-deacetylation introduces additional positive charge into the cell wall, 
potentially affecting the binding of specific cell-wall proteins. As discussed for LTA D-alanylation, 
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increasing the positive charge of the cell wall is likely to increase the resistance of the bacterium 
to CAIVIPs. Thus, next to D-alanylation of LTAs (Article Il), the N-deacetylation of S. suis 
peptidoglycan could be a second way to introduce positive charges into the cell wall to protect 
the pathogen against CAMPs of the host organism. Interestingly, and different from what was 
observed for the fldltA mutant, neither the WT or flpgdA mutant strains showed differences in 
resistance to the action of CAMPs such as polymixin B, magainin Il, colistin and human 
neutrophil peptide (HNP}-l and HNP-2, functional homologues of which are secreted by porcine 
neutrophils (Supplemental Table 2, Appendix). However, since the pgdA gene is upregulated in 
vivo by S. suis, it is possible that, in vivo, an eventual more N-deacetylated peptidoglycan might 
also result in a more positive cell wall. Therefore, in the absence of such a modification for the 
flpgdA mutant peptidoglycan, it could be proposed that in addition to lysozyme, CAMPs may 
also mediate killing of the mutant under in vivo conditions. However, a recent study in S. 
pneumoniae (whose peptidoglycan is highly N-deacetylated in vitro) reported no differences in 
sensitivity to human defensins HNP-1-3 between the WT strain and an isogenic encapsulated 
flpgdA mutant (Beiter et aL, 2008). On the other hand, since our killing assay does not 
differentiate between intra and extracellular killing it is difficult to estimate if increased killing of 
the flpgdA mutant correlates with increased phagocytosis. However, since the flpgdA mutant is 
as encapsulated as the WT strain and, on the other hand, it has been shown that capsular 
material interferes with the uptake of S. suis by phagocytes (Chabot-Roy et aL, 2006; Charland 
et aL, 1998; Segura et aL, 2004; Smith et aL, 1999b), enhanced phagocytosis of the mutant 
might be unlikely. Indeed, we suggest an explanation similar to that put forward before for the 
S. suis fldltA mutant (Article Il). Indeed since both flpgdA and fldltA mutants are encapsulated, 
they might be killed by porcine neutrophils extracellularly in I\lETs. Since neutrophils, in addition 
to delivering their complex antibiotic arsenal into the phagosome, also discharge their Iysozyme-
rich specific granules extracellularly in the NETs (Cho et aL, 2005; Mollinedo et aL, 2006) it might 
be postulated that the flpgdA mutant may also be killed through the action of this enzyme after 
being trapped in these extracellular structures. Further experiments are needed to confirm this 
hypothesis. 
ln conclusion for this section, we have determined the muropeptide composition of S. 
suis and showed that this bacterium, through the action of the pgdA gene product, modifies its 
peptidoglycan by means of N-deacetylation. We showed that this peptidoglycan modification, 
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which is probably enhanced in vivo, greatly contributes to the virulence of S. suis in both the 
murine and porcine models of infection. These results strongly suggest that PG N-deacetylation 
is also a major virulence factor of this swine pathogen and zoonotic agent. 
v. CONCLUSIONS AND FUTURE DIRECTIONS 
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ln this research project, in order to identify novel S. suis virulence factors, we have 
interrogated the differential gene expression of this pathogen during a key step of its 
pathogenesis of infection such as BBB crossing. Within the limits imposed by the use of an in 
vitro model of infection, the identification of the twenty eight SCOTS-identified genes reported 
here, which are preferentially expressed by S. suis upon its interaction with porcine BMEC, 
constitutes an important step forward for our comprehension of how this pathogen may cause 
disease. Indeed, some selected genes were characterized in this research project and shown to 
play important roles in S. suis pathogenesis of infection. Future characterization of the 
remaining SCOTS-identified genes will be of much importance for advancing our understanding 
on the mechanisms of S. suis disease development and progression. Besides, it might be 
anticipated that the current availability of S. suis whole genome sequence data will allow for 
SCOTS to be used in conjunction with DNA microarrays, which will further improve the 
deciphering of the molecular weapons S. suis makes use of for causing disease. Extending the 
analysis to identify transcriptional differences at different in vivo localizations (i.e., blood, brain, 
heart, tonsils) as weil as at different stages of infection are possible future directions for further 
elucidation of S. suis virulence factors. 
Evidence is accumulating that a variety of Gram positive surface proteins contribute to 
the virulence of these organisms. It seems likely, therefore, that S. suis surface proteins may 
play key roles during various stages of the infection. Particularly, it is apparent that 
proteinaceous adhesins/invasins mediate, at least in part, invasion of porcine BMEC. Indeed, 
results presented in this research project suggest that stabilization of surface net charges by D-
alanylation of the LTA may be important for an efficient display and function of these putative 
adhesins/invasins. However, perhaps by the limitations imposed by the model used in this 
research project, an interesting outcome of this study was the lack of isolation of specific genes 
encoding stricto sensu adhesins and/or invasins. Indeed, the only putative structure that might 
have fulfilled that definition, the pilus encoded by cluster F, was in fact found to be adhesin-Iess 
and, as such, did not play a role in adhesion to or invasion of porcine BIVIEC nor was it essential 
for S. suis virulence in general, at least in the mouse. It is to expect that the wealth of 
information that is becoming available from genome sequences as weil as the information about 
known surface proteins in other pathogenic Gram positive organisms will provide the 
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framework for future identification of S. suis surface proteins with adhesin and/or invasin 
capacities. 
The ability to evade host immune surveillance is a critical virulence determinant for any 
pathogenic microorganism. Cell wall components such as the peptidoglycan and the LTA are 
often considered as static structures which provide supportive functions for maintaining and 
protecting the bacterial integrity. In this regard, this research project highlights that, in contrast 
to that view, these structures also fulfill a variety of virulence-related functions in S. suis. Indeed, 
both the peptidoglycan and the LTAs are actively modified by S. suis and these modifications 
constitute important immune evasion mechanisms that protect the pathogen at every stage of 
the infection. These contributions to virulence vary from resistance to host antimicrobial agents 
such as lysozyme and CAMPs, to killing by phagocytes, and to the ability to modulate the host 
inflammatory response. From the results presented here it is apparent that the pgdA and the dit 
operon gene products, responsible for the modifications of these extracell ular structures, are 
major S. suis virulence factors. However, this research project may be considered as the 
beginning of the characterization of the roles of LTA and peptidoglycan modifications in S. suis-
host interactions. These extracellular structures deserve much more attention. In this regard, 
the study of the mechanisms which drive killing by neutrophils of weil encapsulated S. suis 
strains in a background of absence of D-alanylation of the LTA and/or absence of I\J-
deacetylation of the peptidoglycan is a potential future direction of this research project. In 
addition, the reported proinflammatory, endotoxin-like activities of the S. suis cell wall can now 
be further clarified by using the defined mutants generated in this research project. 
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PHi and S. suis virulence 
As discussed in the body of this thesis, a putative cluster encoding pili was identified in 
this research project by the use of SCOTS. Recently, we renamed the full cluster as pili cluster F 
(Takamatsu et al., 2008a) (Figure 31, Appendix). The class C sortase in the pilus cluster has been 
named SrtF, consistently with the nomenclature used in the pa st (Osaki et aL, 2002). The two 
LPXTG proteins were named Sfpl and Sfp2 (for ~rtE-associated Qilin subunit) and, finally, the 
signal peptidase homologue was designated SipF (for ggnal Qeptidase in the srtE cluster) 
(Takamatsu et aL, 2008a). Further, in silico analysis of the region showed that the deduced 
amino acid sequences of these four proteins show 29-60% identity with those of the 
corresponding genes in GBS PI-2b. 
To demonstrate the expression of pili in 5. suis, we decided to accomplish a full 
characterization of the 5. suis pilus cluster F. In addition, we aimed at the evaluation of the role 
played by this pilus in 5. suis pathogenesis of infection. To accomplish these objectives, we have 
generated precise, in-frame mutant strains for each of the four genes belonging to this pilus 
island (sipF, sfp2, sfp2, srtF) as weil as the srtA gene encoding the housekeeping sortase SrtA in 
the weil characterized 5. suis serotype 2 virulent strain Pl/7 (using a knock-out technology 
similar to that described in Articles Il and III). In addition, using commercial vectors and standard 
procedures suitable for expression of proteins in E. coli we cloned, expressed and purified the 
LPXTG-proteins. Antibodies against these proteins were raised in rabbits and used for the 
identification of pili subunits by Western blot in the cell wall fraction of the WT and mutant 
strains. Finally, we tested the WT and the mutant strains generated above in our well-
standardized model of invasion of porcine BIVIEC (Vanier et aL, 2004) as weil as in vivo in our 
murine model of infection (Dominguez-Punaro et al., 2007). 
Results obtained so far suggest that 5. suis expresses an adhesin-Iess F pilus which is 
composed of the major pilin subunit only. Indeed, Western blots of 5. suis cell wall proteins 
revealed with rabbit anti-Sfpl subunit antibodies (Figure 32, Appendix) clearly show, for the WT 
strain, the presence of polymers of the Sfpl pilin subunit, compatible with a pilus structure in 
which this pilin subunit constitutes the backbone. Consistently, these structures are absent from 
the ~sfpl mutant. The role of SrtF in pili polymerization is highlighted by the fact that only 
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monomers of Sfpl are present on the cel! wall of the corresponding l:::.srtF mutant. These 
monomers are attached to the peptidoglycan through the action of SrtA, as shown by the fact 
that they are absent from the cell wall of the corresponding l:::.srtA mutant (Figure 32, Appendix, 
Fittipaldi et al, manuscript in preparation). In this latter mutant, polymerized pilus structures are 
observed, but not the monomer, a phenotype that is compatible with the praposed transient 
non covalent anchoring of pili to the cell wall by the dedicated sortases in a strain lacking the 
housekeeping sortase (Budzik et al., 2007; Dramsi et al., 2006; Mandlik et al., 2008a). 
Interestingly, the sipF mutant was not affected in polymerization of the pilus backbone, which is 
different fram previously reported results for GAS pili (Zahner and Scott, 2008). However, signal 
intensities of higher molecular weight polymers of Sfpl seems to be weaker than that of the WT 
strain. The results may imply a yet undefined raie for SipF in Sfpl polymerization. On the other 
hand, we failed to observe pilus-compatible structures when revealing the blots with anti-Sfp2 
antibodies (data not shown). Moreover, not even single monomers were' revealed with these 
antibodies, suggesting absence of expression of the putative minor subunit of the pilus F cluster. 
These unexpected results are, however, consistent with new genome sequence data recently 
(May, 2008) released by the Sanger Institute (ftp://ftp.sanger.ac.uk/pub4/pathogens/ss). In a 
correction to previously released data, in addition to the four putative pilus-associated genes, a 
short ORF was annotated between sipE and sfp2 (Figure 31, Appendix). This OR.F and sfp2 are 
currently deduced to form a single pseudogene (SSU0425) in the genome sequence data of S. 
suis Pl/7 (Takamatsu et al., 2008a). When we sequenced the region in a large collection of 
serotype 2 strains, data showed that ail of them presented the same nonsense mutation 
(Takamatsu et al., 2008a). 
Despite these results, since a pilus comprised of a polymer of the major pilin subunit 
only is expressed by S. suis, we carried out an evaluation of its contribution to the adhesion and 
the invasion of porcine BMEC, using an in vitro model similar to that described in Article Il. In 
addition, we assessed whether this pilus participates in the virulence of S. suis by experimental 
inoculation of CD 1 mice with the WT and mutant strains (details on this infection model are 
given in Articles Il and III). Results showed that absence of expression of pilus F does not impair 
the interactions of S. suis with porcine BMEC nor does it affect virulence in vivo (Figures 33 and 
34, Appendix, Fittipaldi et al, manuscript in preparation), Although we have not yet tested an 
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eventual contribution to the virulence of S. suis in the pig, which is the natural host of this 
pathogen, from the results presented above, it seems likely that the pilus encoded by cluster F is 
dispensable for adhesion to porcine BMEC and for S. suis virulence in general. Therefore, one 
may wonder why a gene member of this pilus was highly upregulated upon contact of the 
pathogen with porcine BMEC (Article 1). Again, the concept of regulon may be important to 
answer this question. Indeed, it may be hypothesized that despite the fact that this pilus 
(remnant?) does not seem to fulfill a characterized function in S. suis, its expression is still 
triggered by (a) unknown signal(s) sensed by the pathogen upon contact with porcine BMEC. 
ln addition to pili cluster F genes, SCOTS identified the srtE gene (ssu0453), encoding 
one of the S. suis four previously described class C sortases (Dramsi et al., 2005; Osaki et al., 
2002). Previous work on S. suis with serotype 2 reference strain S735 (Osaki et al., 2002), 
analysis of sequencing data from strains P1/7 and 89-1591, as weil as sequencing of the region 
in the strain used for the SCOTS project, virulent isolate 31533 (Takamatsu et al., 2008a), 
indicated that the srtE gene is not flanked by genes encoding LPXTG proteins. In fa ct, in 
sequenced strain P1/7, a putative signal peptidase (SSU0450) is found in the vicinity of srtE 
(SSU0453), but the region lacks the major and the ancillary pilin subunits. Instead, a putative 
exported protein (SSU0451) and a transposase fragment (SSU0452) are found between the 
signal peptidase and srtE (unpublished data). It seems thus possible that the putative exported 
protein represents the N-terminal region of a pilus protein that has been truncated by a deletion 
event that generated the partial transposase sequence. Further analysis of a large collection of 
serotype 2 strains indicated that strains of this serotype do not possess a complete pili E cluster 
(Takamatsu et al., 2008a). Therefore, the functional significance of srtE upregulation upon 
contact with porcine BIVIEC remains obscure. Interestingly, we identified a putative pili cluster E 
upstream of srtE in serotype 1 reference strain NCTC 10237 (Figure 31, Appendix), but then 
again this pilus seems to be non functional (Takamatsu et al., 2008a). Indeed, although the 
predicted product of the third gene of the cluster (designated sepl') has 35% identity with the 
N-terminal half of the fimbrial subunit-like protein SSA1633 of Streptococcus sanguinis SK36, no 
C-terminal sorting signal was found in Sep1'. However, BLASTX analysis revealed that the amino 
acid sequence translated from the downstream region of sepl' showed 40% identity with the C-
terminal half of SSA1633, leading to the notion that sepl' of NCTC 10237 is interrupted by a 
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nonsense mutation (Takamatsu et aL, 2008a). As for pilus cluster F in serotype 2 strains, the 
genetic organization of the pilus cluster E in serotype 1 strains is similar to that of pilus island 2b 
(PI-2b) of GBS COHl (Takamatsu et aL, 2008a; Telford et aL, 2006) (Figure 31, Appendix). 
On the other hand, a putative third pilus cluster has recently been described in strain 
Pl/7 and in some Chinese isolates (Vanier et aL, 2008a; Wang et aL, 2008). We recently 
renamed this region as S. suis srtBCD cluster (Takamatsu et aL, 2008a). It contains three sortase-
like genes (srtB, srtC, and srtD) and four putative genes (designated sbpl, sbp2, sbp3, and sbp4 
[for ~rtQCD-associated Qilin subunit]), which encode putative cell-wall anchor family proteins 
containing C-terminal sorting signais. Sbp3 and Sbp4 were partially similar to the putative 
collagen adhesion proteins of other Gram-positive bacteria, whereas Sbpl had 34% identity with 
the cell-wall anchor family protein of GAS MGAS10750. However, sbp2, homologous to the 
major pilin subunit of the rIrA pilus island of S. pneumoniae TIGR4 (Telford et aL, 2006) is 
truncated by a nonsense mutation in the sequenced strain Pl/7 and in a large collection of 
serotype 2 strains, leading to the notion that no pilus structure can be expressed from this 
cluster in S. suis (Takamatsu et aL, 2008a). On the other hand, a Tn917 insertion in sbp4, which 
probably exerts polar effects in the downstream gene sbp3, has been found to substantially 
attenuate the virulence of the resulting mutant in both the murine and porcine models of 
infection (Vanier et aL, 2008a). These results suggest that the minor subunits of the srtBCD pilus 
cluster might play a role in S. suis virulence even if an actual pilus is not formed. 
From the data discussed above, it is apparent that at least highly virulents S. suis strains 
do not require the formation of pili structures for full virulence in vivo. This is an interesting 
finding, since a review of the literature shows that pili structures fulfill a variety of functions 
linked to virulence in other pathogenic streptococci, such as colonization of specifie host tissues 
and the development of bacterial biofilms (Mandlik et aL, 2008b). Moreover, a recent study 
with GBS has uncovered important functions of the pili backbone itself in pathogenesis and host 
immune responses (Maisey et aL, 2008). In agreement, an S. pneumoniae mutant that lacks 
sortases and pilin subunits encoded by a single pilus gene cluster proved defective in binding to 
epithelial cells grown in cell culture (Barocchi et aL, 2006). This nonpiliated mutant was 
attenuated in a mouse infection model and outcompeted by the WT strain in the upper airways, 
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lungs and blood. Importantly, piliated pneumococci evoked host inflammatory responses, 
reflected by elevated levels of TNF-a and IL-6 release compared with the deletion mutant. 
Inflammation might thus promote subsequent bacterial invasion of the tissue leading to damage 
to mucosal barriers (Barocchi et al., 2006). However, despFte these findings, the notion that pili 
are essential for s. pneumoniae virulence has been challenged bya recent report which analyzed 
the prevalence of pili production by virulent strains of this species (Basset et aL, 2007). From a 
total of 484 virulent strains tested, of which 361 were nasopharyngeal isolates and 123 invasive 
disease isolates, pili were present in only 21.4% of the strains. Moreover, there was no 
difference in the frequencyof pili-positive strains in 'nasopharyngeal and bacteremic isolates. 
Taken together, these results suggest that despite the data obtained fram mouse studies, pili do 
not in fact represent an important virulence factor for s. pneumoniae invasive disease in humans 
(Basset et aL, 2007). It is to be expected that future epidemiological studies carried out with 
other streptococci will shed light on the actual contribution of pili to the virulence traits of 
pathogenic members of this important genus. 50 far, the latter s. pneumoniae report (Basset et 
aL, 2007) sustains findings presented in this research project suggesting that these structures 
may be dispensable for S. suis virulence. 
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Supplemental figures 
Figure 31. Genomic organization of 
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gray arrows, gènes encoding signal 
peptidase homologues; open arrows 
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other genes. Gene sfp2 and a short 
ORF upstream of it are deduced to 
form a single pseudogene (SSU0425), 
in the genome sequence data of 5. 
suis P1/7 annotated by the Wellcome 
Trust Sanger Institute available at ftp:Uftp.sanger.ac.uk/pub4/pathogens/ss. Adapted from 
Takamatsu et al. 2008a. 
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Figure 32. Detection of Sfpl polymers by 
Western blotting. 
Cell surface proteins were extracted from 
5. suis strain P1/7 and the mutant 
derivatives with mutanolysin, as described 
previously (Qsaki et al, 2002). Proteins 
were separated by SDS-PAGE and then 
subjected to Western blot using polyclonal 
anti-Sfp1 sera. Lane 1, molecular weight 
markers. The anti-Sfp1 serum detected a 
ladder of high molecular weight polymers 
in P1/7 (lane 2). However, the lad der was not present in the tJ.sfpl mutant (Iane 5), 
suggesting that Sfp1 is polymerized on the bacterial surface. In the tJ.srtF mutant, Sfp1 
monomers, but not polymers were detected (la ne 6), suggesting that SrtF is required for 
Sfp1 polymerization. In contrast, disruption of sfp2 did not affect the polymerization of Sfp1 
(Iane 4). Interestingly, although Sfp1 polymers were detected in the tJ.sipF mutant, signal 
intensity of higher molecular weight polymers of Sfp1 seems to be weaker than that of wild 
type strain. This result may imply an undefined role for SipF in Sfp1 polymerization. In the 
srtA mutant (Iane 7), polymerized pilus structures are observed, but not the monomer, a 
phenotype compatible with the proposed transient non covalent anchoring of pili to the cell 
wall by the dedicated sortases in a housekeeping sortase-Iess genomic background. Adapted 
from Fittipaldi et al, manuscript in preparation. 
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Figure 33. Interactions of the WT 
and pilus cluster F mutant strains 
with porcine BMEC. 
The mutants showed no significant 
differences in levels of (A) adhesion 
to and (B) invasion of porcine 
BMEC. Data for the WT strain has 
been normalized to 100% Data are 
from at least 4 independent 
experiments_ Adapted from 
Fittipaldi et al, manuscript in 
preparation). 
Figure 34. Survival of mice 
inoculated with the WT or the pili 
cluster F mutant strains. 
No significant differences in survival 
were observed between groups (Log-
. Rank test, P>O.OS) 
Adapted from Fittipaldi et al, 
manuscript in preparation_ 
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Abstract 
Streptococcus suis is responsible for severe economic lasses to the swine industry. 
\ 
Prevention of the diseases caused by this pathogen is hampered by the inability of available 
vaccines ta generate a protective response in pigs. A non-virulent, aromatic amino acid-
auxotrophic and unencapsulated mutant strain of S. suis was generated in this study and a 
preliminary evaluation of its protective capacities was conducted in swine. Deletion of the 
cognate promoter of the ara operon in S. suis virulent strain 5735 resulted in the abolishment of 
the expression of the four members of the operon, aroA, aroK, pheA and orfl0. The resulting 
mutant strain BD101 was auxotrophic for aromatic amino acids as demonstrated by its fallure to 
grow in a chemically defined medium unless it was supplemented with these compounds. In 
addition, as a result of the deletion of the cognate promoter of the aro operon, mutant BD101 
lost its encapsulated phenotype. A protection assay was performed by immunisation of pigs 
with live strain BD101. Vaccination resulted in minor clinical signs but did not substantially 
impair the growth of vaccinated animais. Immunisation of animais with live mutant BD101 
induced a considerable antibody response against S. suis. Vaccinated pigs presented only minor 
clinical signs and a survival rate of 100%, while 57 % of non-vaccinated animais died, after a 
challenge with the virulent parent strain 5735. In arder to prevent S. suis infections in swine, it 
may be useful ta further evaluate strain BD101 as a vaccine candidate. 
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1) Introduction 
Streptococcus suis is an important pathogen of swine causing meningitis, sudden death, 
septicaemia, endocarditis and pneumonia. Among the 35 described serotypes, serotype 2 is the 
most frequently associated with disease [:1.]. This serotype is also a zoonotic agent that has been 
identified as a cause of septieaemia, endocarditis, meningitis and taxie shock syndrome in 
humans [2-4]. Despite increasing research in recent years, knowledge on the pathogenesis of S. 
suis infections remains limited. Previous studies have reported on several S. suis putative 
virulence factors, including the polysaccharide capsule, the cell wall, and several proteins such 
as the extracellular factor (EF) protein, the muramidase-released protein (MRP) and a hemolysin 
known as suilysin [U Th~ absence of one or more of these proteins, however, may not 
necessarily be associated with a lack of virulence, since MRP, EF and hemolysin-negative 
mutants of S. suis serotypes 1 and 2 have been shawn ta be as virulent as the respective wild-
type strains after experimental infection of newborn, germ-free pigs [5, 6]. In addition, most 
virulent strains isolated in North Ameriea do not produce these proteins [7, 8]. On the other 
hand, the capsule of S. suis serotype 2 has proven ta be critical for the virulence of the 
organism. Using unencapsulated isogenie muta~ts, it has been shawn that the absence of a 
capsule correlated with increased phagocytosis by porcine macrophages and killing by porcine 
neutrophils [9-11]. Moreover, unencapsulated mutants have been shawn ta be impaired in 
( 
virulence in two different porcine models of infection [9, la]. 
No efficient vaccine against S. suis is currently available [1]. Several studies have 
reported protection of pigs using killed whole cells. However, the protection observed 
depended upon repeated immunization and/or was either serotype or strain dependent [12, 
13]. Attempts ta elicit protective immunity by vaccination with purified capsular polysaccharide 
have failed [14]. However, differences in protection between bacterins from a wild type virulent 
strain and its unencapsulated isogenic mutant (whieh was less protective) have raised the 
hypothesis that capsular polysaccharide is needed for full protection against homologous 
challenge [15]. Interest has recently shifted toward protein antigens of S. suis as vaccine 
candidates. Subunit vaccines using suilysin [16] or MRP and EF [17] have been shawn ta protect 
pigs from homologous and heterologous serotype 2 strains. However, since these proteins are 
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not widely present among virulent serotype 2 strains, their usefulness is limited. More recently, 
a preliminary evaluation of an 5. suis surface protein (Sao protein) has shown that this protein is 
able to elicit a significant humoral response in immunised animais. However, the antibody 
response did not result in full protection of pigs that were intratracheally challenged with a 
virulent strain [18]. 
A live vaccine based on an avirulent strain and able to induce protective immunity may 
be of interest to counter 5. suis infections in swine. We have previously obtained, using Tn916 
transposon mutagenesis, a 5. suis serotype 2 unencapsulated non-virulent mutant strain 
(mutant 2A) [9]. In this work, we reproduced the unencapsulated phenotype of mutant 2A by 
allelic exchange and showed that the resulting mutant strain is affected in aromatic amino acids 
biosynthesis. We also describe the preliminary evaluation of this new mutant strain as a live 
vaccine in a protection assay in swine. 
2) MateriaIs and methods 
2.1) Bacterial strains and plasmids. 
The bacterial strains and plasmids used in this study, along with their phenotypes and 
sources, are listed in Table 1. 5. suis strains were grown in Todd-Hewitt broth (THB) or on Todd-
Hewitt agar (THA), supplemented when required with 400 Ilg/ml kanamycin (Km) (Roche 
Diagnostics, Laval, QC, Canada). A chemically defined medium (CDM) allowing 5. suis growth was 
adapted from the CDM medium formulated for other streptococci [19]. E. coli strains were 
grown on Luria-Bertani broth or agar containing, when needed, 40 Ilg/ml Km. 
2.2) Nucleic acid techniques. 
If not otherwise indicated, routine DNA manipulations were carried out as previously 
described [20]. Genomic DNA from 5. suis and E. coli was prepared by the guanidium 
thiocyanate method [21]. Custom primers were purchased from Invitrogen (Invitrogen, 
Burlington, Ontario, Canada). Total RNA was prepared by using Trizol (Invitrogen), as 
recommended by the manufacturer. Northern and Southern-blots were performed using the 
DIG-Iabelling and detection kit (Roche), as recommended by the manufacturer. Restriction 
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enzymes, T4 DNA ligase, Taq DNA polymerase, calf intestinal alkaline phosphatase and the 
Klenow fragment of E. coli DNA polymerase 1 were purchased from Amersham (Amersham 
Biosciences, Piscataway, NJ). Ali other reagents and chemicals were purchased from Sigma 
(Sigma-Aldrich, Oakville, Ontario, Canada). PCR fragments were cloned using the TA Cloning Kit 
(Invitrogen), following the manufacturer's instructions. 
2.3) Identification of the insertion site of Tn916 in S. suis unencapsulated mutant 2A. 
The insertion site of Tn9l6 in S. suis mutant 2A was determined using a PCR-based 
procedure allowing amplification of one end of the Tn9l6 insert and the adjacent genomic DNA 
sequence [22]. Mutant 2A genomic DNA was digested with Hindlll, which cleaves the Tn9l6 at a 
unique site. Resulting fragments were ligated into pBluescript KS+ (Stratagene, La Jolla, 
California, USA) previously digested with Hindlll and treated with calf intestinal alkaline 
phosphatase. PCR was performed with primers Tn, specifically annealing to Tn9l6, and T7, 
annealing to the vector (Table 2). A region of 8.4 kb (Figure lA) surrounding the Tn9l6 insertion 
site was th en sequenced using a primer walking strategy. DNA sequences were çetermined at 
the DNA Sequencing Facility of the University of Maine (Orono, Maine, USA), on a 373A DNA 
Sequencing System (Applied Biosystems, Foster City, California, USA). The BLAST software 
package was used to determine sequence homologies in the GenBank databases 
(http://www .ncbi.nlm.nih. gOY IBLAST 1). 
2.4) Single insertion mutant B0105 (otf2::pBEA1013). 
A temperature sensitive suicide vector pBEA756 (Figure 2) was constructed and used to 
generate mutants in S. suis. This plasmid is a derivative of pCIV2 [23]. It carries a Km resistance 
element and an E. coli co/El origin of replication. A thermosensitive Gram positive replication 
origin (repAts) was PCR amplified from plasmid pVE6007 [24] using primers TS1F and TS1R, 
which introduce Kpnl restriction sites (Table 2). The resulting 1.5 kb fragment was cloned into 
the Kpnl site of pCIV2 to obtain pBEA756. The orf2 gene was interrupted in S. suis virulent strain 
S735 by insertion of a recombinant plasmid. A 741 bp amplicon corresponding to an internai 
section of orf2, was amplified using primers B2F and B2R (Table 2), digested with the 
appropriate restriction enzymes and cloned into pBEA756 to obtain plasmid pBEA1013, which 
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was propagated in E. coli. Purified pBEA1013 was electroporated into S. suis as previously 
described [25]. Transformants were grown on Km-selective plates at 28°C (permissive 
temperature for the Gram positive replication origin). Insertion mutants were selected by 
shifting the temperature to 37"C (non-permissive temperature) in the presence of Km selection. 
Integration of pBEA1013 into the S. suis genome was verified by PCR and 50uthern blot. 
2.5) Allelic replacement mutants. 
Deletion of the promoter region of the ara operon was accomplished by allelic exchange 
using virulent strains 5735 and 31533 (Figure lC). Briefly, 2 PCR amplicons were obtained using 
primers pairs BA9 and BA7, and BA8G and BAll respectively, which introduce 8g111 and EcoRI 
restriction sites (Table 2). 8glll-digested amplicons were ligated to generate a mutant allele 
lacking the putative promoter and the 5' end of both aroA and orf2. The EcoRI-digested mutant 
allele was then cloned into pBEA756 to obtain plasmid pBEA860, which was propagated in E. 
coli. Plasmid pBEA860 was electroporated as previously described [25] into recipient S. suis 
strains 5735 and 31533, which were plated on THA containing 400 Ilg/ml Km and incubated at 
28°C for 48 h. Temperature was then shifted to 37"C to select for pla sm id integration. 50me 
single crossover integrants were then cultured several times at 28QC in the absence of selection 
to obtain the excision and 1055 of the plasmid. Allelic exchange in Km sensitive clones was 
confirmed by PCR and 50uthern-blot. 
2.6) Serotyping, coagglutination and biochemical identification. 
Capsular reaction test, coagglutination and biochemical identification of wild-type and 
mutant strains were carried out as previously described [26]. The capsular sialic acid content 
was determined by the thiobarbituric acid assay [27]. 
2.7) Complementation studies in S. suis and E. coli. 
Fragments spanning from the putative ara promoter to the end of aroA (primers AAK52 
and ARA3EC), aroK (primers AAK52 and AAK3) and orflO (primers AAK52 and ORF10-4) were 
amplified by PCR, digested with the appropriate restriction enzymes and cloned into pBEA756 
(Figure lD). Recombinant resulting plasmids pBEAcompl, pBEAcomp2 and pBEAcomp3 were 
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electroporated into S. suis mutant strain BD101. Ali the complementation studies in S. suis were 
carried out at 28°C. Restoration of capsule production in the resulting complemented mutants 
was assessed by dot blot with Z3 monoclonal antibody (Z3 mAb) directed against sialic acid [28], 
and by coagglutination with polyclonal serum directed against S. suis serotype 2 capsule. 
Complementation of E. coli AB2829 (aroA) was achieved using the inducible expression vector 
pMt020, a pACYC184 derivative that contains a chloramphenicol (Cm) resistance element, a lac 
promoter downstream of which lies the multiple cloning site and a loci repressor gene upstréam 
from the cloning site (M. Tessier, unpublished results). A 1.5 kb amplicon comprising the who le 
aroA gene of S. suis strain S735 was amplified using primers ARA3 and ARA5B and cloned into 
8g111 and Xbal-digested pMT020, then electroporated into E. coli AB2829 strain. The 
transformants were spread on CDM agar plates containing Cm but lacking aromatic amino acids. 
IPTG was used as inducer of the lac promoter. 
2.8) Transmission electron microscopy. 
Electron microscopy was performed as previously described [29], with some 
modifications. Briefly, overnight (ON) cultures of S. suis wild type strain S735, mutant strain 
BD10l and complemented strain CA119 were mixed with specifie anti-S. suis serotype 2 
polyclonal serum and incubated at room temperature for 1 h. Cells were fixed in cacodylate 
buffer (0.1 M cacodylate, 5% v/v glutaraldehyde, 0.15% w/v ruthenium red, pH 7.2) for 2 h. After 
fixation, cells were immobilized in 4% (w/v) agar, washed in cacodylate buffer and post-fixed ON 
at 4°C in 2% (v/v) osmium tetraoxyde. Samples were dehydrated in graded series of ethanol and 
then embedded in Spurr low-viscosity resin. Thin sections were post-stained with uranyl acetate 
and lead citrate and examined with a transmission electron microscope (Model 420, Philips 
Eleetronics, The Netherlands). 
2.9) Protection assay in pigs. 
20 four-week old second generation of caesarean-deprived pigs (which tested negative 
for S. suis serotype 2 by ELISA [30] at the beginning of the experiment) were used in this study. 
Ali animais were treated aecording to the Canadian Council on Animal Care Guide to the Care 
and Use of Experimental Animais. Animais were divided in three groups: Group 1 (n=7) was 
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vaccinated with S. suis strain BD101. Groups 2 (n=7) and 3 (n=6) were not vaccinated. Strict 
biosecurity measures were implemented in order to avoid undesirable contamination of the 
pigs: an air filtration system and airlocks for each unit were used during the experiments. In 
addition, unit-specifie clothes and showering before and after visiting the pigs were mandatory 
for researchers and technicians. Animais in group 1 received two doses of the vaccine (at 4 and 
6 weeks old respectively) by intramuscular injection with a 2-ml, live mutant strain BD101 
suspension at 1x109 CFU/ml. After vaccination, fever, clinical symptoms, presence of S. suis in 
blood samples, daily food intake and weight gain were monitored. Animais from groups 1 and 2 
were challenged 28 days after the first immunisation by intravenous injection of 109 CFU of S. 
suis strain S735. Group 3 were sham inoculated animais. The same parameters described above 
were monitored. After euthanasia (at day 42 after the first immunisation; 14 days after 
challenge) animais were examined for pathological lesions. Bacteriological isolation from blood 
and different organs was also performed. Briefly, samples weighing 0.5 g originating from the 
liver, the spleen, the lungs and the heart, were reduced to small pieces with a scalpel and 
diluted in 1 ml phosphate buffered saline (PBS), pH 7,3. Blood samples (100 Ill) were also diluted 
in 1ml PBS. Sheep blood agar plates were inoculated with 100 III of these suspensions and 
incubated ON at 3rC with 5% CO 2• In addition, an enrichment of the samples was performed by 
inoculation of 100 III of blood or tissue suspensions in 5 ml THB and 01\1 incubation at 3rc. 
Seriai dilutions of enriched samples were then plated on sheep blood agar and grown as 
described above. In addition, articulations were swabbed and isolation was performed either 
directly using sheep blood agar, or after enrichment of the swab in THB, as described above. 
Isolated tiny a-hemolytie colonies were assigned to S. suis by serotyping as previously described 
[26]. Differences between groups regarding mortality, presence of les ions and S. suis isolation 
from blood and organs were assessed using the z-test for two proportions. Antibody response 
was verified in ail animais by an indirect enzyme-linked immunosorbent assay (ELISA) using the 
whole unencapsulated mutant strain BD101 as antigen [30]. Sera originating from a pig 
immunised with strain S735 as weil as from a healthy pig were used as positive and negative 
controls, respectively. Statisties was performed using the Student's t-test. 
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3) Results 
3.1) Identification of Tn916 insertion site in unencapsulated mutant 2A. 
Tn916 insertion site in S. suis mutant strain 2A was sequenced and characterised. The 
resulting 8.4 kb sequence has been deposited in GenBank, under accession number AY375303. 
The insertion site of Tn916 in mutant 2A lies within the putative mRNA leader sequences of two 
divergent open reading frames (ORFs), orf2 and oraA, transcribed in opposite directions (Figure 
lA). Four other potential ORFs were deduced downstream of oroA. No function could be 
assigned to the ORF2 in a comparative search in the GenBank database. On the other hand, 
BLA5T sequence comparisons indicated that the first three ORFs transcribed in the opposite 
direction are similar to oraA, oroK and pheA genes from S. suis and other Gram positive bacterial 
species (Table 3). 5earches in public databases showed that the organisation of these 3 genes, 
which are putatively involved in aromatic amine acids biosynthesis, is almost identical in S. suis 
to that observed in several other streptococcal species. The orflO gene downstream pheA 
shares significant homologies with numerous transcriptional regulators of the LytR_cpsA_psr 
family, while the orf13 is homologous to various RNA methyltransferases (Table 3). In Northern-
blot experiments, a 4 kb mRNA was detected in the wild-type strain 5735 using either oroA or 
orflO probes (data not shown). This result is consistent with a polycistronic mRNA spanning 
from the ora promoter to the end of orflO, which we will refer to as oro operon. In contrast, no 
mRNA hybridising with oraA or orflO probes could be detected in mutant 2A (data not shown). 
Thus, in mutant 2A transposon Tn916 prematurely interrupts the transcription of the oro 
operon, exerting polar effects in the expression of genes oraA, oroK, pheA and orflO. 
3.2) Inactivation of the or/2. 
To evaluate if it was responsible for the abolishment of the unencapsulated phenotype, 
the orf2 was interrupted by insertion of a recombinant plasmid in wild type strain 5735. The 
resulting single crossover mutant BDl05 (orf2::pBEAlO13) (Figure lB) reacted as the WT type 
strain in coagglutination tests with a polyclonal serum directed against S. suis serotype 2 capsule 
and with Z3 anti-sialic acid monoclonal antibody (Table 4), indicating that inactivation of the orf2 
does not affect capsule production. 
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3.3) Reproduction of the unencapsulated phenotype by allelic exchange. 
Since the orf2 does not play a role in capsule production, the unencapsulated 
phenotype of mutant 2A could be due to polar effects exerted by the insertion of Tn916 on 
genes belonging to the oro operon. In order to reproduce the unencapsulated phenotype of 
mutant 2A in a stable mutant strain, the region comprising the oro putative promoter in strain 
S735 was deleted by allelic replacement, giving ri se to strain B0101 (Figure 1C). In Northern-blot 
experiments no mRNA was found to hybridise to either aroA or orfl0 probes confirming that 
deletion of the oro promoter results in the abolishment of the expression of the entire oro 
operon in mutant strain B0101 (data not shown). Similar to mutant 2A, strain B0101 did not 
react in dot blot experiments with Z3 anti-sialic acid mAb. It was also negative in coagglutination 
tests with a polyclonal serum directed against S. suis serotype 2 capsule. Furthermore, dosage of 
capsular sialic acid content showed that this sugar was almost absent from strain B0101 (Table 
4). The absence of capsule in mutant strain B0101 was also verified by electron microscopy 
(Figure 3). To further confirm that deletion of the promoter region of the oro operon abolishes 
capsule production in S. suis, an independent serotype 2 strain (virulent field strain 31533) was 
also mutated using the same strategy. The characteristics of t~e resulting mutant strain B0102 
(absence of capsule by dot blot with Z3 mAb, sialic acid dosage and coagglutination) were 
similar to those obtained for mutant B0101 (Table 4). 
3.4) Complementation of s. suis capsular function. 
Complementation of capsule production was achieved by reintroducing different 
fragments of the oro operon into strain B0101 (Figure 10). In each case, genes were under the 
control of their native promoter. Complementation with fragments comprising the region from 
the oro promoter to the end of aroA as weil as from the oro promoter to the end of aroK failed 
to restore the capsulated phenotype. On the other hand, complementation with the entire oro 
operon (from the oro promoter to the end of the orfl0) restored capsule production. Resulting 
strain CA119 reacted in dot blotting experiments with Z3 anti-sialic acid mAb and with 
polyclonal serum directed against S. suis serotype 2 capsule. However, complementation with 
the entire oro operon only partially restored capsule production (Table 4 and Figure 3). 
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3.5) Role of s. suis aro operon in aromatic amino acid biosynthesis. 
Based on homology of functions, deletion of the promoter region of the oro operon 
should result in auxotrophy for aromatic amino acids. To test this hypothesis, we used a CDM 
allowing the growth of s. suis [19]. The wild-type s. suis strain 5735 did not require the addition 
of aromatic amino acids to the CDM formulation to grow while mutant strain BD101 did not 
grow unless the medium was supplemented with these compounds. Complemented strain 
CA119 grew in both formulations (Table 5). To further confirm the involvement of the s. suis oro 
operon in aromatic amino acids biosynthesis, the aroA deficient E. coli strain AB2829 (araA) was 
transformed with the expression plasmid pMT020 carrying the s. suis aroA gene. The 
complemented strain grew in CDM media lacking aromatic amino acids, while E. coli AB2829 
(araA) strain did not. The E. coli strain JM109, used as control, grew in any CDM formulation 
(Table 5). 
3.6) Protection assays in pigs. 
3.6.1) Vaccination: 
After the first vaccine dose with mutant strain BD101, ail animais in vaccinated group 1 
presented slight hyperthermia 4 h post vaccination. 5light hyperthermia was also observed in 4 
animais of this group after the second immunisation. Body temperature returned to normal 
values in ail vaccinated piglets within 24 h. Vaccination did not induce any other symptoms. s. 
suis mutant strain BD101 was isolated in low counts from the blood of 4 pigs after the first 
immunisation and from 2 animais after the second immunisation. In most cases, an enrichment 
of the blood sample was necessary to isolate the strain. Until challenge, vaccinated animais 
showed growth and daily weight gain values similar to those in the non-vaccinated and control 
groups 2 and 3 (Table 6). 
3.6.2) Experimental challenge: 
Tenty-four hours after the experimental challenge with s. suis strain 5735, hyperthermia 
was observed in ail pigs belonging to vaccinated and non-vaccinated groups 1 and 2. However, 
average temperature was higher in non-vaccinated group 2. Two days after the challenge, only 3 
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vaccinated and ail non-vaccinated pigs still presented hyperthermia. Lameness was observed in 
ail pigs in group 1 from day 6 after challenge until euthanasia (Table 7). Articulations were hot 
and swollen at palpation. These latter symptoms were only punctual and did not persist over 
time. No mortality was observed in animais from group 1. On the other hand, lameness was 
observed in ail pigs belonging to non-vaccinated group 2 from day 1 post challenge. Articulations 
were soaring during the 2 weeks that followed the challenge. Four out of 7 animais in group 2 
were shaking 24 hours post challenge, and one pig showed convulsions. Four pigs died or were 
killed for humanitarian reasons in this group. s. suis serotype 2 could be isolated from the blood 
of ail vaccinated and non vaccinated pigs. However, pigs in non-vaccinated group 2 showed 
higher bacterial counts than those observed in vaccinated group 1 (Table 7). Vaccinated animais 
presented higher growth and daily weight gain values compared to those of non-vaccinated 
group 2 during the 2 weeks following the challenge. However, after challenge, daily weight gain 
in vaccinated animais was slightly lower than in the sham-inoculated control group (Table 6). 
After the second immunisation, an increase in antibody titres was observed for ail animais in 
vaccinated group 1. A few days after challenge, production of antibodies was observed in 
vaccinated group 1 and non vaccinated group 2. However, the effect was faster in vaccinated 
group 1 (Figure 4). 5urviving pigs of ail 3 groups were humanely killed two weeks post challenge. 
ln vaccinated group 1, only articulations showed inflammation, with fibrin deposits and excess 
of synovialliquid. Macroscopic lesions were more common in non-vaccinated group 2, especially 
at the pleura, the pericardium and the peritoneum (Table 7). Fibrin deposits were observed in 
the liver and the spleen of ail animais belonging to group 2. Furthermore, pneumonia and 
fibrinal pleurisy were observed for some animais of this group, while 5 animais also presented 
pericarditis. Bacterial isolation from different organs revealed a high bacterial colonization of 
the thoracic cage and abdominal organs. In vaccinated animais, bacterial isolation from organs 
was also possible, but to a much lesser extent (Table 7). 
4) Discussion 
ln our laboratory we have previously obtained an unencapsulated S. suis serotype 2 
mutant (mutant 2A) by means of transposon Tn916 mutagenesis of s. suis virulent strain 5735 
[9]. In this study, we identified and characterised the insertion site of Tn916 in mutant 2A. 
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Tn916 was found to be inserted in the leader section of the mRNA of two divergent ORFs, or/2 
and oroA, this latter being the first gene of an operon also composed by oroK, pheA and or/l0. 
No putative function could be assigned to the or/2 after an exhaustive search in public 
databases. On the other hand, the 3 first genes of the s. suis oro operon, oroA, oroK and pheA, 
are similar to those of many other Gram positive and Gram negative bacteria. The E. coli 
counterparts of AroA and AroK play weil established roles in the chorismate pathway, while 
PheA is a terminal enzyme of the aromatic amino acid biosynthesis pathway that catalyzes the 
conversion of prephenate to phenylpyruvate [31]. Chorismate is a common substrate in the 
biosynthetic pathways of aromatic amino acids and many other compounds like folate, 
ubiquinone and vitamin K [31]. In this work, we provide for the first time evidence that genes in 
the s. suis oro operon are indeed involved in the chorismate pathway. In fact, S. suis oroA 
complemented the oroA mutation in E. coli AB2829 (oroA), suggesting that the s. suis and E. coli 
chorismate biosynthetic pathways are, at least in part, similar. In addition, deletion of the 
promoter region of the oro operon in S. suis resulted in auxotrophy for aromatic amino acids as 
shown by the inability of the s. suis mutant strain BD10l to grow in CDM not supplemented with 
aromatic amino acids. 
Capsular' polysaccharide biosynthesis in S. suis has not yet been fully elucidated. In two 
subsequent studies the s. suis serotype 2 capsular locus (cps2) has been described and 
characterised [10, 32]. It has also been shown that nonencapsulated isogenic mutants can be 
generated by disruption of either the cps28 and cps2EF genes [10]. In this study we show that 
inactivation of the oro operon in both S. suis serotype 2 reference strain 5735 and field strain 
31533 results in an unencapsulated phenotype. Furthermore, complementation of mutant 
BD10l with a recombinant pla sm id containing the entire oro operon allowed restoration, 
although partial, of the capsular phenotype. To the best of our knowledge, this is the first time a 
mutation in a region outside the cps locus resulting in abolishment of capsule production is 
described in S. suis. Although data presented in this study is insufficient to provide a full 
explanation for the absence of capsule in oro deficient mutants, it might be possible to 
hypothesize that capsule synthesis, transport or assembly production depend on the presence 
of chorismate-derived compounds. However, attempts to restore the unencapsulated 
phenotype of mutant BD10l by complementation with the oroA gene only or with both oroA 
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and aroK were unsuccessful. A role for pheA in capsule production could be difficult to be put 
forward; PheA is a regulatory enzyme involved in I-phenylalanine biosynthesis whose disruption 
should only cause an auxotrophy for this amino acid with, a priori, no major changes in global 
metabolism [31]. However, 5. suis mutant strain B0101 growing in COM medium containing 
phenylalanine did not revert to an encapsulated phenotype. On the other hand, the orflO, the 
last gene of the aro operon, is predicted to belong to the LytR_cpsA_psr family of transcriptional 
regulators. Interestingly, members of this family have been shown to act as positive regulators 
of capsule expression in both 5treptococcus agalactiae and 5treptococcus pneumoniae [33, 34]. 
It is therefore tempting to speculate that the orflO gene product might contribute to the 
regulation of capsule production in 5. suis serotype 2. 
Attempts to counter 5. suis infections are hampered by the lack of efficient vaccines 
which can control the diversity of strains that cause disease [l].Vaccination with a live, 
attenuated strain of 5. suis is one of the several approaches that may be' used to elicit protective 
immunity in swine against this bacterium. Unencapsulated 5. suis mutants have proven to be 
non-virulent for swine [9, 10]. Mutant strain B0101 is unencapsulated, and, besides, our results 
show that inactivation of the aro operon results in auxotrophy of this mutant for aromatic 
amino acids. Mutant strains in aro genes have been obtained in several bacterial species. Most 
of these mutants have proven non-virulent to their cognate hosts, since compounds derived 
from the chorismate pathway are essential for bacteria and not easily available in vertebrate 
tissues [35]. Furthermore, it has been shown using different animal models that protection 
against a challenge with a virulent homologous strain may be obtained following immunisation 
with aro mutants [36-39]. Since 5. suis is also a zoonotic agent, safety of a live vaccine is of main 
concern, especially after the report of serious cases of human disease with a high rate of 
mortality described in China, that were directly linked to a concurrent outbreak of 5. suis 
infection in pigs [40]. Based on the absence of capsule and auxotrophy for aromatic amino acids, 
mutant strain B0101 might be safely attenuated and, therefore, a good candidate for live 
vaccination of swine. Although we cannot completely exclude the possibility that the strain 
B010l is not completely attenuated in humans, it is not virulent in the mouse model of infection 
(unpublished results), and, besides, results obtained in this study by monitoring the response to 
vaccination indicate that mutant strain B010l is indeed of low virulence for swine. In addition, it 
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does not significantly affect animal growth. In fa ct, the only symptom observed after 
immunisation of animais was slight hyperthermia that subsided after 24 hours. After challenge 
with the homologous wild type virulent strain 5735, the mortality in the vaccinated group was 
significantly reduced in comparison to the non-vaccinated group. As weil, vaccinated animais 
clearly presented lower rates of clinical signs and no lesions characteristic of s. suis could be 
found on the brain, the liver, the spleen, the lungs and the heart of vaccinated animais. 
Among S. suis serotypes, serotype 2 is responsible for most cases of disease in both 
swine and humans [1, 3]. Almost ail studies on virulence factors, pathogenesis of the infection 
and vaccination have been carried out with this serotype [1, 41]. A previous study used a live, 
non-virulent, unencapsulated 6cpsEF mutant as live vaccine. In that work, immunisation with 
the unencapsulated mutant strain failed to provide protection to pigs against the homologous 
serotype 2 parent strain [15]. By contrast, vaccination with mutant strain BD101 provided a 
relatively good protection level against a challenge with the homologous serotype 2 parent 
strain. Even if the mutant strains used for vaccination in that and the current studies are both 
unencapsulated and non-virulent for swine, other differences exist between the parent strains 
regarding both the genotype and phenotype. In addition, and perhaps more importantly, two 
different experimental models of infection were used in both studies [15, 42]. To evaluate 
virulence, different research groups have used different animal species, pigs with different 
health status and different ages, different routes of infection, or variable bacterial doses [43]. 
This fact has led to a controversy in the definition of "virulent" serotype 2 strains [43] and, 
actually, has hampered the studies on cross protection, because assessing the heterologous 
protection requires a set of strains whose virulence had been characterised in the same 
infection model. Recently, however, a standardised swine infection model for s. suis has been 
reported and used to compare the virulence of some field isolates of s. suis serotype 2 [42]. As 
new data regarding the level of virulence of different serotype 2 strains becomes available, it 
, 
would be interesting to evaluate the ability of mutant strain BD101 to confer protection against 
heterologous virulent serotype 2 strains. 
The actual contribution of humoral immunity to protection of pigs against S. suis is not 
fully understood [18]. Convalescent (and protected) animais do not present high antibody titres 
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against this bacterium (our unpublished observations). In the present study, the immunisation 
of pigs with live mutant BD101 did not elicit a vigorous humoral response after the 
immunisations. However, an acceptable level of protection against the challenge with the 
virulent homologous strain was observed. Host protection against infection caused by S. suis, a 
highly encapsulated microorganism, is mediated primarily by phagocytosis [9, 28]. For 
phagocytosis to occur efficiently the presence of opsonising antibodies capable of triggering 
leukocyte effector functions seems to be required [18]. On the other hand, it has been 
suggested that the generation of opsonising antibodies may depend on a Th1-like response [44]. 
It is thus tempting to speculate that vaccination with mutant strain BD101 might elicit a Type 1 
immune response which in turn would drive the differentiation and activation of B cells to 
secrete antibodies with opsonising capacity. Further studies are needed to evaluate the 
contribution of humoral and cellular immunity in protection of animais against S. suis following 
vaccination with live mutant strain BD1010 
The protection obtained by immunisation with mutant strain BD101 was not complete. 
Indeed, after the challenge, minor secondary effects were recorded among immunised animais. 
The absence of antibodies against capsular polysaccharide might be, at least in part, responsible 
for the inability of the BD101 vaccine to induce full protection in swine [15]. Secondary effects 
might also have been caused, at least in part, by the high dose of S. suis used for inoculation. As 
weil, the extremely aggressive intravenous route of administration may have influenced the 
clinical onset observed in vaccinated animais. For S. suis, very few experimental infection 
models are available and most of them lack repeatability [43]. For that reason, this study has 
prioritised the use of a well-standardized infection model [42], in spite of the fact that it does 
not follow the natural route of infection of S. suis strains. Further studies using a different route 
of inoculation might help to better characterise the protective capacities of a live vaccine based 
on S. suis mutant strain BD1010 
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Artic1e IV Tables 
Table XII. Article IV, Table 1. Bacterial strains and plasmids used in this study. 
Description Source 
Bacterial strains 
E. coli JM109 Host for cloning vectors. endAl, recAl, gyrA96, thi, Promega 
hsdR17 (rn mk+), re/Al, supE44, fJ(lac-proABJ, [F', 
traD36, proAB, laqlqZ fJ M15] 
E. coli AB2829 AroA deficient strain. g/nV42 (AS), À-, aroA354 CGSC a 
S. suis S735 Serotype 2 (Reference strain; virulent) Laboratory 
collection 
S. suis 31533 Serotype 2 (Field strain; virulent) Laboratory 
collection 
S. suis 2A Unencapsulated Tn916 insertional mutant derived Charland et al. [9] 
from strain S735. TetR• 
S. suis BD10l Derived from strain S735. Deletion of the ara This work 
promoter resulting in abolishment of araA, aroK, 
pheA and orflO expression 
S. suis BD102 Derived from strain 31533. Deletion of the ara This work 
promoter resulting in abolishment of araA, araK, 
pheA and orflO expression 
S. suis BD105 orf2::pBEA1013 This work 
S. suis CA119 Mutant BD101compiemented with the entire ara This work 
operon 
Plasmids 
pCR2.1 E. coli vector for cloning of PCR fragments Invitrogen 
pMT020 E. coli inducible expression vector M. Tessier 
(unpublished) 
pCIV2 pUC ori, KmR Okada et al. [23] 
pVE6007 Thermosensitive suicide vector (source of Gram Maguin et al. [24] 
positive repAts) 
pBEA756 Thermosensitive suicide vector for S. suis This work 
mutagenesis 
pBEA1013 pBEA756 carrying 761 bp internai sequence of the This work 
orf2 
pBEA860 pBEA756 carrying the construction for allelic This work 
exchange 
pBEAcomp1 pBEA756 carrying a fragment from the ara promoter This work 
liv 
to the end of aroA 
pBEAcomp2 pBEA756 carrying a fragment from the oro pramoter This work 
to the end of aroK 
pBEAcomp3 pBEA756 carrying a fragment fram the oro pramoter This work 
to the end of the orfl0. 
a Escherichia coli Genetic Stock Center. 
Table XIII. Article IV, Table 2. Oligonucleotide primers used in this study. Bold characters 
indicate restriction sites. 
Primer name Sequence (5/-3') , Restriction enzyme 
Tn CCACTTCTGACAGCTAAGAC 
T7 
TS1F 
TS1R 
B2F 
B2R 
BA7 ' 
BA9 
BA8G 
BAU 
AAK52 
ARA3EC 
AAK3 
ORF10-4 
ARA3 
ARA5B 
GTAATACGACTCACTATAGGGC 
GTTAGGTACCGAAAGCCGATG 
TTGTGGTACCTAATTCAACTTCC 
TCACGAATTCTATATATCCCGTTCG 
TGAAGAATTCAGGAAGGACTGATAGC 
ATTGAGATCTTGTCTTGTCAACC 
ACTCGAATTCTACGATGACCG 
ACTTAGATCTTATATCCCGTTCG 
TTTGGAATTCATTACCTAAAGTATC 
CACTCTGCAGCCACTCCCAATGTTG 
GACTGAATTCGTCAGCAATAGGC 
CGTTCTGCAGGCCTTGATAACCTCTG 
TTTCTGAATTCAGGCCTAACTC 
GACTTCTAGAGTCAGCAATAGGC 
ATTGAGATCTCACAAGTAATTGTC 
Kpnl 
Kpnl 
EcoRI 
EcoRI 
BglIl 
EcoRI 
Bglll 
EcoRI 
Pstl 
EcoRI 
Pstl 
EcoRI 
Xbal 
BglII 
Iv 
Table XIV. Article IV, Table 3. Characteristics of the putative open reading frames (ORFs) 
within the 8.4 kb fragment containing the s. suis aro operon 
ORF Putative function (organism) Gene GenBank Access 
ORF2 
AroA 
AroK 
PheA 
ORF10 
ORF13 
hypothetical protein (5. suis 89-1591) 
3-phosphoshikimate 1-carboxyvinyltransferase (5. suis 89-
1591) 
Shikimate kinase (5. suis 89-1591) 
Prephenate dehydratase (5. suis 89-1591) 
Transcriptional regulator (5. suis 89-1591) 
tRNA (uracil-5-)-methyltransferase (5. suis 89-1591) 
NQ 
ZP_00874823 
araA ZP 00874822 
araK ZP_00874821 
pheA ZP_00874820 
ZP_00874819 
trmA ZP 00874818 
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Table XV. Article IV, Table 4. Results obtained for capsule, sialic acid production and 
coagglutination by S. suis wild type and mutant strains used in this study 
Bacterial strains Coagglutination a Dot blot b 5ialic acid content (ug/ml) C 
5. suis 5735 +d + 4.83 ± 0.97 
5. suis 31533 + + 4.23 ± 0.26 
5. suis 2A 
5. suis BD101 
5. suis BD102 
5. suis CA119 
5. suis BD105 
e 
+ 
+ 
+ 
+ 
0.12 ± 0.03 
0.06 ± 0.03 
0.09 ± 0.02 
'2.20 ± 0.23 
4.18± 1.02 
Ivii 
a Evaluated as previously described [26] using polyclonal serum against 5. suis serotype 2 
capsule. 
b Determined using the Z3 monoclonal antibody directed against sialic acid [28]. 
C Measured using the thiobarbituric acid method [27]. 
d Positive reaction. 
e Negative reaction. 
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Table XVI. Article IV, Table 5. Growth of different s. suis and E. coli strains in a chemical 
defined medium (CDM) with and without aromatic amine acids (aaa). 
Bacterial strains CDM CDM without aaa 
S. suis 5735 
S. suis BD10l 
S. suis BD102 
S. suis CA119 
E. coli JM109 
E. coli AB2829 aroA354 
E. coli AB2829 complemented with S. suis aroA 
a 5imilar to that observed on Todd-Hewitt broth 
b 5imilar to that observed in Luria-Bertani broth 
Normala Normal 
Normal None 
Normal None 
Normal Normal 
Normalb l'Jormal 
Normal None 
Normal Normal 
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Table XVII. Article IV, Table 6. Daily weight gain in pigs (g). 
Group 1 (n=7) Group 2 (n = 7) Group 3 (n = 6) 
Time (days) Vaccinated Not-vaccinated Control 
Before first immunization 
- 4 to 0 450 400 375 
After first immunization 
0-3 600 633 666 
3-7 575 725 675 
7-11 400 675 525 
11-14 1033 866 1033 
After second immunization 
14-18 725 750 800 
18-21 666 800 700 
21-25 725 625 700 
25-28 866 966 833 
After challenge 
28-32 -225 -500 775 
32-35 400 466 a 733 
35-39 1125 300 a 875 
39-42 866 890 b 800 
28-39 549 43 a 804 
a Data from 5 animais 
b Data from 3 animais 
Table XVIII. Article IV, Table 7. Effects of challenging the different groups of animais used in 
this study with S. suis virulent strain 5735. 
Group 1 (n = 7) Group 2 (n = 7) Group 3 (n = 6) 
Vaccinated Not-vaccinated Control 
Mortalitya o 
CliniCal symptoms 
-Lameness + +++ 
-Shaking + +++ 
-Convulsions o 1 o 
Lesions C 
-Brain o 3 o 
-Other organs d o 
-Articu lations 3 4 o 
Bacterial isolation 
-Articulations 4 7 o 
-Organs e 1 b o 
-Blood 7 (86) f 7 (2000) f o 
a Natural mortality or euthanasia for humanitarian reasons. 
b Significant differences between vaccinated and non vaccinated animais (z-test; P<O.OS). 
C Macroscopic lesions characteristic of S. suis infection. 
d The liver, the spleen, the lungs and the heart were examined. 
e Isolation was performed from the same organs described in C and the brain. 
f Mean bacterial counts (CFU/ml). 
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Article IV Figures 
TIl916 Phenotype 
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Figure 35. Article IV, Figure 1. Genetic organization of the S. suis aro region and strategies 
followed for mutant generation. 
Al 5chematic representation of a 8.4 kb genomic DNA surrounding the insertion site of 
transposon Tn916 in mutant 2A. In silico analysis and Northern blot experiments showed the 
presence of 6 ORFs, 4 of which are organised in an operon (aro operon). The putative promoters 
for the orf2 and the aro operon in S. suis virulent strain 5735 are indicated. B) The orf2 was 
inactivated in mutant strain BD105 (orf2::pBEA1013) by insertion of a recombinant plasmid. 
Inactivation of the orf2 does not affect capsule production. C) Deletion of a region comprising 
the putative aro promoter in bath reference strain 5735 and field strain 31533 results in the 
abolishment of the encapsulated phenotype. D) Complementation of mutant strain BD101with 
different constructions under the control of the cognate aro promoter. Capsule production was 
restored partially only when the construction comprised the entire aro operon. 
pBEA756 
5732 bp 
repAis 
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Figure 36. Article IV, Figure 2. Plasmid pBEA756 is a thermosensitive suicide vector derived 
from plasmid pCIV2 [23]. 
It carries a Km resistance element, an E. coli colEl and a thermosensitive Gram positive 
replication origin repAts. MeS, multiple cIoning sites. 
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A 
B 
c 
Figure 37. Article IV, Figure 3. Transmission electron microphotographs of thin sections of S. 
suis WT and mutants used in this study. 
A) 5erotype 2 reference strain 5735, which shows a thick capsule characteristic of this serotype. 
Original magnification 37,500 X; B) Mutant strain 5735 tJ.aro, which exhibits an unencapsulated 
phenotype; C) Complemented strain CA119 (strain BD 101compiemented with a recombinant 
plasmid carrying the entire aro operon under the control of its cognate promoter), which shows 
a partially restored capsular phenotype. Original magnification for Band C: 62,500 X. Bar = 0.5 
Ilm. 
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Figure 38. Article IV, Figure 4. Antibody response in the 3 groups of animais used in this study. 
Animais in group 1 (closed squares) received two doses of S. suis mutant strain BD101 
intramuscularly at days 0 (a) and 14 (b), respectively. Animais in group 2 (closed triangles) and 3 
(open circles) were not vaccinated. Animais in group 3 were not challenged (control group) 
while those in groups 1 ànd 2 were challenged with S. suis serotype 2 virulent strain 5735 at day 
28 (c). + 5ignificant differences between vaccinated and non-vaccinated groups 1 and 2 (t-test; 
P<O.05). 
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Abstract 
Streptococcus suis is an important swine pathogen and a zoonotic agent. Differences in 
virulence have been noted between the 35 described serotypes, the serotype 2 being 
considered the most virul~nt. In this study, we evaluated the serotype distribution among 100 
isolates recovered from diseased pigs in the United States. Results showed that serotype 3 (20 % 
of the isolates) and serotype 2 (17%) were the most prevalent. We also evaluated the presence 
in these isolates of the genes sly, epf and mrp, coding for the virulence-associated markers 
suilysin (SLY), extracellular factor (EF) and muramidase-released (IVIRP) protein, respectively. The 
effective production of the markers by the strains was also verified. Questioning the usefulness 
of PCR for the assessment of the production of these markers in S. suis, results showed that 
presence of gene did not always correlate with actual expression of the respective protein. In 
the case of MRP, this was due, in most cases, to frameshift mutations at the 5' end of the gene 
resulting in premature stop codons. The most prevalent phenotypes among U.5. strains were 
MRP+EF·SLY· (40 %) and MRp·EF·SLY+ (35 %). Serotype distribution as weil as production of 
virulence markers greatly differed from those reported in several European countries, 
particularly for serotype 2. On the other hand, our results for the U.5. S. suis isolates are similar 
to those reported for Canadian strains, suggesting a common status in North America. 
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Introduction 
Streptococcus suis is an important agent of meningitis, septicemia, arthritis, pneumonia, 
and endocarditis in pigs and is also a zoonotic agent (Gottschalk et aL, 2007; Higgins and 
Gottschalk, 2006). Despite increasing research in recent years, which has in part been boosted 
by the 2005 deadly human outbreak in China (Yu et aL, 2006), the pathogenesis of s. suis 
infections remains poorly known. Differences in virulence among the 35 described serotypes is 
weil documented (Higgins and Gottschalk, 2006). s. suis serotype 2 is usually reported as the 
serotype most frequently associated with disease in both swine and humans, although other 
serotypes may also be involved in invasive diseases (Higgins and Gottschalk, 2006). In addition, 
important differences in virulence also exist among strains of the same serotype, particularly 
those belonging to serotype 2 (Berthelot-Herault et aL, 2005; Quessy et aL, 1995; Vecht et aL, 
1992). The capsule, a fibronectin/fibrinogen binding protein and a serum opacity-like factor 
have been reported to be involved in the virulence of this pathogen (Baums et aL, 2006; Chabot-
Roy et aL, 2006; de Greeff et aL, 2002; Smith et aL, 1999). More recently, modifications of the 
cell wall such as the D-alanylation of the lipoteichoic acids and the N-deacetylation of the 
peptidoglycan have been shown to contribute to the virulence traits of this pathogen (Fittipaldi 
. et aL, 2008a; Fittipaldi et aL, 2008b). In addition, a thiol-activated hemolysin known as suilysin 
(SLY) may play a role in S. suis virulence (Jacobs et aL, 1994). Encoded by the sly gene, SLY has a 
cytotoxic effect, is able to affect complement resulting in impaired opsonophagocytosis and 
might allow penetration of s. suis into deeper tissues (Chabot-Roy et aL, 2006; Lalonde et aL, 
2000; Vanier et aL, 2004). However, SLY is not essential for virulence, as demonstrated by the 
fact that isogenic sly mutants did not show any impairment in their ability to induce disease 
when compared to the parent SLY+ strain (Lun et aL, 2003). 
Expression of SLY, together with those of the LPXTG-protein known as muramidase-
released protein (IVIRP, 136 kDa) and the secreted protein extracellular factor (EF, 110 kDa), 
have been used as phenotypic markers to distinguish virulent from avirulent isolates of s. suis 
serotype 2, (Higgins and Gottschalk, 2006). These MRP and EF proteins, and their molecular 
weight variants designated by an asterisk (MRP*, EF*), are encoded by the genes mrp (Smith et 
aL, 1992) and epf (Smith et aL, 1993), respectively. As for SLY, the role of IVIRP and EF proteins 
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has not been clearly defined but they do not appear to confer virulence directly, as 
demonstrated with the use of gene knockout technology (Smith et al., 1996). However, there is 
a positive association between the presence of these proteins and virulence in European and 
Asian strains of s. suis (Gottschalk et al., 2007). Indeed, in several countries of these continents, 
MRP+EF+SLY+ strains of the serotype 2 are isolated mainly from diseased pigs and are associated 
with severe clinical signs of disease after experimental infection. In contrast, MRP-EF-SLY- strains 
have been frequently isolated from healthy pigs and have been reported to be non-pathogenic 
after experimental inoculation (Ailgaier et al., 2001; Vecht et al., 1992). On the other hand, the 
MRP+EF* serotype 2 strains,which produce high molecular weight variants of EF, have been 
reported to be less virulent for young pigs (Vecht et al., 1992). In addition, to the best of our 
knowledge, avirulent strains possessing MRP, EF and suilysin have not been reported. However, 
some European and most Canadian virulent isolates do not produce any of these 3 factors 
(Berthelot-Herault et al., 2000; Gottschalk et al., 1998; Quessy et al., 1994; Segers et al., 1998). 
Despite the fact that many studies addressing the prevalence of MRP, EF and SLY have 
been carried out with European and Canadian isolates, the prevalence of MRP, EF and SLY in the 
United States (U.S.), by far the largest North American swine producer, remains poorly known. 
Indeed, only one study has conducted a phenotypic evaluation of the presence of MRP and EF in 
selected serotype 2 isolates (Galina et al., 1996). In the present study, we carried out a 
genotypic and phenotypic assessment of the presence of these virulence markers in s. suis 
isolates from the U.S. 
Materials and methods 
S. suisisolates. A total of 100 S. suis field strains isolated in the U.S. between January, 
2003 and December, 2005 were used in this study. The isolates had been submitted as part of 
routine diagnostic procedures to the University of Minnesota Veterinary Diagnostic Laboratory 
or the Iowa State University Veterinary Diagnostic Laboratory and identified as s. suis using 
standard biochemical tests. Criteria for inclusion in this study were as follows: a) isolates were 
from different farms b) pigs must have shown clinical signs consistent with s. suis infection; c) 
isolates must have been obtained from organs at necropsy; (i.e. tonsillar or nasal swabs were 
not accepted) and d) isolates obtained in conjunction with other primary bacterial pathogens 
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(i.e. Actinobacillus pleuropneumoniae, Haemophilus parasuis) were not accepted. Isolates 
originated from 17 states (Table 51). The majority of the isolates were fram the major swine-
praducing states Iowa (28 isolates) and North Carolina (25 isolates). Fort y-four samples were 
fram cases of septicemia, isolated fram the liver or spleen (both organs in most cases). Fourteen 
i 
samples were isolated fram the central nervous system (either fram brain, meninges or 
cerebraspinal fluid). Forty isolates were fram cases of pneumonia (39 from lung and 1 from 
pleura). Finally one strain was isolated fram the heart and one fram joints. Serotyping was 
performed by a coagglutination test using rabbit hyperimmune sera and a reference panel of ail 
35 serotypes of S. suis, as previously described (Gottschalk et aL, 1993; Higgins and Gottschalk, 
1990). S. suis seratype 2 strains 5735 (MRP+EF*SLY+), P 1/7 (MRP+EF+SLY+), D282 (MRP+EF+SLY+), 
T15 (MRP-EFSLY-) and 89-1591 (MRP-EFSLY-), originating from our collection, were used as 
contrais. 
Strain culture and genomic DNA preparation. S. suis strains were grown in Todd-Hewitt 
broth (Becton Dickinson, Sparks, MD, USA) at 37"C for 16 h. Genomic DNA was prepared fram 
10 ml of overnight (ON) cultures using the QIAamp DNA Minikit (Qiagen Inc., Valencia, CA, USA) 
or the UltraClean Microbial DNA Isolation Kit (MO BIO Laboratories, Inc., Carlsbad, CA, USA) as 
recommended by the respective manufacturers. 
PCR assay for sly and orf102. Amplification of the sly gene was achieved by using 
previously described (King et aL, 2001) conditions and primers SLY3 and SLY2 (ail 
oligonucleotides primers were fram Invitragen, Burlington, ON, Canada and are presented in 
Table 1). The or/102 gene, which has been described to be mutually exclusive with the sly gene 
(King et aL, 2001; Takamatsu et aL, 2002) was amplified using primers TEF-1025 and TEF-1026. 
The concentrations of PCR reagents per reaction (final volume 25 Ill) were as follows: lX XL 
Buffer Il (Invitragen), 0.8 mM each dNTP, 1.5 mM Mg(OAch, 0.5 IlM of each primer, 1 U rTth 
DNA Polymerase (Invitrogen) and 1111 of genomic DNA as template. PCR parameters consisted of 
35 cycles of 94°C for 20 sec, 55°C for 30 sec, 72°C for 1 min with an initial denaturation step at 
94°C for 2 min and a final extension step at 72°C extension for 7 min. PCR amplicons (1492 bp 
for sly and 481 bp for or/102) were electraphoresed on 1 % aga rase gels and visualized by UV 
transillumination after ethidium bramide staining. 
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PCR assay for epf. Amplification of the epf gene was achieved by using the previously 
described conditions and primers epf-F and epf-R (Table 1) (Wisselink et al., 1999). This PCR test 
was able to discriminate between 6 variants of the epf gene (amplicons of 626, 1278, 1505, 
2313, 2537 and 2993 bp, respectively) (Wisselink et al., 1999). 
Sequencing of the mrp gene. Fuillength mrp was amplified from most isolates using one 
or more of different primer pairs (one of TEF-1067, TEF-1068, TEF-l069, TEF-l070, TEF-l071, 
TEF-l072, TEF-l073, or TEF-l074 with one of TEF-l075, TEF-l076, TEF-1077, TEF-l078, TEF-
1079, TEF-1080, or TEF-l081). Primer sequences are listed in Table 1 and their annealing 
positions to the mrp genetic region are depicted in Fig. lA. The concentrations of PCR reagents 
per reaction (final volume 25 ~I) were those described above for orfl02. Amplifications were as 
follows: 94°C for 2 minutes, 35 cycles of 94°C for 20 seconds, 55°C for 30 seconds and 72°C for 4 
minutes, 72°C for 10 minutes. PCR amplicons ranging from 4 to 5 kb as determined by agarose 
gel electrophoresis were considered positive, purified and sequenced as described below. When 
the fuillength mrp gene could not be amplified, a variable size fragment was amplified using the 
same conditions but with primers TEF-l033 and TEF-l042 (Table 1). PCR-generated mrp 
amplicons were purified using either the QIAquick PCR Purification Kit (Qiagen) or the MinElute 
96UF kit (Qiagen) according to the manufacturer's recommendations. Sequencing reactions 
were performed in a final volume of 13 ~I containing 5 ~I of purified amplicon as template, 2 ~I 
BigDye Terminator v. 3.0 Chemistry kit, 1.5 ~I ABI 5X Sequencing Buffer (Applied Biosystems, 
Foster City, CA, USA), and 0.23 ~M primer. Primer walking was used for the complete and 
overlapping coverage of the mrp gene. Primers were TEF-1075, TEF-l033, TEF-l034, TEF-l05l, 
TEF-l052, TEF-1053, TEF-l054, TEF-l040, TEF-l057, TEF-1082, TEF-l042, TEF-1083, TEF-l084, 
TEF-l046, and TEF-l067 (Table 1 and Fig. lA). Reactions consisted of 50 cycles of 96°C for 10 
seconds, 50°C for 5 seconds and 60°C for 4 minutes. Products were then purified using either 
the Performa DTR 96-well standard plate kit (Edge BioSystems, Gaithersburg, MD, U.S.A.) or 
CentriSep Spin Columns (Princeton Separations, Adelphia, NJ, U.S.A.) according to 
manufacturer's instructions. Samples were analyzed on an ABI 3730 DNA Sequencer (Applied 
Biosystems). 
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Hemolytic assay for suilysin. Citrated horse red blood cells (hrbc, 25 ml) were washed 
with 25 ml of Dulbecco's Phosphate Buffered Saline (PBS), pH 7.3, (Gibco, Grand Island, NY, USA) 
and centrifuged at room temperature (RT) for 10 min at 1000 rpm in a Sorvall RT6000 centrifuge 
with a Sorvall Hl000B rotor. The supernatant was removed and the pellet washed two more 
times as described above. The resulting pellet of washed citrated hrbc was brought up to a final 
volume of 100 ml in PBS. The he moly tic activity of s. suis isolates was assessed by gently mixing 
25 III of ON bacterial culture supernatants with 25 III of washed citrated hrbc in 96-well Costar 
3799 plates (Corning Incorporated, Corning, NY, USA). Plates were incubated at 37°C with 5% 
CO2 for 1 h followed by incubation at room temperature for 16-24 h. Results were evaluated 
visually. Wells in which hrbc were completely Iysed were considered positive. 
Western-blot assays for MRP and EF. Supernatants obtained after centrifugation of ON 
S. suis cultures in THB were concentrated 10-fold by Ultrafree-MC centrifugai filter devices 
(Millipore Corp., Bedford MA, USA). Samples were prepared for the E-PAGE protein 
electrophoresis system (Invitrogen) and 10 III of samples were run on 8% E-PAGE 48 gels as per 
manufacturer's instructions. After electrophoresis, proteins were transferred to nitrocellulose 
filters (BioRad, Hercules, CA, USA). The blots were blocked with 2 % casein and incubated with a 
1:200 dilution of monoclonal antibodies against either MRP or EF (Vecht et aL, 1992). After 
extensive washes with blocking solution, the membranes were incubated with peroxidase-
conjugated, affinity purified rabbit anti-mouse antibodies (Rockland, Gilbertsville, PA, USA) 
diluted 1:10000. The membranes were washed in Tris-Buffered Saline, pH 7.6, prior to detection 
with TMB 1-Component Membrane Peroxidase Substrate (KPL, Gaithersburg, MD, USA). 
Results and discussion 
Serotyping. We first determined the serotype of the isolates included in the panel. 
Results showed that of the 100 isolates, serotype 3 (N=20) was the most prevalent, followed by 
serotypes 2 (N=17), 7 (N=13), 8 (N=l1), 6 (N=9) and 1/2 (N=8). These 6 serotypes together 
accounted for 78 % of the isolates. Four isolates belonged to serotype 5. Serotypes 9, 1 and 23 
comprised three isolates each; serotype 18 two isolates, and serotypes 10, 12, 14, and 30, one 
isolate each. Finally, three strains were nontypable. These strains were confirmed as belonging 
to the S. suis species by using a previously described specifie PCR test targeting the gdh gene 
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(Okwumabua et aL, 2003) (data not shown). Serotype determination remains a valuable tool 
used by veterinary practitioners and diagnosticians to understand the epidemiology of a 
particular outbreak andjor to increase the possibility of success of a vaccination program within 
a herd. To the best of our knowledge, this is the first report of serotype distribution for country-
wide obtained S. suis U.S. isolates. Interestingly, in the present study, the predominant S. suis 
serotypes as weil as their prevalence were comparable to those reported for Canadian isolates 
(Messier et aL, 2008), which seems to confirm a previous hypothesis suggesting that the 
prevalence of S. suis serotypes are similar in these two North American countries (Higgins and 
Gottschalk, 2006). This was expected since many Canadian piglets are routinely sent to 
growingjfinisher units in the U.S. Further studies with a larger numb~r of U.S. isolates would be 
needed to definitively sustain this hypothesis. Previous reports analyzing S. suis isolates in the 
state of Minnesota have shown that serotype 2 was the most prevalent in that state among field 
strains obtained during years 1989 and 1990 (27 to 34%) and years 1992 and 1993 (with a 
surprising 77 %) (Galina et aL, 1992; Galina et aL, 1996). In contrast, data obtained in this study 
showed that only 17 % of isolates of U.S. origin belonged to serotype 2, a percentage that is 
similar to that reported in Canada and considerably lower than those reported in European 
countries for this serotype (Berthelot-Herault et aL, 2000; Messier et aL, 2008; Wisselink et aL, 
2000). 
SLY and EF. The presence of the sly gene was determined by a PCR assay targeting the 
sly gene (King et aL, 2001). Forty-nine isolates were positive for an amplicon of the expected size 
(Table 2). The sly gene lies between the orfl0l gene, encoding for a putative haloacid 
dehalogenase hydrolase and the nonE gene, which encodes for a putative N-
acetylmannosamine-6-phosphate epimerase (King et aL, 2001; Takamatsu et aL, 2002). In 
strains lacking sly an alternative genetic structure has been described, with orfl02 (a gene of 
unknown function) occupying the place of sly (King et aL, 2001; Takamatsu et aL, 2002). In order 
to validate our sly PCR results we designed PCR primers to amplify an orfl02 fragment. There 
was a strong agreement between the two assays: 95 % of the isolates contained either the sly or 
the orfl02 genes. However, 5 isolates were negative for both sly and orfl02 PCR assays. 
Although we cannot exclude that absence of amplification in these 5 isolates may reflect 
mutations affecting annealing of the primers used, our results may also result from a novel 
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organization of the region without any of the sly or orf102 genes. Further studies are needed to 
evaluate this hypothesis. Phenotypically, the 51 isolates that were negative for the sly gene by 
PCR were also negative for hemolytie activity. On the other hand, of the 49 isolates that were 
determined to be positive for sly by PCR, only 39 were able to lyse citrated hrbc (Table 2). The 
remaining 10 isolates did not show hemolytie activity. Although we have not performed 
sequencing of the amplicons obtained by PCR for these 10 isolates, we hypothesize that the sly 
alleles in these isolates are likely to present mutations resulting in the absence of expression of 
a functional protein. Therefore, for any given S. suis isolate, PCR results for sly should be 
interpreted with caution and should not replace the effective evaluation of the hemolytic 
capacity of the strain. 
We also evaluated the presence of the epf gene by using a previously described PCR test 
(Wisselink et aL, 1999). Thirty-one isolates were positive for the epf gene (Table 2). Of them, 6 
presented the expected size for the originally described epf gene, while from the remaining 
samples amplicons had sizes compatible with the epf PCR variant epf*v3 (Wisselink et aL, 1999) 
(data not shown). However, only two isolates expressed EF, as determined by Western blotting 
with an anti-EF monoclonal antibody (Vecht et aL, 1992). As for the sly gene, we did not perform 
sequencing of the epf amplicons generated by PCR. Therefore, we cannot exclude the presence 
of mutations affecting the actual expression of EF in these epf PCR positive strains. However, the 
only two Western-blot EF positive strains belonged to serotype 2. These strains were also the 
only serotype 2 strains positive for epf by PCR. Indeed, most of the epf PCR positive strains 
belonged to serotypes other than 2 (Table 2). Since the monoclonal antibodies against EF were 
generated using serotype 2 EF protein (Vecht et aL, 1992), it might also be hypothesized that 
this monoclonal antibody recognizes an EF epitope present in serotype 2 strains only. 
MRP. When we analyzed the expression of MRP by Western-blot using specifie 
monoclonal antibodies, 46 isolates were found to be positive. Of them, 43 isolates presented 
MRP-reactive bands ranging in size from 120 to 150 kDa, molecular weights (MW) that are 
consistent with previous reports (Silva et aL, 2006; Smith et aL, 1992). On the other hand, 3 
isolates were positive for a much lower MW band (76 kDa) (Table 3). Using different 
combinations of external PCR primers designed to amplify the entire MRP open reading frame 
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(see materials and methods and Fig. lA), amplicons ranging in size from 4 kb to 5 kb (compatible 
with the full length mrp gene and the repbrted mrp variants) were obtained for 82 isolates 
(Table 3). However, we failed to observe amplification for 18 isolates. We therefore designed 
primers annealing within the mrp coding sequence and obtained amplicons for 10 of these 
isolates. The remaining 8 isolates were also negative with these internai primers (Table 3). 
To investigate the discrepancy between the number of IVIRP positive isolates by 
Western-blot and the number of isolates containing putative full-Iength mrp gene copies, the 
PCR amplicons were sequenced. Sequence data have been submitted to GenBank and are 
available under Accession Numbers FJ685523 to FJ685613. Sequencing results divided the 92 
isolates in 3 defined groups. A first group of 43 isolates, which matched perfectly the isolates 
positive for MRP by Western blot, presented an intact mrp open reading frame with the 
reported initiator ATG codon (Smith et al., 1992). A second group of three isolates presented 
nonsense mutations at about 2.1 kb from the ATG initiator codon. In silico translation predicted 
LPXTG-Iess, C-terminally truncated polypeptides of 707 amino acids for these three isolates. In 
strong agreement, these 3 isolates were those that showed a truncated 76 kDa band by Western 
blot (data not shown). Finally, for 46 isolates, sequencing revealed the presence of frameshift 
mutations at different short distances from the reported initiator ATG codon, which resulted in 
premature stop codons (data not shown). Consistently, ail the isolates possessing such a 
defective S'end mrp gene copy had tested negative for MRP by Western blot. Of note, except 
for the frameshift mutations, ail these Western-blot negative isolates presented a "full length" 
mrp gene. Interestingly, in a recent study, a PCR test using primers which anneal to the 3' end of 
the mrp gene was described which allows for the identification of mrp gene variants (Silva et al., 
2006). That study reported a very good agreement between PCR positive results and expression 
of MRP in a panel of European strains. However, given the high percentage of frameshift 
mutations in the mrp gene found in the present study resulting in absence of expression of MRP, 
at least for North American strains, it seems likely that the mrp variant PCR is of limited use for 
the assessment of IVIRP production. 
Irrespective of the actual expression of MRP, sequencing also revealed the presence of 3 
distinct mrp genotypes among the 92 sequenced U.S. isolates. The first of these genotypes, 
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referred to in this study as European (EU), is represented by the mrp sequence originally 
reported for S. suis European strains D282 (GenBank Accession Number X64450) (Smith et aL, 
1992) or P 1/7 (gene SSU_0706, available online at the Sanger Institute, 
http://www.sanger.ac.uk/Projects/S suis/). The second genotype, referred to here as North 
American (NA) 1, is represented by the (anadian isolate 89/1591 (available online at 
http://genome.jgi-psf.org/draftmicrobes/strsu/strsu.home.html), even though this strain does 
not actually express MRP (Quessy et aL, 1995). A third, previously unreported genotype, 
referred to as NA2, was identified in this study in 14 of the tested isolates. Strain PAH-146 
(GenBank Accession Number FJ685609) represents this genotype. The three genotypes are very 
similar at the 5' and 3' ends while variation is observed in the central part of the gene. Indeed, 
predicted translated sequences of these 3 genotypes showed 99 % identity for the first 220 
amino acids and the (-terminal last 147 amine acids. On the other hand, between 50 to 60% 
identity for the more central adjoining 475 amine acids was observed between the genotypes 
(Fig. lB). Distribution-wise, and irrespective of whether MRP was expressed or not, 74 isolates 
belonged to the NA1 genotype, 14 were NA2, and 4 were of the EU type. 
Finally, sequencing data revealed that the heterogeneities in MW observed by Western-
blot were 100% consistent with the open reading frames identified by sequencing and were 
mainly accounted for by the different occurrences (0 to 3) of 137 amino acid repeats located 
within the (-terminal half of the protein (Fig. lB). Most isolates presented one such repeat. 
Therefore, the overall genotypic structure of the mrp locus can be characterized by a 
combination of 1) a 5' end without (intact, 1) or with (defective, D) frameshift mutations, 2) one 
of the 3 related genotypes (EU, NA1, NA2), and 3) the number of repeats (0 to 3). The most 
prevalent mrp genotype among the U.S. S. suis isolates was a combination of an intact 5' end of 
the ORF, the NA1 variable region, and one repeat ("I/NA1/1"), representing over 25 % of the 
isolates. The next most prevalent mrp genotype was D/NA1/1. These two mrp genotypes 
accounted for approximately half of the isolates in the study. 
Phenotypes. Studies carried out with European strains, especially those of serotype 2 
have shown that the IVIRP and EF proteins as weil as SLY are strongly associated with the 
virulence of s. suis (Jacobs et aL, 1995; Wisselink et aL, 2000). On the other hand, these proteins 
1 xxvii 
are not frequently associated with Canadian virulent strains (Gottschalk et al., 1998). Results of 
the present study show that, taking ail the serotypes together, the two most prevalent 
phenotypes found for U.S. isolates are MRP+EFSLY", which accounted for 40 % of the isolates 
and MRP"EFSLY+ (35 % of the isolates) (Table 3). The triple negative phenotype MRP"EFSLY" 
accounted for 16 % of the isolates. EF* expressing strains were not found in our U.S. panel, 
which is in accordance with the situation in Canada (Higgins and Gottschalk, 2006), although, as 
discussed above, some epf*v3 positive results were obtained by PCR for serotypes other than 
serotype 2. Interestingly, among isolates belonging to serotype 2, only 3 different phenotypes 
were observed. The most prevalent phenotype among serotype 2 strains was MRP+EFSLY" 
(76%), followed by the triple negative MRP-EFSLY' phenotype (12%). Although the observed 
prevalence of MRP among serotype 2 isolates was higher than that reported in Canada, the 
prevalence of EF and SLY among U.S. strains of serotype 2 was in agreementwith that reported 
for Canadian strains. Indeed, the triple positive phenotype MRP+EF+SLY+ was observed for only 
two serotype 2 strains. Interestingly, although most MRP positive serotype 2 strains presented a 
NA1 mrp genotype, these 2 MRP+EF+SLY+ isolates showed an EU mrp genotype. These results 
suggest that these 2 isolates might be of European origin and might have been introduced to the 
United States through the importation of animais. Further phylogenetic studies are needed to 
evaluate this proposaI. 
Our results suggest a common situation regarding the distribution of different serotypes 
. of S. suis in the United States and Canada. The production of virulence markers su ch as MRP, EF 
and SLY by U.S. isolates also differs from that reported for European strains but it is similar to 
that reported in Canada. Interestingly, a higher association of S. suis cases with the 
immunosuppressive infection caused by the porcine reproductive and respiratory syndrome 
virus has been reported in North America while, on the other hand, in Europe, S. suis is most 
often the primary agent of infection (Higgins and Gottschalk, 2006). It has been hypothesized 
that European virulent serotype 2 strains, especially those with the phenotype MRP+EF+SLY+, 
may be more virulent than North American strains (Gottschalk and Segura, 2000) and, indeed, 
greater virulence was demonstrated for a serotype 2 European MRP+EF+SLY+ strain compared to 
a virulent Canadian MRP"EFSLY" strain using a standardized experimental infection method 
(Berthelot-Herault et al., 2005). In addition, human S. suis infections are much less common in 
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North America than in Europe and Asia and they have thus far not resulted in mortality of the 
patients, whereas death has been more common among European and Asian S. suis human 
cases (Gottschalk et al., 2007). Results presented here further suggest that North American and 
European strains are dissimilar. However, differences in virulence among strains from these two 
origins may probably not be explained solely based on the differences in MRP, EF, and SLY 
production. The availability of genomic data from the ongoing genome sequencing of European 
(P 1/7) and North American (89-1591) strains will hopefully help to resolve this dichotomy. 
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Article V Tables 
Table XIX. Article V, Table 1. Oligonucleotide primers used in this study. 
Primer Sequence (5'-3") Use (Reference) 
name 
JP4 GCAGCGTATTCTGTCAAACG 
Species detection (Okwumabua et 
aL, 2003) 
JP5 CCATGGACAGATAAAGATGG 
Species detec.tion (Okwumabua et 
aL, 2003) 
Sly-2 ACTCTATCACCTCATCCGCv sly amplification (King et aL, 2001) 
Sly-3 ACTCTATCACCTCATCCGC sly amplification (King et aL, 2001) 
TEF-1025 ACGAGAAAACCTTGCGACTG PCR for orfl02 amplification 
TEF-1026 CTGGATTGATAGGAGTGTTTG PCR for orfl02 amplification 
TEF-1033 CGAAACAACAATTTTCGATTCGTAAG mrp sequencing 
TEF-1034 GGAGCAATTGCTGCACCATTTGG mrp sequencing 
TEF-1040 CAGATGTGGACCGTAGACCAG mrp sequencing 
TEF-1041 CAGCTAAGACAACCGGTACAG mrp sequencing 
TEF-1042 GTTGGTGGTACATAACCCTTACCTGG mrp sequencing 
TEF-1046 CCAACAACACCTGAGAAGGAAACTCC mrp sequencing 
TEF-1051 CCAAATGGTGCAGCAATTGCTCC mrp sequencing 
TEF-1052 CTGTCCTGCAATAGTTTGAAGAC mrp sequencing 
TEF-1053 GTCTTCAAACTATTGCAGGACAG mrp sequencing 
TEF-1054 GACGCGATATTTGCTACCTTG mrp sequencing 
TEF-1057 CCAGCTTCAATCTTACCTGTTGTTGG mrp sequencing 
TEF-1067 GCGAACTCTAAGATGTAACTCTGGAC mrp sequencing 
TEF-1068 GAGTAGTGACTGTTGGAGGTTGG mrp sequencing 
TEF-1069 CCCCACACAGCTCCAACAGTC mrp sequencing 
TEF-1070 GCGTCAGAGGATTGCGAATATCTG mrp sequencing 
TEF-1071 CTCAAAGGATAGAGAGTTTGGAGC mrp sequencing 
TEF-1072 CAGGTATTCCAAGACCTTGCGTTC mrp sequencing 
TEF-1073 GCGGTTGACCTGCTTCTTTCCTATC mrp sequencing 
TEF-1074 AATCATTGCCAGACCAACATCATC mrp sequencing 
TEF-1075 TTTCAAGGCTTTGATACAAAGAGTAG mrp sequencing 
TEF-1076 GTATAATACCTCGRATGATTGCGGGAG mrp sequencing 
TEF-10n GCATTTAAAGTTATTTGTAGTATAATACCTCG mrp sequencing 
TEF-1078 ATGGAGCTAATATTTTTGCGGTGTCG mrp sequencing 
TEF-1079 TGAGCGTTTGGCAAGAGAGC mrp sequencing 
TEF-1080 CAATCGCAAACTCCGTTTGG mrp sequencing 
TEF-1081 GCCGATGTTTGGAATGCTG mrp sequencing 
TEF-1082 CAACAGAGCCAGACGAGCCAATC mrp sequencing 
TEF-1083 GTTGCCATCTTCGTCAGTAACAG mrp sequencing 
TEF-1084 CATCAACTACAGTACGCACATACTC mrp sequencing 
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Table XX. Article V, Table 2. Prevalence of suilysin and EF among the 100 U.S. Streptococcus 
suis isolates. 
Serotype N Suilysin EF 
sly (PCR) orf 102 (PCR) Hemolysis PCR Western-blot 
1 3 0 2 0 0 0 
2 17 2 14 2 2 2 
3 20 5 14 5 5 0 
4 9 9 0 9 9 0 
5 4 3 1 3 4 0 
7 13 10 3 3 3 0 
8 11 10 1 8 1 0 
9 3 1 2 1 1 0 
10 1 1 0 1 1 0 
12 1 1 0 1 0 0 
14 1 1 0 1 0 0 
18 2 1 1 1 1 0 
23 3 3 0 3 3 0 
30 1 1 0 1 0 0 
1/2 8 0 8 0 1 0 
NT a 3 1 0 0 0 0 
Total 100 49 46 39 31 2 
a Non typable 
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Table XXI. Article V, Table 3. Prevalence of MRP among the 100 U.S. Streptococcus suis isolates 
Serotype 1\1 mrp gene Intact N-terminus Western-blot 
1 3 ,3 3 3 
2 17 17 15 15 
3 20 20 13 13 
4 9 9 a a 
5 4 3 a a 
7 13 la Ob Ob 
8 11 11 1 1 
9 3 1 a a 
la 1 1 a a 
12 1 1 1 1 
14 1 1 a a 
18 2 2 1 1 
23 3 3 a a 
30 1 1 a a 
1/2 8 8 8 8 
NT a 3 1 1 1 
Total 100 92 43 43 
a NT non typable 
b Three isolates presented a truncated mrp gene at 2.1 kb from the reported initiator ATG codon 
(Smith et al., 1992). A corresponding truncated MRP (approx 76 KDa) was detected by Western 
blot. 
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Table XXII. Article V, Table 4. Distribution of MRP, EF and SLY phenotypes among the 100 U.S. 
Streptococcus suis isolates. 
Serotype N 
Phenotype 
MRP+EFSLY- MRP-EFSLY+ IVIRP-EFSLY- MRP+EFSLY+ MRP+EF+SLY+ 
1 3 3 a a a a 
2 17 13 a 2 a 2 
3 20 13 5 a a a 
4 9 a 9 a a a 
5 4 a 3 1 a a 
7 13 a 3 7 a a 
8 11 1 6 2 1 a 
9 3 a 1 2 a a 
la 1 a 1 a a a 
12 1 a a a 1 a 
14 1 a 1 a a a 
18 2 1 1 a a a 
23 3 a 3 a a a 
30 1 a 1 a a a 
1/2 8 8 a a a a 
NT a 3 1 a 2 a a 
Total 100 40 35 16 2 2 
a NT non typable 
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Table XXIII. Article V, Supplemental Table 1. State of origin of the 100 U.S. isolates used in this 
State l\Jumber of isolates 
Iowa 29 
North Carolina 25 
Oklahoma 7 
Nebraska 7 
Missouri 6 
Minnesota 5 
Indiana 5 
Illinois 3 
Kentucky 2 
Wisconsin 2 
Utah 2 
Texas 2 
Virginia 1 
Kansas 1 
Ohio 1 
Michigan 1 
Colorado 1 
Total 100 
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Figure 39. Article V, Figure 1. The mrp genetic region and positions of primers used in this 
study. 
A) Schematic representation of the mrp genetic region in serotype 2 strain Pi/7 (available at 
http://www.sanger.ac.uk/Projects/S suis/). Arrows indicate the annealing position of the 
primers used for the determination of the presence and sequencing of the mrp gene. B) 
Sequence alignment of translated predicted amino acid sequences of MRP for the isolates used 
in this study. Sequences were aligned using the CLUSTALW software available at 
http://www.ebi.ac.uk/Tools/clustalw/. The N-terminal and C-terminal regions presented 99% 
identity among the isolates. On the other hand, only between 50 to 60 % identity was observed 
for the central region among isolates, which could be clustered on three different genotypes 
{EU, NAi and NA2)based on their sequence for this variable region. Finally, strains were shown 
to possess a variable number (a to 3) of a 137 aa repeat (indicated by the arrows). 
